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Streptococcus pneumoniae is a common asymptomatic commensal of 
the human nasopharynx. However, it is better known as a threatening 
pathogen that causes serious diseases such as pneumonia, meningitis 
and sepsis, as well as other less severe but more prevalent infections 
(e.g. otitis media). With the increase of antibiotic resistance and the limited 
efficacy of vaccines, pneumococcal infections remain a major problem. 
Therefore, the discovery of new therapeutic targets and preventive drugs 
are in high demand. Given this panorama, much attention has been 
dedicated to classical aspects of virulence (e.g. toxins, capsule or cell wall 
components), but the knowledge of in vivo physiology and metabolism of 
S. pneumoniae is still limited. This is intriguing, considering that to a large 
extent, pneumococcal pathogenesis relies on efficient acquisition and 
metabolism of the nutrients required for growth and survival in the host 
niches. In line with this view, recent work uncovers substantial 
interdependencies between carbohydrate metabolism and virulence. 
These findings denote a far greater importance of basic pneumococcal 
physiology than previously imagined. However, a scarcity of data on sugar 
metabolism and its regulation in S. pneumoniae hampers a 
comprehensive understanding of the connections between these 
processes.  
The ultimate goal of this thesis is to improve our understanding of S. 
pneumoniae basic physiology and discover links between carbohydrate 
metabolism and the ability of the bacterium to colonise and cause disease.  
S. pneumoniae is a strictly fermentative microorganism that relies on 
glycolytic metabolism to obtain energy, but free monosaccharides are 
limited in the airways. The most abundant sugars present in the natural 
niche of S. pneumoniae are the glycoproteins mucins, which are generally 
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composed of N-acetylglucosamine (GlcNAc), N-acetylgalactosamine 
(GalNAc), N-acetylneuraminic acid (NeuNAc), galactose (Gal), fucose 
(Fuc) and sulphated sugars linked to the protein core. Importantly, S. 
pneumoniae possesses a large set of extracellular glycosidases that act 
over glycans and release free sugars that can potentially be used for grow. 
Therefore, we hypothesised that the pneumococcus depends on one or 
multiple glycan-derived sugars to grow. 
To disclose prevalent pathways during growth on mucin we resorted to 
a transcriptome analysis comparing transcript levels during growth on the 
model glycoprotein porcine gastric mucin and glucose (Glc). The gene 
expression profile revealed Gal, Man and GlcNAc as the most probable 
glycan-derived sugars to be used as carbon sources by S. pneumoniae 
D39. Accordingly, D39 was able to grow on these sugars, but not on other 
host-derived glycan monosaccharides (Fuc, NeuNAc, GalNAc), as 
expected from its genomic potential. An in depth characterization of 
growth profiles on a chemically defined medium supplemented with each 
carbohydrate using two different sugar concentrations (30 and 10 mM) 
was performed. S. pneumoniae displayed a preference for GlcNAc, 
whereas Gal was the least preferable carbohydrate for growth, but 
energetically the most favourable. The inefficient Gal catabolism could be 
partially explained by the absence of a high affinity Gal transporter. Gal 
caused a remarkable metabolic shift from homolactic to a truly mixed acid 
fermentation. The in silico predicted pathways for the catabolism of each 
sugar were experimentally validated at the biochemical level by 
determining sugar-specific intracellular metabolites and pathway specific 
enzyme activities. Furthermore, mutants were generated in each pathway 
by inactivation of a gene encoding a pathway specific enzyme, and their 
analysis proved at the genetic level the biochemical analyses. Curiously, 
inactivation of galK (Leloir pathway) rendered a strain unable to grow on 




(tagatose 6-phosphate pathway), suggesting a subtle regulatory link 
between the two pathways. 
Intranasal mouse infection models of pneumococcal colonisation and 
disease (bronchopneumonia with bacteraemia) showed that mutants in 
the Gal catabolic genes (∆lacD, ∆galK, ∆lacD∆galK) were attenuated, but 
mutants on Man (∆manA) and GlcNAc (∆nagA) pathways were not. Our 
data identified Gal as a key nutrient for growth in the respiratory tract. 
Strengthening this view is the large fraction of genes committed to Gal 
catabolism induced by mucin (25%) as well as the considerable group of 
virulence genes (8.2%) displaying altered expression in response to Gal. 
The response to Gal, GlcNAc and Man (test sugars) was also 
evaluated at the transcriptional and metabolic levels. The transcriptional 
response was substantial and sugar-specific. Gal, GlcNAc and Man 
affected the expression of up to 8.4%, 11.4%, and 14.2% of the genome, 
respectively, covering multiple cellular processes, including specific sugar 
pathways, central metabolism and virulence. An overview of the 
transcriptional response of central carbon metabolism functions (sugar 
transport and sugar specific pathways, glycolysis and fermentation 
pathways) to growth on the glycan-derived sugars as compared to Glc is 
presented. A complete correlation between expression profiles and 
pneumococcal phenotypic traits was not observed, denoting regulation at 
other cellular layers, such as post-transcriptional and/or metabolic levels. 
Hence, the glycolytic dynamics of S. pneumoniae D39 during catabolism 
of the glycan-derived sugars were monitored in resting cells by in vivo 13C-
NMR. The rate of GlcNAc utilization was similar to that of the fast 
metabolizable sugar Glc, and likewise the glycolytic metabolite fructose 
1,6-bisphosphate (FBP), a metabolic activator of homolactic metabolism, 
accumulated to considerably high concentrations (circa 30 mM). In line, 
this sugar displayed a fully homolactic end-product profile. In contrast, the 
rates of Gal and Man utilization were 2-fold lower, the accumulation of 
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FBP was considerably reduced to circa 12 mM, and a mixed-acid 
fermentation profile was observed. In addition, specific metabolic 
intermediates (α-galactose 6-phosphate and mannose 6-phosphate) 
accumulated, suggesting metabolic bottlenecks in the specific steps 
converting Gal and Man to glycolytic intermediates. On Man, the 
metabolic constriction most likely occurs at the level of mannose 6-
phosphate isomerase, since growth is improved when this activity is 
positively modulated by varying the gene expression. 
In the host S. pneumoniae has to cope with fluctuating concentrations 
of carbon sources. While free sugars, particularly Glc, are scarce in the 
nasopharynx, in the bloodstream and during infection Glc is comparatively 
higher. Therefore, we hypothesised that during the transition from 
colonisation to invasive disease S. pneumoniae adapts to the nutritional 
changes through a specific response to a Glc stimulus that result in 
changes in gene regulation and metabolism.  
Thus, cells growing in glycan-derived sugars or in a sugar mixture of 
Gal, GlcNAc and Man were challenged in exponential phase with a Glc 
pulse. The response to this stimulus was evaluated at the transcriptional, 
physiological and metabolic (for Gal-adapted cells) levels. Glc was readily 
consumed independently of the initial substrate adaptation, strengthening 
the view that Glc is the preferred carbohydrate for pneumococcal growth. 
The transcriptional response to a Glc stimulus was large, the most 
represented COG category being carbohydrate metabolism and transport. 
Except for Man-adapted cells, Glc exerted mostly negative regulation over 
the majority of genes encoding central carbon metabolism functions. 
Additionally, Glc induced shifts to more homolactic profiles and, which on 
Gal was accompanied by an increase on the FBP concentration following 
the Glc pulse.  
The expression of classical virulence factors was also sugar 




genes. Interestingly, cells adapted to grow on a sugar mixture (Gal, Man 
and GlcNAc) displayed the smallest transcriptional response to Glc, 
suggesting improved fitness of S. pneumoniae when exposed to varied 
sugars. We suggest that the nasopharynx is the reservoir for the 
development of niche-specific virulence traits, essential for successful 
colonisation of the niche. In addition, the majority of these virulence 
factors are downregulated by a Glc stimulus, and are therefore not 
required in disease. The link between sugar metabolism and virulence is 
herein reinforced.  
Overall, the findings of this thesis substantially contribute to the 
comprehension of the interdependency between carbohydrate 
metabolism, adaptation to host niches and virulence. Furthermore, the 
“omic” data collected at different regulatory layers can in the future be 
used to fuel multi-scale metabolic models. Such mathematical 
representations of metabolism are expected to provide robust platforms 
for data integration and interpretation, and thus generate testable 
hypothesis, which in the future will facilitate the identification of novel 







Streptococcus pneumoniae é um organismo comensal assintomático 
comummente encontrado na nasofaringe humana. Contudo, é mais 
conhecido no seu papel patogénico ameaçador que causa doenças como 
a pneumonia, a meningite ou septicémia, bem como outras infeções 
menos severas mas mais recorrentes (e.g. otite média). Com o aumento 
da resistência a antibióticos e a eficácia limitada das vacinas, as infeções 
pneumocócicas permanecem um importante problema. Assim sendo, há 
uma grande necessidade em descobrir novos alvos terapêuticos e drogas 
preventivas. Neste contexto, a atenção tem-se focado em aspetos 
clássicos da virulência (e.g., toxinas, cápsula ou componentes da parede 
celular). No entanto, o conhecimento da fisiologia in vivo e do 
metabolismo de Streptococcus pneumoniae é ainda limitado. Esta 
situação é intrigante, considerando que em grande medida, a 
patogenicidade pneumocócica baseia-se na aquisição eficiente e 
subsequente metabolismo de nutrientes necessários para o crescimento 
e a sobrevivência em nichos no hospedeiro. A corroborar esta afirmação, 
estudos recentes revelam interdependências substanciais entre o 
metabolismo dos hidratos de carbono e a virulência, e sugerem que o 
conhecimento sólido da fisiologia pneumocócica básica é mais 
importante do que antecipado. Contudo, a escassez de dados relativos 
ao metabolismo de açúcares e a sua regulação em S. pneumoniae limita 
a compreensão das ligações entre estes processos.  
O objetivo último desta tese é o de melhorar o conhecimento da 
fisiologia básica de S. pneumoniae e descobrir relações entre o 
metabolismo dos hidratos de carbono e a capacidade da bactéria em 
colonizar e causar doença. 
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S. pneumoniae é um microrganismo estritamente fermentativo que 
depende do metabolismo glicolítico para obter energia, mas os 
monossacáridos livres são escassos nas vias respiratórias. Os açúcares 
mais abundantes presentes no nicho natural de S. pneumoniae são as 
glicoproteínas mucinas, compostas geralmente por N-acetylglucosamina 
(GlcNAc), N-acetylgalactosamina (GalNAc), ácido N-acetilneuramínico 
(NeuNAc), galactose (Gal), fucose (Fuc) e açúcares sulfatados ligados a 
um núcleo proteico. De realçar que S. pneumoniae possui um grande 
conjunto de glicosidases extracelulares que atuam sobre os glicanos e 
libertam açúcares que podem potencialmente ser utilizados para 
crescimento. Por conseguinte, colocámos e testámos a hipótese de que 
os pneumococos podem depender, para crescimento, de um ou de 
múltiplos açúcares derivados destes glicanos.  
Para revelar as vias predominantes durante o crescimento em 
mucinas recorremos a uma análise de transcriptómica comparando os 
níveis de transcrição durante o crescimento na presença de mucina 
gástrica de suíno, enquanto glicoproteína modelo, e na presença de 
glucose (Glc). O perfil de expressão génica revelou que a Gal, Man e 
GlcNAc são os açúcares derivados de glicano mais provavelmente 
utilizados como fontes de carbono por S. pneumoniae D39. Em 
consonância, a estirpe D39 cresce nestes açúcares, mas não em outros 
monossacáridos derivados de glicanos do hospedeiro (Fuc, NeuNAc, 
GalNAc), como antecipado do seu potencial genómico. Realizou-se uma 
caracterização aprofundada dos perfis de crescimento em meio 
quimicamente definido suplementado com cada hidrato de carbono 
usando duas concentrações de açúcar (30 e 10 mM). S. pneumoniae 
demonstrou preferência por GlcNAc, enquanto Gal foi o hidrato de 
carbono menos preferido para crescimento, mas energeticamente mais 
favorável. O ineficiente catabolismo de Gal pode ser parcialmente 




galactose causou um desvio pronunciado da fermentação homolática 
para ácidos mistos. As vias catabólicas previstas in silico para cada 
açúcar foram experimentalmente validadas ao nível bioquímico, pela 
determinação de metabolitos intracelulares específicos de cada açúcar e 
atividades enzimáticas específicas de cada via. Adicionalmente, 
geraram-se mutantes por inativação de um gene que codifica uma 
enzima específica de cada via, e a sua análise confirmou ao nível 
genético a análise bioquímica. Curiosamente, a inativação de galK (via 
Leloir) originou uma estirpe incapaz de crescer em Gal, apesar de ter uma 
via alternativa disponível para o processamento deste açúcar (via da 
tagatose 6-fosfato), sugerindo uma conexão subtil na regulação das duas 
vias. 
Modelos de infeção intranasal de ratinhos de colonização 
pneumocócica e doença (broncopneumonia com bacteriemia) 
demonstraram que mutantes em genes catabólicos da Gal (∆lacD, ∆galK, 
∆lacD∆galK) são atenuados, mas mutantes nas vias da Man (∆manA) e 
GlcNAc (∆nagA), não. Os nossos estudos identificaram a Gal como um 
nutriente crucial para o crescimento no trato respiratório. A grande fração 
de genes do catabolismo da Gal induzida pela mucina (25%) bem como 
um grupo considerável de genes de virulência (8.2%) com expressão 
alterada em Gal, reforçam esta conclusão.  
A resposta à Gal, GlcNAc e Man (açúcares teste) foi também avaliada 
aos níveis transcricional e metabólico. A resposta transcricional foi 
substancial e dependente do açúcar. Gal, GlcNAc e Man afetaram a 
expressão até 8.4%, 11.4% e 14.2% do genoma, respetivamente, 
abrangendo múltiplos processos, incluindo vias específicas de açúcar, 
metabolismo central e virulência. Apresenta-se uma visão geral da 
resposta transcricional de funções do metabolismo central de carbono 
(transporte de açúcar e vias específicas de açúcares, glicólise e vias 
fermentativas) no crescimento em açúcares derivados de glicanos, em 
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comparação com a Glc. Não foi observada uma correlação completa 
entre os perfis de expressão e as características fenotípicas do 
pneumococo, demonstrando a existência de outros níveis de regulação, 
incluindo regulação pós-transcricional e/ou metabólica. 
Consequentemente, a dinâmica glicolítica de S. pneumoniae D39 durante 
o catabolismo de açúcares derivados de glicanos foi monitorizada em 
células em suspensão por in vivo 13C-NMR. A taxa de consumo de 
GlcNAc foi semelhante à do açúcar rapidamente metabolizado Glc e, do 
mesmo modo o metabolito glicolítico frutose 1,6-bifosfato (FBP), um 
ativador do metabolismo homolático, acumulou em concentrações 
elevadas (cerca de 30 mM). Em concordância, este açúcar apresentou 
um perfil de produtos finais totalmente homolático. Em contraste, as taxas 
de consumo de Gal e Man foram 2 vezes inferiores, a acumulação de 
FBP foi consideravelmente reduzida a aproximadamente 12 mM, e o 
perfil de fermentação de ácidos mistos foi observado. Além disso, foi 
detectada a acumulação de intermediários metabólicos específicos (α-
galactose 6-fosfato e manose 6-fosfato), sugerindo estrangulamentos 
metabólicos em passos específicos da conversão de Gal e Man a 
intermediários glicolíticos. Em Man, a constrição metabólica muito 
provavelmente ocorre ao nível da manose 6-fosfato isomerase, uma vez 
que o crescimento é melhorado quando esta atividade é positivamente 
modulada por alteração da expressão do gene.   
No hospedeiro, S. pneumoniae tem que lidar com concentrações 
variáveis de fontes de carbono. Enquanto os açúcares livres, 
particularmente Glc, são escassos na nasofaringe, na corrente sanguínea 
e durante a infeção, a Glc é comparativamente elevada. Deste modo, 
colocámos a hipótese que durante a transição de colonização para 
doença invasiva S. pneumoniae adapta-se às variações nutricionais 
através de uma resposta específica a um estímulo de Glc que resulta em 




Deste modo, células a crescerem em açúcares derivados de glicanos 
ou numa mistura de Gal, GlcNAc e Man foram sujeitas, durante o 
crescimento exponencial, a um pulso de Glc. A resposta a este estímulo 
foi avaliada aos níveis transcricional, fisiológico e metabólico (para 
células adaptadas a Gal). A Glc foi prontamente consumida 
independentemente da adaptação inicial ao substrato, reforçando que a 
Glc é o hidrato de carbono preferido para o crescimento dos 
pneumococos. A resposta transcricional ao estímulo de Glc foi ampla, 
sendo a categoria COG mais representada a do metabolismo de hidratos 
de carbono e do transporte. À exceção de células adaptadas a Man, a 
Glc exerceu principalmente uma regulação negativa sobre a maioria dos 
genes que codificam funções do metabolismo central de carbono. 
Adicionalmente, a Glc induziu desvios para perfis mais homoláticos e, em 
Gal foi acompanhado por um aumento da concentração de FBP após o 
pulso de Glc.  
A expressão de fatores de virulência clássicos foi também dependente 
do açúcar, mas a Glc exerceu consistentemente um efeito repressivo 
sobre os genes de virulência. De interesse, notámos que as células 
adaptadas ao crescimento numa mistura de açúcares (Gal, Man e 
GlcNAc) originaram uma menor resposta transcricional à Glc, sugerindo 
uma melhor aptidão de S. pneumoniae quando exposto a uma variedade 
de açúcares. Sugerimos que a nasofaringe é o reservatório para o 
desenvolvimento de traços específicos de virulência, essenciais para a 
colonização bem-sucedida deste nicho. Adicionalmente, a maioria destes 
fatores de virulência são reprimidos pelo estímulo de Glc, não sendo por 
conseguinte necessários na doença. A ligação entre metabolismo de 
açúcares e virulência é aqui reforçada.  
Globalmente, as descobertas desta tese contribuem substancialmente 
para a compreensão da interdependência entre o metabolismo de 
hidratos de carbono, a adaptação aos nichos do hospedeiro e a 
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virulência. Além disso, os dados “ómicos” recolhidos a diferentes níveis 
de regulação podem no futuro ser utilizados em modelos metabólicos 
multi-escala. É esperado que tais representações matemáticas do 
metabolismo constituam plataformas robustas para a integração e a 
interpretação de dados e, por conseguinte, para a geração de hipóteses 
que no futuro facilitarão a identificação de novos alvos para terapêuticas 
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Pneumococcal infections have high socio-economic impact, and are 
therefore a major burden worldwide. According to the WHO, S. 
pneumoniae causes over 1 million deaths per year in children under 5 
years of age. Moreover, this high mortality is exacerbated by the rate at 
which the organism acquires resistance to traditional antibiotics and by 
the re-emergence of non-vaccine type strains. Therefore, the 
development of new therapeutic and preventive agents demands an 
increasing understanding of S. pneumoniae physiology and virulence. 
The overall goal of this thesis is to gain new insights regarding S. 
pneumoniae adaptive response to sugar availability and the link to in vivo 
fitness and virulence. 
 
Chapter 1 starts with a brief introduction to the main phenotypic traits 
of S. pneumoniae, its ability to colonise the nasopharynx and cause 
disease, and provides an overview of the traits of the bacterium in the 
perspective of a commensal and a pathogen. An overview of the major 
virulence factors is given as well as its link to carbohydrate metabolism. 
The catabolism, of monosaccharides (galactose, mannose, N-
acetylglucosamine, N-acetylgalactosamine, N-acetylneuraminic acid and 
fucose) is reviewed. The relevance of these sugars in the lifestyle of 
different bacteria is discussed. Lastly, the current knowledge concerning 
central metabolism in S. pneumoniae is overviewed.  
 
In Chapter 2 we identified the sugar catabolic pathways likely used 
during growth on a model glycoprotein, porcine gastric mucin, by a whole-
genome transcriptome analysis. An in depth characterization of 
pneumococcal growth on the glycan-derived sugars galactose, mannose 
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and N-acetylglucosamine is provided. The catabolic pathways of those 
sugars were, for the first time, experimentally validated at genetic and 
biochemical levels, confirming the in silico predictions. Finally, the 
relevance of sugar-specific catabolic genes to in vivo fitness was 
assessed in murine models of colonisation (nasopharyngeal carriage) and 
pneumococcal disease (bronchopneumonia with bacteraemia). 
 
Chapter 3 describes the transcriptional and metabolic responses in the 
presence of galactose, mannose and N-acetylglucosamine, by DNA 
microarrays and in vivo 13C-NMR, respectively. Glucose is used as the 
reference sugar. 
The effect of adding the fast metabolizable sugar glucose to S. 
pneumoniae cells actively growing on galactose, mannose, N-
acetylglucosamine or in a mixture thereof is evaluated at the 
transcriptional, physiological and metabolic levels. 
Furthermore, the influence of the carbohydrate source and the glucose 
pulse in the gene expression of known virulence factors is examined at 
the transcriptional level by DNA microarrays. 
 








ABC ATP-binding cassette 
BgaA  β-galactosidase A 
CAP Community-acquired pneumonia  
CcpA Carbon catabolite protein A  
CCR Carbon catabolite repression  
CDM Chemically defined medium  
COG Clusters of orthologous groups 
CRE Catabolite response elements  
DHAP  Dihydroxyacetone phosphate  
DW Dry weight  
EI  Enzyme I  
EMP Embden-Meyerhof-Parnas 
Eno Enolase  
F6P Fructose 6-phosphate  
Fba Fructose-bisphosphate aldolase  
Fuc Fucose  
FucA   L-fuculose phosphate aldolase  
FucI  L-fucose isomerase  
FucK  L-fuculose kinase  
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Streptococcus pneumoniae  
At the core of great discoveries 
Streptococcus pneumoniae, also known as the pneumococcus, was 
discovered in 1881 by Louis Pasteur and George Miller Sternberg in two 
independent studies [1,2]. Shortly after its isolation S. pneumoniae was 
identified as a major causative agent of human lobar pneumonia [1,2]. 
Due to its morphology (pairs of coccoid bacteria) and the involvement in 
pneumonia the bacterium was then named Diplococcus pneumoniae [1]. 
The present nomenclature remains since 1974 [1].  
The story of S. pneumoniae is intertwined with the history of different 
fields of research that range from microbiology, molecular biology, 
biochemistry to immunology (reviewed in [1,2]). Indeed, the study of the 
pneumococcus was at the centre of critical important discoveries. In 1928, 
Griffith demonstrated that when mice were inoculated with a mixture of 
dead virulent pneumococcal strains and live avirulent pneumococci, 
virulent phenotype strains could be recovered from the pneumonia dead 
animals. This phenomenon was denominated the “transforming principle” 
[3], and preceded the discovery of DNA as the hereditary material. Indeed, 
in 1944, Avery, McLeod and McCarthy proved, that the DNA was the 
transforming principle responsible for the phenotypic changes [4].  
Importantly, the discovery that pneumococci were “coated” by a 
polysaccharide capsule (“sugar-coated microbe” as called by Avery) with 
serological reactivity provided the basis for the development of the current 
polysaccharide vaccines [5–10]. Furthermore, the pneumococcus is 
behind the comprehension of antibiotic resistance. It was one of the first 
microorganisms recognized to develop resistance to antibiotics [1]. The 
pneumococcus is also closely associated with key discoveries in 
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molecular processes such as quorum sensing, autolysis and 
opsonisation, as well as to the development of molecular tools, the Gram’s 
stain technique and other identification methods (e.g. Quellung reaction 
and bile solubility test) still in use today  [1,2]. 
 
General characteristics 
Streptococcus pneumoniae is a low-GC (40%), Gram-positive, 
lanceolate cocci (elongated ellipsoid-shape) [11]. These ovoid cells are 
commonly designated ovococci (Fig. 1.1) [12,13]. It is usually arranged in 
pairs (diplococci), but can occur as single cells or in short chains. 
Individual cells can range from 0.5 to 1.25 micrometres in size. S. 
pneumoniae is non-motile and a non-spore forming bacterium. It is an 
aerotolerant anaerobe and a strictly fermentative microorganism that 
mainly converts carbohydrates to lactic acid (homolactic fermentation) 
[11].   
S. pneumoniae is a fastidious bacterium that requires nutritionally rich 
media for growth. Its nutritional requirement for choline is a unique 
characteristic of this microorganism [14]. It grows optimally at 37ºC in a 
pH range of 6.5-7.5. When cultured until stationary phase of growth the 
bacterium displays a tendency to undergo autolysis due to the presence 
of efficient autolysins, such as autolysin, LytA [15]. The pneumococci are 
also naturally transformable, taking up DNA from the medium (other 
bacteria), a phenomenon that contributes to a highly variable genome 
[16].  
The genus Streptococcus belongs to the phylum Firmicutes, 
Lactobacillales order, and Streptococcaceae family. Based on 16S 
ribosomal RNA, the pneumococcus belongs to the mitis group alongside 
with other bacteria that can be isolated from the human oro-nasopharynx 
(e.g. Streptococcus  oralis, Streptococcus gordonii, Streptococcus mitis, 
Streptococcus infantis, S. pseudopneumoniae) [17,18]. The genome 
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similarity within this group of microorganisms together with frequent 
events of horizontal gene transfer makes it difficult to differentiate S. 
pneumoniae from other closely related commensals (S. mitis, S. oralis, S. 
infantis, S. pseudopneumoniae) [18–20]. 
 
 
Figure 1.1. Streptococcus pneumoniae.  
Phase contrast image of S. pneumoniae D39 grown in chemically defined medium 
supplemented with 10 mM glucose, until exponential phase of growth.  
 
Traditionally, S. pneumoniae has been identified based on colony 
morphology and on phenotypic tests [21]. Two properties generally 
assessed are the pneumococcal alpha-hemolytic activity when cultured 
on blood agar plates and its catalase-negative phenotype [11]. 
Commonly, optochin susceptibility and/or bile solubility are used to 
distinguish S. pneumoniae from other viridans streptococci [20]. In 
addition, the ability to ferment inulin has also been used as a 
differentiating parameter [11].  
Some pneumococci are encapsulated and according to the 
polysaccharide composition more than 93 different serotypes have been 
identified [22]. The antigenic properties of the capsule are the basis for 
serotyping (Quellung reaction, agglutination with anti-pneumococcal 
polysaccharide antibodies), important for epidemiological surveillance 
and vaccine impact studies  [21,23,24]. 
General introduction 
7 
Despite the application of different phenotypic and genotypic 
techniques (e.g. PCR targeting virulence genes, pulsed-field gel 
electrophoresis, multilocus sequence typing (MLST), multilocus sequence 
analysis (MLSA)), and recently proteomic profiling (MALDI-TOF MS), 
identification and classification  of S. pneumoniae has been problematic 
and is still controversial [18,20,21,25,26]. Atypical reactions to standard 
identification tests are documented [18,25]. Part of this struggle stems out 
from the pneumococcus’ vast pan-genome and its genomic plasticity. 
 
S. pneumoniae, a commensal and a pathogen 
The scientific interest on S. pneumoniae was primarily raised because 
the organism has been a leading cause of mortality worldwide. In the 
beginning of the 20th century, Sir William Osler referred to it as the “captain 
of the men of death” [27,28], and pneumonia was the “natural end of 
elderly people” [29]. Nowadays, S. pneumoniae is also recognized as a 
commensal microorganism, which resides in the mucosal surface lining 
the upper respiratory tract, i.e. the nasopharynx of humans [30,31]. 
Pneumococci are members of the respiratory tract microflora alongside 
with other prominent opportunistic pathogens such as Haemophilus 
influenzae, Moraxella catarrhalis and Staphylococcus aureus [32]. 
Colonisation is usually asymptomatic and, for that reason, an important 
vehicle for dissemination within the community, which occurs through 
direct contact with contaminated secretions or aerosols of healthy or sick 
carriers [29,30,33,34]. Colonisation is more frequent in small children, 
which are usually colonised during the first year of life [33]. Carriage rates 
are age-related, with higher incidence in the childhood (2-3 years) [33], 
decreasing to less than 10% in the adult age [30].  The close contact with 
children increases the carriage rates in adults [29]. In developing 
countries the frequency of carriage in children is 2-3 times higher than in 
developed countries [31]. Risk factors associated with higher incidences 
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of pneumococcal carriage and disease are: ethnicity, crowding (e.g. 
attendance to day-care centres, hospitals, schools, contact with older 
siblings and children), environmental (e.g. smoking) and socioeconomic 
(e.g. living circumstances, income) ([33], reviewed in [35,36]). 
Colonisation is a dynamic process in terms of duration and colonising 
serotypes in the lifetime of an individual. Carriage with one or more 
serotypes can occur simultaneously or sequentially. It is a transient stage 
and its duration is serotype-dependent and influenced by past carriage 
episodes [31]. It is longer in young than older children [37,38]. Most often 
pneumococcal infections occur following a newly-acquired strain [31]. 
Some serotypes are more commonly involved in carriage while others, a 
relatively small number, are more related with invasive pneumococcal 
disease [16,39,40]. This finding suggests that the latter clones have 
specific genes that facilitate progression to disease [41]. Interestingly, 
high mortality rates were found within serotypes of lower invasive potential 
[16,39]. 
The establishment of a carrier state is a pre-requisite for pneumococcal 
disease with the colonising homologous strain, which usually occurs when 
the bacterium spreads to other parts of the human body [30,33]. Indeed, 
the pneumococcus is an opportunistic bacterium and children, elderly 
(>65 years old) and immunocompromised people are at increased risk of 
pneumococcal disease [33,42]. S. pneumoniae is an etiological agent of 
mild respiratory mucosal infections such as sinusitis or otitis media (non-
invasive diseases), but also less prevalent but more serious invasive 
pneumococcal diseases (IPD), when the pneumococcus gains access to 
normally sterile areas of the human body, such as bacteremic pneumonia 
or pneumonia with empyema, meningitis or sepsis [33]. 
With the advent of antibiotics in the 1950s, there was a general belief 
that bacterial infections could be controlled [2]. However, the emergence 
of antibiotic resistant phenotypes, the genomic plasticity of the 
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pneumococcus, the limited efficacy of pneumococcal vaccines, the aging 
of populations and difficulties in clinical diagnosis of pneumococcal 
diseases makes S. pneumoniae a re-emergent infectious agent and a 
matter of concern. Currently, the impact of pneumococcal disease on 
society is still large, with the pathogen being responsible for high 
mortalities and morbidities worldwide. It was estimated, by the WHO 
(World Health Organization), that the pneumococcus is responsible for 
approximately 700 000 to 1 000 000 children deaths every year worldwide 
[43]. Among children, pneumococcus is the primary cause of acute otitis 
media; this illness is the most common manifestation of pneumococcal 
infection and of antibiotic prescription in the United States of America 
(USA). Although complications resultant from otitis media are rare the 
economic costs are high [44].  
The pneumococcus is the most common cause of community-acquired 
pneumonia (CAP), and the clinical and economic burden of CAP is 
documented [45]. According to the WHO, pneumonia is the largest 
infectious cause of death in children worldwide, with high incidence in 
South Asia and sub-Saharan Africa countries [46]. 
Considering this scenario, it is urgent to circumvent pneumococcal 
disease. While antibiotic treatment is of key importance to fight 
pneumococcal disease, exclusive reliance on this strategy is not prudent 
and prevention is mandatory to minimise the disease burden. Currently, 
there are three pneumococcal conjugate vaccines (PCV) available for 
children (especially younger than 2 years). In 2000, a 7-valent vaccine 
(PCV7, Prevnar) was licensed, containing the 7 serotypes most 
commonly associated with IPD and antibiotic resistance in children of 
North America [29,47]. The immunization with PCV reduced the incidence 
of carriage and pneumococcal disease of vaccine serotypes among 
vaccinated children, but also reduced transmission, carriage and disease 
in non-vaccinated population (children and adults) – the herd effect 
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[29,48]. This indirect effect promoted a positive impact on public health 
systems and economy [48]. However, immunization with PCV accounted 
for replacement by non-vaccine serotypes (serotype replacement), 
contributing to a unaltered colonisation prevalence [48]. Moreover, an 
increase of drug resistant clones not included in PCV7 has also been 
reported [29,49]. Approximately nine years after the launch of PCV7, a 
10- and 13-valent PCV were licensed, PCV10 (Synflorix) and PCV13 
(Prevnar13), respectively, expanding the serotype coverage [47]. Despite 
the availability and positive impact of PCVs, only few countries with high 
incidence rates of pneumococcal disease have introduced the PCV in 
their immunization programmes [47,48]. Today PCV13 is recommended 
for children, and additionally some studies point towards the beneficial 
use of this vaccine for adults (reviewed in [45]). The use of PCV13 in 
adults older than 50 was approved by FDA in 2011 [45]. In a very recent 
study [50], the use of PCV13 was found to have an added benefit in 
diminishing carriage of antibiotic-nonsusceptible S. pneumoniae over 
PCV7, in infants.  
The 23-valent pneumococcal polysaccharide vaccine (PPV), which 
includes the main serotypes that have developed antibiotic resistance and 
causative agents of IPD, is commonly used in adults [29]. This vaccine 
has cross-reactivity with serotypes not included in PPV and therefore 
potentially protects against more than 23 serotypes [51].  
The development of protein-based vaccines has emerged as an 
alternative to the currently available vaccines (reviewed in [45]). Currently, 
a number of these protein based vaccines are in clinical trial phase I [45]. 
These products are based in pneumococcal surface proteins (e.g. 
pneumolysin, autolysin) and are expected to be cheaper, elicit protection 
in all age groups in a serotype-independent way [33]. 
Despite the intrinsic limitations of vaccines (e.g. number of serotypes 
coverage, costs, serotype replacement), it was estimated that 
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pneumococcal vaccination could prevent more than 7 million deaths by 
2030 at a global scale [52]. 
 
Transition from colonisation to disease 
While the exact circumstances that trigger the transition from 
colonisation to disease are still largely unknown, it is surely a multifactorial 
event that results from an imbalance of the equilibrium between the host, 
the pathogen and the other niche residents. Pneumococcal disease starts 
with a successful colonisation, which relies on the adherence of the 
pneumococcus to host structures, the ability to acquire nutrients in 
fluctuating conditions to replicate, compete with co-colonisers (e.g. resist 
to toxic molecules such as bacteriocins produced by other 
microorganisms) and evasion from the host immune system (innate or 
acquired immunity) [42,53]. Several experimental animal models of 
pneumococcal colonisation and disease have been used to study different 
aspects of host-pathogen interactions (e.g. inflammatory host responses, 
bacterial virulence factors) (reviewed in [16,30,54]). 
During colonisation the expression of specific pneumococcal genes 
contributes to its commensal lifestyle and persistence in the airways but, 
simultaneously, might influence the virulence potential of this 
microorganism. Indeed, virulence can only be seen in the context of host-
pathogen interactions, as it is an outcome of these relations [55]. Since 
nasopharynx provides a suitable environment for pneumococcal growth 
and proliferation it is likely that disease is accidental as it can result in a 
dead end for the microorganism. Therefore, some of the virulence factors 
promote pneumococcal lifestyle and for that reason are also considered 
colonisation determinants [34,56]. 
In the following section the classical factors of pneumococcal virulence 





The pneumococcal capsule is recognized as a major virulence factor. 
The polysaccharide capsule produced by S. pneumoniae is protective 
against host defences. This structure is covalently linked to the outer 
surface of the cell wall peptidoglycan and is, in general, negatively 
charged [30]. At first, capsule prevents the entrapment in the airway 
mucus to allow subsequence access to epithelial surfaces [57]. However, 
once in this surface, capsule seems to be disadvantageous because it 
masks pneumococcal molecules that recognize host receptors. 
Therefore, the pneumococcus spontaneously undergoes a phase 
variation phenotype between two forms distinguishable by different colony 
morphologies: opaque and transparent [58]. In the initial stages of 
colonisation transparent variants express a thinner capsule promoting 
adherence to host tissues by expressing higher amounts of surface-
exposed proteins. In contrast to opaque variants which display increased 
amounts of capsule that mask pneumococcal molecules recognizing host 
receptors. These variants are usually isolated from the blood, indicating 
that are selected to cross the epithelial barriers [56,59–62]. Part of this 
peculiarity is due to enhanced opsonophagocytic resistance [63]. Indeed, 
the capsule is highly anti-phagocytic [64], preventing antibodies (e.g. Fc 
of IgG) and complement (e.g. iC3b component) associated with bacterial 
cell surfaces, from interacting with the correspondent receptors on the 
phagocytic cells [65,66]. Moreover, capsule diminishes the spontaneous 
or antibiotic-induced autolysis contributing to antibiotic tolerance and has 
been associated with reduction of natural competence [30,67–69]. 
Capsule is regarded as a sine qua non factor for virulence, as clinical 
isolates from sterile areas of humans are encapsulated whereas non-
encapsulated derivatives are largely non-virulent [30,70]. Strains with 
reduced expression of capsule were avirulent in mouse models of disease 
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[71]. Furthermore, the capsular thickness and serotype are associated 
with different degrees of virulence [64,72]. In summary, the capsule allows 
S. pneumoniae to evade the host immune system during inflammation 
and “invade” the host [56].  
Besides the polysaccharide capsule, S. pneumoniae possesses an 
incredible array of surface-exposed proteins that enable adherence in 
various degrees to host structures (glycoconjugates), either directly or by 
modulating the functional properties of other pneumococcal proteins, and 
thus influencing the colonisation and invasive effectiveness of this 
microorganism (reviewed in [57]).  
Three main clusters of surface-exposed proteins were identified in S. 
pneumoniae: 1) proteins carrying a LPxTG motif covalently linked to the 
cell wall peptidoglycan, 2) the lipoproteins, embedded in the 
phospholipidic bilayer and 3) choline-binding proteins (CBPs), non-
covalently linked to phosphorylcholine (ChoP) of the cell wall and to lipid-
anchored teichoic acids [14,62,73]. Besides this classification, the cell wall 
is decorated with other proteins that do not fulfil these features 
(moonlighting proteins) [62,73] (Fig. 1.2).  
The LPxTG-anchored proteins encompass a variety of glycosidases 
(e.g. neuraminidase (NanA), β-galactosidase (BgaA), β-N-
acetylglucosaminidase (StrH), pullulanase (SpuA), endo-β-N-
acetylglucosaminidase (EndoD), endo-α-N-acetylgalactosaminidase 






Figure 1.2. Schematic representation of pneumococcal virulence factors. 
Abbreviations: NanA, neuraminidase A; StrH, β-N-acetylglucosaminidase; BgaA, β-
galactosidase; Eng, endo-α-N-acetylgalactosaminidase; Hyl, hyaluronate lyase; Eno, 
enolase; PavA, pneumococcal adherence and virulence factor A; GAPDH, glyceraldehyde 
3-phosphate dehydrogenase; SpxB, pyruvate oxidase; Ply, pneumolysin; LytA, autolysin; 
LytC, 1,4-β-N-acetylmuramidase; LytB, endo-β-N-acetylglucosamidase; CbpE, choline-
binding protein E; PspC, pneumococcal surface protein C; PspA, pneumococcal surface 
protein A; PiaA, pneumococcal iron acquisition A, PiuA, pneumococcal iron uptake A, 
PsaA, pneumococcal surface antigen A, H2O2, hydrogen peroxide (adapted from Kadioglu 
et al. [30]). 
 
Adherence of the pneumococcus appears to occur through binding to 
human glycoconjugates [74]. Pneumococcal glycosidases might be 
implicated in such process [75]. At least 10 extracellular exoglycosidases 
have already been identified in S. pneumoniae with different specificities 
for sugar structures present in human airways. Their activity contribute in 
different ways to the lifestyle of the pneumococcus and has broad 
implications in colonisation and the virulence potential of the bacterium 
(reviewed in King [75]). For example, the sequential cleaving activity of 
terminal sugars from human glycoconjugates by NanA, BgaA and StrH 
results in reduction of mucus viscosity, reveals receptors for adherence, 









































opsonophagocytosis by neutrophils [75–77]. Recently, BgaA was found 
to work as an adhesin promoting adherence to epithelial cells [78]. 
Another glycosidase, hyaluronidase (Hyl), acts over hyaluronic acid of the 
extracellular matrix, and is believed to assist in dissemination through 
tissues and colonisation [79,80] (Fig. 1.2).  
The exact role of the serine protease, PrtA, in virulence is still unknown, 
but PrtA-deficient mutants were attenuated in a murine model of disease 
and all clinical isolates possessed this protein [81].  
Among the lipoproteins identified (listed in [14]), PsaA (pneumococcal 
surface antigen A) is the substrate-binding lipoprotein of an ABC 
transporter for manganese. Mutations in this protein caused reduced 
adhesion and virulence and increased sensitivity to oxidative stress 
[82,83]. Other metal-binding lipoproteins (PiuA and PiaA) were identified 
to play role in virulence [30]. 
ChoP is an uncharacteristic component of cell wall that binds to host 
innate immune system components such as receptor for platelet-
activating factor (rPAF) of human epithelial surfaces of nasopharynx and 
C-reactive protein [30,73]. ChoP anchors a diversity of CBPs (listed in 
[14]). Among these are the hydrolytic enzymes autolysin LytA, endo-β-N-
acetylglucosamidase LytB, 1,4-β-N-acetylmuramidase LytC and CbpE. 
LytA degrades the cell wall, leading to the release of highly inflammatory 
cell wall components, and pneumolysin (Ply) from the cytoplasm 
(reviewed in [30,82,84]). Mutants in the CBPs LytB, LytC, CbpE, CbpD 
and CpbG  were attenuated in colonisation models and CpbG also played 
a role in sepsis [85]. Other members of CBP family are the pneumococcal 
surface proteins A (PspA) and C (PspC, also known as CbpA or SpsA). 
PspA interferes with complement activation, preventing binding of C3 
component on pneumococcal cells, and also binds to lactoferrin and 
apolactoferrin protecting the bacterium from the bactericidal activity of 
these molecules. Additionally, PspA has high immunogenicity and elicits 
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antibody response that increase complement deposition, conferring 
protection in diverse models of pneumococcal infection. PspC acts as an 
adhesin and binds to the complement regulatory protein factor H and to 
the human secretory IgA receptor, providing resistance to complement. 
PspC mutants presented attenuated virulence in different models of 
infection. Both PspA and PspC, are considered good candidates for 
protein-based vaccines (reviewed by Nieto et al., 2013 [84] and by 
Kadioglu et al. [30]). 
S. pneumoniae also have other surface proteins, lacking conventional 
anchoring motifs or secretory signals (reviewed in [14]). These “non-
classical surface proteins” display moonlighting functions. They are 
usually cytoplasmic with intracellular roles but when they reach the cell 
surface have other functions. Among these are, the pneumococcal 
adherence and virulence factor A (PavA) and the glycolytic enzymes 
enolase (Eno) and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). PavA is an adhesin that binds to fibronectin, a component of 
the extracellular matrix. PavA mutants were attenuated in diverse models 
of pneumococcal disease and therefore is considered a crucial virulence 
factor [86,87]. Eno and GAPDH are plasmin(ogen)-binding proteins that 
allow transmigration through the basement membrane. Interaction of Eno 
with plasminogen was found to promote adherence in epithelial and 
endothelial cells [88–91].  
Pneumolysin (Ply) is a potent virulence factor of S. pneumoniae which 
has been extensively studied (reviewed in [30,82]). It is a cytoplasmic pore 
forming toxin of the  cholesterol-dependent cytolysins [30], released 
independently of autolysin activity [92]. Its high toxicity arises from the 
ability to bind host cholesterol, thereby leading to the formation of pores 
and subsequent lysis of mammalian cells. Ply also inhibits the mucociliary 
beat of respiratory epithelium and complement deposition in 
pneumococcal surface [93,94]. Ply is presumably essential for the 
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development of pneumonia, as mutants lacking Ply were attenuated in 
models of pneumococcal pneumoniae [30] (Fig. 1.2).  
Other aspect influencing the pneumococcal virulence potential is the 
competitive interactions with other microorganisms occupying the same 
niche during colonisation. Pneumococci produce bacteriocins 
(pneumocins), small antimicrobial peptides to target other bacteria from 
the same or closely species that do not produce the cognate immunity 
factor. This phenomenon has been  hypothesised as the mechanism 
behind serotype replacement due to PCV administration [95]. Chemical 
warfare is also thought to contribute to the virulence potential. S. 
pneumoniae can produce a range of end-products, among them hydrogen 
peroxide (H2O2). This metabolite, produced by pyruvate oxidase (SpxB) 
as a by-product of pyruvate aerobic metabolism, is known to damage host 
tissues and to kill other organisms in the same niche [96–98]. The high 
insensitivity of S. pneumoniae to H2O2 is well described [99]. In sum, the 
vast diversity of pneumococcal virulence factors endows the bacterium 
with an “armory” to survive in the host and compete with other bacteria.  
 
Virulence and carbohydrate metabolism 
Several studies, using signature target mutagenesis (STM) [100–102], 
microarrays analysis of gene expression [103–106], and Tn-seq [107] 
have consistently revealed a link between carbohydrate metabolism and 
virulence of S. pneumoniae. Importantly these studies have shown the 
dynamics and pattern of gene expression in different stages of 
pneumococcal infection, providing a means to evaluate the role of 
different genes in colonisation and disease. Carbohydrate uptake systems 
(e.g. msmK, satABC, SPD_0295-6-7, scrT, susT1T2X) [108–111] and 
glycosidases (e.g. nanA, nanB, eng, bgaC)  [112–117] were established  
as important for in vivo fitness of S. pneumoniae by testing mutants of 
these proteins in different mouse models. Moreover, in addition to Eno 
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and GAPDH, other central metabolic functions such as pyruvate formate-
lyase (PFL) [118], lactate dehydrogenase (LDH) [119], pyruvate oxidase 
(SpxB) [120], have been associated with pathogenicity, as mutant strains 
were attenuated or avirulent in the ability to colonise or cause disease in 
different mouse models (Fig. 1.3). The PFL mutant phenotype likely 
resulted from reduced synthesis of ATP and alterations of membrane lipid 
composition [118]. A LDH-deficient mutant was avirulent after intravenous 
inoculation and attenuated post intranasal infection. These features were 
explained as arising from the different environmental conditions 
(carbohydrate availability) encountered in the two niches [119]. SpxB was 
found important in adaptation to different host environments. It enhances 
colonisation by competing with other host co-colonisers through H2O2 
production or biofilm formation. In contrast its role in virulence is still 
controversial. Some studies showed that downregulation of spxB is 
beneficial for survival in the bloodstream, but this  behaviour is in 
contradiction to the study by Spellerberg et al., [120] that attributed the 
virulence of an SpxB mutant to reduced acetyl-P levels and repression of 
several adhesive properties (reviewed in [121]). More recently, a relation 
between  SpxB expression and capsule production (the major virulence 




Figure 1.3. Schematic representation of sugar transporters and central carbon 
metabolism highlighting proteins implied in virulence of S. pneumoniae, as 
assessed by in vivo studies (except for Eno and GAPDH). 
Reactions are catalysed by the following protein encoding genes: gki, glucokinase; pgi, 
glucose 6-phosphate isomerase; pfkA, 6-phosphofructokinase; fba, fructose-biphosphate 
aldolase; tpiA, triosephosphate isomerase; gap, glyceraldehyde 3-phosphate 
dehydrogenase; pgk, phosphoglycerate kinase; gpmA, phosphoglyceromutase; eno, 
enolase; pyk, pyruvate kinase; ldh, L-lactate dehydrogenase; spxB, pyruvate oxidase; lcto, 
lactate oxidase; pflB, pyruvate formate-lyase; pta, phosphotransacetylase; ackA, acetate 
kinase; adh, bifunctional acetaldehyde-coA/alcohol dehydrogenase (SPD_1834). 
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Intermediates: G6P, glucose 6-phosphate; F6P, fructose 6-phosphate; FBP, fructose 1,6-
biphosphate; GAP, glyceraldehyde 3-phosphate;  DHAP, dihydroxyacetone phosphate; 
BPG, 1,3-biphosphoglycerate; 3-PGA, 3-phosphoglycerate; 2-PGA, 2-phosphoglycerate; 
PEP, phosphoenolpyruvate. 
 
In Gram-positive bacteria, the transcriptional regulator carbon 
catabolite protein A (CcpA) plays a major role in carbon catabolite control, 
i.e., the hierarchical and highly regulated utilization of carbon sources 
[122]. CcpA has been reported to contribute to pneumococcal colonisation 
and virulence [123,124]. The involvement of CcpA has been rationalized 
as a consequence of regulation of enzymes of central metabolism, 
impaired capsule production and/or attachment to the cell envelope, and 
influencing the binding of cell wall components [123–125]. 
 
Glycans at the interface of bacteria-host interactions  
Glycoconjugates are widespread in nature and encompass a wide 
variety of molecules consisting of carbohydrates covalently linked to a 
non-sugar backbone. The principal categories are glycoproteins (N- or O-
linked to a protein core) and glycopeptides (linked to an oligopeptide), 
peptidoglycans (bound to amino acids), glycolipids and 
lipopolysaccharides (linked to a lipid moiety) [126]. Despite the vast 
diversity of host glyconjugates, their glycan portions are often composed 
of the monosaccharides N-acetylglucosamine (GlcNAc), N-
acetylgalactosamine (GalNAc), N-acetylneuraminic acid (NeuNAc), 
galactose (Gal) and fucose (Fuc), mannose (Man), glucose (Glc) and 
fructose. While the first five sugars are widespread in both N- and O-
glycans (e.g. mucins), the other three are generally restricted to N-
glycans.   
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These molecules contribute to important biological functions in different 
kingdoms of life (reviewed in [127,128]). The bacterial glycome (e.g. 
capsule, exopolysaccharides, lipolysaccharides, peptidoglycan, teichoic 
acids and lipoteichoic acids) is far more diverse than that of animals and 
is usually located at the cell surface (exception polysaccharides used as 
energy reserves). As many bacteria (commensal or pathogens) reside in 
mucosal surfaces, the glycoconjugates on the cell envelope play 
important roles in bacteria-host interactions [128]. From the bacteria 
perspective these molecules are highly important for in vivo fitness. On 
the other hand, in animals, and particularly in humans, a glycoconjugate 
barrier often prevents direct contact between bacteria and host cells. 
Among these, mucins are highly important in the mucosal surfaces (e.g. 
respiratory, gastrointestinal tracts). Mucins are major components of the 
mucus that cover the epithelial surfaces [129]. They are high molecular 
weight glycoproteins, heavily O-glycosylated [130,131], composed of a 
protein backbone enriched with threonine or serine (apomucin) containing 
one or multiple tandem repeats (TR) to which a diversity of 
oligosaccharides are linked via a GalNAc residue [129–131]. The 
structure and composition of oligosaccharides in mucins are varied; 
generally, the carbohydrate fraction is composed of GlcNAc, GalNAc, 
NeuNAc, Gal, Fuc and sulphated sugars. Sulphation confers protection to 
the epithelium as it increases resistance against mucin-degrading 
enzymes [131]. N-glycosylation is also found on mucins but it is a small 
contribution to the mucins molecular size when compared to the O-
glycosylation [131]. The oligosaccharide content of mucins can reach up 
to 80% of their total weight [130]. Mucins are produced by eukaryotic cells 
and can be cell surface associated or secreted (gel-forming or non-gel 
forming). Gel-forming mucins, are the major constituents of mucus and 
confer viscoelastic properties [130,132]. 
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Mucus and mucins have a dualistic role. On one hand represent a first 
defence barrier (innate defensive barrier) by trapping the microbes and 
protecting the underlying host surfaces from interaction with bacteria, 
facilitating their removal through mucociliary transport. On the other hand, 
the carbohydrate content of mucins provide adhesion sites and nutrients 
for bacteria enabling their survival and colonisation at these surfaces 
[130,131]. 
Interactions between mucin and microbes are broad in nature. For 
example, expression of mucin can be induced by probiotic bacteria, likely 
limiting the infection by pathogens [133]; the lipopolysaccharides of 
Helicobacter pylori, decrease mucin synthesis in gastric epithelial cells in 
vitro, modulating the mucus barrier [134]; Bacteroides thetaiotaomicron 
induces fucosylation of mucin oligosaccharides, subsequently using 
fucose as nutrient [135]. Also, microbes have developed strategies to 
overcome this barrier: adhesins to bind oligosaccharides (H. pylori, 
possesses four adhesins with different specificities) [136]; motility 
(flagella) or production of mucin degrading enzymes (proteases and 
glycosidases) that destabilize mucus and release carbohydrates that can 
be used for growth [75,137,138].  
 
Pneumococcal carbohydrate metabolism  
Carbohydrate metabolism and its importance for 
pneumococcal lifestyle 
The incidence and impact of pneumococcal infections have prompt 
intense research on the identification of factors that contribute to S. 
pneumoniae pathogenesis. In particular, factors that directly impinge on 
host-pathogen interactions, such as toxins, cell wall components, 
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adhesins and capsule [30]. Even though the relevance of carbohydrate 
metabolism has been recognized for in vivo fitness, only recently the 
underlying mechanisms have been systematically addressed [109–
111,118,125]. With the availability of the pneumococcal genome the 
relevance of carbohydrates for pneumococcal fitness became apparent 
[139]. S. pneumoniae is a strictly fermentative bacterium that relies on 
glycolytic metabolism to obtain energy [139]. It lacks a complete set of 
respiratory genes and is, for that reason, unable to generate energy by 
respiration [139,140]. Among the bacteria sharing the same niche, S. 
pneumoniae possesses the highest number of transport systems, and of 
those more than 30% were predicted to be involved in the uptake of 
sugars [140]. A recent  functional genomics approach validated the 
majority of the homology based predictions, and identified 32 
carbohydrates that can be used by pneumococci [141]. It has been 
postulated that the vast diversity in terms of sugar utilization is driven by 
adaptations to host niches as a means to proliferate [142–144]. 
Additionally, it has been reported that sugar transporters contribute to S. 
pneumoniae colonisation and disease [103,109–111]. Furthermore, 
numerous studies have revealed a consistent link between genes 
involved in sugar catabolism and virulence [100–102,105–107,145]. 
In the human airway free carbohydrates are scarce, being the Glc 
concentration below 1 mM, in contrast to its content in blood (~4-6 mM) 
[145,146]. Hexoses, and in particular Glc, are generally the preferred 
carbon sources for several bacteria and the same seems to be true for 
the pneumococcus [125,141]. Therefore, in vivo growth in the 
nasopharynx requires alternative carbon sources. The host glycoproteins 
(O- and N-linked glycans, and glycosaminoglycans), secreted or lining the 
epithelial surfaces appear as good candidates to serve as carbon and 
energy sources for pneumococcal growth. S. pneumoniae can grow on 
each of the former glycan types as sole carbon source [75,110,147,148]. 
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Furthermore, it is able to grow on mucin as the sole carbon source [147]. 
In addition to mucins and other glycans, carbohydrates might also be 
provided by the host diet and other microbial residents of the same niche 
[143].  
S. pneumoniae is equipped with at least 10 extracellular (exo- or endo) 
glycosidases with a broad range of specificities (reviewed by King [75]). 
These enzymes can break down O-linked glycans (e.g. BgaC, Eng) [114–
116], N-linked glycans (e.g. NanA, StrH, BgaA, NanB) [77,148], and 
glycosaminoglycans (hyaluronic acid)  (e.g. Hyl) [110], providing free 
sugars that can potentially be used by the pneumococcus to grow 
[110,148].  
 
Sugar transport systems in S. pneumoniae  
Sugar transport across the membrane is the first step in catabolism. In 
Streptococcaceae there are three types of transport systems: the 
secondary carriers, the primary active transporters ATP-binding cassette 
superfamily (ABC transporters) and the phosphoenolpyruvate-dependent 
carbohydrate phosphotransferase systems (PTS systems) (Fig. 1.4). 
Secondary carriers couple the translocation of the carbohydrate to an 
electrochemical gradient and comprise symporters (a carbohydrate is 
imported together with a solute), antiporters (carbohydrate and solute are 
transported in opposite directions) and uniporters (catalyse the 
unidirectional translocation of the sugar across the cytoplasmic 
membrane) [149]. 
ABC transporters take up carbohydrate at the expense of ATP, which 




Figure 1.4. Schematic representation of sugar transport systems in S. pneumoniae. 
Abbreviations: A, general solute; SBP, solute-binding protein; NBD, nucleotide-binding 
domains; TMD, transmembrane domains; ABC,  ATP-Binding Cassette transporter; PEP, 
phosphoenolpyruvate; PTS, phosphoenolpyruvate-dependent-carbohydrate 
phosphotransferase systems; EI, enzyme I and HPr, histidine phosphocarrier protein are 
general components of the PTS system; IIAB cytoplasmic proteins and IICD, 
transmembrane domains of the PTS system. The occurrence of IID component is typical 
of mannose type-PTS transporter. P~ corresponds to the phosphorylated form of each 
component.  
 
In general, an ABC is composed of four core domains: two 
transmembrane domains (TMD) spanning in the membrane, forming the 
pathway of entry of the solute and defining the specificity of the transporter 
through the substrate-binding site and two ATP- or nucleotide-binding 
domains (NBD) associated with the inner face of the membrane, that 
energize the transport via ATP hydrolysis. ABC importers require auxiliary 
proteins, the solute-binding proteins (SBP), anchored outside the cell via 
lipid groups, that confer high affinity, specificity and directionality to the 
transporter [151].  
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In S. pneumoniae there are 1 CUT2 family ABC transporter and 6-7 
CUT1 ABC transporters, differing in the nature of the substrate and 
structure. Each locus of the CUT1 family ABC transporter lacks the 
predicted ATPase [141]. Recently, a single ATPase (MsmK), was found 
to energize multiple carbohydrate ABC transporters, that are involved in 
the uptake of sialic acid, raffinose and maltotetraose [108].  
The PTS system involves uptake and concomitant phosphorylation of 
the incoming sugar via a phosphorylation cascade that transfers a 
phosphate group from PEP. It consists of a series of cytoplasmic and 
membrane-bound proteins [152]. The PTS permeases (EII complexes), 
generally comprise 3 or 4 domains (the cytoplasmic subunits IIA, IIB and 
membrane-bound subunits IIC, IID) arranged in different ways, which 
allow the transport and phosphorylation of the substrate. While IIAB 
domains participate in the phosphorylation of the substrate, IICD 
correspond to the membrane permeases. The PTS is also composed by 
two PTS energy-coupling proteins, Enzyme I (EI) and the heat stable 
histidine phosphocarrier protein HPr, encoded by ptsI and ptsH, 
respectively. While the EII subunits are usually substrate-specific, the EI 
and HPr are common to all PTS carbohydrates and therefore 
denominated general proteins [153,154]. PTS systems are energetically 
more favourable since transport and phosphorylation occurs in one step 
spending a PEP molecule instead of ATP. PEP is energetically equivalent 
to one molecule of ATP as one ATP is formed from PEP to pyruvate in 
glycolysis. In non-PTS systems more ATP is expended in both processes. 
This likely explains the high number of these systems in anaerobic 
bacteria [154].  
In S. pneumoniae,  the functional genomics approach conducted by 
Bidossi et al. [141], identified twenty-one PTS systems, six to seven CUT1 
ABC transporters, one CUT2 ABC transporter, one sodium solute 
symporter and three aquaporin/glycerol permeases potentially involved in 
General introduction 
27 
carbohydrate uptake. The total number of transporters varies with the 
strain [141]. At the time, only a few transporters (beta-glucosides, 
sucrose, sialic acid, maltose and raffinose) had been partially 
characterized in S. pneumoniae [141]. Thirty-two carbohydrates can be 
metabolized by the pneumococcus. Some of these were internalized by 
more than one transporter and the same transporter could take up 
different sugars [141]. Even though the complement of transporters is well 
covered in Bidossi et al. [141], the specificity for substrates is only fully 
elucidated for a reduced number of transport systems. More in-depth 
studies combining biochemical and genetic approaches are needed to 
establish the specificity range of pneumococcal transport systems.  
 
Glycan-derived monosaccharides: pathways and functions 
In this section, catabolic pathways for the assimilation of selected 
carbohydrates, i.e. monosaccharides present in host glycans, will be 
described. The focus will be on S. pneumoniae and closely related 
organisms, but alternative pathways in other bacteria are also presented.  
In S. pneumoniae the pathways for the catabolism of monosaccharides 
can be deduced from genome annotations, but their functionality remains 
largely to be proven. In this work we focused on the six carbohydrates 
constituents of the highly available glycoprotein, mucin. 
Galactose 
Galactose is abundant in the airway glycoconjugates (e.g. mucins) 
[116]. Available as a monosaccharide through the action of pneumococcal 
galactosidases (BgaA, BgaC) [77,115,116,155].  However, it is usually 
regarded as a less efficiently metabolized sugar and the type of transport 
system dictates, at some extent, the catabolic pathway to be followed. It 
has been postulated that its efficient uptake could determine the outcome 





In several Streptococcaceae, metabolism by the Leloir pathway is 
preceded by the entry of Gal in the cell through the secondary carrier 
galactose permease (GalP) [158–160]. However, homologues of this 
protein were not found in the pneumococcus. Recently, Bidossi et al. 
[141], implicated the CUT1-family ABC transporter SPD_0088-9-0 in the 
uptake of Gal, but the evidence presented was relatively weak, since 
inactivation of the transporter resulted in a very mild reduction in Gal 
utilization. Possible explanations can be that the inactivation of the ABC 
transporter is masked by the activity of other transporters or Gal is 
exclusively taken up via PTS-type transporters. 
Metabolism of Gal via tagatose 6-phosphate (T6P) pathway is 
preceded by transport via a PTS system. In other Streptococcaceae it 
occurs through a lactose-specific PTS (PTSlac), encoded by lacFE genes, 
albeit with a low efficiency [161–164]. In S. pneumoniae, duplication of 
lacFE genes appears to have occurred, but the involvement of these 
transporters is not yet disclosed. Nevertheless, our team showed that 
lacFE genes were induced by Gal, suggesting a potential contribution of 
the lactose-PTS to the uptake of the sugar [125]. Transport of Gal by a 
PTS complex other than PTSlac  was proposed for Lactococcus lactis, 
Streptococcus mutans, Streptococcus gordonii and Streptococcus 
oligofermentans (e.g. galactose-specific PTS and/or PTSMan) 
[156,157,163,165,166]. 
In the pneumococcus Gal uptake was attributed to the galactitol-PTS 
SPD_0559-1 [141,167]. This seems to be the major Gal uptake system 
[141]. Two additional PTS systems were then allocated to Gal, the 
mannose-family PTS (ManMNL) and probably a mannose-family PTS 
(SPD_0066-7-8-9) [141]. The latter, was assigned based on the presence 




In S. pneumoniae genes for the catabolism of Gal through the T6P and 
Leloir pathways are encoded in the genome (Fig. 1.5). The product of PTS 
transport, galactose 6-phosphate (Gal6P), is metabolized by the T6P 
pathway. Briefly, Gal6P is converted to tagatose 6-phosphate (T6P), by 
the heteromeric galactose-6-phosphate isomerase (LacAB), which is 
subsequently converted to tagatose 1,6-biphosphate (TBP) by tagatose 
6-phosphate kinase (LacC) and finally to the glycolytic intermediates 
glyceraldehyde 3-phosphate (GAP) and dihydroxyacetone phosphate 
(DHAP) by the tagatose 1,6-diphosphate aldolase (LacD). The non-PTS 
transport leads the incoming Gal to the Leloir pathway, in which Gal is 
phosphorylated to α-galactose 1-phosphate (α-Gal1P) through the 
sequential activity of galactose mutarotase (GalM) and galactokinase 
(GalK). Through the galactose 1-phosphate uridylyltransferase 
(GalT)/UDP-glucose 4-epimerase (GalE) activities α-Gal1P is then 
converted to α-glucose 1-phosphate  (α-G1P), which is then  converted to 
glucose 6-phosphate (G6P) by the phosphoglucomutase (PGM), thus 
entering in the Embden-Meyerhof-Parnas (EMP) pathway.  
Interestingly, in L. lactis and S. mutans a phosphatase that converts 
the PTS product, Gal6P to Gal, allowing its processing through the Leloir 
has been described, but its identity remains elusive [163,165] (Fig. 1.5). 
In contrast to L. lactis, S. mutans apparently does not possess 
homologues of galP and galM and therefore Gal enters the exclusively via 
PTS [163]. 
In S. pneumoniae, both pathways seem to be simultaneous active 
[125], but the relative contribution of each and conditions that trigger the 
prevalence of one pathway over the other remains to be elucidated.   
In S. mutans, S. oligofermentans and S. gordonii both pathways are 
present but T6P seems to be the preponderant route for Gal catabolism 
[156,163,166]. In contrast, in the dairy bacterium L. lactis this feature 
seems to be strain dependent [165]. While laboratorial strains possess the 
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Leloir, dairy strains have and express both pathways [165]. Other 
microorganisms possess only one pathway. Streptococcus salivarius 
uses Gal exclusively via the Leloir, because it lacks a galactose-lactose 
PTS and therefore Gal likely enters through a symport-driven permease, 
whereas Streptococcus thermophilus does not grow on Gal unless GalK 
is expressed in sufficient amounts [168,169].  
 
 
Figure 1.5. Schematic representation of pathways for the dissimilation of galactose 
(Gal) in bacteria. 
Reactions are catalysed by the following protein encoding genes: galM, galactose 
mutarotase; galK, galactokinase; galT, galactose 1-phosphate uridylyltransferase; galE, 
UDP-glucose 4-epimerase; pgm, phosphoglucomutase; lacA, galactose 6-phosphate 
isomerase subunit LacA; lacB, galactose 6-phosphate isomerase subunit LacB; lacC, 
tagatose 6-phosphate kinase; lacD, tagatose 1,6-diphosphate aldolase; pgi, glucose 6-
phosphate isomerase; pfkA, 6-phosphofructokinase; fba, fructose-biphosphate aldolase; 
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tpiA, triosephosphate isomerase. The lower glycolytic pathway is represented by a dashed 
arrow. 
Intermediates: Gal, galactose; α-Gal, α-galactose; α-Gal1P, α-galactose 1-phosphate; α-
G1P, α-glucose 1-phosphate; UDP-Glc, UDP-glucose; UDP-Gal, UDP-galactose; Gal6P, 
galactose 6-phosphate; T6P, tagatose 6-phosphate; TBP, tagatose 1,6-diphosphate; G6P, 
glucose 6-phosphate; F6P, fructose 6-phosphate; FBP, fructose 1,6-biphosphate; GAP, 
glyceraldehyde 3-phosphate;  DHAP, dihydroxyacetone phosphate. 
In rose are depicted the intermediates and genes committed specifically to galactose 
catabolism. 
For the sake of simplicity transporters other than PTS are designated generically as non-
PTS. 
 
While the necessary genes for T6P pathway (lacABCD) are organized 
in one operon the Leloir genes are dispersed in the pneumococcal 
genome. The organization of Leloir genes seems to be species-specific 
probably reflecting the genomic plasticity among LAB [170,171]. Various 
combinations of the gal and lac genes have been reported among 
streptococci, lactococci and lactobacilli [166]. 
 
Mannose 
Mannose is the major component of N-glycans [172]. High-mannose-
type glycoproteins are present in host tissues and are components of the 
extracellular matrix (e.g. laminin) [173]. Mannosidase activity over 
glycoconjugates has been reported in  viridans group streptococci and in 
particular in S. pneumoniae [173]. The exact role of these enzymes has 
not yet been determined but it is possible that their action provides 
substrates for growth. In contradiction  S. pneumoniae, but not S. mitis 
and S. oralis, expose mannose residues of host glycoproteins defence 
molecules, through the sequential action of NanA, BgaA and StrH, that 
bind pneumococcus and protect the airway, likely allowing its persistence 
in the nasopharynx [77]. According to King et al. [77]., the lack of further 
deglycosylation through mannosidase is likely due to the of low efficiency 
(activity) of this enzyme, it is only present in some isolates or is not 
expressed under the conditions used where other sugars were present.  
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Man metabolism also provides the phosphorylated  intermediate 
mannose 6-phosphate (Man6P), which is a precursor of GDP-mannose, 
important for biosynthesis of glycosylated components of cell wall in 
several microorganisms [174]. 
 
Mannose catabolism 
In S. pneumoniae Man likely enters into the cell via a PTS system and 
the resultant Man6P is converted to fructose 6-phosphate (F6P) by the 
mannose 6-phosphate isomerase (ManA) (Fig. 1.6), in a pathway similar 
to that described in E. coli [175,176]. Two PTSs (Man-PTS and Lac-PTS, 
the latter with a very mild phenotype) were identified as putative Man 
uptake systems [141]. The involvement of other PTSs (fructose-PTS) has 
been reported for other bacteria [174,177–179]. Whether this is true for S. 
pneumoniae remains to be elucidated. Nevertheless, the existence of 
non-PTS transporters for Man uptake cannot be excluded [141]. 
Man catabolism has been studied in Escherichia coli [175,176]. More 
recently, the same pathway was characterized in the gram-positive 
bacteria Corynebacterium glutamicum and Bacillus subtilis [174,180]. In 
these microorganisms, mannose 6-phosphate isomerase was essential 
for growth on mannose as sole carbon source. 
Different types (based on amino acid sequence similarity and domain 
organization) of this enzyme were described in Xanthomonas campestris 
and Rhizobium  meliloti [181,182]. In these microorganisms deletion of 
ManA did not hamper growth on Man. In R. meliloti a different Man 
catabolic route was proposed involving active transport of Man (whether 
is mediated by an ABC or by a secondary carrier was not disclosed), 
subsequent phosphorylation by mannokinase and isomerization to F6P 





Figure 1.6. Schematic representation of pathways for the dissimilation of mannose 
(Man) in bacteria. 
Reactions are catalysed by the following protein encoding genes: manA, mannose 6-
phosphate isomerase; manK, mannose kinase; pfkA, 6-phosphofructokinase; fba, 
fructose-biphosphate aldolase; tpiA, triosephosphate isomerase. The lower glycolytic 
pathway is represented by a dashed arrow. 
Intermediates: Man6P, mannose 6-phosphate; F6P, fructose 6-phosphate; FBP, fructose 
1,6-biphosphate; GAP, glyceraldehyde 3-phosphate;  DHAP, dihydroxyacetone 
phosphate. 
In blue are depicted the intermediates and genes committed specifically to mannose 
catabolism. 
 
Recently, two loci for mannoside catabolism were predicted in two 
species of Shewanella. These pathways are different from that descried 
in E. coli and its experimental validation is required [184]. According to 




Amino sugars: N-acetylneuraminic acid, N-
acetylglucosamine and N-acetylgalactosamine 
The amino sugars NeuNAc, GlcNAc and GalNAc are valuable carbon 
and nitrogen sources for growth and are present in high content in mucins, 
as determined in the model glycoprotein, porcine gastric mucin: 30% 
(wt/v) GlcNAc, 15% (wt/v) GalNAc and 2.6% (wt/v) NeuNAc [116]. The 
presence of pneumococcal extracellular glycosidases, with specificity for 
GlcNAc (StrH) and NeuNAc (NanA and NanB) residues, contributing to 
growth on human glycoconjugates, further supports this claim [148,185–
187]. Besides the mucins, there are other glycan sources of these sugars. 
NeuNAc (or generically sialic acid) is copious as a terminal sugar of 
eukaryotic surface-exposed glycoconjugates but also in prokaryotes 
surfaces [188,189]. GlcNAc can be provided from host diet and 
secretions, as well as from peptidoglycan recycling (GlcNAc is a building 
block of this structure and also of lipopolysaccharides) and is present in 
the extracellular matrix of mammals and chito-oligosaccharides [190–
192]. GalNAc is widespread in host receptors and glycoconjugates and is 
a component of bacterial cell wall, lipopolysaccharides and 
exopolysaccharides [114,193,194]. 
Nevertheless, the importance of these sugars goes beyond their 
nutritional value. For instances, these sugars contribute to cell wall 
synthesis. More recently, NeuNAc was found to act as a signalling 
molecule in the pneumococcus, promoting increased colonisation, 
invasion of the host’s lower respiratory tract and biofilm formation in vitro 
[109,195,196]. In other pathogenic bacteria the presence of NeuNAc in 
the bacterial cell surfaces permits evasion from immune system (e.g. H. 
influenzae) and is important for interaction with host-cell surfaces 
(reviewed in [188]). 
Similarly, GlcNAc has been found to act as a signalling molecule in 
different kingdoms (reviewed in [190]). In bacteria GlcNAc ensures 
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regulation between its catabolism and anabolism ensuring the desired 
quantities of UDP-GlcNAc necessary for peptidoglycan synthesis. In E. 
coli it is responsible for regulation of virulence factors (e.g. fimbriae) and 
its catabolism is important for gut colonisation  ([197], reviewed in [190]). 
In soil bacteria, such as streptomycetes, it is involved in morphogenesis 
regulation namely sporulation and antibiotic production [198–200]. Under 
adverse conditions (famine) development (leading to sporulation) and 
antibiotic production are triggered whereas under feast periods these 
mechanisms are blocked [200]. In addition, the ubiquity of GlcNAc across 
kingdoms has revealed a multiplicity of interspecies communication 
mediated by this amino sugar (reviewed in [190]). 
Adherence of S. pneumoniae and other viridans group streptococci via 
carbohydrate-containing receptors of host glycoconjugates has been 
demonstrated [193,201,202]. GalNAc-containing receptors were 
identified as important for the pneumococcus adherence [203,204]. An O-
glycosidase, Eng, endo-α-N-acetylgalactosaminidase, with specificity for 
Galβ1-3GalNAc from core-1 O-linked glycans was characterized. In 
conjunction with NanA these glycosidases sequentially deglycosylate the 
sialylated core-1 O-linked glycans of glycoconjugates. Moreover, a role in 
colonisation of respiratory tract and adherence to human epithelial cells 
was established [114].  
GalNAc-sensitive coaggregations have also been shown between 
viridans group streptococci and between streptococci and actinomyces 
[193]. 
 
NeuNAc and GlcNAc catabolism 
In S. pneumoniae the transport of NeuNAc remains largely unknown, 
even though putative sugar transporters are annotated in nanA, nanB and 
nanC loci. In the nanAB locus two ABC transporters are encoded 
(SPD_1493-4-5 and SPD_1500-1-2) [205]. The first was recently 
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identified as the main NeuNAc transporter contributing to growth on a 
human glycoprotein and colonisation in vivo [109,141]. In this region a 
third transporter, Glc-PTS SPD_1496, was allocated to glucosamine 
[141]. A major facilitator superfamily (MFS) sodium solute symporter 
(SSS) (SP_1328) was identified, in some pneumococcal strains, in the 
nanC locus [141,188,206]. This region also comprises a neuraminidase 
(nanC), a kinase, a lyase and an epimerase [141]. D39 does not possess 
this locus and alternatively carries a putative oligopeptide ABC 
transporter, a mutarotase and an epimerase [141]. In opposition, the 
nanAB cluster is conserved and was proposed as the responsible for the 
uptake and metabolism of NeuNAc [141,205–208], but little is known 
about the nanC locus. A relation of nanC presence and invasive 
phenotypes in a tissue-specific manner was established and mutations in 
nanC locus did not influence the growth on NeuNAc [141,209]. 
There is a great diversity of NeuNAc transport systems widespread 
among bacteria and even in bacteria belonging to the same genus (e.g. 
genus Streptococcus) [206]. The first system to be studied in detail was 
in E. coli, the NanT, which is a single component system, secondary 





Figure 1.7. Schematic representation of pathways for the dissimilation of the amino 
sugars N-acetylglucosamine (GlcNAc), N-acetylneuraminic acid (NeuNAc) and N-
acetylgalactosamine (GalNAc) in bacteria. 
Reactions are catalysed by the following protein encoding genes: nanA, N-
acetylneuraminate lyase; nanK, N-acetylmannosamine kinase; nanE, N-
acetylmannosamine 6-phosphate epimerase; rokA,  hexokinase; nagA, N-
acetylglucosamine 6-phosphate deacetylase; nagB, glucosamine 6-phosphate isomerase; 
nagB’, glucosamine 6-phosphate isomerase non-homologues of nagB; nagK, N-
acetylglucosamine kinase; agaK, N-acetylgalactosamine kinase; agaA  or gnbF, N-
acetylgalactosamine 6-phosphate deacetylase; agaAI non-orthologous variants of agaA; 
agaS or gnbE, galactosamine 6-phosphate deaminase/isomerase; agaZ or lacC, tagatose 
6-phosphate kinase; kbaZ/kbaY or lacD, tagatose 1,6-biphosphate aldolase; pfkA, 6-
phosphofructokinase; fba, fructose-biphosphate aldolase; tpiA, triosephosphate 
isomerase. The lower glycolytic pathway is represented by a dashed arrow. 
Intermediates: NeuNAc, N-acetylneuraminic acid; ManNAc, N-acetylmannosamine; 
ManNAc6P, N-acetylmannosamine 6-phosphate; GlcNAc6P, N-acetylglucosamine 6-
phosphate; GlcN6P, glucosamine 6-phosphate; GalNAc6P, N-acetyl-galactosamine 6-
phosphate; GalN6P, galactosamine 6-phosphate; T6P, tagatose 6-phosphate; TBP, 
tagatose 1,6-biphosphate; F6P, fructose 6-phosphate; FBP, fructose 1,6-biphosphate; 
GAP, glyceraldehyde 3-phosphate;  DHAP, dihydroxyacetone phosphate. 
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In green, purple and orange are depicted the intermediates and genes committed to 
NeuNAc, GlcNAc and GalNAc catabolism. 
For the sake of simplicity transporters other than PTS are designated generically as non-
PTS. 
 
In H. influenzae and Pasteurella multocida another type of secondary 
transporter was characterized: a tripartite ATP-independent periplasmic 
(TRAP) transporter (SiaPQM). This is a multicomponent system with an 
additional substrate-binding protein (SBP, SiaP) [211–213]. An ATP-
binding cassette (ABC) transporter (SatABCD) was described in 
Haemophilus ducreyi [214]. More recently, a secondary carrier of the 
sodium solute symporter (SSS) family was reported [205,215].  
Opposite to the NeuNAc transporters, for which bacteria have evolved 
multiple systems, the catabolic genes of the nan cluster (comprising a 
lyase (nanA), a kinase (nanK) and an epimerase (nanE)) seem to be 
shared among bacteria, despite the diversity in its organization, and are 
confined to human pathogens and commensals. Many of them occupying 
mucus rich regions (e.g. gut and respiratory tract) [205]. As demonstrated 
in oral streptococci which share the core metabolic activity for NeuNAc 
processing [208,216].  
One exception is Bacteroides fragilis which lacks NanK and for which 
a new epimerase was described, with activity over unphosphorylated N-
acetylmannosamine converting it to GlcNAc, using ATP as a cofactor. The 
latter is then phosphorylated by a RokA kinase and the concomitant 
product proceeds through the NagAB pathway. Hence a different 
catabolic route was established [217,218]. A similar pathway was 
predicted in the periodontal pathogen Tannerella forsythia [219] (Fig. 1.7). 
The enzymes required for NeuNAc catabolism are encoded in the 
pneumococcal genome [140,205]. Catabolism of N-acetylneuraminic acid 
involves five specific steps (Fig. 1.7). A pyruvate group is first removed 
from the intracellular NeuNAc by N-acetylneuraminate lyase (NanA) 
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yielding N-acetylmannosamine (ManNAc). A subsequent phosphorylation 
step, mediated by N-acetylmannosamine kinase (NanK), originates N-
acetylmannosamine 6-phosphate (ManNAc6P). ManNAc6P is then 
epimerized to N-acetylglucosamine 6-phosphate (GlcNAc6P) by N-
acetylmannosamine 6-phosphate epimerase (NanE). The sequential 
removal of the acetyl group by N-acetylglucosamine 6-phosphate 
deacetylase (NagA) and removal of amino group and isomerization by 
glucosamine 6-phosphate isomerase/deaminase (NagB), yields 
glucosamine 6-phosphate (GlcN6P) and the glycolytic intermediate 
fructose 6-phosphate (F6P), respectively. The enzymes NagA and NagB 
are also involved in the degradation route of GlcNAc, with GlcNAc6P and 
GlcN6P as common intermediates of both pathways. Interestingly, in 
different bacteria, the nagAB orthologues are not coded closely to the nan 
system (except for H. influenzae) [206]. In S. pneumoniae, GlcNAc6P 
arises most likely as a product of PTS-mediated transport, as recently 
demonstrated by Bidossi et al. [141]. These authors found that ptsI 
mutants of strains G54 and the D39 rough derivative DP1004, which lack 
PTS activity, were unable to utilize GlcNAc. Similarly, in the closely related 
S. mutans UA159, GlcNAc is imported exclusively by a PTS system, with 
manLMN playing a dominant role. In contrast, in S. gordonii strain DL1 
other GlcNAc transport systems must be present [191]. As for NeuNAc 
the diversity in transport systems is wide among bacteria. In E. coli is well 
described the PTS-mediated uptake of GlcNAc (NagE) [220,221]. And 
recently the same type of transport has been shown for Bacillus subtilis 
(NagP) [222]. In contrast, in Streptomyces olivaceoviridis and 
Xanthomonas campestris pv. campestris an ABC transporter (Ngc) and a 
secondary active transporter from the MFS (NagP), respectively, were 
described [192,223]. Novel permeases (NagP and presumably NagX) 
were identified in the genome of Alteromonadales (e.g. Shewanella 
oneidensis) and Xanthomonadales, lacking GlcNAc-PTS or GlcNAc-ABC 
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systems [224]. NagP functionality was experimentally validated in S. 
oneidensis MR-1 [184]. In these cases, the existence of GlcNAc specific 
kinases (NagK) that phosphorylate the incoming sugar is pivotal for 
GlcNAc catabolism, and therefore an alternative pathway was proposed 
that includes this step before the action of NagAB [192,224]. Indeed, 
GlcNAc kinases were identified and characterized in S. oneidensis and X. 
campestris pv. campestris [192,224]. In addition, NagB enzymes (NagB-
II), non-homologous to the one found in E. coli, were also characterized 
in these microorganisms [192,224] (Fig. 1.7). In contrast, NagA 
orthologous are conserved across bacteria and eukaryotes [224]. 
Genomic reconstruction of GlcNAc catabolism was made for several 
proteobacteria [224].   
 
GalNAc catabolism  
The transport and catabolism of GalNAc in the pneumococcus is 
unknown. Genes for a full catabolic route are not annotated in the 
genome. In opposition, GalNAc catabolism has been studied in E. coli K-
12 and C [225–227]. However, K-12 does not grow on GalNAc, due to 
deletion and truncation of genes comprising a transporter (agaW’EF) and 
a deacetylase (agaA’) [226]. Although this pathway has been proposed in 
silico many years ago [225,226], only recently it was experimentally 
validated [226–229]. In E. coli, GalNAc enters the cell via a PTS (coded 
by agaVWEF), and the concomitant phosphorylated product is 
deacetylated by GalNAc deacetylase (AgaA) to form galactosamine 6-
phosphate (GalN6P). The NagA, involved in GlcNAc catabolic pathway, 
is seemingly a surrogate for AgaA [227,230]. GalN6P is then deaminated 
and isomerised by AgaS to yield T6P. The latter is phosphorylated by 6-
phosphofructokinase (PfkA) yielding TBP, which is then converted to the 
glycolytic intermediates DHAP and GAP by a dimeric aldolase 
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(KbaY/KbaZ). It was proposed that KbaZ subunit is needed for full activity 
and stability of KbaY [226–229] (Fig. 1.7). 
A different variant of GalNAc catabolic pathway was proposed for 
Shewanella strains and more recently some of those enzyme activities 
were experimentally validated for Shewanella sp ANA-3, which grows on 
GalNAc [184,230]. In Shewanella the PTS system is substituted by a 
permease (AgaP) and a subsequent phosphorylation step mediated by a 
GalNAc kinase (AgaK). A nonorthologous GalNAc deacetylase (AgaAII) 
converts GalNA6P to GalN6P and AgaS (E. coli like-enzyme) functions 
as the main GalN6P isomerase [184,230]. While Shewanella possesses 
a gene encoding AgaZ (E. coli like-T6P kinase) genes coding for AgaY 
(predicted TBP aldolase) are missing and likely this activity is replaced by 
fructose biphosphate aldolase, but confirmation is required [230] (Fig. 
1.7). 
The genomic GalNAc pathway reconstruction was extended for other 
bacteria of the Proteobacteria philum  [230]. The initial steps of GalNAc 
catabolism are the most variable among proteobacteria, whereas AgaS is 
the most conserved. The identities of the enzymes mediating the two final 
steps of GalNAc catabolism are not totally disclosed and experimental 
validation is needed, as differential patterns of distribution of these genes 
was observed among Proteobacteria. Whether AgaZ acts in conjunction 
with AgaY or separately or are replaced by other enzymes needs to be 
addressed   [230]. 
The first example of a GalNAc pathway in Firmicutes was studied more 
recently in Lactobacillus casei [194]. The GalNAc gene cluster 
(gnbREFGBCDA) differs from that of proteobacteria studied so far [230]. 
It comprises a mannose-type PTS (encoded by gnbBCDA, PTSGnb) 
involved in transport of GalNAc and the enzymes for subsequent 
GalNAc6P catabolism, GalNAc6P deacetylase (GnbF) and GalN6P 
deaminase (GnbE). Interestingly it was shown that NagA is also required 
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for full growth on GalNAc. The genes for T6P processing are encoded in 
a different cluster (lacR1ABD2C) comprising a T6P kinase (LacC) and 
TBP aldolase (LacD), subsequently leading to triose phosphates (DHAP 
and GAP) [194] (Fig. 1.7). However, the gnb cluster is only present in 
three lactobacilli species [194].  
  
Fucose 
Fucose differs from the other monosaccharides by lacking the hydroxyl 
group at position C6 and possessing an L-configuration. It is a widespread 
and abundant sugar found in mammalian cells as a major component of 
glycoconjugates (N- and O-linked glycans and glycolipids), usually 
localized at terminal positions of glycan structures [231]. The diversity of 
fucosylated glycoconjugates is wide [231]. Fucose is highly abundant in 
the mucins ranging from 4-14% according to the origin of the glycoprotein 
[116,232], in the ABO blood group antigens [231,233,234], in intestine 
epithelial surfaces and in dietary polysaccharides (e.g. pectin, human  
milk oligosaccharides) [235,236], but it can also be found in bacterial 
polysaccharides [237]. Therefore it is likely a potential sugar for bacterial 
growth. Indeed, both pathogenic and commensal bacteria are able to 
grow on Fuc (e.g. Bacteroides thetaiotaomicron [238], Salmonella 
enterica serovar Typhimurium LT2 [239], Roseburia inulinivorans [235] or 
E. coli [240]). 
Interestingly, S. pneumoniae seems unable to use this sugar for growth 
despite possessing the genes required to assemble a catabolic pathway 
which suggests a non-metabolic role of Fuc metabolism [41,234,241]. In 
support, different reports reveal the implication of Fuc metabolic genes in 
pneumococcal virulence. A STM analysis implicated two transporter 
subunits, a fuculose kinase and an extracellular hydrolase of the Fuc 
operon, in pneumococcal virulence [102]. Later, deletion of the whole 
operon resulted in attenuated virulence in a mouse model of pneumonia 
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but does not have a role in colonisation [241]. More recently it was 
suggested that the strain dependency ability to scavenge distinct 
fucosylated glycans antigens might play a role in virulence in the 
interaction with the host, in a strain-dependent manner [233,242]. Higgins 
et al., [234] suggested that Fuc pathway in S. pneumoniae could act as a 
mechanism for sensing Fuc-containing oligosaccharides, conducting Fuc 
through the pathway being one intermediate, likely fuculose, the signalling 
molecule.  
Similarly, in other bacteria, non-metabolic functions were described for 
Fuc. The enterohemorragic bacteria E. coli (EHEC) uses a Fuc sensing 
mechanism to regulate gut colonisation (TCST, FusKR), by modulating 
the expression of virulence genes in EHEC [243]. The regular intestinal 
coloniser B. thetaiotaomicron, coordinates the expression of Fuc 
utilization pathway with expression of a locus regulating the production of 
fucosylated glycans in the intestinal enterocytes of the host, controlling 
the supply and demand of Fuc [238,244]. Additionally, fucosylated 
glycans are adherence targets for bacteria (e.g. Helicobacter pylori, 
Campylobacter jejuni [245,246]) and Fuc was found to be a 
chemoattractant in C. jejuni [232]. More interestingly H. pilory induces 
host cells to produce α-L-fucosidase activity and can attach Fuc to the 
bacterial cell surface [247]. 
All these examples highlight the relevance of fucose for bacteria at a 
variety of levels. 
 
Fucose catabolism 
Two types of Fuc utilization operons were identified in the 
pneumococcal genomes [41,233,234]. Type 1 operon, disclosed by 
homology to E. coli and H. influenzae fucose metabolic proteins, is 
widespread among pneumococcal genomes (e.g. TIGR4, R6, D39) 
whereas Type 2 seems to be confined to a fewer strains (e.g.  SP3-BS71) 
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[41,233]. The general operon (Type 1) codes a fucose regulator (FucR, a 
repressor controlling the whole operon), a fucose mutarotase (FucU) that 
likely accelerates the conversion of the β and α forms of L-fucose, a L-
fucose isomerase (FucI) that acts over α-L-fucose to yield L-fuculose, a 
L-fuculose kinase (FucK) that phosphorylates L-fuculose to L-fuculose 1-
phosphate and a L-fuculose phosphate aldolase (FucA) converts the latter 
into DHAP and L-lactaldehyde. DHAP then enters in the glycolysis 
[233,234] (Fig. 1.8). Both operons possess conserved features: the 
regulator and the fucose processing genes fucI, fucK and fucA [233,234]. 
The main differences rely on the transport system - the PTS (EIIABCD) of 
Type 1 operon is replaced by an ABC transporter in the Type 2 operon -, 
and in the extra- and intracellular glycan-processing enzymes. The 
extracellular family 98 glycoside hydrolases (GH98) with endo-β-D-
galactosidase activity, present in both operons, have different substrate 
specificities. GH98 of Type 1 acts over Lewisantigen to release H-
disaccharide and GH98 of Type 2 operon cleaves A- and B- blood group 
antigens to yield A/B trisaccharide products. Moreover, while Type 1 
operon encodes a putative intracellular α-1,2-fucosidase GH95A, in 
alternative, Type 2 operon codes GH29 and two additional glycosidases: 
GH36A (putative α-N-acetylgalactosaminidase) and GH36B (putative α-
galactosidase) [233,234,242]. The different glycan substrate specificities 
of GH98 enzymes of both operons, lead to the formulation of two models 
for fucosylated-glycan uptake and metabolism [242]. In brief, in Type 1 
model, H-disaccharide is transported and concomitantly phosphorylated 
via PTS. The intracellular product is then cleaved to β-Fuc and Gal6P, by 
GH95A. β-Fuc is converted to α-Fuc by FucU entering in Fuc catabolic 
route [242,248]. In Type 2 model the trisaccharides enter the cell without 
modification, by an ABC transporter, and are subject to GH36A/GH29 
activities yielding α-Fuc, Gal and GalNAc or subject to GH29/GH36B to 
yield Gal and α-Fuc [242,248].  
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Higgins et al. [234], suggested that Fuc transport is mediated by a non-
specific permease, but the identity of such transporter is not yet known.  
The pathway for Fuc metabolism is well established in E. coli [240,249–
251]. The major distinct features between Fuc catabolism in E. coli and in 
the pneumococcus are the transport system, E. coli possesses a fucose 
permease (H+-symporter [252]) not present in pneumococcal genomes, 
and different glycoside hydrolases [234]. Moreover, while FucU catalyzes 
the first step in Fuc catabolism in E. coli, in S. pneumoniae it links 
glycoside hydrolase activity to bacterial Fuc catabolism [248].  
More recently Campylobacter jejuni was found to grow on Fuc in a 
strain dependent manner [253,254]. A new pathway, with no homologous 
genes (except the permease for Fuc transport and lactaldehyde 
dehydrogenase for aerobic degradation of lactaldehyde) to those 
described in the enteric bacteria, was proposed, but is yet 
uncharacterized [254,255]. Experimental evidence suggest that Fuc 
enters the cell by a FucP, but is not phosphorylated, as in E. coli or 
Bacteroides [254]. Surrounding FucP a set of genes, with homology to 
those of the plant pathogen Xanthomonas campestris which code a new 
Fuc pathway, was identified suggesting that Fuc is likely metabolized by 





Figure 1.8. Schematic representation of pathways for the dissimilation of fucose 
(Fuc) in bacteria. 
Reactions are catalysed by the following protein encoding genes: fucU, fucose 
mutarotase; fucI, L-fucose isomerase; fucK, L-fuculose kinase; fucA, L-fuculose 
phosphate aldolase; tpiA, triosephosphate isomerase. 
Intermediates: Fucl, fuculose; Fucl1P, fuculose 1-phosphate; DHAP, dihydroxyacetone 
phosphate; GAP, glyceraldehyde 3-phosphate. 
In orange are depicted the intermediates and genes committed specifically to Fuc 
catabolism. 
 
The general Fuc degradation pathway, comprising an isomerase, a 
kinase, and an aldolase has been identified/proposed in several 
microorganisms (e.g. E. coli [240,249–251], R. inulinivorans [235], B. 
thetaiotaomicron [238], Clostridium phytofermentans [257]). Under 
anaerobic conditions, the resultant L-lactaldehyde is reduced to L-1,2-
propanediol by a L-1,2-propanediol oxidoreductase (fucO) [240]. But 
whereas in E. coli and B. thetaiotaomicron, L-1,2-propanediol is likely 
excreted [235,240], in other microorganisms it is further metabolized. 
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Salmonella serovar Typhimurium LT2 encodes an operon (pdu) for 
propanediol utilization [258–260]. A different organization of pdu genes, 
and with some distinct enzymatic features, was found in R. inulinivorans 
[235,257]. Alternatively, in aerobiosis, L-lactaldeheyde is metabolized to 
lactate by a lactaldehyde dehydrogenase (ald), and the latter to pyruvate, 
in E. coli [260].  
Opposite to the previous bacteria several strains of Lactobacillus were 
unable to use or only moderately use Fuc [261]. Lactobacillus casei BL23 
lacks genes for Fuc catabolism but expresses three α-fucosidases. This 
bacterium grows on the fucosylated glycan Fuc-α-1,3-GlcNAc, but uses 
only the GlcNAc moiety. The liberated Fuc is released to the environment 
by a yet unknown mechanism [262]. 
 
Glycolysis, glucose and pyruvate metabolism  
Glucose is the preferred carbon and energy sources of the majority of 
the Streptococcaceae. S. pneumoniae seems to be no exception 
[125,141].  
Glucose enters the cell usually by PTS systems and is concomitantly 
phosphorylated to glucose 6-phosphate (G6P). Bidossi et al. [141] 
proposed the PTS-Man, ManLMN (PTSMan) as the main Glc uptake 
system in S. pneumoniae, but transport through other PTSs was not ruled 
out. Glc can also be up taken by non-PTS transporters and 
phosphorylated by a glucokinase (GKI) yielding G6P. This hypothesis is 
in line with the ability of ptsI mutants of S. pneumoniae to use glucose as 
sole carbon source for growth [141] (Fig. 1.9). The presence of more than 
one transporter for Glc internalization is widespread in bacteria (e.g. L. 
lactis, E. coli or B. subtilis) [263–265]. The further processing of G6P into 
pyruvate occurs via the Embden-Meyerhof-Parnas depicted in Fig. 1.9. 
The net gain of Glc catabolism is two pyruvate molecules, two NADH and 





Figure 1.9. Schematic representation of the glucose uptake and catabolism via the 
Embden-Meyerhof-Parnas (EMP) pathway, and homolactic fermentation in S. 
pneumoniae. 
Reactions are catalysed by the following protein encoding genes: gki, glucokinase; pgi, 
glucose 6-phosphate isomerase; pfkA, 6-phosphofructokinase; fba, fructose-biphosphate 
aldolase; tpiA, triosephosphate isomerase; gap, glyceraldehyde 3-phosphate 
dehydrogenase; pgk, phosphoglycerate kinase; gpmA, phosphoglyceromutase; eno, 
enolase; pyk, pyruvate kinase; ldh, L-lactate dehydrogenase.  
Intermediates: G6P, glucose 6-phosphate; F6P, fructose 6-phosphate; FBP, fructose 1,6-
biphosphate; GAP, glyceraldehyde 3-phosphate;  DHAP, dihydroxyacetone phosphate; 
BPG, 1,3-biphosphoglycerate; 3-PGA, 3-phosphoglycerate; 2-PGA, 2-phosphoglycerate; 
PEP, phosphoenolpyruvate. 
 
Generally pyruvate is converted to lactate, by lactate dehydrogenase 
(LDH), with oxidation of NADH to NAD+ - homolactic fermentation (Fig. 
1.10). While LDH is encoded by multiple genes in other bacteria [266–
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268], S. pneumoniae possesses only a single copy of the gene [140]. 
Recently, successful construction of a pneumococcal ldh mutant was 
attained resulting in total abrogation of lactate production [119]. In this 
study the importance of LDH for NAD+ regeneration and maintenance of 
redox balance was established. LDH was suggested as the most efficient 
enzyme for pyruvate consumption [119]. 
However, under certain conditions, such as the presence of slow 
metabolizable carbohydrates (e.g. galactose), sugar limitation, 
aerobiosis, and in the LDH mutant described above, a shift to mixed acid 
fermentation profile is observed with production of ethanol, acetate or 
formate [269–272].  
Pyruvate metabolism involves several enzymes (Fig. 1.10). Besides 
LDH, pyruvate can be processed by pyruvate oxidase (SpxB) or pyruvate 
formate-lyase (PFL). SpxB catalyses the conversion of pyruvate, in 
presence of O2 and inorganic phosphate, to acetyl-P, H2O2 and CO2. This 
enzyme has been extensively studied in S. pneumoniae and its 
involvement in several important biological processes was established 
(e.g. competitive advantage over co-colonisers, streptococcal resistance 
to H2O2) (reviewed in [99,121]). Part of these features are connected with 
the high amounts (in mM range) of H2O2 produced. Recently, a relation 
between SpxB and sugar utilization capabilities was established, under 
microaerobic conditions [99]. 
Yesilkaya et al. [118] identified the pneumococcal genes responsible 
for PFL activity and demonstrated its relevance for mixed acid 
fermentation under microaerobic and anaerobic conditions, in S. 
pneumoniae. PFL converts pyruvate to formate and acetyl-CoA. The latter 
can be further metabolized to ethanol or acetate by alcohol 
dehydrogenase (adh) or phosphotransacetylase/acetate kinase 
(pta/ackA), respectively. While acetate production leads to an additional 





Figure 1.10. Schematic representation of pyruvate metabolism in S. pneumoniae. 
Reactions are catalysed by the following protein encoding genes: spxB, pyruvate oxidase; 
ldh, L-lactate dehydrogenase; lcto, lactate oxidase; pflB, pyruvate formate-lyase; pta, 
phosphotransacetylase; ackA, acetate kinase; adh, bifunctional acetaldehyde-coA/alcohol 
dehydrogenase (SPD_1834); PDHC, pyruvate dehydrogenase complex. 
The occurrence of the reaction catalysed by PDHC is unknown and therefore is depicted 
in grey. 
 
Several Streptococcaceae also possess the pyruvate dehydrogenase 
complex (PDHC), which canalizes the oxidative decarboxylation of 
pyruvate to acetyl-CoA and CO2, under aerobic conditions. S. pneumoniae 
lacks genes homologous to those encoding PDHC [139,140,273]. 
However, the presence of a functional pyruvate dehydrogenase in the 
pneumococcus is still controversial [118,274]. 
The versatility of pyruvate metabolism has been proposed to be a way 





In this thesis, we study the transcriptional response of S. pneumoniae 
to mucin. In addition, we assess which monosaccharides, present in the 
representative airway glycan mucin, are utilized by the pneumococcus to 
grow and how it benefits from the diversity of sugars generated from its 
deglycosylation. The biochemical routes predicted in silico for the 
catabolism of mannose, galactose and N-acetylglucosamine in S. 
pneumoniae D39 are experimentally validated (Chapter 2). 
 The importance of sugar-specific catabolic genes in galactose, 
mannose and N-acetylglucosamine pathways is studied in mouse models 
of pneumococcal colonisation and disease (Chapter 2). Furthermore, we 
address the impact of carbohydrate availability (nasopharynx 
carbohydrates and glucose) in the expression of known virulence factors 
(Chapter 3).  
We study, at transcriptional and metabolic levels, the response of the 
pneumococcus to carbohydrates present in the airways and how S. 
pneumoniae responds to the presence of the fast metabolizable sugar, 
glucose, existing in comparatively high abundance in blood (Chapter 3).  
 
References 
1.  Watson DA, Musher DM, Jacobson JW, Verhoef J. A brief history of the 
pneumococcus in biomedical research: a panoply of scientific discovery. Clin Infect 
Dis Off Publ Infect Dis Soc Am. 1993;17: 913–924.  
2.  López R. Pneumococcus: the sugar-coated bacteria. Int Microbiol Off J Span Soc 
Microbiol. 2006;9: 179–190.  
3.  Griffith, F. The significance of pneumococcal types. J Hyg. 1928;27: 113–159.  
4.  Avery OT, Macleod CM, McCarty M. Studies on the chemical nature of the substance 
inducing transformation of pneumococcal types: induction of transformation by a 
desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med. 
1944;79: 137–158.  
5.  Dochez A, Avery OT. The elaboration of specific soluble substance by pneumococcus 
during growth. J Exp Med. 1917;26: 477–493.  
Chapter 1 
52 
6.  Dochez AR, Avery OT. Soluble substance of pneumococcus origin in the blood and 
urine during lobar pneumonia. Exp Biol Med. 1917;14: 126–127. 
doi:10.3181/00379727-14-75 
7.  Avery OT. Immunological relationships of cell constituents of pneumococcus: second 
paper. J Exp Med. 1925;42: 367–376. doi:10.1084/jem.42.3.367 
8.  Avery OT, Goebel WF. Chemoimmunological studies on the soluble specific 
substance of pneumococcus: I. The isolation and properties of the acetyl 
polysaccharide of pneumococcus type I. J Exp Med. 1933;58: 731–755.  
9.  M Heidelberger, Avery OT. The soluble specific substance of pneumococcus. J Exp 
Med. 1923;38: 73–79.  
10.  Heidelberger M. Immunologically specific polysaccharides. Chem Rev. 1927;3: 403–
423. doi:10.1021/cr60012a004 
11.  Tuomanen E. Streptococcus pneumoniae. In: Dworkin M, Falkow S, Rosenberg E, 
Schleifer K-H, Stackebrandt E, editors. The Prokaryotes. New York, NY: Springer US; 
2006. pp. 149–162. Available: http://link.springer.com/10.1007/0-387-30744-3_4 
12.  Zapun A, Vernet T, Pinho MG. The different shapes of cocci. FEMS Microbiol Rev. 
2008;32: 345–360. doi:10.1111/j.1574-6976.2007.00098.x 
13.  Pinho MG, Kjos M, Veening J-W. How to get (a)round: mechanisms controlling growth 
and division of coccoid bacteria. Nat Rev Microbiol. 2013;11: 601–614. 
doi:10.1038/nrmicro3088 
14.  Pérez-Dorado I, Galan-Bartual S, Hermoso JA. Pneumococcal surface proteins: 
when the whole is greater than the sum of its parts: Structural biology of 
pneumococcal surface proteins. Mol Oral Microbiol. 2012;27: 221–245. 
doi:10.1111/j.2041-1014.2012.00655.x 
15.  Martner A, Skovbjerg S, Paton JC, Wold AE. Streptococcus pneumoniae autolysis 
prevents phagocytosis and production of phagocyte-activating cytokines. Infect 
Immun. 2009;77: 3826–3837. doi:10.1128/IAI.00290-09 
16.  Henriques-Normark B, Tuomanen EI. The pneumococcus: epidemiology, 
microbiology, and pathogenesis. Cold Spring Harb Perspect Med. 2013;3: a010215–
a010215. doi:10.1101/cshperspect.a010215 
17.  Nobbs AH, Lamont RJ, Jenkinson HF. Streptococcus adherence and colonization. 
Microbiol Mol Biol Rev MMBR. 2009;73: 407–450, Table of Contents. 
doi:10.1128/MMBR.00014-09 
18.  Arbique JC, Poyart C, Trieu-Cuot P, Quesne G, Carvalho M d. GS, Steigerwalt AG, 
et al. Accuracy of phenotypic and genotypic testing for identification of Streptococcus 
pneumoniae and description of Streptococcus pseudopneumoniae sp. nov. J Clin 
Microbiol. 2004;42: 4686–4696. doi:10.1128/JCM.42.10.4686-4696.2004 
19.  Doern CD, Burnham C-AD. It’s not easy being green: the viridans group streptococci, 
with a focus on pediatric clinical manifestations. J Clin Microbiol. 2010;48: 3829–
3835. doi:10.1128/JCM.01563-10 
20.  Facklam R. What happened to the streptococci: overview of taxonomic and 
nomenclature changes. Clin Microbiol Rev. 2002;15: 613–630. 
doi:10.1128/CMR.15.4.613-630.2002 
21.  Reller LB, Weinstein MP, Werno AM, Murdoch DR. Laboratory diagnosis of invasive 
pneumococcal disease. Clin Infect Dis. 2008;46: 926–932. doi:10.1086/528798 
General introduction 
53 
22.  Song J-H, Dagan R, Klugman KP, Fritzell B. The relationship between pneumococcal 
serotypes and antibiotic resistance. Vaccine. 2012;30: 2728–2737. 
doi:10.1016/j.vaccine.2012.01.091 
23.  Vernet G, Saha S, Satzke C, Burgess DH, Alderson M, Maisonneuve J-F, et al. 
Laboratory-based diagnosis of pneumococcal pneumonia: state of the art and unmet 
needs: Laboratory-based diagnosis of pneumococcal pneumonia. Clin Microbiol 
Infect. 2011;17: 1–13. doi:10.1111/j.1469-0691.2011.03496.x 
24.  Habib M, Porter BD, Satzke C. Capsular serotyping of Streptococcus pneumoniae 
using the quellung reaction. J Vis Exp. 2014; doi:10.3791/51208 
25.  Leegaard TM, Bootsma HJ, Caugant DA, Eleveld MJ, Mannsaker T, Froholm LO, et 
al. Phenotypic and genomic characterization of pneumococcus-like streptococci 
isolated from HIV-seropositive patients. Microbiology. 2010;156: 838–848. 
doi:10.1099/mic.0.035345-0 
26.  Bandettini R, Melioli G. Laboratory diagnosis of Streptococcus pneumoniae 
infections: past and future. J Prev Med Hyg. 2012;53: 85–88.  
27.  Koornhof HJ, Madh SA, Feldman C, Gottberg A von, Klugman KP. A century of South 
African battles against the pneumococcus  –“the Captain of Death.” South Afr J 
Epidemiol Infect. 2009;24: 7–19.  
28.  Gennaris A, Collet J-F. The “captain of the men of death”, Streptococcus pneumoniae 
, fights oxidative stress outside the “city wall”: A novel antioxidant surface defence. 
EMBO Mol Med. 2013;5: 1798–1800. doi:10.1002/emmm.201303482 
29.  Braido F, Bellotti M, De Maria A, Cazzola M, Canonica GW. The role of pneumococcal 
vaccine. Pulm Pharmacol Ther. 2008;21: 608–615. doi:10.1016/j.pupt.2008.04.001 
30.  Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus 
pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev 
Microbiol. 2008;6: 288–301. doi:10.1038/nrmicro1871 
31.  Obaro S, Adegbola R. The pneumococcus: carriage, disease and conjugate 
vaccines. J Med Microbiol. 2002;51: 98–104.  
32.  Bosch AATM, Biesbroek G, Trzcinski K, Sanders EAM, Bogaert D. Viral and bacterial 
interactions in the upper respiratory tract. Hobman TC, editor. PLoS Pathog. 2013;9: 
e1003057. doi:10.1371/journal.ppat.1003057 
33.  Bogaert D, de Groot R, Hermans P. Streptococcus pneumoniae colonisation: the key 
to pneumococcal disease. Lancet Infect Dis. 2004;4: 144–154. doi:10.1016/S1473-
3099(04)00938-7 
34.  Hava DL, LeMieux J, Camilli A. From nose to lung: the regulation behind 
Streptococcus pneumoniae virulence factors: Virulence gene regulation in S. 
pneumoniae. Mol Microbiol. 2003;50: 1103–1110. doi:10.1046/j.1365-
2958.2003.03764.x 
35.  Lynch JP, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and 
strategies for prevention. Semin Respir Crit Care Med. 2009;30: 189–209. 
doi:10.1055/s-0029-1202938 
36.  Feldman C, Anderson R. New insights into pneumococcal disease. Respirology. 
2009;14: 167–179. doi:10.1111/j.1440-1843.2008.01422.x 
37.  Hill PC, Cheung YB, Akisanya A, Sankareh K, Lahai G, Greenwood BM, et al. 
Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian infants: a 




38.  Högberg L, Geli P, Ringberg H, Melander E, Lipsitch M, Ekdahl K. Age- and 
serogroup-related differences in observed durations of nasopharyngeal carriage of 
penicillin-resistant pneumococci. J Clin Microbiol. 2007;45: 948–952. 
doi:10.1128/JCM.01913-06 
39.  Sandgren A, Sjostrom K, Olsson-Liljequist B, Christensson B, Samuelsson A, 
Kronvall G, et al. Effect of clonal and serotype-specific properties on the invasive 
capacity of Streptococcus pneumoniae. J Infect Dis. 2004;189: 785–796. 
doi:10.1086/381686 
40.  Brueggemann AB, Peto TEA, Crook DW, Butler JC, Kristinsson KG, Spratt BG. 
Temporal and geographic stability of the serogroup-specific invasive disease 
potential of Streptococcus pneumoniae in children. J Infect Dis. 2004;190: 1203–
1211. doi:10.1086/423820 
41.  Chan PF, O’Dwyer KM, Palmer LM, Ambrad JD, Ingraham KA, So C, et al. 
Characterization of a novel fucose-regulated promoter (PfcsK) suitable for gene 
essentiality and antibacterial mode-of-action studies in Streptococcus pneumoniae. J 
Bacteriol. 2003;185: 2051–2058. doi:10.1128/JB.185.6.2051-2058.2003 
42.  Nobbs AH, Jenkinson HF, Everett DB. Generic determinants of Streptococcus 
colonization and infection. Infect Genet Evol. 2014; 
doi:10.1016/j.meegid.2014.09.018 
43.  O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden 
of disease caused by Streptococcus pneumoniae in children younger than 5 years: 
global estimates. The Lancet. 2009;374: 893–902. doi:10.1016/S0140-
6736(09)61204-6 
44.  Advisory Committee on Immunization Practices. Preventing pneumococcal disease 
among infants and young children. Recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR Recomm Rep Morb Mortal Wkly Rep 
Recomm Rep Cent Dis Control. 2000;49: 1–35.  
45.  Feldman C, Anderson R. Review: Current and new generation pneumococcal 
vaccines. J Infect. 2014;69: 309–325. doi:10.1016/j.jinf.2014.06.006 
46.  Wardlaw TM, Johansson EW, Hodge MJ, UNICEF, Division of Communication, World 
Health Organization. Pneumonia: the forgotten killer of children. New York: UNICEF : 
Geneva, Switzerland : World Health Organization; 2006.  
47.  Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger 
R, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease 
among children under five: the pneumococcal global serotype project. Cohen J, 
editor. PLoS Med. 2010;7: e1000348. doi:10.1371/journal.pmed.1000348 
48.  Davis SM, Deloria-Knoll M, Kassa HT, O’Brien KL. Impact of pneumococcal 
conjugate vaccines on nasopharyngeal carriage and invasive disease among 
unvaccinated people: Review of evidence on indirect effects. Vaccine. 2013;32: 133–
145. doi:10.1016/j.vaccine.2013.05.005 
49.  Frazão N, Hiller NL, Powell E, Earl J, Ahmed A, Sá-Leão R, et al. Virulence potential 
and genome-wide characterization of drug resistant Streptococcus pneumoniae 
clones selected in vivo by the 7-valent pneumococcal conjugate vaccine. Miyaji EN, 
editor. PLoS ONE. 2013;8: e74867. doi:10.1371/journal.pone.0074867 
50.  Dagan R, Juergens C, Trammel J, Patterson S, Greenberg D, Givon-Lavi N, et al. 
Efficacy of 13-valent versus 7-valent pneumococcal conjugate vaccine against 
General introduction 
55 
nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus 
pneumoniae. J Infect Dis. 2014; doi:10.1093/infdis/jiu576 
51.  El-Solh A, Assaad, El-Masri, Porhomayon J. Pneumonia immunization in older adults: 
review of vaccine effectiveness and strategies. Clin Interv Aging. 2012; 453. 
doi:10.2147/CIA.S29675 
52.  Improving global health by preventing pneumococcal disease. Report from the all-
party parliamentary group on pneumococcal disease prevention in the developing 
world. 2008.  
53.  Jenkinson HF, Lamont R. Streptococcal adhesion and colonization. Crit Rev Oral Biol 
Med. 1997;8: 175–200. doi:10.1177/10454411970080020601 
54.  Catterall JR. Streptococcus pneumoniae. Thorax. 1999;54: 929–937. 
doi:10.1136/thx.54.10.929 
55.  Casadevall A, Pirofski L. Host-pathogen interactions: the attributes of virulence. J 
Infect Dis. 2001;184: 337–344. doi:10.1086/322044 
56.  Weiser JN. The pneumococcus: why a commensal misbehaves. J Mol Med Berl. 
2010;88: 97–102. doi:10.1007/s00109-009-0557-x 
57.  Nelson AL, Roche AM, Gould JM, Chim K, Ratner AJ, Weiser JN. Capsule enhances 
pneumococcal colonization by limiting mucus-mediated clearance. Infect Immun. 
2007;75: 83–90. doi:10.1128/IAI.01475-06 
58.  Weiser JN, Austrian R, Sreenivasan PK, Masure HR. Phase variation in 
pneumococcal opacity: relationship between colonial morphology and 
nasopharyngeal colonization. Infect Immun. 1994;62: 2582–2589.  
59.  Cundell DR, Weiser JN, Shen J, Young A, Tuomanen EI. Relationship between 
colonial morphology and adherence of Streptococcus pneumoniae. Infect Immun. 
1995;63: 757–761.  
60.  Weiser JN, Bae D, Epino H, Gordon SB, Kapoor M, Zenewicz LA, et al. Changes in 
availability of oxygen accentuate differences in capsular polysaccharide expression 
by phenotypic variants and clinical isolates of Streptococcus pneumoniae. Infect 
Immun. 2001;69: 5430–5439.  
61.  Hammerschmidt S, Wolff S, Hocke A, Rosseau S, Müller E, Rohde M. Illustration of 
pneumococcal polysaccharide capsule during adherence and invasion of epithelial 
cells. Infect Immun. 2005;73: 4653–4667. doi:10.1128/IAI.73.8.4653-4667.2005 
62.  Voß S, Gámez G, Hammerschmidt S. Impact of pneumococcal microbial surface 
components recognizing adhesive matrix molecules on colonization: Impact of 
pneumococcal MSCRAMMs on colonization. Mol Oral Microbiol. 2012;27: 246–256. 
doi:10.1111/j.2041-1014.2012.00654.x 
63.  Kim JO, Romero-Steiner S, Sørensen UB, Blom J, Carvalho M, Barnard S, et al. 
Relationship between cell surface carbohydrates and intrastrain variation on 
opsonophagocytosis of Streptococcus pneumoniae. Infect Immun. 1999;67: 2327–
2333.  
64.  Austrian R. Some observations on the pneumococcus and on the current status of 
pneumococcal disease and its prevention. Rev Infect Dis. 1981;3 Suppl: S1–17.  
65.  Musher DM. Infections caused by Streptococcus pneumoniae: clinical spectrum, 
pathogenesis, immunity, and treatment. Clin Infect Dis Off Publ Infect Dis Soc Am. 
1992;14: 801–807.  
66.  Winkelstein JA. The role of complement in the host’s defense against Streptococcus 
pneumoniae. Rev Infect Dis. 1981;3: 289–298.  
Chapter 1 
56 
67.  Van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal 
pneumonia. Lancet. 2009;374: 1543–1556. doi:10.1016/S0140-6736(09)61114-4 
68.  Fernebro J, Andersson I, Sublett J, Morfeldt E, Novak R, Tuomanen E, et al. Capsular 
expression in Streptococcus pneumoniae negatively affects spontaneous and 
antibiotic-induced lysis and contributes to antibiotic tolerance. J Infect Dis. 2004;189: 
328–338. doi:10.1086/380564 
69.  Weiser JN, Kapoor M. Effect of intrastrain variation in the amount of capsular 
polysaccharide on genetic transformation of Streptococcus pneumoniae: implications 
for virulence studies of encapsulated strains. Infect Immun. 1999;67: 3690–3692.  
70.  Iannelli F, Pearce BJ, Pozzi G. The type 2 capsule locus of Streptococcus 
pneumoniae. J Bacteriol. 1999;181: 2652–2654.  
71.  Shainheit MG, Mule M, Camilli A, Pirofski L. The core promoter of the capsule operon 
of Streptococcus pneumoniae is necessary for colonization and invasive disease. 
Infect Immun. 2014;82: 694–705. doi:10.1128/IAI.01289-13 
72.  MacLEOD CM, Kraus MR. Relation of virulence of pneumococcal strains for mice to 
the quantity of capsular polysaccharide formed in vitro. J Exp Med. 1950;92: 1–9.  
73.  Bergmann S. Versatility of pneumococcal surface proteins. Microbiology. 2006;152: 
295–303. doi:10.1099/mic.0.28610-0 
74.  Hammerschmidt S. Adherence molecules of pathogenic pneumococci. Curr Opin 
Microbiol. 2006;9: 12–20. doi:10.1016/j.mib.2005.11.001 
75.  King SJ. Pneumococcal modification of host sugars: a major contributor to 
colonization of the human airway? Mol Oral Microbiol. 2010;25: 15–24. 
doi:10.1111/j.2041-1014.2009.00564.x 
76.  Dalia AB, Standish AJ, Weiser JN. Three surface exoglycosidases from 
Streptococcus pneumoniae, NanA, BgaA, and StrH, promote resistance to 
opsonophagocytic killing by human neutrophils. Infect Immun. 2010;78: 2108–2116. 
doi:10.1128/IAI.01125-09 
77.  King SJ, Hippe KR, Weiser JN. Deglycosylation of human glycoconjugates by the 
sequential activities of exoglycosidases expressed by Streptococcus pneumoniae. 
Mol Microbiol. 2006;59: 961–974. doi:10.1111/j.1365-2958.2005.04984.x 
78.  Limoli DH, Sladek JA, Fuller LA, Singh AK, King SJ. BgaA acts as an adhesin to 
mediate attachment of some pneumococcal strains to human epithelial cells. 
Microbiology. 2011;157: 2369–2381. doi:10.1099/mic.0.045609-0 
79.  Kostyukova NN, Volkova MO, Ivanova VV, Kvetnaya AS. A study of pathogenic 
factors of Streptococcus pneumoniae strains causing meningitis. FEMS Immunol 
Med Microbiol. 1995;10: 133–137.  
80.  Zwijnenburg PJ, van der Poll T, Florquin S, van Deventer SJ, Roord JJ, van Furth 
AM. Experimental pneumococcal meningitis in mice: a model of intranasal infection. 
J Infect Dis. 2001;183: 1143–1146. doi:10.1086/319271 
81.  Bethe G, Nau R, Wellmer A, Hakenbeck R, Reinert RR, Heinz HP, et al. The cell wall-
associated serine protease PrtA: a highly conserved virulence factor of Streptococcus 
pneumoniae. FEMS Microbiol Lett. 2001;205: 99–104.  
82.  Mitchell AM, Mitchell TJ. Streptococcus pneumoniae: virulence factors and variation. 
Clin Microbiol Infect. 2010;16: 411–418. doi:10.1111/j.1469-0691.2010.03183.x 
83.  Berry AM, Paton JC. Sequence heterogeneity of PsaA, a 37-kilodalton putative 




84.  Nieto PA, Riquelme SA, Riedel CA, Kalergis AM, Bueno SM. Gene elements that 
regulate Streptococcus pneumoniae virulence and immunity evasion. Curr Gene 
Ther. 2013;13: 51–64.  
85.  Gosink KK, Mann ER, Guglielmo C, Tuomanen EI, Masure HR. Role of novel choline 
binding proteins in virulence of Streptococcus pneumoniae. Infect Immun. 2000;68: 
5690–5695. doi:10.1128/IAI.68.10.5690-5695.2000 
86.  Holmes AR, McNab R, Millsap KW, Rohde M, Hammerschmidt S, Mawdsley JL, et 
al. The pavA gene of Streptococcus pneumoniae encodes a fibronectin-binding 
protein that is essential for virulence. Mol Microbiol. 2001;41: 1395–1408.  
87.  Pracht D, Elm C, Gerber J, Bergmann S, Rohde M, Seiler M, et al. PavA of 
Streptococcus pneumoniae modulates adherence, invasion, and meningeal 
inflammation. Infect Immun. 2005;73: 2680–2689. doi:10.1128/IAI.73.5.2680-
2689.2005 
88.  Eberhard T, Kronvall G, Ullberg M. Surface bound plasmin promotes migration of 
Streptococcus pneumoniae through reconstituted basement membranes. Microb 
Pathog. 1999;26: 175–181. doi:10.1006/mpat.1998.0262 
89.  Bergmann S, Rohde M, Chhatwal GS, Hammerschmidt S. alpha-enolase of 
Streptococcus pneumoniae is a plasmin(ogen)-binding protein displayed on the 
bacterial cell surface. Mol Microbiol. 2001;40: 1273–1287.  
90.  Bergmann S, Rohde M, Hammerschmidt S. Glyceraldehyde-3-phosphate 
dehydrogenase of Streptococcus pneumoniae is a surface-displayed plasminogen-
binding protein. Infect Immun. 2004;72: 2416–2419. doi:10.1128/IAI.72.4.2416-
2419.2004 
91.  Bergmann S, Schoenen H, Hammerschmidt S. The interaction between bacterial 
enolase and plasminogen promotes adherence of Streptococcus pneumoniae to 
epithelial and endothelial cells. Int J Med Microbiol. 2013;303: 452–462. 
doi:10.1016/j.ijmm.2013.06.002 
92.  Balachandran P, Hollingshead SK, Paton JC, Briles DE. The autolytic enzyme LytA 
of Streptococcus pneumoniae is not responsible for releasing pneumolysin. J 
Bacteriol. 2001;183: 3108–3116. doi:10.1128/JB.183.10.3108-3116.2001 
93.  Yuste J, Botto M, Paton JC, Holden DW, Brown JS. Additive inhibition of complement 
deposition by pneumolysin and PspA facilitates Streptococcus pneumoniae 
septicemia. J Immunol Baltim Md 1950. 2005;175: 1813–1819.  
94.  Feldman C, Mitchell TJ, Andrew PW, Boulnois GJ, Read RC, Todd HC, et al. The 
effect of Streptococcus pneumoniae pneumolysin on human respiratory epithelium in 
vitro. Microb Pathog. 1990;9: 275–284.  
95.  Dawid S, Roche AM, Weiser JN. The blp bacteriocins of Streptococcus pneumoniae 
mediate intraspecies competition both in vitro and in vivo. Infect Immun. 2007;75: 
443–451. doi:10.1128/IAI.01775-05 
96.  Pericone CD, Overweg K, Hermans PW, Weiser JN. Inhibitory and bactericidal effects 
of hydrogen peroxide production by Streptococcus pneumoniae on other inhabitants 
of the upper respiratory tract. Infect Immun. 2000;68: 3990–3997.  
97.  Regev-Yochay G, Trzcinski K, Thompson CM, Malley R, Lipsitch M. Interference 
between Streptococcus pneumoniae and Staphylococcus aureus: In vitro hydrogen 




98.  Hoffmann O, Zweigner J, Smith SH, Freyer D, Mahrhofer C, Dagand E, et al. Interplay 
of pneumococcal hydrogen peroxide and host-derived nitric oxide. Infect Immun. 
2006;74: 5058–5066. doi:10.1128/IAI.01932-05 
99.  Carvalho SM, Farshchi Andisi V, Gradstedt H, Neef J, Kuipers OP, Neves AR, et al. 
Pyruvate oxidase influences the sugar utilization pattern and capsule production in 
Streptococcus pneumoniae. Chi J-TA, editor. PLoS ONE. 2013;8: e68277. 
doi:10.1371/journal.pone.0068277 
100. Lau GW, Haataja S, Lonetto M, Kensit SE, Marra A, Bryant AP, et al. A functional 
genomic analysis of type 3 Streptococcus pneumoniae virulence. Mol Microbiol. 
2001;40: 555–571.  
101. Polissi A, Pontiggia A, Feger G, Altieri M, Mottl H, Ferrari L, et al. Large-scale 
identification of virulence genes from Streptococcus pneumoniae. Infect Immun. 
1998;66: 5620–5629.  
102. Hava DL, Camilli A. Large-scale identification of serotype 4 Streptococcus 
pneumoniae virulence factors. Mol Microbiol. 2002;45: 1389–1406.  
103. Ogunniyi AD, Mahdi LK, Trappetti C, Verhoeven N, Mermans D, Van der Hoek MB, 
et al. Identification of genes that contribute to the pathogenesis of invasive 
pneumococcal disease by in vivo transcriptomic analysis. Infect Immun. 2012;80: 
3268–3278. doi:10.1128/IAI.00295-12 
104. LeMessurier KS. Differential expression of key pneumococcal virulence genes in 
vivo. Microbiology. 2006;152: 305–311. doi:10.1099/mic.0.28438-0 
105. Orihuela CJ, Radin JN, Sublett JE, Gao G, Kaushal D, Tuomanen EI. Microarray 
analysis of pneumococcal gene expression during invasive disease. Infect Immun. 
2004;72: 5582–5596. doi:10.1128/IAI.72.10.5582-5596.2004 
106. Song X-M, Connor W, Hokamp K, Babiuk LA, Potter AA. Streptococcus pneumoniae 
early response genes to human lung epithelial cells. BMC Res Notes. 2008;1: 64. 
doi:10.1186/1756-0500-1-64 
107. Van Opijnen T, Camilli A. A fine scale phenotype-genotype virulence map of a 
bacterial pathogen. Genome Res. 2012;22: 2541–2551. doi:10.1101/gr.137430.112 
108. Marion C, Aten AE, Woodiga SA, King SJ. Identification of an ATPase, MsmK, which 
energizes multiple carbohydrate ABC transporters in Streptococcus pneumoniae. 
Infect Immun. 2011;79: 4193–4200. doi:10.1128/IAI.05290-11 
109. Marion C, Burnaugh AM, Woodiga SA, King SJ. Sialic acid transport contributes to 
pneumococcal colonization. Infect Immun. 2011;79: 1262–1269. 
doi:10.1128/IAI.00832-10 
110. Marion C, Stewart JM, Tazi MF, Burnaugh AM, Linke CM, Woodiga SA, et al. 
Streptococcus pneumoniae can utilize multiple sources of hyaluronic acid for growth. 
Infect Immun. 2012;80: 1390–1398. doi:10.1128/IAI.05756-11 
111. Iyer R, Camilli A. Sucrose metabolism contributes to in vivo fitness of Streptococcus 
pneumoniae. Mol Microbiol. 2007;66: 1–13. doi:10.1111/j.1365-2958.2007.05878.x 
112. Tong HH, Blue LE, James MA, DeMaria TF. Evaluation of the virulence of a 
Streptococcus pneumoniae neuraminidase-deficient mutant in nasopharyngeal 
colonization and development of otitis media in the chinchilla model. Infect Immun. 
2000;68: 921–924.  
113. Manco S, Hernon F, Yesilkaya H, Paton JC, Andrew PW, Kadioglu A. Pneumococcal 
neuraminidases A and B both have essential roles during infection of the respiratory 
tract and sepsis. Infect Immun. 2006;74: 4014–4020. doi:10.1128/IAI.01237-05 
General introduction 
59 
114. Marion C, Limoli DH, Bobulsky GS, Abraham JL, Burnaugh AM, King SJ. 
Identification of a pneumococcal glycosidase that modifies O-linked glycans. Infect 
Immun. 2009;77: 1389–1396. doi:10.1128/IAI.01215-08 
115. Jeong JK, Kwon O, Lee YM, Oh D-B, Lee JM, Kim S, et al. Characterization of the 
Streptococcus pneumoniae BgaC protein as a novel surface β-galactosidase with 
specific hydrolysis activity for the Galβ1-3GlcNAc moiety of oligosaccharides. J 
Bacteriol. 2009;191: 3011–3023. doi:10.1128/JB.01601-08 
116. Terra VS, Homer KA, Rao SG, Andrew PW, Yesilkaya H. Characterization of novel 
β-galactosidase activity that contributes to glycoprotein degradation and virulence in 
Streptococcus pneumoniae. Infect Immun. 2010;78: 348–357. 
doi:10.1128/IAI.00721-09 
117. Brittan JL, Buckeridge TJ, Finn A, Kadioglu A, Jenkinson HF. Pneumococcal 
neuraminidase A: an essential upper airway colonization factor for Streptococcus 
pneumoniae: Streptococcus pneumoniae neuraminidase. Mol Oral Microbiol. 
2012;27: 270–283. doi:10.1111/j.2041-1014.2012.00658.x 
118. Yesilkaya H, Spissu F, Carvalho SM, Terra VS, Homer KA, Benisty R, et al. Pyruvate 
formate lyase is required for pneumococcal fermentative metabolism and virulence. 
Infect Immun. 2009;77: 5418–5427. doi:10.1128/IAI.00178-09 
119. Gaspar P, Al-Bayati FAY, Andrew PW, Neves AR, Yesilkaya H. Lactate 
dehydrogenase is the key enzyme for pneumococcal pyruvate metabolism and 
pneumococcal survival in blood. Infect Immun. 2014;82: 5099–5109. 
doi:10.1128/IAI.02005-14 
120. Spellerberg B, Cundell DR, Sandros J, Pearce BJ, Idanpaan-Heikkila I, Rosenow C, 
et al. Pyruvate oxidase, as a determinant of virulence in Streptococcus pneumoniae. 
Mol Microbiol. 1996;19: 803–813.  
121. Hakansson AP. Pneumococcal adaptive responses to changing host environments. 
J Infect Dis. 2014;210: 1–3. doi:10.1093/infdis/jiu084 
122. Deutscher J, Francke C, Postma PW. How phosphotransferase system-related 
protein phosphorylation regulates carbohydrate metabolism in bacteria. Microbiol Mol 
Biol Rev. 2006;70: 939–1031. doi:10.1128/MMBR.00024-06 
123. Giammarinaro P, Paton JC. Role of RegM, a homologue of the catabolite repressor 
protein CcpA, in the virulence of Streptococcus pneumoniae. Infect Immun. 2002;70: 
5454–5461.  
124. Iyer R, Baliga NS, Camilli A. Catabolite Control Protein A (CcpA) Contributes to 
virulence and regulation of sugar metabolism in Streptococcus pneumoniae. J 
Bacteriol. 2005;187: 8340–8349. doi:10.1128/JB.187.24.8340-8349.2005 
125. Carvalho SM, Kloosterman TG, Kuipers OP, Neves AR. CcpA ensures optimal 
metabolic fitness of Streptococcus pneumoniae. Horsburgh MJ, editor. PLoS ONE. 
2011;6: e26707. doi:10.1371/journal.pone.0026707 
126. Sharon N. Nomenclature of glycoproteins, glycopeptides and peptidoglycans 
(Recommendations 1985). Pure Appl Chem. 1988;60. 
doi:10.1351/pac198860091389 
127. Sasaki N, Toyoda M. Glycoconjugates and related molecules in human vascular 
endothelial cells. Int J Vasc Med. 2013;2013: 1–10. doi:10.1155/2013/963596 
128. Tytgat HLP, Lebeer S. The sweet tooth of bacteria: common themes in bacterial 




129. Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in 
health and disease. Physiol Rev. 2006;86: 245–278. 
doi:10.1152/physrev.00010.2005 
130. Thornton DJ. From mucins to mucus: toward a more coherent understanding of this 
essential barrier. Proc Am Thorac Soc. 2004;1: 54–61. doi:10.1513/pats.2306016 
131. Derrien M, van Passel MW, van de Bovenkamp JH, Schipper RG, de Vos WM, 
Dekker J. Mucin-bacterial interactions in the human oral cavity and digestive tract. 
Gut Microbes. 2010;1: 254–268. doi:10.4161/gmic.1.4.12778 
132. Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA. Mucins in the mucosal 
barrier to infection. Mucosal Immunol. 2008;1: 183–197. doi:10.1038/mi.2008.5 
133. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit 
enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene 
expression. Am J Physiol. 1999;276: G941–950.  
134. Slomiany BL, Slomiany A. Cytosolic phospholipase A2 activation in Helicobacter 
pylori lipopolysaccharide-induced interference with gastric mucin synthesis. IUBMB 
Life. 2006;58: 217–223. doi:10.1080/15216540600732021 
135. Bry L, Falk PG, Midtvedt T, Gordon JI. A model of host-microbial interactions in an 
open mammalian ecosystem. Science. 1996;273: 1380–1383.  
136. Lindén SK, Wickström C, Lindell G, Gilshenan K, Carlstedt I. Four modes of adhesion 
are used during Helicobacter pylori binding to human mucins in the oral and gastric 
niches. Helicobacter. 2008;13: 81–93. doi:10.1111/j.1523-5378.2008.00587.x 
137. Corfield AP, Wagner SA, Clamp JR, Kriaris MS, Hoskins LC. Mucin degradation in 
the human colon: production of sialidase, sialate O-acetylesterase, N-
acetylneuraminate lyase, arylesterase, and glycosulfatase activities by strains of fecal 
bacteria. Infect Immun. 1992;60: 3971–3978.  
138. Homer KA, Whiley RA, Beighton D. Production of specific glycosidase activities by 
Streptococcus intermedius strain UNS35 grown in the presence of mucin. J Med 
Microbiol. 1994;41: 184–190.  
139. Hoskins J, Alborn WE, Arnold J, Blaszczak LC, Burgett S, DeHoff BS, et al. Genome 
of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol. 2001;183: 5709–
5717. doi:10.1128/JB.183.19.5709-5717.2001 
140. Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, et al. Complete 
genome sequence of a virulent isolate of Streptococcus pneumoniae. Science. 
2001;293: 498–506. doi:10.1126/science.1061217 
141. Bidossi A, Mulas L, Decorosi F, Colomba L, Ricci S, Pozzi G, et al. A functional 
genomics approach to establish the complement of carbohydrate transporters in 
Streptococcus pneumoniae. Miyaji EN, editor. PLoS ONE. 2012;7: e33320. 
doi:10.1371/journal.pone.0033320 
142. Rohmer L, Hocquet D, Miller SI. Are pathogenic bacteria just looking for food? 
Metabolism and microbial pathogenesis. Trends Microbiol. 2011;19: 341–348. 
doi:10.1016/j.tim.2011.04.003 
143. Buckwalter CM, King SJ. Pneumococcal carbohydrate transport: food for thought. 
Trends Microbiol. 2012;20: 517–522. doi:10.1016/j.tim.2012.08.008 
144. Price CE, Zeyniyev A, Kuipers OP, Kok J. From meadows to milk to mucosa - 
adaptation of Streptococcus and Lactococcus species to their nutritional 




145. Shelburne SA, Davenport MT, Keith DB, Musser JM. The role of complex 
carbohydrate catabolism in the pathogenesis of invasive streptococci. Trends 
Microbiol. 2008;16: 318–325. doi:10.1016/j.tim.2008.04.002 
146. Philips BJ, Meguer J-X, Redman J, Baker EH. Factors determining the appearance 
of glucose in upper and lower respiratory tract secretions. Intensive Care Med. 
2003;29: 2204–2210. doi:10.1007/s00134-003-1961-2 
147. Yesilkaya H, Manco S, Kadioglu A, Terra VS, Andrew PW. The ability to utilize mucin 
affects the regulation of virulence gene expression in Streptococcus pneumoniae. 
FEMS Microbiol Lett. 2008;278: 231–235. doi:10.1111/j.1574-6968.2007.01003.x 
148. Burnaugh AM, Frantz LJ, King SJ. Growth of Streptococcus pneumoniae on human 
glycoconjugates is dependent upon the sequential activity of bacterial 
exoglycosidases. J Bacteriol. 2008;190: 221–230. doi:10.1128/JB.01251-07 
149. Konings WN, Poolman B, van Veen HW. Solute transport and energy transduction in 
bacteria. Antonie Van Leeuwenhoek. 1994;65: 369–380.  
150. Davidson AL, Dassa E, Orelle C, Chen J. Structure, function, and evolution of 
bacterial ATP-binding cassette systems. Microbiol Mol Biol Rev. 2008;72: 317–364. 
doi:10.1128/MMBR.00031-07 
151. Higgins CF. ABC transporters: physiology, structure and mechanism – an overview. 
Res Microbiol. 2001;152: 205–210.  
152.Postma PW, Lengeler JW. Phosphoenolpyruvate:carbohydrate phosphotransferase 
system of bacteria. Microbiol Rev. 1985;49: 232–269.  
153. Lorca GL, Barabote RD, Zlotopolski V, Tran C, Winnen B, Hvorup RN, et al. Transport 
capabilities of eleven gram-positive bacteria: Comparative genomic analyses. 
Biochim Biophys Acta BBA - Biomembr. 2007;1768: 1342–1366. 
doi:10.1016/j.bbamem.2007.02.007 
154. Postma PW, Lengeler JW, Jacobson GR. Phosphoenolpyruvate:carbohydrate 
phosphotransferase systems of bacteria. Microbiol Rev. 1993;57: 543–594.  
155. Zähner D, Hakenbeck R. The Streptococcus pneumoniae beta-galactosidase is a 
surface protein. J Bacteriol. 2000;182: 5919–5921.  
156. Cai J, Tong H, Qi F, Dong X. CcpA-dependent carbohydrate catabolite repression 
regulates galactose metabolism in Streptococcus oligofermentans. J Bacteriol. 
2012;194: 3824–3832. doi:10.1128/JB.00156-12 
157. Zeng L, Xue P, Stanhope MJ, Burne RA. A galactose-specific sugar: 
phosphotransferase permease is prevalent in the non-core genome of Streptococcus 
mutans. Mol Oral Microbiol. 2013;28: 292–301. doi:10.1111/omi.12025 
158. Grossiord BP, Luesink EJ, Vaughan EE, Arnaud A, de Vos WM. Characterization, 
expression, and mutation of the Lactococcus lactis galPMKTE genes, involved in 
galactose utilization via the Leloir pathway. J Bacteriol. 2003;185: 870–878. 
doi:10.1128/JB.185.3.870-878.2003 
159. Thomas TD, Turner KW, Crow VL. Galactose fermentation by Streptococcus lactis 
and Streptococcus cremoris: pathways, products, and regulation. J Bacteriol. 
1980;144: 672–682.  
160. Thompson J. Galactose transport systems in Streptococcus lactis. J Bacteriol. 
1980;144: 683–691.  
161. De Vos WM, Vaughan EE. Genetics of lactose utilization in lactic acid bacteria. FEMS 
Microbiol Rev. 1994;15: 217–237.  
Chapter 1 
62 
162. LeBlanc DJ, Crow VL, Lee LN, Garon CF. Influence of the lactose plasmid on the 
metabolism of galactose by Streptococcus lactis. J Bacteriol. 1979;137: 878–884.  
163. Zeng L, Das S, Burne RA. Utilization of lactose and galactose by Streptococcus 
mutans: transport, toxicity, and carbon catabolite repression. J Bacteriol. 2010;192: 
2434–2444. doi:10.1128/JB.01624-09 
164. Abranches J, Chen Y-YM, Burne RA. Galactose metabolism by Streptococcus 
mutans. Appl Env Microbiol. 2004;70: 6047–6052. doi:10.1128/AEM.70.10.6047-
6052.2004 
165. Neves AR, Pool WA, Solopova A, Kok J, Santos H, Kuipers OP. Towards enhanced 
galactose utilization by Lactococcus lactis. Appl Env Microbiol. 2010;76: 7048–7060. 
doi:10.1128/AEM.01195-10 
166. Zeng L, Martino NC, Burne RA. Two gene clusters coordinate galactose and lactose 
metabolism in Streptococcus gordonii. Appl Env Microbiol. 2012;78: 5597–5605. 
doi:10.1128/AEM.01393-12 
167. Kaufman GE, Yother J. CcpA-dependent and -independent control of beta-
galactosidase expression in Streptococcus pneumoniae occurs via regulation of an 
upstream phosphotransferase system-encoding operon. J Bacteriol. 2007;189: 
5183–5192. doi:10.1128/JB.00449-07 
168.Chen Y-YM, Betzenhauser MJ, Snyder JA, Burne RA. Pathways for lactose/galactose 
catabolism by Streptococcus salivarius. FEMS Microbiol Lett. 2002;209: 75–79.  
169. Vaillancourt K, LeMay J-D, Lamoureux M, Frenette M, Moineau S, Vadeboncoeur C. 
Characterization of a galactokinase-positive recombinant strain of Streptococcus 
thermophilus. Appl Environ Microbiol. 2004;70: 4596–4603. 
doi:10.1128/AEM.70.8.4596-4603.2004 
170. Afzal M, Shafeeq S, Kuipers OP. LacR is a repressor of lacABCD and LacT an 
activator of lacTFEG, constituting the lac-gene cluster in Streptococcus pneumoniae. 
Appl Environ Microbiol. 2014; doi:10.1128/AEM.01370-14 
171. Grossiord B, Vaughan EE, Luesink E, de Vos WM. Genetics of galactose utilisation 
via the Leloir pathway in lactic acid bacteria. Le Lait. 1998;78: 77–84. 
doi:10.1051/lait:1998110 
172. Sharma V, Ichikawa M, Freeze HH. Mannose metabolism: More than meets the eye. 
Biochem Biophys Res Commun. 2014; doi:10.1016/j.bbrc.2014.06.021 
173. Homer KA, Roberts G, Byers HL, Tarelli E, Whiley RA, Philpott-Howard J, et al. 
Mannosidase production by viridans group Streptococci. J Clin Microbiol. 2001;39: 
995–1001. doi:10.1128/JCM.39.3.995-1001.2001 
174. Sasaki M, Teramoto H, Inui M, Yukawa H. Identification of mannose uptake and 
catabolism genes in Corynebacterium glutamicum and genetic engineering for 
simultaneous utilization of mannose and glucose. Appl Microbiol Biotechnol. 2011;89: 
1905–1916. doi:10.1007/s00253-010-3002-8 
175. Darzins A, Nixon LL, Vanags RI, Chakrabarty AM. Cloning of Escherichia coli and 
Pseudomonas aeruginosa phosphomannose isomerase genes and their expression 
in alginate-negative mutants of Pseudomonas aeruginosa. J Bacteriol. 1985;161: 
249–257.  
176. Stolz B, Huber M, Marković-Housley Z, Erni B. The mannose transporter of 
Escherichia coli. Structure and function of the IIABMan subunit. J Biol Chem. 
1993;268: 27094–27099.  
General introduction 
63 
177. Martin-Verstraete I, Michel V, Charbit A. The levanase operon of Bacillus subtilis 
expressed in Escherichia coli can substitute for the mannose permease in mannose 
uptake and bacteriophage lambda infection. J Bacteriol. 1996;178: 7112–7119.  
178. Kornberg HL, Lambourne LTM. Role of the phosphoenolpyruvate-dependent fructose 
phosphotransferase system in the utilization of mannose by Escherichia coli. Proc 
Biol Sci. 1992;250: 51–55.  
179. Pelletier G, Frenette M, Vadeboncoeur C. Transport of mannose by an inducible 
phosphoenolpyruvate:fructose phosphotransferase system in Streptococcus 
salivarius. Microbiol Read Engl. 1994;140 ( Pt 9): 2433–2438.  
180. Sun T, Altenbuchner J. Characterization of a mannose utilization system in Bacillus 
subtilis. J Bacteriol. 2010;192: 2128–2139. doi:10.1128/JB.01673-09 
181. Köplin R, Arnold W, Hötte B, Simon R, Wang G, Pühler A. Genetics of xanthan 
production in Xanthomonas campestris: the xanA and xanB genes are involved in 
UDP-glucose and GDP-mannose biosynthesis. J Bacteriol. 1992;174: 191–199.  
182. Schmidt M, Arnold W, Niemann A, Kleickmann A, Pühler A. The Rhizobium meliloti 
pmi gene encodes a new type of phosphomannose isomerase. Gene. 1992;122: 35–
43. doi:10.1016/0378-1119(92)90029-O 
183. Arias A, Gardiol A, Martínez-Drets G. Transport and catabolism of D-mannose in 
Rhizobium meliloti. J Bacteriol. 1982;151: 1069–1072.  
184. Rodionov DA, Yang C, Li X, Rodionova IA, Wang Y, Obraztsova AY, et al. Genomic 
encyclopedia of sugar utilization pathways in the Shewanella genus. BMC Genomics. 
2010;11: 494. doi:10.1186/1471-2164-11-494 
185. Berry AM, Lock RA, Paton JC. Cloning and characterization of nanB, a second 
Streptococcus pneumoniae neuraminidase gene, and purification of the NanB 
enzyme from recombinant Escherichia coli. J Bacteriol. 1996;178: 4854–4860.  
186. Cámara M, Boulnois GJ, Andrew PW, Mitchell TJ. A neuraminidase from 
Streptococcus pneumoniae has the features of a surface protein. Infect Immun. 
1994;62: 3688–3695.  
187. Clarke VA, Platt N, Butters TD. Cloning and expression of the beta-N-
acetylglucosaminidase gene from Streptococcus pneumoniae. Generation of 
truncated enzymes with modified aglycon specificity. J Biol Chem. 1995;270: 8805–
8814.  
188. Severi E, Hood DW, Thomas GH. Sialic acid utilization by bacterial pathogens. 
Microbiology. 2007;153: 2817–2822. doi:10.1099/mic.0.2007/009480-0 
189. Pezzicoli A, Ruggiero P, Amerighi F, Telford JL, Soriani M. Exogenous sialic acid 
transport contributes to group B streptococcus infection of mucosal surfaces. J Infect 
Dis. 2012;206: 924–931. doi:10.1093/infdis/jis451 
190. Konopka JB. N-acetylglucosamine (GlcNAc) functions in cell signaling. Scientifica. 
2012. doi:10.6064/2012/489208 
191. Moye ZD, Burne RA, Zeng L. Uptake and metabolism of N-acetylglucosamine and 
glucosamine by Streptococcus mutans. Appl Env Microbiol. 2014; 
doi:10.1128/AEM.00820-14 
192. Boulanger A, Dejean G, Lautier M, Glories M, Zischek C, Arlat M, et al. Identification 
and regulation of the N-acetylglucosamine utilization pathway of the plant pathogenic 




193. Takahashi Y, Ruhl S, Yoon J-W, Sandberg AL, Cisar JO. Adhesion of viridans group 
streptococci to sialic acid-, galactose- and N-acetylgalactosamine-containing 
receptors. Oral Microbiol Immunol. 2002;17: 257–262.  
194. Bidart GN, Rodríguez-Díaz J, Monedero V, Yebra MJ. A unique gene cluster for the 
utilization of the mucosal and human milk-associated glycans galacto- N -biose and 
lacto- N -biose in L actobacillus casei: Galacto- and lacto- N -biose utilization in 
Lactobacillus. Mol Microbiol. 2014;93: 521–538. doi:10.1111/mmi.12678 
195. Trappetti C, Kadioglu A, Carter M, Hayre J, Iannelli F, Pozzi G, et al. Sialic acid: a 
preventable signal for pneumococcal biofilm formation, colonization, and invasion of 
the host. J Infect Dis. 2009;199: 1497–1505. doi:10.1086/598483 
196. Parker D, Soong G, Planet P, Brower J, Ratner AJ, Prince A. The NanA 
neuraminidase of Streptococcus pneumoniae is involved in biofilm formation. Infect 
Immun. 2009;77: 3722–3730. doi:10.1128/IAI.00228-09 
197. Chang D-E, Smalley DJ, Tucker DL, Leatham MP, Norris WE, Stevenson SJ, et al. 
Carbon nutrition of Escherichia coli in the mouse intestine. Proc Natl Acad Sci U S A. 
2004;101: 7427–7432. doi:10.1073/pnas.0307888101 
198. Rigali S, Nothaft H, Noens EEE, Schlicht M, Colson S, Müller M, et al. The sugar 
phosphotransferase system of Streptomyces coelicolor is regulated by the GntR-
family regulator DasR and links N-acetylglucosamine metabolism to the control of 
development. Mol Microbiol. 2006;61: 1237–1251. doi:10.1111/j.1365-
2958.2006.05319.x 
199. Rigali S, Titgemeyer F, Barends S, Mulder S, Thomae AW, Hopwood DA, et al. Feast 
or famine: the global regulator DasR links nutrient stress to antibiotic production by 
Streptomyces. EMBO Rep. 2008;9: 670–675. doi:10.1038/embor.2008.83 
200. Swiatek MA, Tenconi E, Rigali S, van Wezel GP. Functional analysis of the N-
acetylglucosamine metabolic genes of Streptomyces coelicolor and role in control of 
development and antibiotic production. J Bacteriol. 2012;194: 1136–1144. 
doi:10.1128/JB.06370-11 
201. Barthelson R, Mobasseri A, Zopf D, Simon P. Adherence of Streptococcus 
pneumoniae to respiratory epithelial cells is inhibited by sialylated oligosaccharides. 
Infect Immun. 1998;66: 1439–1444.  
202. Andersson B, Beachey EH, Tomasz A, Tuomanen E, Svanborg-Edén C. A sandwich 
adhesion on Streptococcus pneumoniae attaching to human oropharyngeal epithelial 
cells in vitro. Microb Pathog. 1988;4: 267–278.  
203. Cundell DR, Tuomanen EI. Receptor specificity of adherence of Streptococcus 
pneumoniae to human type-II pneumocytes and vascular endothelial cells in vitro. 
Microb Pathog. 1994;17: 361–374. doi:10.1006/mpat.1994.1082 
204. Krivan HC, Roberts DD, Ginsburg V. Many pulmonary pathogenic bacteria bind 
specifically to the carbohydrate sequence GalNAc beta 1-4Gal found in some 
glycolipids. Proc Natl Acad Sci U S A. 1988;85: 6157–6161.  
205. Almagro-Moreno S, Boyd EF. Insights into the evolution of sialic acid catabolism 
among bacteria. BMC Evol Biol. 2009;9: 118. doi:10.1186/1471-2148-9-118 
206. Vimr ER, Kalivoda KA, Deszo EL, Steenbergen SM. Diversity of microbial sialic acid 
metabolism. Microbiol Mol Biol Rev. 2004;68: 132–153. 
doi:10.1128/MMBR.68.1.132-153.2004 
207. King SJ, Hippe KR, Gould JM, Bae D, Peterson S, Cline RT, et al. Phase variable 
desialylation of host proteins that bind to Streptococcus pneumoniae in vivo and 
General introduction 
65 
protect the airway: Pneumococcal desialylation of host proteins. Mol Microbiol. 
2004;54: 159–171. doi:10.1111/j.1365-2958.2004.04252.x 
208. Gualdi L, Hayre J, Gerlini A, Bidossi A, Colomba L, Trappetti C, et al. Regulation of 
neuraminidase expression in Streptococcus pneumoniae. BMC Microbiol. 2012;12: 
200. doi:10.1186/1471-2180-12-200 
209. Pettigrew MM, Fennie KP, York MP, Daniels J, Ghaffar F. Variation in the presence 
of neuraminidase genes among Streptococcus pneumoniae isolates with identical 
sequence types. Infect Immun. 2006;74: 3360–3365. doi:10.1128/IAI.01442-05 
210. Vimr ER, Troy FA. Identification of an inducible catabolic system for sialic acids (nan) 
in Escherichia coli. J Bacteriol. 1985;164: 845–853.  
211. Steenbergen SM, Lichtensteiger CA, Caughlan R, Garfinkle J, Fuller TE, Vimr ER. 
Sialic acid metabolism and systemic pasteurellosis. Infect Immun. 2005;73: 1284–
1294. doi:10.1128/IAI.73.3.1284-1294.2005 
212. Allen S, Zaleski A, Johnston JW, Gibson BW, Apicella MA. Novel sialic acid 
transporter of Haemophilus influenzae. Infect Immun. 2005;73: 5291–5300. 
doi:10.1128/IAI.73.9.5291-5300.2005 
213. Severi E, Randle G, Kivlin P, Whitfield K, Young R, Moxon R, et al. Sialic acid 
transport in Haemophilus influenzae is essential for lipopolysaccharide sialylation and 
serum resistance and is dependent on a novel tripartite ATP-independent periplasmic 
transporter. Mol Microbiol. 2005;58: 1173–1185. doi:10.1111/j.1365-
2958.2005.04901.x 
214. Post DMB, Mungur R, Gibson BW, Munson RS. Identification of a novel sialic acid 
transporter in Haemophilus ducreyi. Infect Immun. 2005;73: 6727–6735. 
doi:10.1128/IAI.73.10.6727-6735.2005 
215. Severi E, Hosie AHF, Hawkhead JA, Thomas GH. Characterization of a novel sialic 
acid transporter of the sodium solute symporter (SSS) family and in vivo comparison 
with known bacterial sialic acid transporters: An SSS transporter for sialic acid from 
Salmonella. FEMS Microbiol Lett. 2010;304: 47–54. doi:10.1111/j.1574-
6968.2009.01881.x 
216. Byers HL, Homer KA, Beighton D. Utilization of sialic acid by viridans streptococci. J 
Dent Res. 1996;75: 1564–1571. doi:10.1177/00220345960750080701 
217. Brigham CJ, Malamy MH. Characterization of the RokA and HexA broad-substrate-
specificity hexokinases from Bacteroides fragilis and their role in hexose and N-
acetylglucosamine utilization. J Bacteriol. 2005;187: 890–901. 
doi:10.1128/JB.187.3.890-901.2005 
218. Brigham C, Caughlan R, Gallegos R, Dallas MB, Godoy VG, Malamy MH. Sialic acid 
(N-acetyl neuraminic acid) utilization by Bacteroides fragilis requires a novel N-acetyl 
mannosamine epimerase. J Bacteriol. 2009;191: 3629–3638. doi:10.1128/JB.00811-
08 
219. Roy S, Douglas CWI, Stafford GP. A novel sialic acid utilization and uptake system 
in the periodontal pathogen Tannerella forsythia. J Bacteriol. 2010;192: 2285–2293. 
doi:10.1128/JB.00079-10 
220. Rogers MJ, Ohgi T, Plumbridge J, Söll D. Nucleotide sequences of the Escherichia 
coli nagE and nagB genes: the structural genes for the N-acetylglucosamine transport 
protein of the bacterial phosphoenolpyruvate: sugar phosphotransferase system and 
for glucosamine-6-phosphate deaminase. Gene. 1988;62: 197–207.  
Chapter 1 
66 
221. Alvarez-Añorve LI, Calcagno ML, Plumbridge J. Why does Escherichia coli grow 
more slowly on glucosamine than on N-acetylglucosamine? Effects of enzyme levels 
and allosteric activation of GlcN6P deaminase (NagB) on growth rates. J Bacteriol. 
2005;187: 2974–2982. doi:10.1128/JB.187.9.2974-2982.2005 
222. Gaugué I, Oberto J, Putzer H, Plumbridge J. The use of amino sugars by Bacillus 
subtilis: presence of a unique operon for the catabolism of glucosamine. Uversky VN, 
editor. PLoS ONE. 2013;8: e63025. doi:10.1371/journal.pone.0063025 
223. Xiao X, Wang F, Saito A, Majka J, Schlösser A, Schrempf H.  The novel Streptomyces 
olivaceoviridis ABC transporter Ngc mediates uptake of N-acetylglucosamine and 
N,N’-diacetylchitobiose. Mol Genet Genomics. 2002;267: 429–439. 
doi:10.1007/s00438-002-0640-2 
224. Yang C, Rodionov DA, Li X, Laikova ON, Gelfand MS, Zagnitko OP, et al. 
Comparative genomics and experimental characterization of N-acetylglucosamine 
utilization pathway of Shewanella oneidensis. J Biol Chem. 2006;281: 29872–29885. 
doi:10.1074/jbc.M605052200 
225. Reizer J, Ramseier TM, Reizer A, Charbit A, Saier MH Jr. Novel phosphotransferase 
genes revealed by bacterial genome sequencing: a gene cluster encoding a putative 
N-acetylgalactosamine metabolic pathway in Escherichia coli. Microbiol Read Engl. 
1996;142 ( Pt 2): 231–250.  
226. Brinkkötter A, Klöss H, Alpert C, Lengeler JW. Pathways for the utilization of N-acetyl-
galactosamine and galactosamine in Escherichia coli. Mol Microbiol. 2000;37: 125–
135.  
227. Hu Z, Patel IR, Mukherjee A. Genetic analysis of the roles of agaA, agaI, and agaS 
genes in the N-acetyl-D-galactosamine and D-galactosamine catabolic pathways in 
Escherichia coli strains O157:H7 and C. BMC Microbiol. 2013;13: 94. 
doi:10.1186/1471-2180-13-94 
228. Ezquerro-Sáenz C, Ferrero MA, Revilla-Nuin B, López Velasco FF, Martínez-Blanco 
H, Rodríguez-Aparicio LB. Transport of N-acetyl-D-galactosamine in Escherichia coli 
K92: effect on acetyl-amino sugar metabolism and polysialic acid production. 
Biochimie. 2006;88: 95–102. doi:10.1016/j.biochi.2005.06.011 
229. Brinkkötter A, Shakeri-Garakani A, Lengeler JW. Two class II D-tagatose-
bisphosphate aldolases from enteric bacteria. Arch Microbiol. 2002;177: 410–419. 
doi:10.1007/s00203-002-0406-6 
230. Leyn SA, Gao F, Yang C, Rodionov DA. N-Acetylgalactosamine utilization pathway 
and regulon in proteobacteria: genomic reconstruction and experimental 
characterization in Shewanella. J Biol Chem. 2012;287: 28047–28056. 
doi:10.1074/jbc.M112.382333 
231. Becker DJ, Lowe JB. Fucose: biosynthesis and biological function in mammals. 
Glycobiology. 2003;13: 41R–53R. doi:10.1093/glycob/cwg054 
232. Hugdahl MB, Beery JT, Doyle MP. Chemotactic behavior of Campylobacter jejuni. 
Infect Immun. 1988;56: 1560–1566.  
233. Higgins MA, Abbott DW, Boulanger MJ, Boraston AB. Blood group antigen 
recognition by a solute-binding protein from a serotype 3 strain of Streptococcus 
pneumoniae. J Mol Biol. 2009;388: 299–309. doi:10.1016/j.jmb.2009.03.012 
234. Higgins MA, Suits MD, Marsters C, Boraston AB. Structural and functional analysis 
of fucose-processing enzymes from Streptococcus pneumoniae. J Mol Biol. 
2014;426: 1469–1482. doi:10.1016/j.jmb.2013.12.006 
General introduction 
67 
235. Scott KP, Martin JC, Campbell G, Mayer C-D, Flint HJ. Whole-genome transcription 
profiling reveals genes up-regulated by growth on fucose in the human gut bacterium 
“Roseburia inulinivorans.” J Bacteriol. 2006;188: 4340–4349. doi:10.1128/JB.00137-
06 
236. Yu Z-T, Chen C, Newburg DS. Utilization of major fucosylated and sialylated human 
milk oligosaccharides by isolated human gut microbes. Glycobiology. 2013;23: 1281–
1292. doi:10.1093/glycob/cwt065 
237. Coyne MJ, Reinap B, Lee MM, Comstock LE. Human symbionts use a host-like 
pathway for surface fucosylation. Science. 2005;307: 1778–1781. 
doi:10.1126/science.1106469 
238. Hooper LV, Xu J, Falk PG, Midtvedt T, Gordon JI. A molecular sensor that allows a 
gut commensal to control its nutrient foundation in a competitive ecosystem. Proc 
Natl Acad Sci U S A. 1999;96: 9833–9838.  
239. Badía J, Ros J, Aguilar J. Fermentation mechanism of fucose and rhamnose in 
Salmonella typhimurium and Klebsiella pneumoniae. J Bacteriol. 1985;161: 435–437.  
240. Baldomà L, Aguilar J. Metabolism of L-fucose and L-rhamnose in Escherichia coli: 
aerobic-anaerobic regulation of L-lactaldehyde dissimilation. J Bacteriol. 1988;170: 
416–421.  
241. Embry A, Hinojosa E, Orihuela CJ. Regions of Diversity 8, 9 and 13 contribute to 
Streptococcus pneumoniae virulence. BMC Microbiol. 2007;7: 80. doi:10.1186/1471-
2180-7-80 
242. Higgins MA, Whitworth GE, El Warry N, Randriantsoa M, Samain E, Burke RD, et al. 
Differential recognition and hydrolysis of host carbohydrate antigens by 
Streptococcus pneumoniae family 98 glycoside hydrolases. J Biol Chem. 2009;284: 
26161–26173. doi:10.1074/jbc.M109.024067 
243. Pacheco AR, Curtis MM, Ritchie JM, Munera D, Waldor MK, Moreira CG, et al. 
Fucose sensing regulates bacterial intestinal colonization. Nature. 2012;492: 113–
117. doi:10.1038/nature11623 
244. Hooper LV, Gordon JI. Glycans as legislators of host-microbial interactions: spanning 
the spectrum from symbiosis to pathogenicity. Glycobiology. 2001;11: 1R–10R. 
doi:10.1093/glycob/11.2.1R 
245. Ilver D, Arnqvist A, Ogren J, Frick IM, Kersulyte D, Incecik ET, et al. Helicobacter 
pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. 
Science. 1998;279: 373–377.  
246. Cinco M, Banfi E, Ruaro E, Crevatin D, Crotti D. Evidence for l-fucose (6-deoxy-l-
galactopyranose)-mediated adherence of Campylobacter spp. to epithelial cells. 
FEMS Microbiol Lett. 1984;21: 347–351.  
247. Liu T-W, Ho C-W, Huang H-H, Chang S-M, Popat SD, Wang Y-T, et al. Role for 
alpha-L-fucosidase in the control of Helicobacter pylori-infected gastric cancer cells. 
Proc Natl Acad Sci U S A. 2009;106: 14581–14586. doi:10.1073/pnas.0903286106 
248. Higgins MA, Boraston AB. Structure of the fucose mutarotase from Streptococcus 
pneumoniae in complex with L-fucose. Acta Crystallograph Sect F Struct Biol Cryst 
Commun. 2011;67: 1524–1530. doi:10.1107/S1744309111046343 
249. Chen YM, Zhu Y, Lin EC. The organization of the fuc regulon specifying L-fucose 
dissimilation in Escherichia coli K12 as determined by gene cloning. Mol Gen Genet 
MGG. 1987;210: 331–337.  
Chapter 1 
68 
250. Chen YM, Zhu Y, Lin EC. NAD-linked aldehyde dehydrogenase for aerobic utilization 
of L-fucose and L-rhamnose by Escherichia coli. J Bacteriol. 1987;169: 3289–3294.  
251. Lu Z, Lin EC. The nucleotide sequence of Escherichia coli genes for L-fucose 
dissimilation. Nucleic Acids Res. 1989;17: 4883–4884.  
252. Sugihara J, Sun L, Yan N, Kaback HR. Dynamics of the L-fucose/H+ symporter 
revealed by fluorescence spectroscopy. Proc Natl Acad Sci. 2012;109: 14847–
14851. doi:10.1073/pnas.1213445109 
253. Muraoka WT, Zhang Q. Phenotypic and genotypic evidence for L-Fucose utilization 
by Campylobacter jejuni. J Bacteriol. 2011;193: 1065–1075. doi:10.1128/JB.01252-
10 
254. Stahl M, Friis LM, Nothaft H, Liu X, Li J, Szymanski CM, et al. L-Fucose utilization 
provides Campylobacter jejuni with a competitive advantage. Proc Natl Acad Sci. 
2011;108: 7194–7199. doi:10.1073/pnas.1014125108 
255. Hofreuter D. Defining the metabolic requirements for the growth and colonization 
capacity of Campylobacter jejuni. Front Cell Infect Microbiol. 2014;4. 
doi:10.3389/fcimb.2014.00137 
256. Yew WS, Fedorov AA, Fedorov EV, Rakus JF, Pierce RW, Almo SC, et al. Evolution 
of enzymatic activities in the enolase superfamily: L-fuconate dehydratase from 
Xanthomonas campestris. Biochemistry (Mosc). 2006;45: 14582–14597. 
doi:10.1021/bi061687o 
257. Petit E, LaTouf WG, Coppi MV, Warnick TA, Currie D, Romashko I, et al. Involvement 
of a bacterial microcompartment in the metabolism of fucose and rhamnose by 
Clostridium phytofermentans. de Crécy-Lagard V, editor. PLoS ONE. 2013;8: 
e54337. doi:10.1371/journal.pone.0054337 
258. Havemann GD, Bobik TA. Protein content of polyhedral organelles involved in 
coenzyme B12-dependent degradation of 1,2-propanediol in Salmonella enterica 
serovar Typhimurium LT2. J Bacteriol. 2003;185: 5086–5095. 
doi:10.1128/JB.185.17.5086-5095.2003 
259. Bobik TA, Xu Y, Jeter RM, Otto KE, Roth JR. Propanediol utilization genes (pdu) of 
Salmonella typhimurium: three genes for the propanediol dehydratase. J Bacteriol. 
1997;179: 6633–6639.  
260. Chen YM, Lu Z, Lin EC. Constitutive activation of the fucAO operon and silencing of 
the divergently transcribed fucPIK operon by an IS5 element in Escherichia coli 
mutants selected for growth on L-1,2-propanediol. J Bacteriol. 1989;171: 6097–6105.  
261. Schwab C, Gänzle M. Lactic acid bacteria fermentation of human milk 
oligosaccharide components, human milk oligosaccharides and 
galactooligosaccharides: LAB fermentation of HMOs and GOSs. FEMS Microbiol 
Lett. 2011;315: 141–148. doi:10.1111/j.1574-6968.2010.02185.x 
262. Rodriguez-Diaz J, Rubio-del-Campo A, Yebra MJ. Lactobacillus casei ferments the 
N-acetylglucosamine moiety of fucosyl-alpha -1,3-N-acetylglucosamine and excretes 
L-Fucose. Appl Environ Microbiol. 2012;78: 4613–4619. doi:10.1128/AEM.00474-12 
263. Castro R, Neves AR, Fonseca LL, Pool WA, Kok J, Kuipers OP, et al. 
Characterization of the individual glucose uptake systems of Lactococcus lactis : 
mannose-PTS, cellobiose-PTS and the novel GlcU permease. Mol Microbiol. 
2009;71: 795–806. doi:10.1111/j.1365-2958.2008.06564.x 
General introduction 
69 
264. Gosset G. Improvement of Escherichia coli production strains by modification of the 
phosphoenolpyruvate:sugar phosphotransferase system. Microb Cell Factories. 
2005;4: 14. doi:10.1186/1475-2859-4-14 
265. Paulsen IT, Chauvaux S, Choi P, Saier MH. Characterization of glucose-specific 
catabolite repression-resistant mutants of Bacillus subtilis: identification of a novel 
hexose:H+ symporter. J Bacteriol. 1998;180: 498–504.  
266. Neves AR, Ramos A, Shearman C, Gasson MJ, Almeida JS, Santos H. Metabolic 
characterization of Lactococcus lactis deficient in lactate dehydrogenase using in vivo 
13C-NMR. Eur J Biochem FEBS. 2000;267: 3859–3868.  
267. Gaspar P, Neves AR, Shearman CA, Gasson MJ, Baptista AM, Turner DL, et al. The 
lactate dehydrogenases encoded by the ldh and ldhB genes in Lactococcus lactis 
exhibit distinct regulation and catalytic properties − comparative modeling to probe 
the molecular basis: Lactacte dehydrogenases of Lactococcus lactis. FEBS J. 
2007;274: 5924–5936. doi:10.1111/j.1742-4658.2007.06115.x 
268. Gaspar P, Neves AR, Gasson MJ, Shearman CA, Santos H. High yields of 2,3-
butanediol and mannitol in Lactococcus lactis through engineering of NAD+ cofactor 
recycling. Appl Environ Microbiol. 2011;77: 6826–6835. doi:10.1128/AEM.05544-11 
269. C. Garrigues, P. Loubiere, N. D. Lindley, M. Cocaign-Bousquet. Control of the shift 
from homolactic acid to mixed-acid fermentation in Lactococcus lactis: predominant 
role of the NADH/NAD+ ratio. J Bacteriol. 1997;179: 5282–5287.  
270. Melchiorsen CR,  Jokumsen KV,  Villadsen J,  Israelsen H,  Arnau J. The level of 
pyruvate-formate lyase controls the shift from homolactic to mixed-acid product 
formation in Lactococcus lactis. Appl Microbiol Biotechnol. 2002;58: 338–344. 
doi:10.1007/s00253-001-0892-5 
271. Neves AR, Ventura R, Mansour N, Shearman C, Gasson MJ, Maycock C et al. Is the 
glycolytic flux in Lactococcus lactis primarily controlled by the redox charge? Kinetics 
of NAD+ and NADH pools determined in vivo by 13C NMR. J Biol Chem. 2002;277: 
28088–28098. doi:10.1074/jbc.M202573200 
272. Thomas TD, Ellwood DC, Longyear VM. Change from homo- to heterolactic 
fermentation by Streptococcus lactis resulting from glucose limitation in anaerobic 
chemostat cultures. J Bacteriol. 1979;138: 109–117.  
273. Lanie JA, Ng W-L, Kazmierczak KM, Andrzejewski TM, Davidsen TM, Wayne KJ, et 
al. Genome sequence of Avery’s virulent serotype 2 strain D39 of Streptococcus 
pneumoniae and comparison with that of unencapsulated laboratory strain R6. J 
Bacteriol. 2007;189: 38–51. doi:10.1128/JB.01148-06 
274. Ramos-Montañez S, Kazmierczak KM, Hentchel KL, Winkler ME. Instability of ackA 
(acetate kinase) mutations and their effects on acetyl phosphate and ATP amounts 









Host glycan sugar-specific pathways in 
Streptococcus pneumoniae: galactose as a 
key sugar in colonisation and infection 
 
 
The results of this chapter are published in: 
Paixão, L, Oliveira, J, Veríssimo, A, Vinga, S, Lourenço, EC, Ventura, 
MR, Kjos, M, Veening, J-W, Fernandes, VE, Andrew, PW, Yesilkaya, 
H and Neves, AR (2015). Host glycan sugar-specific pathways in 
Streptococcus pneumoniae: galactose as a key sugar in colonisation 
and infection. Plos One. 2015. In press. 
Chapter 2 - Host glycan sugar-specific pathways in 
Streptococcus pneumoniae 

Host glycan sugar-specific pathways in S. pneumoniae 
73 
Chapter 2 – Contents 
Abstract .................................................................................................. 75 
Introduction ............................................................................................ 75 
Materials and Methods ........................................................................... 78 
Bacterial strains and growth conditions .............................................. 78 
Statistical analysis of the growth parameters ..................................... 79 
Multiple non-linear regression method for generating confidence 
interval bands ..................................................................................... 80 
General molecular techniques ............................................................ 80 
Construction of loss-of-function mutants ............................................ 81 
Construction of the pKB01 derivatives for complementation studies . 82 
Complementation of deletion strains .................................................. 83 
Growth of complemented strains ........................................................ 83 
Transcriptome analysis ...................................................................... 83 
Microarray experiments ...................................................................... 84 
Analysis of microarrays ...................................................................... 84 
Quantitative RT-PCR .......................................................................... 85 
In silico analysis for catabolic pathway prediction .............................. 85 
Growth assay for assessment of sugar utilization by S. pneumoniae 
D39 ..................................................................................................... 86 
Quantification of sugar consumption and fermentation products ....... 86 
Cold ethanol extractions and determination of intracellular metabolites 
by 31P-NMR ........................................................................................ 87 
Enzyme activity determination ............................................................ 88 
In vivo analysis of pneumococcal strains ........................................... 90 
Chemicals ........................................................................................... 92 
Ethical disclaimer ............................................................................... 92 
Results ................................................................................................... 93 
Genomic potential for the utilization of host monosaccharides .......... 93 
Chapter 2 
74 
The ability of host glycan-derived sugars to support growth is sugar 
dependent .......................................................................................... 95 
Mucin induces expression of genes involved in utilization of Gal, 
GlcNAc and Man ................................................................................ 96 
Growth properties on Gal, GlcNAc and Man or on a mixture thereof 99 
Growth profiles on Gal, Man and GlcNAc. ..................................... 99 
Fermentation products. ................................................................ 105 
Growth profiles, substrate consumption and end-products of 
fermentation in a mixture of Gal, GlcNAc and Man. ..................... 107 
Catabolic pathways for the utilization of Gal, GlcNAc and Man as 
assessed using biochemical and molecular tools ............................ 108 
Intracellular metabolites during growth on glycan-derived sugars.
 ..................................................................................................... 109 
Enzymatic activities of key enzymes involved in the catabolism of 
glycan-derived sugars. ................................................................. 111 
Genetic confirmation of pathway functionality. ............................. 113 
Attenuated virulence in the absence of a functional Gal pathway ... 115 





Author’s contribution ............................................................................ 129 
References .......................................................................................... 130 
Supporting Information ........................................................................ 137 
  
Host glycan sugar-specific pathways in S. pneumoniae 
75 
Abstract  
The human pathogen Streptococcus pneumoniae is a strictly 
fermentative organism that relies on glycolytic metabolism to obtain 
energy. In the human nasopharynx S. pneumoniae encounters 
glycoconjugates composed of a variety of monosaccharides, which can 
potentially be used as nutrients once depolymerized by glycosidases. 
Therefore, it is reasonable to hypothesise that the pneumococcus would 
rely on these glycan-derived sugars to grow. Here, we identified the sugar-
specific catabolic pathways used by S. pneumoniae during growth on 
mucin. Transcriptome analysis of cells grown on mucin showed specific 
upregulation of genes likely to be involved in deglycosylation, transport 
and catabolism of galactose, mannose and N-acetylglucosamine. In 
contrast to growth on mannose and N-acetylglucosamine, S. pneumoniae 
grown on galactose re-route their metabolic pathway from homolactic 
fermentation to a truly mixed acid fermentation regime. By measuring 
intracellular metabolites, enzymatic activities and mutant analysis, we 
provide an accurate map of the biochemical pathways for galactose, 
mannose and N-acetylglucosamine catabolism in S. pneumoniae. 
Intranasal mouse infection models of pneumococcal colonisation and 
disease showed that only mutants in galactose catabolic genes were 
attenuated. Our data pinpoint galactose as a key nutrient for growth in the 
respiratory tract and highlights the importance of central carbon 
metabolism for pneumococcal pathogenesis.  
 
Introduction 
Streptococcus pneumoniae is an important human pathogen 
responsible for high morbidity and mortality worldwide, mainly due to 
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community-acquired pneumonia, meningitis, bacteraemia and otitis 
media [1,2]. The pneumococcus is, however, also a transient commensal 
that asymptomatically resides and proliferates in the human nasopharynx 
[3]. Colonisation of the nasopharynx is of importance as it represents a 
reservoir from which bacteria can disseminate throughout the community 
[2,4]. Furthermore, the establishment of a carrier state is accepted to be 
a pre-requisite for disease [3,5]. Despite the significance of colonisation 
to the lifestyle of S. pneumoniae, little is known about the mechanisms 
employed by the bacterium to grow and proliferate in the human 
nasopharynx. 
S. pneumoniae is a strictly fermentative bacterium that relies on 
glycolytic metabolism to obtain energy [6]. Therefore, the ability to acquire 
and metabolize sugars is of major importance for in vivo fitness of this 
microorganism. Indeed, the pneumococcus lacks a complete set of genes 
for respiratory proteins and is for this reason unable to generate energy 
by respiration [6,7]. The genomic abundance of genes involved in sugar 
transport further supports the significant role of carbohydrates in the 
lifestyle of S. pneumoniae [6,7]. Over 30% of the transporters in the S. 
pneumoniae genome were predicted to be involved in the uptake of 
carbohydrates [7], and these predictions were validated by a recent 
functional genomic approach targeting carbohydrate transport [8]. 
Furthermore, several putative carbohydrate degradation pathways have 
been annotated in the genome sequences of S. pneumoniae [6,7]. In 
summary, S. pneumoniae potentially harbours an incredible flexibility with 
respect to sugar consumption. Hexoses, and in particular glucose (Glc), 
are the preferred carbon and energy sources of S. pneumoniae [9]. 
However, in the human airway the abundance of free sugars is scarce, 
the concentration of Glc being below 1 mM [10,11]. In this case, in vivo 
growth must rely on alternative nutritional reservoirs. In the human 
nasopharynx, the glycoproteins lining the epithelial surfaces appear as 
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good candidates to serve as carbon and energy sources for 
pneumococcal growth. Importantly, S. pneumoniae is able to grow on 
mucin as a sole carbon source [12]. Mucins are major components of the 
mucus that cover the epithelial surfaces [13]. These structures are heavily 
O-glycosylated glycoproteins and despite their composition variability, 
mucins are generally composed of N-acetylglucosamine (GlcNAc), N-
acetylgalactosamine (GalNAc), N-acetylneuraminic acid (NeuNAc), 
galactose (Gal), fucose (Fuc) and sulphated sugars linked to the protein 
core, most commonly via a N-acetylgalactosamine moiety [13,14]. 
Furthermore, S. pneumoniae can use other host glycans, such as N-
glycans and glycosaminoglycans [15,16]. In fact, the pneumococcus is 
equipped with a high number of extracellular glycosidases covering a wide 
range of substrates specificities (reviewed in [17]). The action of these 
enzymes on host glycans generates a variety of free sugars that 
potentially can be used by the pneumococcus. The deglycosylation 
activity of both exo- and endoglycosidades has been previously 
demonstrated in S. pneumoniae [15,18–20]. Furthermore, the role of 
these enzymes in in vivo fitness is substantiated by the observations that 
glycosidase mutants show attenuated ability to colonise and to cause 
disease in mouse models [14,19–23]. 
In this study, we set out to identify the putative catabolic pathways 
important for growth on mucin. To this end, we used the well-established 
laboratorial model for pneumococcal studies S. pneumoniae D39 [24]. 
Subsequently, the predicted utilization routes of the glycan-derived sugars 
Gal, GlcNAc and Man were functionally established, by positive detection 
of phosphorylated metabolic intermediates and measurement of specific 
enzyme activities. Inactivation of a unique gene in each catabolic pathway 
rendered mutant strains unable or with impaired ability to grow in the 
presence of the corresponding sugar. Finally, the contribution of the 
sugar-specific catabolic pathways to colonisation and pneumococcal 
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disease was assessed in appropriate mouse models, demonstrating that 
mutants in Gal catabolic pathways were attenuated in their ability to 
colonise and had reduced virulence in respiratory infection models.  
Overall, we experimentally validated the catabolic pathways of glycan-
derived Gal, Man and GlcNAc and found Gal as a key nutrient during 
pneumococcal in vivo growth.  
 
Materials and Methods 
Bacterial strains and growth conditions  
Streptococcus pneumoniae strain D39 (serotype 2) and its derivatives 
are listed in Table S2.1. The D39 isolate was obtained from the culture 
collection of the Department of Infection, Immunity and Inflammation, of 
the University of Leicester. Stocks and working stocks were prepared as 
described elsewhere [25] and stored in 25% (vol/vol) glycerol M17 
medium (Difco) at -80°C.  
Routinely, S. pneumoniae was grown statically in M17 broth containing 
0.5% (wt/vol) glucose (Glc-M17) at 37C. For physiological studies, 
bacteria were grown in static rubber-stoppered bottles (80 ml in 100 ml 
bottles) at 37ºC and without pH control (initial pH 6.5) in the chemically 
defined medium (CDM) described by Carvalho et al. [25]. For each sugar 
tested (Gal, GlcNAc, Man and Glc), growth was analysed under sugar 
excess (34±2 mM) and a lower concentration (13±1 mM). In sugar 
mixtures each carbohydrate (Gal, Man and GlcNAc) was added to an 
initial concentration of circa 6.5 mM. Cultures were started by inoculating 
fresh CDM, to an initial optical density at 600 nm (OD600) of ~0.05, with a 
pre-culture grown until late-exponential phase of growth. Pre-cultures 
were performed as described previously [25]. Pre-cultures for growth on 
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sugar mixtures were grown in CDM containing 30 mM of each carbon 
source. Growth was monitored by measuring OD600 hourly. Maximum 
specific growth rates (μmax) were calculated through linear regressions of 
the plots of ln(OD600) versus time during the exponential phase of growth. 
The values reported are averages of at least eight independent growths. 
Representative growth curves were selected based on the minimum value 
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Where, maxOD  and max are the averages of the maximum optical density 
(ODmax) and μmax, respectively; maxODSD and maxSD  are the standard 
deviation of ODmax and μmax, respectively. 
 
Statistical analysis of the growth parameters 
ANOVA was applied to test the hypothesis that max values are 
independent of the sugar. Additionally, the differences across the two 
initial substrate conditions were also compared. The same ANOVA 
procedure was taken to assess if differences of ODmax values depended 
on the sugar and initial condition and assess if they were statistically 
significant.  
The null hypothesis of equal values for the µmax was tested for all possible 
pairwise combinations of initial conditions and sugars. This was 
accomplished by independent two-sample t-tests, whose results are 
summarized on Table S2.2. Likewise, similar tests were also performed 





Multiple non-linear regression method for generating 
confidence interval bands 
Multiple non-linear regressions were performed for all the combinations 
of experimental conditions (4 sugars and 2 initial concentrations) using 
the Gompertz model [26]: 
 maxmax
exp(1)
( ; , , ) exp exp 1f t A A t
A
           
  
, 
where μ  is the tangent in the inflection point (maximum growth rate), 
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and the parameters estimated directly with 
the BGFit web-application [27] using non-linear least squares. 
After obtaining the estimates for each sugar and initial concentration 
condition, a 95% confidence interval for the data and bands for the 
predicted responses of the model were computed. These computations 
were performed in MATLAB and Statistics Toolbox R2013a using the 
function nlpredci. 
 
General molecular techniques  
Chromosomal DNA isolation was performed according to the 
procedure described by Johansen and Kibenich [28]. Pwo polymerase 
was used according to the supplier’s instructions (Roche). PCRs were 
performed with a MyCycler thermal cycler (Bio-Rad). Purification of the 
PCR fragments was accomplished using the High Pure PCR product 
Purification Kit (Roche) according to the supplier’s instructions. Plasmid 
isolation was done using a High Pure Plasmid Isolation Kit (Roche), 
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according to the manufacturer’s protocol. Restriction enzymes were 
purchased from New England Biolabs. 
 
Construction of loss-of-function mutants  
Chromosomal DNA of S. pneumoniae D39 was used as template in 
the PCR amplifications. Oligonucleotide primers used for these constructs 
are listed in Table S2.3. galK (SPD_1634), lacD (SPD_1050), manA 
(SPD_0641), nagA (SPD_1866) and galT-2 (SPD_1633) disruption was 
accomplished by allelic replacement mutagenesis, essentially as 
described by Song et al. [29]. The upstream and downstream flanking 
regions of the genes to be disrupted were amplified using the appropriate 
primers’ combinations KO1_Fw/KO2_Rv_Spe and 
KO3_Fw_Spe/KO4_Rv, respectively (Table S2.3). Flanking fragments 
were fused to the spectinomycin resistance marker (Spe) (1032 bp, 
amplified with primers Spe_Fp and Spe_Rp from pORI38), by overlap 
extension PCR using the appropriate primers KO1_Fw and KO4_Rv. The 
resulting fused fragments were purified and transformed into D39 as 
described before [30]. Positive transformants were selected on Glc-M17 
sheep blood (1% vol/vol) agar plates supplemented with 150 µg ml-1 of 
spectinomycin. The correct integration of the insert in the mutant clones 
was confirmed by PCR. Genomic DNA was used as template for PCR 
with primers designed to anneal around 100 bp upstream and 
downstream of the recombination site, as well as combinations of these 
primers with those used to construct the mutants (Table S2.3).  
A double mutant, D39∆lacD∆galK, was constructed by allelic replacement 
of the galK gene in the D39∆lacD mutant using trimethoprim (Tmp) 
selection. The up and downstream flanking regions of the galK gene were 
amplified using the appropriate primer combinations: 
GalK_KO1_Fw/GalK_KO2_Rv_Tmp and 
GalK_KO3_Fw_Tmp/GalK_KO4_Rv, respectively (Table S2.3). The 
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regions flanking galK were fused to the Tmp cassette in an overlap 
extension PCR reaction with the primer combination 
GalK_KO1_Fw/GalK_KO4_Rv, yielding ∆galK::tmp. The purified fused 
fragment was transformed into D39∆lacD and positive clones were 
selected on Glc-M17 sheep blood (1% vol/vol) agar plates supplemented 
with 18 µg ml-1 of trimethoprim. Gene replacement was confirmed as 
described above, using the primers listed in Table S2.3. 
 
Construction of the pKB01 derivatives for complementation 
studies 
pKB01, containing a zinc-inducible PczcD promoter (PZn), was used as 
a complementation system [31]. The target genes were amplified using 
chromosomal DNA from S. pneumoniae D39. For the construction of 
pKB01-lacD, pKB01-galK and pKB01-manA, lacD, galK and manA genes 
were amplified using LacD_Fw_EcoRI/LacD_Rv_BamHI, 
GalK_Fw_EcoRI/GalK_Rv_BamHI and 
ManA_Fw_EcoRI/ManA_Rv_BamHI, respectively. The PCR-amplified 
fragments and pKB01 were digested with EcoRI and BamHI and 
subsequently ligated. To generate pKB01-nagA the gene was amplified 
with its own promoter using primers NagA_Fw_NotI/NagA_Rv_BamHI. 
The digested fragment (NotI/BamHI) was cloned into pKB01 using the 
same restriction sites. pKB01-galT-2 was made by amplifying galT-2 with 
GalT-2_Fw_EcoRI/GalT-2_Rv_NotI. The PCR-fragment and PKB01 were 
cleaved using EcoRI/NotI enzymes and ligated. To construct PKB01-
galKgalT-2, galKgalT-2 was amplified using GalK_Fw_EcoRI_B/GalT-
2_Rv_XbaI, digested with EcoRI and XbaI and ligated into pKB01 at the 
same restriction sites. The primers used are listed in Table S2.3. 
All the generated constructs were transformed into E. coli DH5α [32]. E. 
coli was grown in Luria broth at 37ºC supplemented with 100 µg ml-1 
ampicillin. The constructs were verified by sequencing at Macrogen.  
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Complementation of deletion strains 
The pKB01-based plasmids were transformed into competent cells of 
S. pneumoniae D39 loss-of-function mutants. For transformation, 2 µl of 
the competence-stimulating peptide (CSP, 0.1 mg ml-1) was added to pre-
competent cells and activation achieved by 12 min at 37ºC. Plasmid DNA 
was added and transformation was accomplished by 20 min at 30ºC, 
followed by a phenotypic expression period of 90 min at 37ºC and 
overnight growth on Columbia blood agar plates supplemented with 1 μg 
ml-1 of tetracycline [33]. pKB01 constructs integrate by a double cross-
over into the chromosomal bgaA locus. Correct integration was verified, 
in single colonies, by PCR. The constructed strains are listed in Table 
S2.1. 
 
Growth of complemented strains 
Growth experiments were performed in a 96 well microtiter plate reader 
(Tecan Genius) in a total volume of 200 μl C+Y medium [34], devoid of 
Glc and sucrose. The medium was supplemented with 55 mM of the 
desired carbon source in the presence or absence of 0.1 mM ZnCl2. Cells 
were grown at 37ºC and OD595 was measured hourly. 
 
Transcriptome analysis 
For microarrays analysis, S. pneumoniae D39 was grown using 
Sicard’s defined medium with or without modification [35]. Modification 
was done to include mucin as the sole carbon source, replacing Glc and 
bovine serum albumin. Porcine gastric mucin (Sigma) was dissolved in 
water at a concentration of 10 mg ml-1 and dialysed against water 
overnight at 4ºC using snake skin dialysis membrane (MWCO 10 kDa, 
Pierce). After freeze drying, the mucin was dissolved in 10 mM potassium 
phosphate buffer, pH 7.0, autoclaved at 121ºC for 15 min. This was then 
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briefly centrifuged to remove insoluble residues and mixed with 2X 
concentrated Sicard’s medium. The extraction of RNA was done as 
described previously [36,37].  
 
Microarray experiments 
Microarray slides were purchased from the Bacterial Microarray Group 
at St. George’s Hospital Medical School, University of London. The 
SPv1.1.0 array contained spotted PCR products that represent all of the 
genes in the S. pneumoniae TIGR4 and R6 genomes. The array design 
is available in BµG@Sbase (accession number: A-BUGS-14; 
http://bugs.sgul.ac.uk/A-BUGS-14) and also ArrayExpress (accession 
number: A-BUGS-14). The Materials and Methods for microarray analysis 
followed previously reported methodology [37].  
 
Analysis of microarrays  
The microarray slides were scanned using an Axon GenePix 4000A 
microarray scanner, which utilises GenePix 5.1 software (Molecular 
Devices Ltd) for identification and for a visual analysis of the quality of the 
spots. The raw intensity data obtained from four independent experiments 
were normalised and further analysed using GeneSpring 7.3 software 
(Agilent Technologies). Data were subjected to LOWESS intensity-
dependent normalisation. Statistically significant changes in gene 
expression were determined as t-test p-values < 0.05 after Benjamini and 
Hochberg false discovery rate correction [38]. Genes of interest were 
further identified by requiring >2-fold differences in all four samples 
analysed. In addition, the microarray results for selected genes whose 
expression significantly altered in the presence of mucin were verified and 
confirmed by real time quantitative reverse transcription PCR (qRT-PCR), 
in order to ensure that dye affinity did not bias the results. 
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Fully annotated microarray data have been deposited in BµG@Sbase 
(accession number E-BUGS-159; http://bugs.sgul.ac.uk/E-BUGS-159) 
and also ArrayExpress (accession number E-BUGS-159). 
 
Quantitative RT-PCR   
To assess the expression of specific Gal catabolic genes (galT-2, galT-
1, galK, lacD), by qRT-PCR, cells were grown in CDM supplemented with 
the appropriate carbohydrate, as previously described, and a 4 ml aliquot 
was collected (16,100 x g, 2 min at 27ºC) in mid-exponential phase of 
growth. The supernatant was discarded and the pellet suspended in 0.5 
ml Trizol (Life Technologies). Samples were stored at -80ºC until further 
analysis. RNA extraction was performed as described previously [37]. 
To confirm the microarray results, two independent RNA preparations 
were used for qRT-PCR analysis. First strand cDNA synthesis was 
performed on approximately 1 µg DNase-treated total RNA, immediately 
after isolation, using 200 U of SuperScript II reverse transcriptase 
(Invitrogen) and random hexamers at 42oC for 55 min [39]. cDNA (15 ng) 
was amplified in a 20 µl reaction volume that contained 1 x SYBR Green 
PCR master mix (Applied Biosystems) and 3 pmol of each primer (Table 
S2.3). The transcription level of genes was normalised to gyrB 
transcription, amplified in parallel with SPDRT0709F and SPDRT0709R 
primers. The reactions were performed in triplicate using the following 
cycling parameters with a Rotor Gene real time PCR cycler (Qiagen): 1 
cycle of 10 min 95ºC followed by 40 cycles of 30 sec 95ºC, 1 min 55°C, 
and 30 sec 72°C. The results were interpreted using the comparative CT 
method [40]. 
 
In silico analysis for catabolic pathway prediction  
Potential catabolic pathways for the monosaccharides Gal, Man, 
GlcNAc, NeuNAc, GalNAc and Fuc were predicted in silico by combining 
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data obtained from the metabolic databases MetaCyc 
(http://metacyc.org/META/class-tree?object=Pathways) and Kegg 
(http://www.genome.jp/kegg/pathway.html), literature surveys and 
genome sequences. In addition, functionally characterized proteins from 
other microorganisms were used as query for BlastP searches of S. 
pneumoniae D39 genome deposited at NCBI 
(http://www.ncbi.nlm.nih.gov/genome/176?project_id=58581). 
 
Growth assay for assessment of sugar utilization by S. 
pneumoniae D39  
The ability of monosaccharides Glc, Gal, Man, GlcNAc, glucosamine 
(GlcN), galactosamine (GalN), and GalNAc to support growth of S. 
pneumoniae D39 was investigated using 96-well microtiter plates 
containing 250 µl CDM supplemented with 30 mM of each sugar. Cultures 
were started at an initial OD595 of ~0.05 by addition of an overnight Glc-
grown pre-culture pelleted (6300 x g, 7 min, RT) and suspended in fresh 
CDM without sugar. Growth was monitored at 595 nm over 24 h at 37ºC. 
Readings were taken every 30 min, after 1 s shaking, using an ELx808 
Absorbance Microplate Reader (BioTek Instruments, Inc.). The growth 
curves were generated by using Gen5TM (BioTek Instruments, Inc.). Each 
growth condition was done in triplicate using two independent pre-
cultures. 
 
Quantification of sugar consumption and fermentation 
products  
Strains were grown in CDM supplemented with the appropriate sugar 
as described above. Culture samples (2 mL) were taken immediately after 
inoculation and at the onset of the stationary phase of growth, and 
centrifuged (16,100 x g, 3 min, 4ºC). For high performance liquid 
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chromatography (HPLC) analysis, samples were treated as described by 
Carvalho et al. [9]. Fermentation products and Glc were quantified by 
HPLC as before [9]. Gal, Man, GlcNAc and formate were quantified by 1H-
NMR and the spectra were acquired with a Bruker AMX300 spectrometer 
(Bruker BioSpin GmbH). To quantify Gal the temperature of the probe was 
set to 18ºC, whereas for Man and GlcNAc it was 37ºC. DSS (3-
(trimethylsilyl) propionic acid sodium salt) was added to the samples as 
an internal concentration standard in 1H-NMR quantifications. 
Yields were calculated using the data from samples taken immediately 
after inoculation and at the onset of stationary phase of growth. A factor 
of 0.38, determined from a dry weight (DW) (mg ml-1) versus OD600 curve, 
was used to convert OD600 into DW (mg biomass ml-1). The yield in 
biomass was calculated as g of dry weight per mol of substrate consumed. 
The ATP yield was determined as the ratio of ATP produced to substrate 
consumed at the time of growth arrest assuming that all ATP was 
synthesized by substrate-level phosphorylation. The values reported are 
averages of at least two independent growths. 
 
Cold ethanol extractions and determination of intracellular 
metabolites by 31P-NMR  
For ethanol extractions, the Na2-β-glycerophosphate in the CDM 
growth medium was replaced by 15.4 g l-1 MES (2-(N-morpholino) 
ethanesulfonic acid), to avoid the intense buffer resonance in the 
phosphomonoester (PME) region. The ethanol extracts were prepared as 
described previously by Carvalho et al. [9]. Cells were harvested (20,980 
x g, 4ºC, 5 min) during exponential growth and the pellet suspended in 
milliQ water, pH 6.5. Cell suspensions were transferred to the appropriate 
volume of cold ethanol 70% (vol/vol) in an ice bath, and extraction was 
performed for 30 min with vigorous agitation. Cell debris was removed by 
centrifugation (39,191 x g, 4ºC, 20 min). The ethanol in the supernatant 
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was removed via a rotavap and the extract frozen in liquid nitrogen, and 
lyophilized overnight. The dried extract was dissolved in 1 ml of 
deuterated water containing 5 mM EDTA. The pH was set to 6.5 and the 
extract was stored at -20ºC until analysis by 31P-NMR. Resonances were 
assigned by addition of pure compounds to the extracts or on basis of 
comparison with previous studies [9]. 31P-NMR spectra were recorded 
using a selective probe head (31P-SEX) at 30ºC on a Bruker AVANCE II 
500 MHz spectrometer (Bruker BioSpin GmbH) by using standard Bruker 
pulse programs. Spectra were referenced to the resonance of external 
85% H3PO4, designated at 0 ppm.  
 
Enzyme activity determination 
For enzyme activity determination, cells of S. pneumoniae were grown, 
in CDM supplemented with 30 mM sugar (Gal, Man, GlcNAc or Glc), until 
late-exponential phase of growth, and harvested by centrifugation (7,519 
x g, 7 min, 4ºC). The supernatant was removed, the pellet suspended in 
cold potassium phosphate buffer (KPi) 10 mM, pH 7.0, and stored at -20ºC 
until further analysis. Dithiothreitol (1 mM) was added to the suspension 
and cell-free extracts prepared by mechanical disruption in a French 
Press (6.21 MPa). Cell debris was removed (16,100 x g for 15 min, at 4ºC) 
and the supernatant was used for enzyme activity measurements. 
Extracts were kept on ice during these measurements. 
For measurement of galactokinase (GalK) activity, removal of low 
molecular weight substances from the cell-free extract was performed 
using a PD-10 desalting column equilibrated with KPi buffer 10 mM pH 
7.0 according to the supplier’s instructions (GE Healthcare Life Sciences). 
The GalK assay mixture contained 100 mM triethanolamine (TEA) buffer 
pH 7.6, 5 mM MgCl2, 10 mM ATP and 10 mM galactose. The mixture was 
incubated at 37ºC, in a Thermomixer® comfort (Eppendorf) and the 
reaction started by the addition of the cell-free extract. The reaction was 
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stopped, at different time points, by incubating for 5 min at 85ºC and 
subsequently freezing in liquid nitrogen. Samples were stored at -20ºC 
until further analysis. Quantification of galactose 1-phosphate formed was 
accomplished by 1H-NMR spectroscopy using a Brucker AMX300 
spectrometer (Brucker BioSpin GmbH). DSS was added to the samples 
and used as an internal concentration standard. The slopes of the 
galactose 1-phosphate (Gal1P) formed versus time were determined 
using linear regression.  
Tagatose 1,6-diphosphate aldolase (LacD) activity was determined 
essentially as described by Crow and Thomas [41]. The reaction mixture 
(1 ml) contained 50 mM TEA buffer pH 7.8, 0.25 mM NADH, 1.2 U α-
glycerolphosphate dehydrogenase (Roche), 11.5 U triosephosphate 
isomerase from rabbit muscle (Sigma-Aldrich) and 0.16 mM tagatose 1,6-
diphosphate (TBP). The oxidation of NADH was measured by the 
decrease in absorbance at 340 nm.  
N-acetylglucosamine 6-phosphate deacetylase (NagA) activity was 
enzymatically assayed as described by Homer et al. [42]. The method 
couples this activity to the other GlcNAc-specific catabolic enzyme – 
glucosamine 6-phosphate isomerase (NagB). To ensure the applicability 
of this protocol, the specific activity of NagB was measured [43]. The 
specific activity of this enzyme was higher than that of NagA for all 
conditions assayed, thus showing that the glucosamine 6-phosphate 
isomerase activity was not a rate limiting step. The reaction mixture (1 ml) 
contained 40 mM sodium phosphate buffer pH 7.5, 1 mM N-
acetylglucosamine 6-phosphate, 0.2 mM NADP+, 4 U phosphoglucose 
isomerase (Sigma) and 1.5 U glucose 6-phosphate dehydrogenase 
(Roche). Glucosamine 6-phosphate isomerase was measured in an 
identical assay but N-acetylglucosamine 6-phosphate was replaced by 
glucosamine 6-phosphate. NADPH formation was monitored by 
measuring the increase in absorbance at 340 nm spectrophotometrically. 
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Mannose 6-phosphate isomerase (ManA) activity was measured 
essentially as described by Gracy and Noltmann [44], and modified as 
follows: the assay mixture contained 100 mM TEA pH 7.6, 10 mM 
mannose 6-phosphate, 2 mM NADP+, 1 U of phosphoglucose isomerase 
(Sigma) and 1 U of glucose 6-phosphate dehydrogenase (Roche), in a 
total volume of 250 μl. The rate of change of absorbance at 340 nm (due 
to NADP+ reduction), coupled to mannose 6-phosphate isomerization, 
was measured spectrophotometrically. 
The coupled enzyme protocols were carried out at 25ºC. All the reactions 
were started by adding adequate amounts of freshly prepared cell-free 
extracts. The absorbance changes were recorded in a Shimadzu UV-
1603 spectrophotometer (Shimadzu Corporation). 
One unit (U) of GalK activity is defined as the amount of protein required 
for the formation of 1 μmol of Gal1P per minute. For the coupled enzyme 
protocols, the enzyme activity is given as the amount of protein required 
to catalyse the oxidation or reduction of 1 µmol of NADH or NADP+, 
respectively, per minute. Specific activity was expressed as units (µmol 
min-1) per milligram of protein (U mg protein-1). Protein concentration in 
the cell-free extracts was determined by the Pierce BCA protein assay kit 
(Thermo Scientific). All the determinations were made at least in triplicate 
in two extracts obtained from independent cultures. 
 
In vivo analysis of pneumococcal strains 
Ten-week-old female MF1 outbred mice (Charles River) were used. 
Before use, a standard inoculum for each pneumococcal strain was 
prepared as described before [39]. 
To assess the virulence of pneumococcal strains, mice were lightly 
anesthetized with 3% (vol/vol) isoflurane over oxygen, and an inoculum of 
50 µl containing approximately 1 X 106 CFU in PBS was given drop by 
drop into the nostrils. After infection, the inoculum dose was confirmed by 
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viable counting on blood agar plates. Animals were monitored for disease 
signs (progressively starry coat, hunched, and lethargic) every six hours 
in the first 24 h. After the onset of disease signs, which is after 24 h post-
infection, the mice were monitored every 2 hours [39,45]. When the mice 
become lethargic, they were culled by cervical dislocation. Therefore, time 
to reach lethargic state was defined as the “survival time.” Mice that were 
alive 7 days after infection were deemed to have survived the infection.  
Colonisation experiments were done essentially as described above 
except that mice were administered with 5 X 105 CFU of S. pneumoniae 
in 10 µl PBS. For intravenous infections, approximately 5 X 105 CFU of S. 
pneumoniae in 100 µl PBS (pH 7.0) were administered via a tail vein. The 
inoculum dose was confirmed by plating onto blood agar, as described 
above. 
To monitor the development of bacteraemia, approximately 20 µl of 
venous blood was obtained from each mouse at predetermined time 
points after infection, and viable counts were determined, as described 
above. The growth of pneumococci in the nasopharynx was also 
determined, as described previously [39,45]. For this, at predetermined 
time intervals following intranasal infection, pre assigned groups of mice 
were deeply anesthetized with 5% (vol/vol) isoflurane over oxygen, and 
the mice were subsequently killed by cervical dislocation. 
Nasopharyngeal tissue was collected as described previously  [39,45] and 
transferred into 10 ml of sterile PBS, weighed, and then homogenized with 
an Ultra Turrax blender (Ika-Werke). Viable counts in homogenates were 
determined as described above. 
Survival times were calculated by using GraphPad Prism software and 
analysed by the Mann-Whitney U test. Data were analysed by an analysis 
of variance followed by the Bonferroni post-test. Statistical significance 





N-acetylglucosamine 6-phosphate (GlcNAc6P) was obtained through 
a modification of established procedures [46,47] according to Fig. S2.1. 
The synthesis of tagatose 1,6-diphosphate (TBP) is described in Fig. 
S2.2. Modifications to the synthesis of TBP previously published [48] were 
made in order to optimize the process (see Text S2.1). The synthesized 
compounds were quantified by 1H-NMR, using a Brucker AMX300 
spectrometer (Brucker BioSpin GmbH). DSS, used as an internal 
concentration standard in 1H-NMR quantifications, was purchased from 
Merck. 
Galactose, mannose, and N-acetylneuraminic acid were purchased from 
Sigma-Aldrich. Glucose was supplied by Merck and N-acetyl-D-
galactosamine, N-acetyl-D-glucosamine, glucosamine and 
galactosamine were purchased from Applichem. All other chemicals used 
were reagent grade.  
 
Ethical disclaimer 
Mouse experiments at the University of Leicester were performed 
under appropriate project (no. 60/4327) and personal (no. 80/10279) 
licenses according to the United Kingdom Home Office guidelines and 
local ethical approval. The animal work is approved by Animal Welfare 
and Ethical Review Body (AWERB) ethics committee. Where appropriate, 
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Results  
Genomic potential for the utilization of host 
monosaccharides 
Host glycans are rich in the carbohydrate monomers Gal, GalNAc, 
GlcNAc, NeuNAc, mannose (Man) and Fuc. We set out to uncover the 
genomic potential of S. pneumoniae D39 for utilization of these sugars 
and amino sugars by performing pathway reconstruction using data from 
the literature and deposited in metabolic databases (MetaCyc and Kegg), 
as well as by protein homology (BlastP) to functionally characterized 
enzymes (Fig. 2.1 and Table S2.4). In general, our systematic analysis 
confirmed genome annotations, and a schematic representation of the 
inferred sugar catabolic pathways is depicted in Fig. 2.1. A more detailed 
description is provided as supplemental material (Table S2.4 and Text 
S2.2). 
Galactose can be metabolized via the Leloir or tagatose 6-phosphate 
(T6P) pathways (Fig. 2.1), and homologues of the genes involved in both 
pathways are present in the genome (Table S2.4). A duplication event of 
the Leloir genes, galT and galE, seems to have occurred (Table S2.4), 
but whether the proteins are functional is unknown. Mannose is, most 
likely, taken up via a PTS [8] and the phosphorylated product isomerised 
to fructose 6-phosphate (F6P) via mannose 6-phosphate isomerase. 
Complete pathways for utilization of GalNAc and Fuc could not be 
successfully reconstituted using the tools in this work. S. pneumoniae D39 
also possesses homologues of all proteins involved in the bacterial 
superpathway for the dissimilation of the amino sugars N-





Figure 2.1.  Schematic representation of the proposed pathways for the 
dissimilation of monosaccharides originating from deglycosylation of host glycans 
in S. pneumoniae D39. 
Pathways were reconstructed resorting to metabolic databases (MetaCyc and KEGG), 
genome annotations at NCBI and literature. Genes and intermediates involved in the 
galactose (Gal), mannose (Man), N-acetylneuraminic acid (NeuNAc), N-
acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc) and fucose (Fuc) 
catabolism are shown. Initial steps of glycolysis are depicted. 
galM, aldolase 1-epimerase; galK, galactokinase; galT-1, galT-2, galactose 1-phosphate 
uridylyltransferase; galE-1, galE-2, UDP-glucose 4-epimerase; pgm, 
phosphoglucomutase/phosphomannomutase family protein; lacA, galactose 6-phosphate 
isomerase subunit LacA; lacB, galactose 6-phosphate isomerase subunit LacB ; lacC, 
tagatose 6-phosphate kinase; lacD, tagatose 1,6-diphosphate aldolase; manA, mannose 
6-phosphate isomerase; SPD_1489, SPD_1163, N-acetylneuraminate lyase; SPD_1488, 
ROK family protein,  nanE-1, nanE-2, N-acetylmannosamine 6-phosphate 2-epimerase; 
nagA, N-acetylglucosamine 6-phosphate deacetylase; nagB, glucosamine 6-phosphate 
isomerase; fucI, L-fucose isomerase; fucK, L-fuculose kinase; fucA, L-fuculose phosphate 
aldolase. 
α-Gal, α-galactose; α-Gal1P, α-galactose 1-phosphate; α-G1P, α-glucose 1-phosphate; 
UDP-Glc, UDP-glucose; UDP-Gal, UDP-galactose; Gal6P, galactose 6-phosphate; T6P, 
tagatose 6-phosphate; TBP, tagatose 1,6-diphosphate; Man6P, mannose 6-phosphate; 
ManNAc, N-acetylmannosamine; ManNAc6P, N-acetylmannosamine 6-phosphate; 
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fuculose; Fucl1P, fuculose 1-phosphate; GalNAc6P, N-acetylgalactosamine 6-phosphate; 
GalN6P, galactosamine 6-phosphate.  
The upper glycolytic intermediates and gene annotations are as follows: G6P, glucose 6-
phosphate; F6P, fructose 6-phosphate; FBP, fructose 1,6-biphosphate; GAP, 
glyceraldehyde 3-phosphate;  DHAP, dihydroxyacetone phosphate. gki, glucokinase; pgi, 
glucose 6-phosphate isomerase; pfkA, 6-phosphofructokinase; fba, fructose-biphosphate 
aldolase; tpiA, triosephosphate isomerase. The lower glycolytic pathway is represented by 
a dashed arrow. Pathways or steps present in other organisms but uncertain in D39 are 
represented in grey. 
Vertical arrows near the gene name indicate the upregulation during growth on mucin as 
compared to Glc, in S. pneumoniae D39.  
 
The ability of host glycan-derived sugars to support growth 
is sugar dependent 
The presence of the genes for a full metabolic pathway in the genome 
does not confirm that the pathway is functional. Thus, we assessed the 
ability of monosaccharide constituents of host glycans to support growth 
of S. pneumoniae D39 in a chemically defined medium (Fig. 2.2). Of the 
monosaccharides tested, growth was observed on glucosamine, GlcNAc, 
Gal and Man. In contrast, S. pneumoniae was unable to use GalNAc, 
galactosamine (Fig. 2.2) and NeuNAc (data not shown) as single carbon 
sources for growth. Fucose was not tested, since inability to grow in this 
sugar has been previously documented [8,50–52]. The ability of each 






Figure 2.2.  Growth of S. pneumoniae D39 in glycan-derived sugars.  
Growth profiles of D39 grown in CDM supplemented with 30 mM of galactose (Gal), 
mannose (Man), N-acetylglucosamine (GlcNAc), glucosamine (GlcN), N-
acetylgalactosamine (GalNAc), galactosamine (GalN) and glucose (Glc). Growth 
experiments were performed at 37ºC and at an initial of pH 6.5, using a 96-well microtiter 
plate reader. 
Symbols: ( ) Glc; ( ) GlcNAc; ( ) GlcN; ( ) Gal; ( ) Man, ( ) GalNAc and ( ) GalN.  
Growth curves are plotted in decimal scale to assess for significant differences in the 
growth profiles. 
 
Mucin induces expression of genes involved in utilization of 
Gal, GlcNAc and Man 
Mucins are the most abundant glycoproteins in the human respiratory 
tract, and S. pneumoniae is capable of growing on mucin as sole carbon 
source [12]. To reveal prevalent pathways during growth on mucin, we 
performed a whole transcriptome analysis comparing the mRNA levels of 
S. pneumoniae D39 cells grown on porcine gastric mucin to those of cells 
grown on glucose (Glc) (see Materials and Methods). The reasoning for 
this experimental design was that genes potentially involved in the 
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39 out of 83 genes that were significantly differentially expressed 
(according to the established criterion) encode for proteins with predicted 
functions in sugar processing (modification, uptake and catabolism) 
(Table 2.1).  
Seven of the upregulated genes were involved in the hydrolysis of 
sugars (Table 2.1). Of note, bgaA encoding a β-galactosidase, the activity 
of which results in free Gal, showed the highest differential expression 
value. strH, which codes for a β-N-acetylhexosaminidase, involved in the 
hydrolysis of terminal non-reducing N-acetyl-D-hexosamine residues, 
was the second most upregulated glycosidase (Table 2.1).  
Among the genes implicated in sugar processing (Table 2.1), 49% 
encode components of PTS or ABC transporters. Three genes encoding 
a complete PTS in the galactitol family, and presumably involved in Gal 
uptake [8,53], showed a high positive response to mucin. In the genome 
of D39, this Gat-PTS transport system is located upstream of the bgaA 
locus. Also, highly overexpressed was the Man-PTS family transporter 
(SPD_0066-8-9) presumably involved in Gal and Man transport (Tables 
2.1 and S2.4) [8]. In fact, genes putatively involved in Man uptake 
represented the highest fraction of transport systems upregulated in the 
presence of mucin (Tables 2.1 and S2.4). Moreover, a gene (SPD_1496) 
presumed to be involved in the translocation of GlcNAc was found 
differentially overexpressed (Tables 2.1 and S2.4), in accordance with the 
observed upregulation of strH. Mucin also induced the expression of 
genes potentially involved in NeuNAc uptake (Tables 2.1 and S2.4).  
Finally, genes involved in both Gal catabolic routes, lacAB and lacD of 
T6P pathway and galM of the Leloir pathway were highly overexpressed 
during growth on mucin (Table 2.1 and Fig. 2.1). Expression levels of 
selected genes, obtained by qRT-PCR, confirmed the transcriptome 




Table 2.1. Expression levels of genes upregulated in S. pneumoniae D39 
cells grown in mucin as compared to glucose-grown cells a,b.  
Locus-tag Gene Function 
Overexpression 
fold 
SPD_0562 bgaA Beta-galactosidase 71.8 
SPD_1057  PTS system transporter subunit IIB 61.3 
SPD_0561  PTS system transporter subunit IIC 45.5 
SPD_0068  PTS system transporter subunit IID 25.4 
SPD_1053 lacA 
Galactose 6-phosphate isomerase subunit 
LacA 
24.5 
SPD_0069  PTS system transporter subunit IIA 23.9 
SPD_1052 lacB 
Galactose 6-phosphate isomerase subunit 
LacB 
21.7 
SPD_0071 galM Aldose 1-epimerase 19.4 
SPD_1050 lacD Tagatose 1,6-diphosphate aldolase 17.6 
SPD_0559  PTS system transporter subunit IIA 15.1 
SPD_0560  PTS system transporter subunit IIB 12.1 
SPD_1494  Sugar ABC transporter permease 10.3 
SPD_0070 agaS Sugar isomerase 9.8 
SPD_0063 strH Beta-N-acetylhexosaminidase 8.7 
SPD_1663 treC Alpha,alpha-phosphotrehalase 8.0 
SPD_0066  PTS system transporter subunit IIB 7.8 
SPD_0287  Hyaluronate lyase 7.7 
SPD_1495  
Sugar ABC transporter sugar-binding 
protein 
6.7 





SPD_0292  Gluconate 5-dehydrogenase 5.3 
SPD_1409  




Maltose/maltodextrin ABC transporter 
maltose/maltodextrin-binding protein
4.8 
SPD_0297  PTS system transporter subunit IID 4.4 
SPD_1496  PTS system transporter subunit IIBC 4.4 
SPD_1006 glgC Glucose 1-phosphate adenylyltransferase 4.4 
SPD_0621 lctO Lactate oxidase 4.0 
SPD_1935 malC Maltodextrin ABC transporter permease 3.9 
SPD_0420 pflB Formate acetyltransferase 3.7 
SPD_1007 glgD 
Glucose 1-phosphate adenylyltransferase, 
GlgD subunit 
3.5 
SPD_1005 glgB Glycogen branching protein 2.9 
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Locus-tag Gene Function 
Overexpression 
fold 
SPD_1936 malD Maltodextrin ABC transporter permease 2.9 
SPD_0250  Pullulanase, extracellular 2.9 
SPD_1989  PTS system transporter subunit IID 2.6 
SPD_0427 lacG-1 6-phospho-beta-galactosidase 2.5 
SPD_1675 rafG Sugar ABC transporter permease 2.4 
SPD_0925  Hydrolase 2.4 
SPD_1937 malA Maltodextrose utilization protein MalA 2.3 
SPD_0424  




a Only genes potentially involved in sugar hydrolysis, uptake and metabolism are shown. 
Hypothetical proteins have been omitted. 
b For a complete appreciation a full list of the significantly differentially expressed genes is 
provided in Table S2.5. 
 
In summary, our transcriptome analysis revealed that mucin induced 
the expression of genes required to benefit from Gal, GlcNAc and Man 
residues present in host glycans. Capitalizing on the growth and 
expression data, we surmised that these sugars are important carbon 
sources for D39 during colonisation of the nasopharynx. Hence, we set 
out to characterize growth and validate predicted metabolic pathways for 
utilization of Gal, GlcNAc and Man.  
 
Growth properties on Gal, GlcNAc and Man or on a mixture 
thereof  
Growth parameters and fermentation end-products were determined in 
batch cultures of S. pneumoniae D39 using chemically defined medium 
and two concentrations of Gal, GlcNAc or Man: 13±1 mM and a higher 
non-limiting 34±2 mM. 
Growth profiles on Gal, Man and GlcNAc. 
Representative growth profiles (experimental data) and model 95% 
confidence and prediction curves that best describe the growth data are 
Chapter 2 
100 
depicted in Fig. 2.3. In general, the model fits well with the experimental 
data. The 95% confidence curves (Fig. 2.3) reveal that the larger 
differences between biological growth replicas occur at the final stage of 
the growth, as shown by higher discrepancies in the final optical density 
(ODmax) rather than specific growth rate (µmax). The parameters derived 
from the growth analysis are shown in Table 2.2. Analysis through ANOVA 
and pairwise t-tests allowed assessment of the statistical significance of 
the growth parameter differences across the experimental conditions 
(Table S2.2). 
In medium containing the higher substrate concentration, GlcNAc 
supported a significantly faster growth than Gal and Man (Tables 2.2 and 
S2.2). However, no significant differences (p=0.15) were found between 
cells growing on higher concentrations of Gal or Man, with the specific 
growth rate similar in both conditions (Tables 2.2 and S2.2). In contrast, 
for the lower substrate concentration, the growth rate was sugar 
dependent with the amino sugar supporting a significantly higher growth 
rate than Man or Gal (Tables 2.2 and S2.2). The specific growth rate is 
independent of the initial substrate concentration (Table 2.2), except for 
Gal which supports higher growth rates when the substrate is in excess. 
The involvement of a low affinity transporter in the uptake of this sugar 
would explain this behaviour. 
When the higher substrate concentration was used, Gal supported the 
highest final biomass, which was similar to that on Glc (p=0.06) (Tables 
2.2 and S2.2). No significant differences in the final biomass (p=0.89) 
were observed between growths on GlcNAc and Man, which were lower 
than that on Gal (Tables 2.2 and S2.2). At the lower substrate 
concentration the biomass formed was similar for the glycan-derived 
sugars and Glc, and unsurprisingly lower than those obtained using non-
limiting sugar concentrations (Fig. 2.3, Tables 2.2 and S2.2). 
 




Figure 2.3. Representative growth profiles of S. pneumoniae D39 grown in CDM in 
the presence of two different concentrations of galactose (Gal), N-













































































































































































Growth profiles in 80 ml batch cultures using (A) excess substrate concentration (34±2 
mM) and (B) a 3-fold lower initial substrate concentration (13±1 mM). 
Representative growth curves (empty dots) were selected based on the established 
criterion (see Materials and Methods). The experimental data was fitted using the 
Gompertz model with all replicates (estimated curve in black dashed line) and the 95% 
confidence bands (small dashed light grey lines) and 95% predicted bands (big dashed 
dark grey lines) were determined (see Materials and Methods). 
Growth was performed at 37ºC, under semi-anaerobic conditions, without pH control 
(initial pH 6.5). Growth curves are plotted in decimal scale to allow the visual discernment 
between significantly differences in the growth parameters using the two initial substrate 
concentrations. 
 
In medium with Gal, growth arrest occurred before substrate depletion, 
even for the low Gal concentration (Table 2.2). For the higher sugar 
concentrations, a pH decrease of about one unit was observed at the 
onset of stationary phase, which is consistent with growth arrest due to 
acidification. However, the observed change in pH of 0.5 units does not 
explain the arrest of growth in the lower Gal concentration. Even though 
a full explanation cannot be put forward, the possession of only low-affinity 
Gal importers can be proposed as a cause for growth slow-down with 
decreasing Gal concentrations.  
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Table 2.2. Growth and energetic parameters of S. pneumoniae D39 on sugars present in host glycans. 
                                                                                                                                                                                                                                                           
 
Growth rate, maximal biomass, yields, carbon and redox balances, substrate consumed and variation of pH were obtained for S. pneumoniae 
D39 grown in CDM in the presence of N-acetylglucosamine (GlcNAc), galactose (Gal), mannose (Man) and glucose (Glc) using two substrate 
concentrations or in a mixture of Gal, Man and GlcNAc (circa 6.5 mM each). Growth was performed at 37ºC without pH control (initial pH 6.5). 
Values represent the average and standard deviation of at least two independent growth experiments and are estimated at the time point of 
growth arrest (maximal biomass). 
aThe value represents the average ± standard deviation of the concentration of sugars present in the mixture. Individual values are: Gal, 
6.4±0.7 mM; Man, 6.6±0.1 mM and GlcNAc, 6.7±0.2 mM. 
bSecond specific growth rate. 
 GlcNAc Gal Man Glc Mix 
[substrate]initial (mM) 30.8±0.6 12.3±0.6 33.7±1.5 13.4±1.3 33.4±0.3 12.4±0.1 34.2±1.8 12.9±0.4 6.5±0.3a 
µmax (h
-1
) 0.55±0.06 0.54±0.08 0.48±0.04 0.32±0.03 0.45±0.04 0.44±0.04 0.93±0.07 0.93±0.09 0.61±0.05 
0.07±0.01b 
OD600max 1.76±0.25 0.99±0.08 2.16±0.12 1.12±0.26 1.77±0.16 1.03±0.08 2.29±0.17 1.06±0.04 1.19±0.11 
ΔpH 1.10±0.08 0.41±0.05 1.02±0.06 0.48±0.07 1.23±0.15 0.44±0.03 1.28±0.09 0.44±0.03 0.57±0.08 
Substrate Consumed (%) 93±6 100±0 69±9 84±7 87±10 100±0 92±4 100±0 86±2 
Substrate Recovery 87±5 84±3 72±1 76±9 85±9 89±3 86±5 84±2 79±3 
Redox Balance 86±5 83±3 70±2 75±5 85±9 85±3 85±5 82±1 81±4 
ATP yield (mol mol-1 
substrate) 
1.77±0.09 1.74±0.08 2.08±0.03 2.27±0.31 1.80±0.21 1.98±0.04 1.75±0.11 1.71±0.04 1.73±0.06 
YATP (g biomass mol-
1ATP) 
12.1±0.7 16.8±0.9 17.5±1.4 14.9±0.5 13.6±1.4 16.2±0.4 15.3±0.8 18.8±0.0 16.4±0.4 
Ybiomass (g mol-1 
substrate) 
21.4±2.4 29.3±2.9 36.3±2.4 34.1±5.8 24.3±0.3 31.9±0.1 26.7±0.3 32.0±0.8 28.3±1.8 
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ΔpH is the difference between the initial pH and the pH at the time of growth arrest; substrate recovery is the percentage of carbon in 
metabolized sugar that is recovered in the fermentation products (lactate, ethanol, acetate, and formate); redox balance is the ratio between 





























End-products resulting from the fermentations of Gal, GlcNAc and Man 
are shown in Table 2.3. S. pneumoniae displayed a fully homolactic 
fermentation profile when GlcNAc was the sole carbon source, regardless 
of the initial concentration. In addition to lactate, acetate, ethanol and 
formate were produced as minor fermentation products (Table 2.3). On 
Man, the fermentation profile was still mainly homolactic. However, a shift 
towards mixed acid fermentation was evident, accounting for 9% and 17% 
of the substrate consumed in the higher and lower substrate 
concentrations, respectively. In contrast, cells grown on Gal showed a 
pronounced mixed acid fermentation (Table 2.3), independently of the 
initial concentration of sugar. Formate, ethanol and acetate were 
produced in the ratio 2:1:1, as expected from mixed acid fermentation 
under anaerobic conditions. Lactate was detected as a minor fermentation 
product, accounting for 8% and 2% of the consumed Gal, for the higher 
and lower substrate concentration, respectively (Table 2.3). The shift 
towards mixed acid fermentation profile was generally higher for the lower 
substrate concentrations. 
The calculated values for substrate recovery are in good agreement 
with fermentative metabolism (above 80%). On Gal, carbon balances in 
the 70% range were determined, indicating an additional carbon sink 











Table 2.3. End-products derived from the catabolism of N-acetylglucosamine (GlcNAc), galactose (Gal), mannose 
(Man) and glucose (Glc) by S. pneumoniae D39, using 34±2 mM or 13±1 mM initial substrate concentrations. 
 
 
Growth was done in CDM supplemented with the appropriate sugar, at 37ºC, under semi-anaerobic conditions, without pH control (initial pH 
6.5). The results represent averages of at least two experiments and the error bars the standard deviation. 
BDL, below detection limit. In glucose grown cells, formate was produced, but in quantities below the limit of quantification. 
 
 Higher substrate concentration Lower substrate concentration  
Sugar GlcNAc Man Gal Glc GlcNAc Man Gal Glc 
[End-products] (mM) 
Lactate 49.02±8.19 43.80±0.11 3.88±0.54 53.10±1.59 19.42±0.35 17.27±1.63 0.50±0.00 20.93±0.29 
Acetate 0.92±0.10 2.68±0.17 14.91±1.24 0.83±0.38 0.79±0.14 2.44±0.26 8.43±0.06 0.46±0.12 
Ethanol 0.48±0.08 2.66±1.67 14.30±1.53 0.10±0.04 0.42±0.11 1.64±0.43 8.16±0.86 0.08±0.02 
Formate 1.62±0.43 5.10±0.75 29.43±1.85 BDL 1.82±0.73 3.77±0.44 16.53±0.84 BDL 
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Growth profiles, substrate consumption and end-
products of fermentation in a mixture of Gal, GlcNAc and Man. 
In its ecological niche, S. pneumoniae is exposed to a multiplicity of 
sugars. Thus, we set out to evaluate growth on a sugar mixture containing 
Gal, GlcNAc and Man. An initial concentration of approximately 6.5 mM 
for each carbohydrate, was tested (Fig. 2.4). On the sugar mixture, S. 
pneumoniae D39 displayed a biphasic growth profile. The maximal growth 
rate (µ1) was observed within the first 4 h of growth and was about nine 
times higher than the second growth rate (µ2) (Fig. 2.4A). Interestingly, µ1 
was similar to that determined in the presence of the lower concentration 




Figure 2.4. Growth profile of D39 in a mixture of galactose (Gal), mannose (Man) and 
N-acetylglucosamine (GlcNAc). 
(A) Representative growth curve of S. pneumoniae D39 grown in CDM supplemented with 
a mixture of Gal, GlcNAc and Man (6.5 mM each), at 37ºC, under semi-anaerobic 
conditions, without pH control (initial pH 6.5). (B) End-products of fermentation derived 
from the catabolism of the sugars in the mixture (Gal, Man and GlcNAc), determined at 
the time of growth arrest (maximal biomass). (C) Gal, Man and GlcNAc consumption, over 
time, during the growth of S. pneumoniae D39 in CDM. The values are percentages of the 
initial sugar concentration for each sugar. 
The representative growth curve was selected based on the established criterion (see 
Materials and Methods). The results represent averages of two independent growths and 

















































































The profile of sugar utilization was determined by measuring the 
sugars in the culture medium using 1H-NMR (Fig. 2.4C). We confirmed 
that GlcNAc was consumed first and was totally depleted after 6 h of 
growth. Consumption of Man started while GlcNAc was still available, and 
its depletion occurred 8 h after inoculation. Interestingly, Gal was only 
used after depletion of GlcNAc and Man. This is in good agreement with 
the two distinct growth rates found: the first is related to GlcNAc and Man 
consumption, whereas the second mostly reflects the utilization of Gal.  
In the sugar mixture, the end-products profile was mainly homolactic, 
with lactate as the major product (21.2 ± 0.5 mM) (Fig. 2.4B). Minor 
quantities of formate, ethanol and acetate were formed in a proportion of 
2:1:1. (Fig. 2.4B). Growth arrest was most likely not due to acidification, 
since only a modest change in pH (ΔpH) was registered (Table 2.2). On 
the other hand, Gal was not fully consumed, with approximately 40% 
remaining in the medium at the time of growth arrest (12 h after 
inoculation) (Table 2.2 and Fig. 2.4C). A similar behaviour was observed 
when Gal was used as single carbon source. These results demonstrated 
that S. pneumoniae D39 is able to metabolize different carbon sources 
simultaneously or sequentially. In a mixture consisting of 6.5 mM GlcNAc, 
Man and Gal, strain D39 had a preference for GlcNAc, but could use Man 
concurrently. Gal was the least preferred sugar, and was only consumed 
after exhaustion of the two other carbon sources.  
 
Catabolic pathways for the utilization of Gal, GlcNAc and 
Man as assessed using biochemical and molecular tools 
Experimental confirmation of the predicted metabolic routes for the 
catabolism of Gal, Man and GlcNAc was performed at the biochemical 
level through metabolite profiling by 31P-NMR and enzyme activity 
measurements, and at the genetic level by mutating key genes in the 
pathways. 
Host glycan sugar-specific pathways in S. pneumoniae 
 
109 
Intracellular metabolites during growth on glycan-derived 
sugars. 
Ethanol extracts of growing cells were examined for phosphorylated 
intermediates of catabolic pathways by targeted metabolomics using 31P-
NMR. In extracts derived from S. pneumoniae D39 Gal-grown cells, 
phosphorylated intermediates of the Leloir pathway, α-galactose 1-
phosphate (α-Gal1P) and α-glucose 1-phosphate (α-Glc1P), as well as 
phosphorylated metabolites involved in the T6P pathway: galactose 6-
phosphate (Gal6P) and tagatose 1,6-diphosphate (TBP), were detected 
(Fig. 2.5), indicating the active presence of both catabolic routes for Gal 
catabolism. These data are in agreement with an earlier report for a 
different isolate of S. pneumoniae strain D39 [9]. The accumulation of 
mannose 6-phosphate (Man6P) during growth on Man is a strong 
indication of the functioning of the predicted catabolic route (Figs. 2.1 and 
2.5). The intracellular intermediates predicted in the catabolic pathway of 
GlcNAc, N-acetylglucosamine 6-phosphate (GlcNAc6P) and glucosamine 
6-phosphate (GlcN6P), were detected in the extracts of cells grown on 
this carbon source (Figs. 2.1 and 2.5). Surprisingly, fructose 6-phosphate 
(F6P) was highly accumulated under this condition.  
Thus, the occurrence of specific phosphorylated metabolites in cell 
extracts correlated well with the predicted metabolic intermediates in the 






Figure 2.5. Phosphomonoester region of 31P-NMR spectra of ethanol extracts 
obtained in late-exponential cells of S. pneumoniae D39 grown in CDM with 
galactose (Gal), mannose (Man) or N-acetylglucosamine (GlcNAc).  
Ethanol extracts of glucose (Glc) grown cells were used as control. The glycolytic 
intermediates fructose 1,6-biphosphate (FBP), glucose 6-phosphate (G6P) and 3-
phosphoglycerate (3-PGA) were firmly assigned.   
Abbreviations: αGal1P, α-galactose 1-phosphate; αGlc1P, α-glucose 1-phosphate; TBP, 
tagatose 1,6-diphosphate; Gal6P, galactose 6-phosphate; Man6P, mannose 6-phosphate; 
GlcN6P, glucosamine 6-phosphate; GlcNAc6P, N-acetylglucosamine 6-phosphate and 
F6P, fructose 6-phosphate. 
Identification of phosphorylated intermediates was performed by spiking the ethanol 
extracts with pure compounds. Symbols: ( ) FBP, ( ) G6P, ( ) 3-PGA. 
 
*
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Enzymatic activities of key enzymes involved in the 
catabolism of glycan-derived sugars. 
To further substantiate the functioning of the predicted pathways, we 
selected enzymes presumed to be required for pathway activity, 
galactokinase (GalK, SPD_1634) and tagatose 1,6-diphosphate aldolase 
(LacD, SPD_1050) for Gal, mannose 6-phosphate isomerase (ManA, 
SPD_0641) for Man and N-acetylglucosamine 6-phosphate deacetylase 
(NagA, SPD_1866) for GlcNAc, and determined their specific activities 
using specific biochemical assays (see Materials and Methods).   
On galactose, the specific activities of GalK and LacD in cell-free 
extracts of D39 were considerably higher than those measured on Glc-
grown cells (Table 2.4), suggesting induction of the pathway on Gal. 
These data are consistent with the functioning of both pathways during 
growth on Gal. The GalK specific activity was higher than the LacD 
specific activity, under the conditions assayed (Table 2.4).  
The specific activity of N-acetylglucosamine 6-phosphate deacetylase 
(NagA), the enzyme dedicated to GlcNAc catabolism, was 2-fold higher 
when grown on GlcNAc than in Glc-grown cells (Table 2.4). The method 
to assay NagA, couples its activity to that of glucosamine 6-phosphate 
isomerase (NagB). The latter was not limiting in the assay, since its 











Table 2.4. Enzyme specific activities determined in extracts of S. 
pneumoniae derived from cells grown to late-exponential phase of growth 
in CDM supplemented with different monosaccharides.  










0.08 ± 0.01 - - 
D39 GlcNAc - - 0.04 ± 0.00 - 
D39 Man -              - - 0.10 ± 0.01 
D39 Glc BDL BDL 0.02 ± 0.00 0.07 ± 0.01 
D39∆galK Glc BDL - - - 
D39∆lacD Gal - BDL - - 
D39∆nagA Glc - - BDL - 
D39∆manA Glc - - - 0.04 ± 0.01 
 
Specific activity is expressed as units (U) (µmol min-1) per milligram of protein (U mg 
protein-1).  
GalK specific activity is defined as the amount of protein required for the formation of 1 
μmol of Gal1P min-1 mg protein-1. LacD specific activity is given as the amount of protein 
required to catalyse the oxidation of 1 µmol of NADH min-1 mg protein-1. NagA and ManA 
specific activities are the amount of protein to reduce 1 µmol of NADP min-1 mg protein-1. 
The values reported represent averages ± standard deviation obtained in cell-free extracts 
of at least two independent cultures. 
-, not determined. 
BDL, below detection limit.  
 
The key enzyme of the Man catabolic pathway, ManA, was detected in 
Man-grown cells, but the level was only marginally reduced (30%) in Glc-
grown cells (Table 2.4).  
In summary, enzyme activities of dedicated sugar catabolic enzymes 
were detected for each metabolic pathway assayed, indicating the 
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Genetic confirmation of pathway functionality. 
The biochemical approach to investigate the Gal, Man and GlcNAc 
catabolic pathways was complemented by a genetic approach. Mutants 
in key enzymatic steps of each catabolic route were constructed by allelic 
replacement mutagenesis, yielding D39∆galK, D39∆lacD, D39∆manA 
and D39∆nagA (Fig. S2.3). The mutations were confirmed by growth 
profiles and enzyme activity measurement (Table 2.4 and Fig. 2.6). The 
deletion mutants lost the activity encoded by the inactivated gene, except 
for the D39∆manA mutant (Table 2.4).  
 
Figure 2.6. Growth profile of D39 sugar-specific mutants. 
Growth phenotypes of (A) D39∆galK, (B) D39∆lacD, (C) D39∆nagA and (D) D39∆manA. 
Growth was performed in CDM supplemented with galactose (Gal), N-acetylglucosamine 
(GlcNAc), mannose (Man) or glucose (Glc), using the 96-well microplate reader. 
















































































































In Glc-grown D39∆manA, the activity of mannose 6-phosphate 
isomerase showed a 43% and 60% reduction compared to that in Glc- or 
Man-grown wild type D39 cells, respectively (Table 2.4).  
Importantly, the D39∆manA or D39∆nagA strains were unable to use 
Man or GlcNAc as sole carbon source, respectively (Fig. 2.6C and 6D). 
D39∆lacD was able to grow on Gal, although only after a lag period of 
circa 20 h (Fig. 2.6B). A mutant in both Gal catabolic pathways was 
constructed, D39∆lacD∆galK, which lost the ability to grow on this 
monosaccharide. Unexpectedly, inactivation of galK alone resulted in a 
strain unable to grow on Gal, even though the T6P pathway was still intact 
(Fig. 2.6A). All pathway-specific mutants were able to grow on sugars 
other than the substrate of the targeted catabolic pathway (Fig. 2.6). To 
ensure that growth abrogation was unrelated to possible polar effects, 
complementation studies were conducted (see Materials and Methods, 
Fig. S2.4). D39∆manA and D39∆lacD complemented with manA and lacD 
under the Zn2+-inducible promoter (PczcD) [54], had fully restored growth 
on Man and Gal, respectively. It is worth noting that growth on Man was 
better in the complemented D39∆manA as compared to wild type D39, 
suggesting that the ManA activity level might be a limiting factor for Man 
utilization (Fig. S4D). For the D39∆nagA, the ability to grow on GlcNAc 
was recovered by expressing, in trans, nagA under its own promoter (Fig. 
S4C). 
For D39∆galK, the ability to grow on Gal was not recovered by 
complementation in trans with galK. RNA-Seq data [55] showed that galK 
is co-transcribed with the downstream gene galT-2 and a polar effect of 
the galK deletion on galT-2 is therefore possible (Fig. S2.3). Indeed, the 
growth phenotype on Gal could be restored by complementation in trans 
with galKgalT-2 (Fig. S4A). Importantly, complementation with galT-2 
alone was not successful, suggesting that abrogation of growth on Gal is 
a consequence of galK inactivation.  
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To further analyse the effect of gene deletions in the Leloir pathway, a 
D39∆galT-2 mutant was constructed. The D39∆galT-2 grew on Gal, but 
the time to reach maximal biomass was 2.3-fold longer as compared to 
the wild type (data not shown). This result indicates the occurrence of an 
alternative galactose 1-phosphate activity, likely to be encoded by galT-1. 
On Gal, the expression level of galT-1 in D39∆galT-2 was 49-fold higher 
than in D39, as shown by qRT-PCR (Table S2.7). Expression of lacD was 
87-fold higher in Gal-grown D39∆galT-2 (Table S2.7) than in Gal-grown 
wild type, indicating that in the D39∆galT-2 mutant the lac operon is 
expressed and the T6P pathway is active. 
 
Attenuated virulence in the absence of a functional Gal 
pathway 
The contribution of genes encoding proteins involved in catabolism of 
host-derived glycans was tested in mouse models of colonisation, and of 
models of bronchopneumonia with bacteraemia that result from intranasal 
infection. While the bronchopneumonia model allows evaluation of factors 
that are important for acute infection and invasiveness, the colonisation 
model is ideal to evaluate the determinants of longer term pneumococcal 
survival in vivo [56].  
Mice infected with the mutants in Gal catabolic pathways survived 
significantly longer than wild type D39 strain in the bronchopneumonia 
model (Fig. 2.7A) (average survival time of mice infected with: D39 
44±30.7 h, n=20; D39∆galK 60±36.3 h, n=10; D39∆lacD 59±54.1 h, n=10 
and D39∆lacD∆galK 123±55.8 h, n=10; p<0.01 for D39∆galK, and 
p<0.001 for D39∆lacD and D39∆lacD∆galK; Mann-Whitney U test). In 
addition, reintroduction of an intact copy of galK and lacD into D39∆galK 
and D39∆lacD, respectively, reconstituted the virulence of these strains 
with the median survival times of mice infected with D39∆galKcomp 




significantly different from the wild type infected cohort (p>0.05). This 
shows that the observed reduction in virulence was not due to polar effect 
of mutations.  
 
Figure 2.7. Impaired virulence of pneumococcal strains defective in galactose 
catabolic pathways following intranasal infection.  
(A) Survival time of mice after infection with approximately 1 X 106 CFU pneumococci. 
Symbols show the times mice became severely lethargic. The horizontal bars mark the 
median times to the severely lethargic state. (B) Growth of bacteria in the blood. Each 
point is the mean of data from ten mice except for D39, which represents 20 mice. Error 
bars show the standard error of the mean. 
Symbols: * p<0.05; ** p<0.01; *** p<0.001. 
 
The progression of bacteraemia in animals infected with the 
pneumococcal strains was also determined. At 24 h post-infection mice 
infected either with D39∆galK (log10 3.10±0.7, n=10), D39∆lacD (log10 
3.54±0.6, n=10), or D39∆lacD∆galK (log10 2.23±0.75, n=10) had 
significantly lower mean CFU ml-1 of bacteria in the blood than that of the 
wild type infected cohort (log10 5.21±0.4, n=20) (p<0.01 for D39∆galK, 
p<0.05 for D39∆lacD, and p<0.001 for D39∆lacD∆galK) (Fig. 2.7B). At 48 
h post-infection, the blood bacterial counts recovered from 
D39∆lacD∆galK (log10 3.48±1.16, n=10) infected cohort was still 
significantly lower than that of the wild type infected (log10 7.76±0.48, 
n=20) (p<0.001), however, the numbers of D39∆galK (log10 6.53±0.81, 
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(p>0.05). Furthermore, no significant difference could be detected in the 
numbers of D39∆galKcomp (24 h: log10 4.47±0.64 and 48 h: log10 
6.86±0.82 n=10), D39∆lacDcomp (24 h: log10 3.81±0.86 and 48 h: log10 
5.59±1.24 n=10), and the wild type at 24 and 48 h post-infection (p>0.05). 
D39∆manA and D39∆nagA were also tested in bronchopneumonia 
model, however, the virulence properties of these strains were similar to 
the wild type (data not shown). 
In the colonisation model, the counts for all the pneumococcal strains 
were determined in nasopharyngeal tissue at the time of infection, and at 
3 and 7 days after infection (Fig. 2.8). The results show that at 3 and 7 
days post-infection the numbers of D39∆galK (log10 1.75±0.14 and log10 
1.80±0.17 n=5), D39∆lacD (log10 1.72±0.2 and log10 1.87±0.24, n=5), and 
D39∆lacD∆galK (log10 1.08±0.33 and log10 0.89±0.25, n=5) were 
significantly lower than the counts of wild type (log10 2.82±0.02;  and log10 
2.77±0.08, n=5, for days 3 and 7, respectively) (p<0.01 for D39∆galK, 
p<0.0001 for D39∆lacD∆galK,  and p<0.01 and p<0.05 for D39∆lacD for 
3 and 7 days post-infection, respectively).  
Similar to the bronchopneumonia model, in the colonisation model no 
phenotypic differences were observed between the wild type and 
D39galKcomp, D39lacDcomp (Fig. 2.8) (p>0.05), and the wild type and 






Figure 2.8. Pneumococcal strains defective in galactose catabolic pathways are less 
able to colonise nasopharynx.  
Mice were infected with approximately 1 X 105 CFU pneumococci. At predetermined times, 
five mice were culled, and CFU mg-1 of bacteria were determined by serial dilutions of 
nasopharyngeal homogenates. Each column represents the mean of data from five mice. 
Error bars show the standard error of the mean. Symbols: * p<0.05; ** p<0.01, **** 
p<0.0001. 
 
In addition to respiratory infection models, we also tested all the strains 
in a bacteraemia model through direct administration of bacteria through 
a tail vein in order to distinguish niche-specific contribution of individual 
pneumococcal proteins. There was no difference in the median survival 
times of cohorts (Fig. S5A) (p>0.05). In addition, the mutants had grown 
as well as the wild type strain in the blood at 24 and 48 h post-infection 
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colonisation in D39∆galK, D39∆lacD and D39∆lacD∆galK was specific to 
the respiratory tract.  
Overall, the results showed that Gal catabolic mutants, particularly 
D39∆lacD∆galK, were attenuated in the ability to colonise the 
nasopharynx and have reduced virulence in a respiratory infection mouse 
model.  
 
Discussion and Conclusions 
The study of S. pneumoniae has been heavily focused on factors that 
directly impinge on host-pathogen interactions, such as toxins, cell wall 
components, adhesins and capsule [3]. In contrast, investigation of 
pneumococcal physiology has only recently been addressed, in spite of it 
being a fundamental aspect of pneumococcal survival in vivo. This 
important pathogen is a strictly fermentative organism, which possesses 
one of the highest genomic abundances of genes encoding sugar 
transporters [6,7,24]. Thus, we surmised that the ability to take up and 
metabolize sugars is of key importance for the lifestyle of S. pneumoniae. 
Our view is strongly supported by previous studies consistently identifying 
genes involved in sugar catabolism as essential for virulence [11,57–61] 
as well as reports showing that sugar transporters contribute to S. 
pneumoniae colonisation and disease [16,62–64]. In the nasopharynx 
free sugars are scarce, but recent findings indicate that sugars derived 
from deglycosylation provide suitable carbon and energy sources for 
nasopharyngeal growth [12,14,15]. In order to understand the role of 
different host derived sugars in pneumococcal lifestyle and pathogenicity, 
we followed a top-down approach to identify, establish and validate 




sugars that may originate from glycan deglycosylation and evaluated the 
impact of sugar-specific pathways on the ability to colonise and cause 
disease in vivo. 
Despite the vast diversity of host glyconjugates, their glycan portions 
are often composed of the monosaccharides GalNAc, Gal, NeuNAc, 
GlcNAc, Fuc, Man, Glc and fructose. While the first five sugars are 
widespread in both N- and O-glycans (e.g. mucins), the other three are 
generally restricted to N-glycans. S. pneumoniae can grow on mucin as 
sole carbon source [12]. This ability is associated to a range of 
glycosidases that hydrolyse the mucins releasing to the medium 
neuraminic acids (NeuNAc and N-glycolylneuraminic acid), Gal and 
GalNAc, and to a less extent also GlcNAc and Fuc [14]. From our own 
analysis of the genomic content and the work of others [8,9,14,39,49,63], 
S. pneumoniae D39 harbours genes to potentially catabolise the glycan 
components Gal, GlcNAc, NeuNAc and Man. A bias towards utilization of 
the monosaccharide Gal and GlcNAc by S. pneumoniae D39 during 
growth on an O-glycan was hypothesised, since the monosaccharides 
account respectively for 14% and 30% (wt/vol) of the mucin [14]. 
Furthermore, S. pneumoniae is equipped with the machinery to utilize 
those constituents including glycosidases (at least two galactosidases, 
BgaA and BgaC, and a N-acetylglucosaminidase StrH [14,20,65,66]), 
putative transporters and catabolic genes (Table S2.4). This hypothesis 
was corroborated in a transcriptome analysis comparing gene expression 
of cells growing on porcine gastric mucin to Glc. Of the genes showing 
significant increased expression on mucin, the vast majority was 
implicated in the uptake and internal metabolism of Gal (25% of genes 
involved in sugar metabolism (Table 2.1)), and GlcNAc. Of note, mucin 
highly induced the expression of bgaA and strH encoding a β-
galactosidase and a β-N-acetylglucosaminidase, whose activities result in 
free Gal and GlcNAc, respectively [18,65–68]. Growth of S. pneumoniae 
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on mucin was shown to reduce by 30% the content in Gal of the 
glycoprotein, while the content in GlcNAc was not altered. This was 
rationalized as resulting from the complex structure of mucin, in which 
GlcNAc residues might be masked by other sugars. 
Genes associated with the transport of Man, a monosaccharide 
generally found in N-glycans, were also upregulated in mucin. Like Gal 
and GlcNAc, Man could sustain growth of S. pneumoniae D39 in a 
chemically defined medium (Fig. 2.2). Whether all the transporters 
upregulated show affinity for mannose remains to be investigated. Activity 
of α-mannosidase has been described for S. pneumoniae and 
homologues of previously characterized streptococcal mannosidase 
genes are found in the genome of D39 [69–71], but these genes were not 
differentially expressed in mucin-grown cells.  
Previously, it was shown that growth on mucin required the activity of 
neuraminidase A (NanA) [12]. Initial removal of terminal NeuNAc seems 
to be essential for further breakdown by other glycosidases and 
subsequent utilization of the glycan-derived sugars [14,18,72]. In our 
study, neuraminidase A was not significantly induced in presence of 
mucin as compared to Glc, which leads us to propose that its constitutive 
expression is sufficient to ensure the activity level to remove terminal 
NeuNAc. Furthermore, we (and others) verified that NeuNAc cannot 
sustain growth of strain D39 in chemically defined medium, most likely 
due to a frame shift mutation in the N-acetylneuraminate lyase gene of the 
nanAB operon [8]. The mucin derivatives GalNAc and Fuc also failed to 
support growth of S. pneumoniae. For GalNAc we could not firmly identify 
genes encoding the activities converting N-acetylgalactosamine 6-
phosphate to tagatose 6-phosphate, although genes with homology to E. 
coli counterparts are present in the genome (Text S2.2). Genes implicated 
in the downstream processing of L-lactaldehyde, the product of L-fuculose 




This inability to identify the full catabolic pathways for Fuc and GalNAc is 
in good agreement with previous reports that S. pneumoniae is unable to 
grow on these sugars as sole carbon sources [8,50–52].  
Overall, our integrated approach combining genomic, transcriptomic 
and growth data identified Gal, GlcNAc and Man as the glycan-originating 
monosaccharides more likely to be used as substrates for growth of S. 
pneumoniae D39 in the respiratory tract.   
The predicted routes for Gal, GlcNAc and Man dissimilation in S. 
pneumoniae D39 (Fig. 2.1) were validated at the biochemical and genetic 
level in this study. 
Mannose 
The phosphorylated intermediate Man6P accumulated to high levels in 
exponential cells and the activity of Man6P isomerase (ManA) was 
induced by Man. A manA mutant was unable to grow on Man, even though 
mannose 6-phosphate isomerase activity was detected to a certain extent 
in the loss-of-function mutant. Homologues of genes coding for ManA or 
other known Man6P isomerases were not found in the genome of D39, 
suggesting that the residual isomerase activity is non-specific, and 
insufficient to support growth on Man, as shown in Fig. 2.6D. Of interest, 
a strain expressing manA in trans under the control of an inducible zinc 
promoter showed better growth than the wild type D39, suggesting a 
bottleneck at the level of ManA. This observation is further supported by 
the high accumulation of Man6P during growth on Man. 
N-acetylglucosamine 
Both intermediates for the catabolism of GlcNAc, GlcNAc6P and 
GlcN6P, were present in exponentially-growing cells. Furthermore, the 
activity of GlcNAc6P deacetylase was induced by GlcNAc. A nagA mutant 
lost the ability to grow on the amino sugar, and the growth could be 
restored by in trans complementation. In other bacteria GlcNAc can be 
taken up via PTS or non-PTS transporters [73–78]. A recent report 
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indicated that S. pneumoniae internalizes this amino sugar exclusively via 
PTS transporter(s) [8], and this has been confirmed for strain D39 (A. M. 
Cavaleiro, P. Gaspar, T. Kloosterman, O. P. Kuipers and A. R. Neves, 
unpublished data). 
Galactose  
In a previous study using a different isolate of S. pneumoniae D39, we 
reported activity of both the Leloir and the T6P pathways in the utilization 
of Gal, since intermediates of both pathways (α-Gal1P and α-Glc1P from 
the Leloir and TBP from the T6P pathway) were observed during growth 
on Gal [9], and this was confirmed with D39 isolate used in the present 
study. Specific activities of enzymes for the Leloir (galactokinase, GalK) 
or T6P (tagatose 1,6-diphosphate aldolase, LacD) pathways were 
detected during growth on Gal, but not on Glc. This result for GalK and 
LacD contrasts with the activities of the other enzymes tested (NagA and 
ManA), which showed activity also when grown on Glc and not only on 
their dedicated sugars (Table 2.4). These findings may be explained by 
the fact that both NagA and ManA are involved in cellular processes other 
than the catabolism of the monosaccharides, such as providing 
precursors for biosynthesis. Inactivation of both galK and lacD in D39 
rendered the pneumococcus unable to grow on Gal. Surprisingly, 
inactivation of galK alone abolished growth on Gal, whereas exponential 
growth of a lacD mutant was observed although only after a long lag 
phase. The behavior of the lacD mutant can be partially explained in the 
context of carbon catabolite repression. The Leloir genes are under strong 
negative control by the carbon catabolite protein A, CcpA [9], thus 
alleviation of the repression is required before the pathway is activated. In 
line with this conclusion, in D39 Glc-grown cells the activity of 
galactokinase was undetectable. Catabolism via the Leloir pathway is 
normally associated with uptake of Gal via a non-PTS permease 




ABC transporter SPD_0088-9-90 CUT1 in the uptake of Gal. On the other 
hand, a Lactococcus lactis strain exclusively harboring the Leloir pathway, 
inactivated for the Gal permease, translocates Gal by a PTS and the 
resulting Gal6P enters the Leloir pathway upon dephosphorylation by a 
phosphatase [79]. The same could be active in S. pneumoniae, however, 
exclusive transport via the PTS is not in agreement with the observations 
that S. pneumoniae G54 and DP1004 devoid of PTS activity (ptsI mutants) 
are capable of growing on Gal [8]. Interestingly, a D39 ptsI mutant shows 
good growth on Gal, but only after a lag phase of about 11 h (A. M. 
Cavaleiro, P. Gaspar, T. Kloosterman, O. P. Kuipers and A. R. Neves, 
unpublished data). In light of these results, we propose that induction of 
an adequate transport system, presumably a non-PTS type, and 
alleviation of the carbon catabolite repression exerted over the Leloir 
genes are strict requirements for Gal dissimilation via the Leloir pathway 
in S. pneumoniae D39. Our hypothesis is in agreement with the 
elimination of the lag phase upon subculturing of the lacD strain on Gal 
containing-medium (Fig. S2.6).  
While the residual growth on Gal in the lacD mutant can be attributed 
to activation of the Leloir pathway, we do not know why growth on Gal is 
totally abolished in the galK mutant. A plausible explanation relies on the 
unintentional elimination of Gal1P uridylyltransferase (GalT) activity that 
provides essential precursors for the biosynthesis of structural 
polysaccharides. Indeed, inactivation of galK affected the expression of 
galT-2, and reversion of the galK mutant to the wild type phenotype on 
Gal required complementation with both galK and galT-2. However, 
inability to grow on Gal could be largely attributed to the galK mutation, 
since expression in trans of galT-2 did not restore growth and a galT-2 
mutant was able to grow on Gal (data not shown). In the latter mutant, 
expression of galT-1 was substantially increased, indicating that the 
product of the duplicated gene accounts for the lost GalT-2 activity, thus 
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restoring the Leloir pathway functionality. Based on our data, we therefore 
conclude that Gal metabolism in S. pneumoniae requires an operational 
Leloir pathway, or at least an active galactokinase.  
In other streptococci, efficient dissimilation of Gal has been associated 
with the presence of a high affinity specific Gal transporter [80,81]. 
According to Bidossi et al. [8], the PTS transporters implicated in the 
import of Gal in S. pneumoniae are the mannose-family PTS (ManMNL), 
a galactitol-family PTS (SPD_0559-0-1) and probably a mannose-family 
PTS (SPD_0066-7-8-9). In addition, our team showed that lacFE genes 
are induced by Gal, suggesting a potential contribution of the lactose-PTS 
to the uptake of the sugar [9]. Interestingly, the galactitol-family PTS, 
which has previously been implicated in Gal uptake [8,53], is a homologue 
of the specific galactose-PTS identified in Streptococcus gordonii, 
Streptococcus mutans and Streptococcus oligofermentans  [80–82]. 
However, the affinity of this putative galactose-specific PTS for Gal is 
seemingly not very high, as noted by markedly decreased growth rates at 
low Gal concentration and the inability to fully scavenge Gal from the 
culture medium (Fig. 2.3 and Table 2.2). The absence of high-affinity 
PTSs would certainly be a bottleneck for efficient functionality of the T6P 
pathway, but cannot fully explain the galK phenotype. Moreover, the 
uptake of Gal via a PTS system ensures a typical PTS-mediated signal 
transduction pathway for CcpA regulation and renders Gal an effective 
inducer of catabolite repression [9]. Of note, our team has previously 
reported that CcpA repression of key metabolic genes (Leloir pathway and 
fermentative pathways) is counterbalanced by a Gal-dependent activation 
[9]. In view of the results with the galK mutant we propose that 
galactokinase activity is essential for Gal catabolism, and that its product, 
α-Gal1P, is likely to be the inducer of gene expression. Collectively, our 
data provide evidence that utilization of Gal in S. pneumoniae is subject 




and the T6P pathways. Unravelling these regulatory mechanisms 
certainly deserves future investigations.    
Growth in non-preferential sugars is usually associated with mixed acid 
fermentation profiles [83,84]. This is indeed the case for S. pneumoniae 
D39 growing on Gal as sole carbon source (Table 2.3; [9]). Unexpectedly, 
growth on the other slowly metabolizable monosaccharide, Man, resulted 
in only a modest shift towards mixed acid products suggesting a different 
regulation of the central carbon pathways in the presence of Man. The 
underlying mechanisms are, however, out of the scope of this work and 
will be further investigated in the future.  
We hypothesised that the ability to efficiently use monosaccharides 
originating from mucins conferred on S. pneumoniae a metabolic 
advantage during colonisation and subsequent invasive states. S. 
pneumoniae strains defective in Gal catabolic genes, and in particular the 
double mutant, D39∆lacD∆galK, presented impaired ability to colonise the 
murine nasopharynx and had reduced virulence. Inactivation of nagA or 
manA had no significant effect in test mice. Importantly, direct 
administration of the Gal mutants into the bloodstream induced responses 
of the same magnitude (similar survival times and CFU per ml of blood) 
as the wild type D39 strain. In the bloodstream the main sugar present is 
Glc [10,11], and thus the Gal-deficient phenotype was not expected to 
have any impact. Furthermore, this finding adds to the importance of Gal 
metabolism in the airways, further supporting the view connecting Gal 
metabolism in S. pneumoniae to its virulence in this niche.  
At first glance, the inefficient Gal metabolism and the observation that 
Gal is a less preferred sugar compared to Man and GlcNAc in vitro, seems 
to be in conflict with the role of Gal genes in colonisation and virulence. 
The lack of correlation between sugar preferences in vitro and the effect 
of mutations in specific sugar catabolic pathways in vivo has been 
reported before for E. coli [85]. This apparent inconsistency might arise 
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from the multifactorial milieu in host niches. Furthermore, we showed that 
Gal catabolic genes represent the largest fraction of genes induced by 
mucin and others had previously established that Gal is widespread and 
abundant in the airway glycoconjugates (e.g. mucins). The relevance of 
Gal acquisition and metabolism had been previously suggested. Indeed, 
loss of beta-galactosidase activity, resulted in attenuated pneumococcal 
growth in the nasopharynx [14], and mutants defective in pyruvate formate 
lyase, an enzyme essential for Gal fermentation, were attenuated in 
virulence [39]. Furthermore, using Tn-seq in S. pneumoniae TIGR4 van 
Opijnen et al. [86] identified lacD as relevant for pneumococcal fitness in 
the nasopharynx. In addition, they also showed that both galK and lacD 
played a critical role for fitness of TIGR4 during in vitro growth on Gal. In 
S. pneumoniae D39, galK is essential for growth on Gal, while loss of lacD 
causes a long lag phase prior to exponential growth. The different results 
in the two studies most likely derive from using different serotypes (D39 
vs. TIGR4) or different experimental conditions for growth of S. 
pneumoniae. Nevertheless, both studies highlight the relevance of Gal 
and its catabolism in the airways.  
In light of these results we propose that pneumococcal Gal metabolism 
is of key importance during colonisation and throughout the transition from 
carriage to an invasive state. The loss of fitness in the Gal mutants can 
be due to metabolic impairment and deficient expression of specific 
virulence traits induced by Gal. We have previously reported that Gal-
grown cells produce twice as much capsule as Glc-grown cells [9], and it 
has been reported that a thicker capsule allows evasion from immune 
system and from initial mucociliary clearance in vivo [87]. On Gal, the 
carbon balance was lower than on other sugars, but no other end-
products/metabolites were detected, thus we propose that Gal is directed 
to processes other than fermentation such as the polysaccharide 




carbon availability that determines the Gal-associated virulence remains 
to be investigated.  
In summary, we followed a multidisciplinary approach to identify the 
monosaccharides in host glycoproteins that serve as carbon sources for 
growth of S. pneumoniae strain D39. Accumulating evidence connects 
pathogenesis to carbohydrate metabolism, and the findings herein 
presented further strengthen this view as we specifically show that 
mutants in Gal catabolic genes showed attenuated ability to colonise and 
reduced virulence following intranasal infection in mouse models. With 
widespread antibiotic resistance and re-emergence of non-type vaccine 
strains, it is urgent that new targets are found for the development of novel 
therapeutic and preventive drugs. One such opportunity is perhaps 
offered by the discovery of Gal as an “essential” nutrient for pneumococcal 
growth and persistence in the host. The Leloir and the tagatose 6-
phosphate pathways are present and conserved across pneumococcal 
serogroups (Table S2.8) supporting our suggestion that Gal catabolism 
could be a potential target for novel therapeutics. 
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Table S2.1. Bacterial strains and plasmids used in this study. 
Strain Relevant genotype Reference/Source 
S. pneumoniae   
D39 serotype 2 strain, cps2 (a)  
D39∆galK D39 ∆galK::spe, SpeR This work 
D39∆lacD D39 ∆lacD::spe, SpeR This work 
D39∆manA D39 ∆manA::spe, SpeR This work 
D39∆nagA D39 ∆nagA::spe, SpeR This work 
D39∆lacDΔgalK 
D39 ∆lacD::spe ∆galK::tmp, 
SpeR, TmpR  
This work 
D39∆galT-2 D39 ∆galT-2::spe, SpeR This work 





























E. coli   
DH5α 
F– Φ80lacZΔM15 Δ(lacZYA-
argF) U169 recA1 endA1 hsdR17 
(rK–, mK+) phoA supE44 λ– thi-
1 gyrA96 relA1  
Invitrogen (b) 
DH5α + pKB01 AmpR (b) 
Plasmids   
pORI138 


































SpeR, spectinomycin resistance marker, TmpR, trimethoprim resistance marker, AmpR, 
ampicillin resistance marker, TetR, tetracycline resistance marker. 
(a) Laboratory stock obtained from the Department of Infection, Immunity & Inflammation, 
University of Leicester.  
(b) Laboratory stock obtained from the Molecular Genetics Department, Groningen 
Biomolecular Sciences and Biotechnology Institute (GBB), Centre for Synthetic Biology, 
University of Groningen. 
1. Leenhouts K, Buist G, Bolhuis A, ten Berge A, Kiel J, Mierau I, et al. A general system 
for generating unlabelled gene replacements in bacterial chromosomes. Mol Gen Genet 
MGG. 1996;253: 217–224.  
2. Overkamp W, Beilharz K, Detert Oude Weme R, Solopova A, Karsens H, Kovacs AT, 
et al. Benchmarking various green fluorescent protein variants in Bacillus subtilis, 
Streptococcus pneumoniae, and Lactococcus lactis for live cell imaging. Appl Env 
Microbiol. 2013;79: 6481–6490. doi:10.1128/AEM.02033-13 
 
 
Table S2.2. Pairwise comparisons, across combinations of different 
sugars and initial substrate concentrations, to test the null hypothesis of 
equal values for the µmax and ODmax.  
    Lower sugar concentration Higher sugar concentration 
Sugar A Sugar B nA nB µmax ODmax nA nB µmax ODmax 
Glc Gal 12 9 < 10⁻⁷ NS 10 10 < 10⁻⁷ NS 
Glc GlcNAc 12 8 < 10⁻⁷ 0.049621 10 8 < 10⁻⁷ 0.000041
Glc Man 12 14 < 10⁻⁷ NS 10 9 < 10⁻⁷ 0.000002
Gal GlcNAc 9 8 0.000057 NS 10 8 0.009460 0.000329
Gal Man 9 14 < 10⁻⁷ NS 10 9 NS 0.000017
GlcNAc Man 14 8 0.008151 NS 8 9 0.001814 NS 
 
For each comparison, the p-values of the Student’s t-test are reported. Statistically 
significant values (p-value<0.05) are shown. P-values>0.05 were considered non-
significant (NS). The number of replicates for each condition is depicted (n). 
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Table S2.3. Oligonucleotide primers used in this study (from 5’ to 3’). 
Primer Sequence (from 5’ to 3’)   Description 
Allelic replacement mutagenesis  
GalK_KO1_Fw CTAGACGCTTGTCCTGAATG  
GalK_KO2_Rv_Spe TCCTCCTCACTATTTTGATTAGGCGAAGAGTTTCAGCAGTAAGATG Overlap with spe 
GalK_KO3_Fw_Spe CGTTTTAGCGTTTATTTCGTTTAGTGTTGCAGGTGGCACTCGCGTC Overlap with spe 
GalK_KO4_Rv CGGCAGGTCGGCATTAGATCC  
LacD_KO1_Fw CTCAATTCAGGGAGAAACTCG  
LacD_KO2_Rv_Spe TCCTCCTCACTATTTTGATTAGGATGATACCATTTTCATCAGAAAG Overlap with spe 
LacD_KO3_Fw_Spe CGTTTTAGCGTTTATTTCGTTTAGTGCGACTTCATGGAAAGAACGTGTG Overlap with spe 
LacD_KO4_Rv CAATCGACTCCACAAGTTCCAC  
ManA_KO1_Fw GACTTTCCTGATAGAGTTGTTC  
ManA_KO2_Rv_Spe TCCTCCTCACTATTTTGATTAGGGTACCACCCCAGATTTTTTCTTGC Overlap with spe 
ManA_KO3_Fw_Spe CGTTTTAGCGTTTATTTCGTTTAGTTCTTGGACTCTAGAAGGGC Overlap with spe 
ManA_KO4_Rv GGTTCTTTACTTCCTCAAACCAG  
NagA_KO1_Fw CTAAGACGGTGGTCATTGCGACTG  
NagA_KO2_Rv_Spe TCCTCCTCACTATTTTGATTAGGTGTGGGTAGAAAAACTGATCCGC Overlap with spe 
NagA_KO3_Fw_Spe CGTTTTAGCGTTTATTTCGTTTAGTGATGGCGTAAAACGTTATCAAGCA Overlap with spe 
NagA_KO4_Rv CACGTAGATATTCAGCCTGCATACC  
Spe_Fp  CTAATCAAAATAGTGAGGAGG  
Spe_Rp  ACTAAACGAAATAAACGC   
GalK_KO2_Rv_Tmp TCCAAGCTCACAAAAATCCGCGAAGAGTTTCAGCAGTAAGATG  Overlap with tmp 
GalK_KO3_Fw_Tmp  CCGTCTATGCGCGTCGTAACGTTGCAGGTGGCACTCGCGTC  Overlap with tmp 
Tmp_ FW  GGATTTTTGTGAGCTTGGA   




Primer Sequence (from 5’ to 3’)   Description 
GalT-2_KO1_Fw CTTCAGCATCCTTGGAGATCTTG  
GalT-2_KO2_Rv_Spe TCCTCCTCACTATTTTGATTAGGACATGTGTTACAAATTTATCTACTAAGGTCAC Overlap with spe 
GalT-2_KO3_FW_Spe CGTTTTAGCGTTTATTTCGTTTAGTGGAATTTTACTAGACTAG Overlap with spe 
GalT-2_KO4_Rv CCCACAATTAGGGCAATAAGAC  
Confirmation of genotype by PCR  
GalK_S_Fw CCGATAGCTAAACTATCGCTGGC  
GalK_S_Rv GAAGTCAAGCGTAGGACAGACATTGG   
ManA_S_Fw GGCGCTTCAACAGTTGATAG  
ManA_S_Rv GCCATTGCTCTAGGAGCTCAAGCG  
LacD_S_Fw CGGCTGGTGGTAAGGGACTCAATG  
LacD_S_Rv CGTATGTTGCGTAATCACATCATAG  
NagA_S_Fw GTGGGAGCGTTTGAGACAGAC  
NagA_S_Rv CGCACCGAATGATAGGGCAG  
GalT-2_S_Fw GGGGTTCTTCATTTCTTGCAAGAAGC  
GalT-2_S_Rv TGCATAAGCACCATCATTGATTG  
Complementation of loss-of-function mutants REnz 
GalK_Fw_EcoRI   AATTGAATTCCAAAGGAGAAATCATATGACACAACATCTTACTGC EcoRI 
GalK_Rv_BamHI  GATCGGATCCCTAGTCAAGGACGCGAGTGCC  BamHI 
GalK_Fw_EcoRI_B AATTGAATTCTAAGGAGGCAAATATGACACAACATCTTACTGC EcoRI 
GalT-2_Rv_XbaI ACGTCTAGATGTGCAAGGAGAAAGCTCCT XbaI 
LacD_Fw_EcoRI  AATTGAATTCTAAAAGAGGTATAAAATGGCTTTAACAGAAC  EcoRI 
LacD_Rv_BamHI GATCGGATCCTTACACACGTTCTTTCC BamHI 
NagA_Fw_NotI AATTGCGGCCGCGAGTTGGAGAAATCCAGC    NotI 
NagA_Rv_BamHI GATCGGATCCTTATGCTTGATAACGTTTTACGC   BamHI 
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Primer Sequence (from 5’ to 3’)   Description 
ManA_Fw_EcoRI AATTGAATTCAGACAGGAGATTAAGATGTCAGAACCATTATTTTTAC  EcoRI 
ManA_Rv_BamHI GATCGGATCCTTATGGATGACTAACAATTAATTC   BamHI 
GalT-2_Fw_EcoRI AATTGAATTCAGGAGGCTCTATAGTGACCTTAGTAGATAAATTTG EcoRI 
GalT-2_Rv_NotI GGCCGCGGCCGCCTAGTCTAGTAAAATTCCGACC NotI 
Confirmation of integration in the bgaA locus of the pneumococcal chromosome  
Integration 1 CTTGATGAAACCTACATTTG  
Integration 2 GCTTCCATTAAGGATAGTTC  
Integration 5 GCTATCGCTGAGCGCCGG  
Integration 6 AGCTAGAGTTCCGCAATTGG  
P up gatC Fw ATGGATGCAATCTTTGACCTAATCGG   
P Tet Rv CACATCGAAGTGCCGCCAAATCC   
Primers used for qRT-PCR  
GALT1RTF CTCGTAAAGTGGACGGGAGA   
GALT1RTR GCAAGTCCCATCACTTCGAT  
GALT2RTF TCACACCAATAGCGCGTAAG  
GALT2RTR AGCCCATGACCTCAATCAAG  
SPD1050F GCCAGACTGCTTGGATGTTT  
SPD1050R TCAGCCACACACTCAGAACC  
SPD1634F TCTCGGTGCTCGTATGACAG  
SPD1634R CACCTGCAACTTCAGCGATA  
SP0645RTF GCTTAGAAGCGGATAGTCAAG  
SP0645RTR GTGAGGAATCGCTACATTTGG  
SP0647RTF TTGCCACTTGCAGGTATCATC  




Primer Sequence (from 5’ to 3’)   Description 
SP1197RTF CTGGTTCAAAACCAAGGTCTG  
SP1197RTR GCGGTGCAGGTGTTAACTC  
SP1682RTF TGATGGGCTGACCAACTG  
SP1682RTR GTGTTGCCGTGACAGTTG  
SP2184RTF ACCTGTTGTCCCACCTAGTG  
SP2184RTR TACTGGACCAGCCATCAAGG  
SP703RTF TAGCGCCTATAGTGGGTCAG  
SP703RTR CTGGATTCCAAGAACCTGAAG  
SP1507RTF ATCGGTTCGAACTCTGGATG  
SP1507RTR ATAACGCCACCGTTTACTGC  
SP1615RTF AAAATGTTCGCGTCCGTTAC  
SP1615RTR GGGTGAGCCGTAACCAATTA  
SP2126RTF TCATGCCACTTGAAAATCCA  
SP2126RTR GCCTGAATCGCATCTTCTTC  
SPDRT0709F AAGGAGACTCAGCTGGTGGA  
SPDRT0709R CCCATGGCTGTGAAAAGACT  
       
                   Abbreviations: Spe, spectinomycin; Tmp, trimethoprim. REnz, restriction enzyme. Restriction enzyme sites are underlined. 
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Table S2.4. Genes proposed to be involved in the uptake and dedicated 
catabolism of galactose (Gal), mannose (Man), N-acetylneuraminic acid 
(NeuNAc), N-acetylglucosamine (GlcNAc), fucose (Fuc), and glucose 
(Glc) in S. pneumoniae D39. 




        Gal transport 
SPD_0263 manM 
PTS system mannose-specific transporter 
subunit IIC  
[1] 
SPD_0067a - PTS system transporter subunit IIC [1–3] 
SPD_0561 - PTS system transporter subunit IIC [1,4] 
SPD_0090 - ABC transporter substrate-binding protein [1] 
       Gal catabolism 
SPD_0071 galM Aldose 1-epimerase 
Genome annotation at 
NCBI 
SPD_1634 galK Galactokinase 
Genome annotation at 
NCBI 
SPD_1613 galT-1 Galactose 1-phosphate uridylyltransferase 
Genome annotation at 
NCBI 
SPD_1633 galT-2 Galactose 1-phosphate uridylyltransferase 
Genome annotation at 
NCBI 
SPD_1432 galE-1 UDP-glucose 4-epimerase 
Genome annotation at 
NCBI 
SPD_1612 galE-2 UDP-glucose 4-epimerase 





Genome annotation at 
NCBI 
SPD_1053 lacA 
Galactose 6-phosphate isomerase subunit 
LacA 
Genome annotation at 
NCBI 
SPD_1052 lacB 
Galactose 6-phosphate isomerase subunit 
LacB 
Genome annotation at 
NCBI 
SPD_1051 lacC Tagatose 6-phosphate kinase 
Genome annotation at 
NCBI 
SPD_1050 lacD Tagatose 1,6-diphosphate aldolase 
Genome annotation at 
NCBI 
Mannose 
         Man transport  
SPD_0263 manM 




PTS system, lactose-specific transporter 
subunit IIBC 
[1] 
SPD_0090 - ABC transporter, substrate-binding protein [1] 
SPD_0067 - PTS system transporter subunit IIC Database annotationb 
SPD_0296 - PTS system transporter subunit IIC Database annotationb 
SPD_1990 - PTS system transporter subunit IIC Database annotationb 




Locus_Tag Gene  Description 
Identification Method 
or Ref. 
SPD_0641 manA Mannose 6-phosphate isomerase 
Genome annotation at 
NCBI 
N-acetylneuraminac acid and N-acetylglucosamine 
         NeuNAc transport 
SPD_1495 - Sugar ABC transporter, sugar-binding protein [1,5–7] 
SPD_1502 - ABC transporter, substrate-binding protein [1,6,7] 
SPD_1170c - 
Oligopeptide ABC transporter, oligopeptide-
binding protein 
[1,7] 
        GlcNAc transport 
SPD_0263 manM 
PTS system, mannose specific transporter 
subunit IIC 
[1] 
SPD_0661 exp5 PTS system transporter subunit IIABC Database annotationb 
SPD_1496 - PTS system transporter subunit IIBC Database annotationb 
SPD_1532 - PTS system IIABC components Database annotationb 
SPD_1664 - 
PTS system, trehalose-specific IIABC 
components 
Database annotationb 
        NeuNAc & GlcNAc catabolism 
SPD_1489 - N-acetylneuraminate lyase 
Genome annotation at 
NCBI  BlastP searchd 
SPD_1163 - N-acetylneuraminate lyase 
Genome annotation at 
NCBI BlastP searchd 









Genome annotation at 
NCBI 




Genome annotation at 
NCBI 
SPD_1246 nagB Glucosamine 6-phosphate isomerase 
Genome annotation at 
NCBI 
Fucose 
        Fuc transport 
SPD_1990f - PTS system, transporter subunit IIC  [1,8] 
        Fuc catabolism 
SPD_1995 fucK L-fuculose kinase [8] 
SPD_1994 fucA L-fuculose phosphate aldolase [8] 
SPD_1986 fucI L-fucose isomerase [8] 
SPD_1993 fucU RbsD/FucU transport protein family protein 
Genome annotation at 
NCBI 
Glucose 
          Glc transport 
SPD_0263g manM 
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Locus_Tag Gene  Description 
Identification Method 
or Ref. 
SPD_0580 gki Glucokinase 
Genome annotation at 
NCBI 
SPD_1897 pgi Glucose 6-phosphate isomerase 
Genome annotation at 
NCBI 
SPD_0789 pfkA 6-phosphofructokinase 
Genome annotation at 
NCBI 
SPD_0526 fba Fructose-bisphosphate aldolase 
Genome annotation at 
NCBI 
SPD_1404 tpiA Triosephosphate isomerase 
Genome annotation at 
NCBI 
SPD_1823 gap Glyceraldehyde 3-phosphate dehydrogenase 
Genome annotation at 
NCBI 
SPD_0445 pgk Phosphoglycerate kinase 
Genome annotation at 
NCBI 
SPD_1468 gpmA Phosphoglyceromutase 
Genome annotation at 
NCBI 
SPD_1012 eno Phosphopyruvate hydratase 
Genome annotation at 
NCBI 
SPD_0790 pyk Pyruvate kinase 
Genome annotation at 
NCBI 
 
aTheoretical Gal transporter. Inferred from genomic context. 
bAccording to http://www.membranetransport.org/. For the sake of simplicity, only the 
genes encoding the EIIC component of the PTS system and the substrate binding protein 
in case of ABC transporters are shown. 
cAllelic variation of SP1328 of S. pneumoniae TIGR4 [1]. 
dFor BlastP searches functionally characterized E. coli proteins were used as query.  
eHomology (22% identity; 39% positives) with YjhT from E. coli K-12 MG1655. A recently 
characterized sialic acid mutarotase [9]. 
fPutative transporter. Fucose transport by this PTS is not yet fully disclosed [1,8,10]. 
 gDue to the high multiplicity of glucose transporters of S. pneumoniae, only the main 
glucose uptake system identified in D39 is shown [1]. 
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Table S2.5. Expression levels of genes upregulated in S. pneumoniae 
D39 cells grown in mucin as compared to glucose-grown cells, according 
to the established criterion (see Materials and Methods). 
Gene Fold P-value Description 
SPD_0562  71.8 0.0062 beta-galactosidase 
SPD_1057 61.3 0.0085 PTS system transporter subunit IIB 
SPD_0561 45.5 0.0478 PTS system transporter subunit IIC 
SPD_0068 25.4 0.0206 PTS system transporter subunit IID 
SPD_1053 24.5 0.0201 galactose-6-phosphate isomerase subunit LacA 
SPD_0069 23.9 0.0185 PTS system transporter subunit IIA 
SPD_1052 21.7 0.0307 galactose-6-phosphate isomerase subunit LacB 
SPD_2013 20.8 0.0074 glycerol kinase 
SPD_0071 19.4 0.0281 aldose 1-epimerase 
SPD_1050 17.6 0.0411 tagatose 1,6-diphosphate aldolase 
SPD_0559 15.1 0.0041 PTS system transporter subunit IIA 
SPD_0560 12.1 0.0127 PTS system transporter subunit IIB 
SPD_2011 10.3 0.0031 glycerol uptake facilitator protein 
SPD_1494 10.3 0.0197 sugar ABC transporter permease 
SPD_0070 9.8 0.0393 sugar isomerase 
SPD_0610 8.9 0.0096 hypothetical protein 
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Gene Fold P-value Description 
SPD_0063 8.7 0.0335 beta-N-acetylhexosaminidase 
SPD_1590 8.6 0.0463 general stress protein 24 
SPD_1663 8.0 0.0191 alpha,alpha-phosphotrehalase 
SPD_0066 7.8 0.0255 PTS system transporter subunit IIB 
SPD_0287 7.7 0.0017 hyaluronate lyase 
SPD_1495 6.7 0.0252 sugar ABC transporter sugar-binding protein 
SPD_0293 6.5 0.0292 PTS system transporter subunit IIA 
SPD_1834 5.8 0.0216 
bifunctional acetaldehyde-CoA/alcohol 
dehydrogenase 
SPD_1977 5.6 0.0114 carbamate kinase 
SPD_0613 5.5 0.0091 hypothetical protein 
SPD_0292 5.3 0.0093 gluconate 5-dehydrogenase 
SPD_0259 5.3 0.0398 hypothetical protein 
SPD_1976 5.2 0.0018 ornithine carbamoyltransferase 
SPD_0337 5.2 0.0425 Holliday junction-specific endonuclease 
SPD_1979 5.1 0.0009 hypothetical protein 
SPD_1652 4.9 0.038 
iron-compound ABC transporter iron-compound-
binding protein 
SPD_1978 4.9 0.0063 hypothetical protein 
SPD_1409 4.8 0.0271 sugar ABC transporter ATP-binding protein 
SPD_1934 4.8 0.0048 
maltose/maltodextrin ABC transporter 
maltose/maltodextrin-binding protein 
SPD_1975 4.7 0.0083 pseudo 
SPD_0619 4.5 0.0175 hypothetical protein 
SPD_0297 4.4 0.0419 PTS system transporter subunit IID 
SPD_1496 4.4 0.0193 PTS system transporter subunit IIBC 
SPD_1006 4.4 0.0092 glucose-1-phosphate adenylyltransferase 
SPD_0308 4.4 0.0101 ATP-dependent Clp protease, ATP-binding subunit 
SPD_0336 4.0 0.0238 penicillin-binding protein 1A 
SPD_0621 4.0 0.0104 lactate oxidase 
SPD_1935 3.9 0.0058 maltodextrin ABC transporter permease 
SPD_1651 3.8 0.0115 
iron-compound ABC transporter ATP-binding 
protein 
SPD_0420 3.7 0.021 formate acetyltransferase 
SPD_0093 3.6 0.0308 hypothetical protein 
SPD_0095 3.6 0.0036 hypothetical protein 
SPD_0094 3.6 0.001 hypothetical protein 
SPD_1007 3.5 0.0081 
glucose-1-phosphate adenylyltransferase, GlgD 
subunit 
SPD_2012 3.4 0.0029 alpha-glycerophosphate oxidase 




Gene Fold P-value Description 
SPD_1566 3.2 0.0015 hypothetical protein 
SPD_1567 3.1 0.0153 thioredoxin 
SPD_1005 2.9 0.0272 glycogen branching protein 
SPD_1936 2.9 0.0286 maltodextrin ABC transporter permease 
SPD_0250 2.9 0.038 pullulanase, extracellular 
SPD_0086 2.8 0.0004 hypothetical protein 
SPD_0692 2.7 0.0207 hypothetical protein 
SPD_1709 2.6 0.0298 chaperonin GroEL 
SPD_0691 2.6 0.019 hypothetical protein 
SPD_1989 2.6 0.0438 PTS system transporter subunit IID 
SPD_0628 2.6 0.0281 
transcriptional activator TenA, TENA/THI-4 family 
protein 
SPD_0616 2.5 0.0251 amino acid ABC transporter ATP-binding protein 
SPD_0427 2.5 0.0268 6-phospho-beta-galactosidase 
SPD_1675 2.4 0.0355 sugar ABC transporter permease 
SPD_0925 2.4 0.0443 hydrolase 
SPD_0440 2.4 0.0139 hypothetical protein 
SPD_1789 2.4 0.0194 cell wall surface anchor family protein 
SPD_1937 2.3 0.0231 maltodextrose utilization protein MalA 
SPD_0627 2.3 0.0275 hypothetical protein 
SPD_1554 2.2 0.0428 iojap-like protein 
SPD_0626 2.2 0.023 ABC transporter ATP-binding protein 
SPD_1282 2.2 0.0192 hypothetical protein 
SPD_0424 2.2 0.0259 
PTS system cellobiose-specific transporter subunit 
IIC 
SPD_0814 2.2 0.004 agmatine iminohydrolase 
SPD_1944 2.1 0.0112 hypothetical protein 
SPD_0008 2.1 0.0103 hypothetical protein 
SPD_1557 2.1 0.0109 nicotinic acid mononucleotide adenylyltransferase 
SPD_1558 2.1 0.0391 hypothetical protein 
SPD_0439 2.1 0.042 hypothetical protein 
SPD_1655 2.1 0.003 segregation and condensation protein B 
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Table S2.6. Expression ratio as determined by qRT-PCR of genes 
selected from the microarray experiment comparing mRNA levels in 





SPD_0559 PTS system transporter subunit IIA 32.9 5.0 
SPD_0561 PTS system transporter subunit IIC 31.4 3.1 
SPD_0610 Hypothetical protein 2.4 0.5 
SPD_1057 PTS system transporter subunit IIB 38.2 6.3 
SPD_1494 Sugar ABC transporter permease 67.0 16.9 
SPD_2011 Glycerol uptake facilitator protein 16.0 1.1 
SPD_1334 F0F1 ATP synthase subunit epsilon (EC:3.6.3.14) 0.3 0.1 
SPD_1839 Transketolase (EC:2.2.1.1) 0.2 0.0 
SPD_1956 Dihydroxy-acid dehydratase 0.2 0.1 
 
SD, standard deviation. 
 
Table S2.7. Expression ratio of genes involved in galactose catabolism in 
exponentially growing S. pneumoniae D39 cells disrupted in galK or galT-
2 genes.  
 Carbon source - strain 
Gene Glc-∆galK / Glc-D39 Glc-∆galK / Gal-D39 Gal-∆galT-2 / Gal-D39 
galT-2 0.54 ± 0.24 0.51 ± 0.22 - 
galT-1 ND ND 49.41 ± 3.55 
lacD 0.81 ± 0.03 0.0044 ± 0.0002 87.42 ± 5.41 
galK - - 19.29 ± 0.74 
 
Values represent the fold difference ± standard deviation transcript levels in the mutant 
strain as compared to the wild type. Cells were grown in CDM supplemented with glucose 
or galactose. In the qRT-PCR experiments, the expression values were normalized 
relative to the housekeeping gene gyrB.  
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1 The table was obtained by a unidirectional Blast search, where the genes of S. 
pneumoniae D39 was used a query to find homologs in the 25 other genomes. Only the 
best hit in each genome is shown. Each cell contains the locus tag, e-value and the number 
of blast hits. The e-value is reflected in the blue colour code. The darker the blue colour, 
the lower the e-value (and more significant hit). 
This table is also available on the CD. 
 
 






Figure S2.1. Schematic representation of N-acetylglucosamine 6-phosphate 
synthesis.  
N-acetylglucosamine 6-phosphate 4 was obtained through a modification of established 
procedures [1,2]. 
Benzylation of the anomeric hydroxyl group afforded compound 2 [2], which was 
selectively phosphorylated at the primary hydroxyl group using dibenzyldiisopropyl 
phosphoramidite and pyridinium hydrochloride followed by oxidation of the resulting 
phosphite, with cumene hydroperoxide, to the corresponding phosphate 3. Hydrogenolysis 
of 3 with H2/Pd/C (10%) in ethanol/water afforded N-acetylglucosamine 6-phosphate 4 
quantitatively. Interestingly, when the hydrogenation was performed under anhydrous 




1. Szabó P. Phosphorylated sugars. Part 25. Synthesis and behaviour in acidic media of 
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2. Yeager AR, Finney NS. Synthesis of fluorescently labeled UDP-GlcNAc analogues and 







Figure S2.2. Schematic representation of tagatose 1,6-biphosphate 11 synthesis. 
Modifications to the synthesis previously published [1] were made in order to optimize the 
process (details in Text S2.1). 1,2:3,4-di-O-isopropylidene-α-D-tagatofuranose 6 was 
obtained in one step (78%) from D-tagatopyranose [2], instead of the 4 steps required 
when starting from D-galacturonic acid. Phosphorylation of 6, under the same reaction 
conditions used for the synthesis of 3 (Fig. S2.1), afforded protected tagatose 6-phosphate 
7 in 94% yield. Hydrogenolysis of the benzyl protecting groups of the phosphate afforded 
phosphate 8 and partially hydrolysed compound 9, which was probably catalysed by the 
acidic hydrogen phosphate group. However, this was not a problem, since the next step 
was the removal of the isopropylidene acetals to afford tagatose 6-phosphate 10. The 
enzymatic phosphorylation [2] of the primary alcohol at C-1 of 10 afforded tagatose 1,6-
bisphosphate in 66% yield, as the salt of triethylammonium. All attempts to chemically 
phosphorylate the C-1 primary alcohol failed. 
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Figure S2.3. Genomic environment of the target genes. 
(A) Schematic representation of the genomic context of sugar pathway mutant strains 
generated in this study. Mutants were constructed by allelic replacement mutagenesis. (B) 
Organization of genes involved in the catabolism of galactose (A), mannose (B) and N-
acetylglucosamine (C). Genes are represented by large arrows. Genes known to be 




the same operons are shown in grey. Promoters (arrows) and terminators (lollipops) were 
determined by RNA-seq [1].  
Gene annotations (as from NCBI): galR,  galactose operon repressor; galK, galactokinase; 
galT-2, galactose 1-phosphate uridylyltransferase; lacC, tagatose 6-phosphate kinase; 
lacD, tagatose 1,6-diphosphate aldolase; lacT, transcription antiterminator LacT; 
SPD_1867, hypothetical protein; nagA, N-acetylglucosamine 6-phosphate deacetylase; 
SPD_1865, zinc-containing alcohol dehydrogenase; SPD_0640, pseudo; manA, mannose 
6-phosphate isomerase; SPD_0642, sodium-dependent transporter; agaS, sugar 
isomerase; galM, aldose 1-epimerase; SDP_1617, cell wall surface anchor family protein; 
SPD_1616, hypothetical protein; SPD_1615, hypothetical protein; SPD_1614, phosphate 
transport system regulatory protein PhoU; galT-1, galactose 1-phosphate 
uridylyltransferase; galE-2, UDP-glucose 4-epimerase; SPD_1611, hypothetical protein; 
SPD_1610, hypothetical protein; SPD_1609, ABC transporter substrate-binding protein; 
SPD_1608, ABC transporter ATP-binding protein; SPD_1607, ABC transporter permease; 
SPD_1606, MgtC/SapB family protein; galE-1, UDP-glucose 4-epimerase; SPD_1431, 
glycosyl transferase family protein; fer, ferredoxin; SPD_1429, hypothetical protein; cmk, 
cytidylate kinase; pgm, phosphoglucomutase/phosphomannomutase family protein; lacA, 
galactose 6-phosphate isomerase subunit LacA; lacB, galactose 6-phosphate isomerase 
subunit LacB; nagB, glucosamine 6-phosphate isomerase; rpsU, 30S ribosomal protein 
S21. SpeR spectinomycin resistance marker. 
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Figure S2.4. Growth profiles of the sugar specific deletion mutants and their 
complemented derivatives in C+Y medium.  
(A) Growth on galactose (Gal) of D39∆galK complemented with pKB01-galKgalT-2. (B) 
Growth on galactose (Gal) of D39∆lacD complemented with pKB01-lacD. (C) Growth on 
N-acetylglucosamine (GlcNAc) of D39nagA complemented with pKB01-nagA. (D) 
Growth on mannose (Man) of D39manA complemented with pKB01-manA.  
Growths were made in C+Y (without sucrose and glucose) with or without 0.1 mM ZnCl2, 
at 37ºC. 
Symbols: ( ) D39 grown in presence of zinc; ( ) D39 loss-of-function mutants grown in 
presence of zinc; ( ) complemented strains grown in presence of zinc; ( ) complemented 

















































































Figure S2.5. Analysis of pneumococcal strains in bacteremia model.  
Mice were infected intravenously with 100 µl PBS containing approximately 5 X105 CFU 
through dorsal tail vein. (A) The animals were monitored over 168 h. Symbols show the 
times when individual mice became severely lethargic, the point when the animals were 
culled. The horizontal bars mark the median times to the severely lethargic state. (B) 
Growth of bacteria in the blood. Each point is the mean of data from five mice. Error bars 




Figure S2.6. Subculturing of S. pneumoniae D39∆lacD in chemically defined 
medium (CDM) supplemented with galactose (Gal).  
(A) Pre-culture of S. pneumoniae D39∆lacD in CDM-Gal (55 mM). 1 ml glycerol stock 
inoculated in 80 ml CDM-Gal (see Materials and Methods). (B) Subculturing of S. 
pneumoniae D39∆lacD. Inoculation of fresh CDM-Gal (30 mM), to an initial optical density 
at 600 nm (OD600) of ~ 0.05, with a pre-culture grown in the same sugar (Gal) until late-
exponential phase of growth.  
Growth was performed at 37ºC, under semi-anaerobic conditions, without pH control 













































































































Text S2.1. Modifications to the previously published synthesis of 
tagatose 1,6-biphosphate. 
Modifications to the synthesis previously published [1] were made in order 
to optimize the process. 
General. 
1H NMR spectra were obtained at 400MHz in CDCl3, with chemical shift 
values () in ppm downfield from tetramethylsilane, DMSO-d6 and in D2O, 
13C NMR spectra were obtained at 100.61 MHz, 31P NMR spectra were 
obtained at 161.97 MHz. Assignments are supported by 2D correlation 
NMR studies. Medium pressure preparative column chromatography: 
Silica Gel Merck 60 H. Analytical TLC: Aluminium-backed Silica Gel Merck 
60 F254. Reagents and solvents were purified and dried according to 




tagatofuranose 7. To a stirred solution of 6 (0.53 g, 2.01 mmol) in THF 
(10 mL) at r.t. was added dibenzyl N,N-diisopropylphosphoramidite (1.33 
mL, 4.02 mmol) and tetrazole (0.28 g, 4.02 mmol). After 24 hours and 
complete conversion of the starting material, the reaction was cooled 
down to -78ºC and mCPBA (0.69 g, 4.02 mmol) was added. The 
temperature was allowed to rise to r.t., and after 90 minutes the reaction 
mixture was evaporated. Purification by flash column chromatography on 
silica gel (20:80, EtOAc/hexane) afforded the product 6 as a viscous 
colourless foam (0.98 g, 94%). 1H NMR (CDCl3):  7.37-7.31 (m, 10H, 
CH2Ph), 5.08-5.05 (m, 4H, CH2Ph), 4.73 (dd, 1H, J=3.5 Hz, J=5.8 Hz, H-




1H, J=9.7 Hz, H-1), 4.01 (d, 1H, J=9.7 Hz, H-1), 1.42 (s, 3H, OMe), 1.38 
(s, 3H, OMe), 1.35 (s, 3H, OMe), 1.26 (s, 3H, OMe). 13C NMR (CDCl3):  
135.8, 135.7, 128.7, 128.6, 128.5, 128.0, 127.9 (CH2Ph), 112.9 (C-2), 
111.9 (C(CH3)2), 111.8 (C(CH3)2), 85.0 (C-3), 79.6 (C-4), 77.7 (d, JC,P=8.0 
Hz, C-5), 69.3 (d, JC-P=3.2 Hz, CH2Ph), 69.2 (d, JC-P =2.9 Hz, CH2Ph), 67.3 
(d, JC-P=5.7 Hz, C-1), 65.5 (d, JC-P=5.4 Hz, C-6)  26.4 (OMe), 26.3 (OMe), 
25.9 (OMe), 24.8 (OMe). 31P NMR (CDCl3):  -1.15 (s). 
(1,2:3,4)-di-O-isopropylidene-α-D-tagatofuranose 6-(dihydrogen 
phosphate) 8. Dibenzyl phosphate 7 (0.98 g, 1.88 mmol) was 
hydrogenated at 50 psi in the presence of Pd/C 10% (0.19 g, 0.18 mmol) 
in EtOH (12 mL), for 20 hours at r.t. The reaction mixture was then filtered 
through celite, washed with EtOH and evaporated. Purification by column 
chromatography on silica gel (60:40, MeOH/CH2Cl2) afforded phosphate 
diacetal 8 (0.36 g, 56%) and phosphate monoacetal 9 (α/β 1:8.7, 0.23 g, 
41%) as colourless viscous foams. The characterisation data for 8 was 
identical to the literature [3]. 
3,4-O-isopropylidene-α/β-D-tagatofuranose 6-(dihydrogen 
phosphate) 9. 1H NMR (D2O) :  4.95 (dd, J=3.8 Hz, J=5.9 Hz, H-4 β), 
4.91 (dd, J=4.0 Hz, J=6.1 Hz, H-4 α) 4.59 (d, J=5.9 Hz, H-3 β), 4.54 (d, 
J=5.9 Hz, H-3 α), 4.36-4.32 (m, H-5 β), 4.30-4.27 (m, H-5 α), 4.10-4.04 
(m, H-6 β), 3.96-3.90 (m, H-6 β), 3.74 (d, J=11.6 Hz, H-1 β), 3.60 (d, 
J=11.6 Hz, H-1 β), 1.49 (s, OMe α), 1.41 (s, OMe β), 1.32 (s, OMe α), 1.28 
(s, OMe β). 31P NMR (D2O):  -0.32 (s). 
D-Tagatose 6-(dihydrogen phosphate). The product was obtained 
following the procedure described in the literature [3]. 1H NMR (D2O):  
4.29-4.25 (m), 4.23-4.20 (m), 4.11-4.06 (m), 4.04-3.82 (m), 3.51 (dd, 
J=12.0 Hz, J=16.6 Hz, H-1 α), 3.42 (dd, J=12.0 Hz, J=16.6 Hz, H-1 β). 13C 
NMR (D2O):  102.7 (C-2), 79.2 (d, JC,P=7.9 Hz, C-5), 70.9, 70.7, 64.6 (d, 
JC,P=4.7 Hz, C-6), 62.9 (C-1). 31P NMR (D2O):  -0.01 (s). 
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D-Tagatose 6-phosphate, disodium salt 10. The product was obtained 
following the procedure described in the literature [3]. Yield 73%. 1H NMR 
(D2O):  4.35-4.32 (m), 4.30-4.28 (m), 4.19-4.11 (m), 4.09-4.00 (m), 3.59 
(dd, J=12.0 Hz, J=19.0 Hz, H-1 α), 3.50 (dd, J=12.0 Hz, J=16.4 Hz, H-1 
β). 
D-Tagatose 1,6-bisphosphate, tetrakis(triethylammonium) salt 11. 
The enzymatic phosphorylation of 10 was accomplished following the 
procedure described in the literature [3]. The tetrakis(triethylammonium) 
salt of 11 was prepared instead of the tetrakis(cyclohexylammonium) salt. 
Anomers α:β 1:4, yield 66%. 1H NMR (D2O):  4.54 (t, 1H, J=5.1 Hz, H-4 
α), 4.45-4.42 (m, 1H, H-5 α), 4.38 (dd, 1H, J=4.8, J=4.0 Hz, H-4 β), 2.28 
(d, 1H, J=4.9 Hz, H-3 β), 4.25-4.20 (m, 1H, H-5 β), 4.17-4.11 (m, 1H, H-6 
β), 4.04-4.00 (m, 1H, H-6 β), 3.88 (dd, 1H, J=10.8, J=5.8 Hz, H-1 β), 3.82 
(dd, 1H, J=10.8, J=5.08 Hz, H-1 β), 3.19 (q, 24H, J=7.3 Hz, CH3CH2N), 
1.27 (t, 36H, J=7.3 Hz, CH3CH2N). 13C NMR (D2O), Anomer β:  101.8 (C-
2), 79.04 (d, J=8.1 Hz, C-5), 70.78 and 70.73 (C-3 and C-4), 65.6 (d, 
J=4.99 Hz, C-1), 64.3 (d, J=5.0 Hz, C-6), 46.6 (CH3CH2N), 8.2 
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Homologues of genes encoding the E. coli Fuc degradation pathway 
were found in the D39 genome (Fig. 1 and S4 Table) [1–3]. To further 
metabolize anaerobically the final product of Fuc metabolism, L-
lactaldehyde, an L-1,2-propanediol oxidoreductase (FucO) gene is 
present in some operons [4]. A BlastP search using as query FucO from 
E. coli K-12 MG1655 showed homology (42% identity; 60% positives) to 
an iron-containing alcohol dehydrogenase (SPD_1985) of D39, but 
whether this protein is functionally active remains to be elucidated. 
However, the downstream steps of L-lactaldehyde aerobic degradation 
seem to be missing in S. pneumoniae. A PTS system is present in the Fuc 
operon of D39, but the implication of this transporter in the uptake of Fuc 
is not yet proven. It has been proposed to transport Fuc-containing 
oligosaccharides that would subsequently be processed by intracellular 
glycoside hydrolases releasing Fuc [2–4]. 
N-acetylgalactosamine metabolism 
Genes involved in the initial steps for the intracellular catabolism of 
GalNAc [5–7] remain elusive in the pneumococcus (Fig. 1). However, the 
N-acetylgalactosamine 6-phosphate deacetylase (coded by agaA) for 
conversion of GalNAc6P to GalN6P in E. coli C str. ATCC 8739, shares 
37% amino acid sequence identity with N-acetylglucosamine 6-phosphate 
deacetylase (coded by nagA) of D39. Recently, it was shown that NagA 
can substitute the activity of AgaA, in E. coli [7,8]. Moreover, in this 
microorganism, it was proposed that the isomeration/deamination of 
GalN6P to T6P was accomplished by galactosamine 6-phosphate 
isomerase (coded by agaS) and not by agaI [7]. The first is annotated in 
the genome of D39 and encodes a sugar isomerase (45% amino acid 
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sequence identity with the one present in E. coli C str. ATCC 8739). A 
putative GalNAc transporter (SPD_0293-5-6-7) is annotated in the D39 
genome [3] and shares 33% amino acid sequence identity with the 
GalNAc transporter subunit EIIC (EcolC_0566) of E. coli C str. ATCC 
8739. Additionally, the latter shares 32% amino acid sequence identity 
with SPD_1990, which is annotated as being potentially involved in amino 
sugar metabolism in D39.  
Very recently, the GalNAc pathway was established for Lactobacillus 
casei and is encoded in the gnb gene cluster [9]. This route includes a 
PTSGnb that transports and phosphorylates the substrate to GalNAc6P 
and is subsequently processed through GnbF and GnbE, which encode 
for the activities of GalNAc6P deacetylase and GalN6P 
deaminase/isomerase, respectively. Moreover, it was found that 
conversion of GalNAc6P to GalN6P could also be accomplished by NagA, 
as full growth on GalNAc requires both activities.  
The PTSGnb shares high amino acid sequence homology with the 
pneumococcal mannose-family PTS SPD_0066-7-8-9. In particular the 
PTS transport system subunit IIC (LCABL_02930) shares 50% identity 
and 65% positives with the S. pneumoniae D39 protein encoded by 
SPD_0067. The degradation enzymes GnbF and GnbE share 54% and 
48% amino acid sequence identity with NagA (SPD_1866) and AgaS 
(SPD_0070) of S. pneumoniae D39, respectively. 
In summary, GalNAc catabolic pathways were established in E. coli 
and L. casei and according to our analysis S. pneumoniae possesses 
gene products showing considerable homology to the proteins in these 
organisms. Therefore, it is tempting to suggest that GalNAc is processed 
through the combined action of nagA and agaS in S. pneumoniae D39. 
However, how to reconcile this hypothesis with the inability to grow on 
GalNAc still remains to be investigated. 




The NeuNAc utilization has been recently studied [3,10,11]. 
A duplication event might have occurred for the N-acetylneuraminate 
lyase gene (SPD_1489 and SPD_1163). N-acetylmannosamine kinase is 
annotated in the metabolic database MetaCyc as a glucokinase (gki). 
However, a BlastP search led us to suggest that this function is most likely 
performed by the ROK family protein (SPD_1488) as this locus is part of 
the nanAB operon.  
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Abstract  
During the progression from colonisation to disease S. pneumoniae 
has to cope with changes in the availability of nutrients, namely glucose 
(Glc) a prevailing sugar in blood and inflamed tissues is scarce in the 
nasopharynx. We assessed the pneumococcus response to galactose 
(Gal), N-acetylglucosamine (GlcNAc) and mannose (Man), which are 
present in glycans and support growth of S. pneumoniae D39. The gene 
expression and metabolic profiles on glycan-derived sugars were 
compared to those on Glc. Gal, GlcNAc and Man affected respectively the 
expression of 8.4%, 11.4%, and 14.2% of the genome, covering cellular 
functions including central carbon metabolism and virulence. Glycolytic 
dynamics were monitored in resting cells using in vivo 13C-NMR. GlcNAc 
(and Glc) rendered homolactic fermentation, while Gal and Man 
generated mixed-acid profiles. The glycolytic metabolite fructose 1,6-
bisphosphate accumulated, but the pool size was considerably higher 
(circa 2.5 times) on GlcNAc (and Glc) than on Man or Gal, consistent with 
the homolactic profile. On Gal and Man, the accumulation of specific 
metabolic intermediates (α-galactose 6-phosphate and mannose 6-
phosphate) indicated catabolic bottlenecks possibly causing growth 
retardation.   
S. pneumoniae growing on glycan-derived sugars was challenged with 
Glc, and the response to this stimulus was evaluated at transcriptional, 
physiological and metabolic levels. Glc was readily consumed (preferred 
sugar) and elicited a metabolic shift towards a homolactic profile. On Gal, 
this was accompanied by a transient increase of fructose 1,6-
bisphosphate. The transcriptional response to Glc was large (over 5% of 
the genome). In central carbon metabolism (most represented category), 
Glc exerted mostly negative regulation. Interestingly, the smallest 




varied sugars improves the fitness of S. pneumoniae. The expression of 
classical virulence factors was negatively controlled by Glc in a sugar-
dependent manner. Overall, our results strengthen the link between 
carbohydrate metabolism, adaptation to host niches and virulence.  
 
Introduction  
Streptococcus pneumoniae is a common asymptomatic commensal of 
the human nasopharynx, but also a life-threatening pathogen responsible 
for severe illnesses such as bacterial meningitis, pneumonia, 
septicaemia, as well as milder respiratory infections [1,2]. The 
establishment of a carrier state (colonisation) is a precursor for 
pneumococcal disease and an important feature for dissemination 
through the community [2–4]. Indeed, from the microbe’s fitness 
perspective, the success of pneumococcal infections relies on 
colonisation, multiplication and transmission to a new host [5]. 
Consequently, the factors required for its commensal lifestyle might also 
be considered virulence factors [5,6]. The mechanisms underlying the 
progression from a carrier state to invasive disease are complex, probably 
multifactorial and are still poorly understood [7,8]. Notwithstanding, 
several studies based on different techniques to evaluate pneumococcal 
gene expression, revealed that pneumococcal virulence genes were 
differentially expressed in different host niches [7,9–14]. Therefore, we 
hypothesise that transition from carriage to disease involves modulation 
of pneumococcal gene expression in response to environmental changes. 
Indeed, it was shown that changes in the concentrations of metal ions in 
different host sites, contributes to virulence in S. pneumoniae (reviewed 
in [15,16]). 
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To a large extent the pneumococcal pathogenesis relies on efficient 
acquisition and metabolism of carbohydrates required for growth and 
survival, but the knowledge of pneumococcal physiology and 
pathogenesis is still limited. S. pneumoniae is a strictly fermentative 
bacterium relying exclusively on carbohydrates to obtain energy for 
growth (Fig. 3.1). Compared to other colonisers of its ecological niche like 
Haemophilus influenzae and Neisseria meningitidis, S. pneumoniae 
displays the broadest sugar utilization range [17]. Analysis of the genome 
suggested the existence of pathways for catabolism of a wide diversity of 
carbohydrates [17] and a recent study showed that S. pneumoniae is able 
to use at least 32 substrates [18]. In particular, the bacterium has catabolic 
pathways for the utilization of galactose (Gal), mannose (Man) and N-
acetylglucosamine (GlcNAc) ([17,18]; Chapter 2). The pneumococcus 
possesses at least ten extracellular glycosidases, which enable the 
modification and breakdown of host glycans generating free sugars that 
can potentially be used for growth (reviewed in King et al. [4]). 
Furthermore, over 30% of all the transporters in the genome are 
presumably involved in sugar uptake [17,18], a by far larger proportion 
than that found in the other microorganisms occupying the same niche 
[17,19].  
However, to thrive in diverse host environments, the bacterium has to 
cope with fluctuations in nature and availability of carbon sources. In the 
nasopharynx free sugars are scarce, but glycans are plentiful both in 
secretions and on the surface of epithelial cells. In contrast to the airways, 
the generally preferred sugar in Streptococcaceae, glucose (Glc), is 
present in comparatively higher concentrations in the bloodstream and 
during infection [20,21]. We hypothesise that this metabolic flexibility is 
important during the transition from colonisation to invasive disease in S. 
pneumoniae. To adapt to host environments, the pneumococcus has 






Figure 3.1. Schematic representation of Gal, Man, GlcNAc and Glc metabolism in S. 
pneumoniae D39.  
Sugar-specific steps, glycolysis and fermentative metabolism are depicted. Putative and 
functional characterized genes encoding depicted metabolic steps are shown in white 
boxes. Proposed pathways were reconstructed based on genome information 
(http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi), literature and database surveys 
(KEGG, MetaCyc). Gene annotation downloaded from NCBI: gki, glucokinase; pgi, 
glucose 6-phosphate isomerase; pfkA, 6-phosphofructokinase; fba, fructose bisphosphate 
aldolase; tpiA, triosephosphate isomerase; gap, glyceraldehyde-3-phosphate 
dehydrogenase; pgk, phosphogltcerate kinase; gpmA, phosphoglyceromutase; eno, 
phosphopyruvate hydratase (enolase); pyk, pyruvate kinase; ldh, L-lactate 
dehydrogenase; lctO, lactate oxidase; spxB, pyruvate oxidase; ackA, acetate kinase; pta, 
phosphotransacetylase; pflB, pyruvate formate-lyase; adh (spd_1834), bifunctional 
acetaldehyde-CoA/alcohol dehydrogenase; galM, aldose 1-epimerase; galK, 
galactokinase; galE-1, UDP-glucose 4-epimerase; galT-2, galactose 1-phosphate 
uridylyltransferase; pgm, phosphoglucomutase/phosphomannomutase family protein; 
lacA, galactose 6-phosphate isomerase subunit LacA; lacB, galactose 6-phosphate 
isomerase subunit LacB; lacC, tagatose 6-phosphate kinase; lacD, tagatose 1,6-
diphosphate aldolase; manA, mannose 6-phosphate isomerase; nagA, N-
acetylglucosamine 6-phosphate deacetylase; nagB, glucosamine 6-phosphate isomerase.  
Intermediates: G6P, glucose 6-phosphate; F6P, fructose 6-phosphate; FBP, fructose 1,6-
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1,3-BPG, 1,3-biphosphoglycerate; 3-PGA, 3-phosphoglycerate; 2-PGA, 2-
phosphoglycerate; PEP, phosphoenolpyruvate; GlcNAc6P, N-acetylglucosamine 6-
phosphate; GlcN6P, glucosamine 6-phosphate; Man6P, mannose 6-phosphate; Gal, 
galactose; α-Gal, α-galactose; αGal1P, α-galactose 1-phosphate; αG1P, α-glucose 1-
phosphate; UDP-Glc, UDP-glucose; UDP-Gal, UDP-galactose; Gal6P, galactose 6-
phosphate; T6P, tagatose 6-phosphate; TBP, tagatose 1,6-diphosphate.  
Sugar transporters depicted as rectangles and ovoids generically represent 
phosphoenolpyruvate phosphotransferase systems or ABC transporters, respectively. 
 
It has been proposed that exchanging genetic material (genetic 
transformation) provides a selective advantage in the adaptation of the 
pneumococcus to distinct environmental conditions [22,23]. Moreover, 
when exposed to a mixture of substrates bacteria can sense the nutritional 
environment and adjust its catabolic capabilities, in a process termed as 
carbon catabolite repression (CCR) [24]. CCR is a regulatory process that 
enables bacteria to utilize preferred carbon sources in detriment of others, 
by downregulating the expression of genes and inhibiting enzyme 
activities involved in the use of secondary carbon sources [25,26]. The 
molecular mechanisms mediating CCR are diverse (reviewed in [24–26]) 
and act at different regulatory layers: gene expression (transcription 
activation and gene repression), protein activities (control of translation, 
post-translational modification) and metabolites (allosteric regulation) 
[26,27]. In the Firmicutes, CCR typically comprises the general 
phosphoenolpyruvate phosphotransferase system component HPr, the 
bifunctional HPr kinase/phosphorylase (HPrK) and the transcription factor 
catabolite control protein A (CcpA). The latter binds to catabolite response 
elements (CRE) in promoter regions of CCR-sensitive genes [26]. Hence, 
a global understanding of the physiological response of S. pneumoniae to 
shifts in substrate availability requires the integration of diverse data sets 
collected at distinct “omic” levels.  
With the aim to study the response of S. pneumoniae to the 
monosaccharides present in host glycans we have collected transcript 




single carbon sources and compared to the profiles on Glc. Previously, 
we have shown that Glc supported the fastest growth followed by GlcNAc 
which was a better substrate than Gal or Man (Paixão et al., 2015, 
Chapter 2). The markedly different growth profiles led us to surmise that 
growth on these sugars is differently regulated. Furthermore, we 
investigated the effect of adding the fast metabolizable sugar (Glc) to S. 
pneumoniae cells actively growing on Gal, Man, GlcNAc or in a mixture 
thereof on the growth physiology and at the transcriptional and metabolic 
levels (by in vivo 13C-NMR, for Gal-adapted cells). Finally, we evaluated 
the impact of the substrate for growth on the expression of virulence 
factors. 
In this work we have generated data at transcript, metabolic and 
physiological levels, in respect to S. pneumoniae’ response to sugar 
availability. These data can in the future be used as input for predictive 
multi-level mathematical models of the pneumococcus metabolic 
networks. It is expected that such tools will facilitate our understanding of 
complex phenomena and enable the identification of novel targets for the 
development of therapeutics. 
 
Materials and Methods 
Bacterial strains and growth conditions 
Streptococcus pneumoniae strain D39 (serotype 2) and its derivative 
D39∆cps (A. M. Cavaleiro, P. Gaspar, T. Kloosterman, O. P. Kuipers and 
A. R. Neves., unpublished) were used throughout this study. The D39 
isolate was obtained from the culture collection of the Department of 
Infection, Immunity and Inflammation, of the University of Leicester. 
Stocks were prepared as described elsewhere [28] and stored in glycerol 
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(25% vol/vol) at -80°C. Working stocks were done by transferring 1 ml of 
the frozen stock to 25 ml Glc-M17 medium (Difco), followed by incubation 
at 37ºC until late exponential phase (OD600 ~0.8). Cultures were 
centrifuged (6300 x g, 7min, 4ºC), the supernatant discarded and the 
pellet suspended in 20 ml 25% (vol/vol) glycerol-M17. 1 ml aliquots were 
stored at -80ºC until further use. 
Routinely, S. pneumoniae was grown statically in M17 broth (Difco) 
containing 0.5% (wt/vol) glucose (Glc-M17) at 37C. For physiological 
studies and transcriptome analysis, S. pneumoniae D39 was grown in 
static rubber stoppered bottles at 37ºC and without pH control (initial pH 
6.5) in the chemically defined medium (CDM) described by Carvalho et 
al. [28]. Growth was performed as reported before (Paixão et al. 2015, 
Chapter 2). Cells actively metabolizing single sugars Gal, GlcNAc and 
Man (12-15 mM) or a sugar mixture (approximately 6 mM each, herein 
denominated sugar mix) were challenged or not with a 10 mM pulse of 
Glc at mid-exponential phase of growth. In the case of Glc challenge, cells 
metabolizing other sugars were herein denominated “sugar”-adapted 
cells. Cultures were started by inoculating fresh CDM, to an initial optical 
density at 600 nm (OD600) of ~ 0.05, with a pre-culture grown until late 
exponential phase of growth. Pre-cultures were performed as described 
by Carvalho et al. [28], except pre-cultures for growth on sugar mix, which 
were grown in CDM containing 30 mM of each carbon source. Growth 
was monitored by measuring OD600 hourly. Maximum specific growth 
rates (μmax) were calculated through linear regressions of the plots of 
ln(OD600) versus time during the exponential phase of growth after the Glc 






Quantification of substrate consumption and fermentation 
products  
Strains were grown in CDM supplemented with the appropriate sugar 
as described above. Culture samples (2 mL) were taken at inoculation, 
immediately and 1 h after the Glc pulse, and at the onset of the stationary 
phase of growth, and centrifuged (16,100 x g, 3 min, 4ºC). The 
supernatants were filtered (Q-Max® RR NY syringe 0.22 µm filters) and 
stored at - 20ºC until further analysis. Fermentation products, Glc and 
GlcNAc were quantified by high performance liquid chromatography 
(HPLC) equipped with a refractive index detector (Shodex RI-101, Showa 
Denko K. K., Japan) using an HPX-87H anion exchange column (Bio-Rad 
Laboratories Inc., California, USA) at 60ºC, with 5 mM H2SO4 as the 
elution fluid and a flow rate of 0.5 ml min-1. Gal and Man were quantified 
by 1H-NMR and the spectra were acquired in a Bruker AMX300 
spectrometer (Bruker BioSpin GmbH). To quantify Gal and Man the 
temperature of the probe was set to 18ºC and to 37ºC, respectively. DSS 
(3-(trimethylsilyl) propionic acid sodium salt) was added to the samples 
and used as an internal concentration standard in 1H-NMR quantifications. 
Yields were calculated using the data from samples taken immediately 
after inoculation and at the onset of stationary phase of growth. A factor 
of 0.38, determined from a dry weight (DW) (mg ml-1) versus OD600 curve, 
was used to convert OD600 into DW (mg biomass ml-1). The yield in 
biomass was calculated as g of dry weight per mol of substrate consumed. 
The ATP yield was determined as the ratio of ATP produced to substrate 
consumed at the time of growth arrest assuming that all ATP was 
synthesized by substrate-level phosphorylation. The values reported are 
averages of two independent growths. 
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Transcriptome analysis 
The transcript levels of S. pneumoniae D39 growing in CDM 
supplemented with Gal, Man or GlcNAc were compared by transcriptome 
analysis to Glc-grown cells. Additionally, cells of D39 grown on a single 
sugar (Gal, Man or GlcNAc) or in their mixture challenged with a Glc pulse 
(10 mM) were compared to unchallenged cells using whole-genome S. 
pneumoniae DNA microarrays [29]. Cells were harvested by 
centrifugation (7197 x g, 2.5 min, at room temperature) at exponential 
phase of growth 1 h after the pulse challenge that was given at mid-
exponential growth. Cell pellets were suspended in the remaining 
medium, frozen in liquid nitrogen and stored at -80 °C. mRNA isolation, 
synthesis and labelling of cDNA and hybridization were performed as 
described before [29]. RNA extraction was performed from three 
independent cultures. Microarray experiments and analysis were done 
essentially as described elsewhere [29,30].  
In all cases, genes were considered significantly differentially 
expressed when the Bayesian p-value was < 0.05 / n. The Bonferroni 
correction factor n = 1769 x 7 corresponds to the total number of 
differential expression significance tests performed and thus accounts for 
multiple hypothesis testing. Overrepresentation of COG categories and 
Metacyc pathways (with more than five genes) among significant genes 
was assessed via hypergeometric tests with a p-value threshold of p < 
0.05 / n, with the Bonferroni correction factor n = 63 x 7 corresponding to 
the total number of overrepresentation tests performed.  
Heatmap were generated by taking into account the genes that were 
differentially expressed in each sample subset (single sugars vs. Glc and 
Glc challenged experiments vs. unchallenged cells), and intersecting 
those genes with the annotated subset categories: sugar transporters and 




glycolytic genes and genes devoted to pyruvate metabolism (according to 
NCBI annotation) and virulence factors (Table S3.1). 
Venn diagrams were generated with the Venny tool: 
http://bioinfogp.cnb.csic.es/tools/venny/. When creating the gene lists, we 
consider D39 genes that are differentially expressed in each conditions, 
regardless of the direction of differential expression.  
 
In vivo 13C-NMR experiments with resting cells 
Cells of S. pneumoniae D39∆cps were grown under anaerobic 
conditions, in a 2-L bioreactor (Sartorius Biostat® B plus) in CDM 
supplemented with 55 mM of Gal or GlcNAc. On Man, the biomass 
generated was insufficient for NMR studies, thus the cells were grown in 
presence of 55 mM of Glc supplemented with 0.5 mM of Man. Growth was 
performed with controlled pH (6.5) and temperature (37ºC), under 
anaerobic conditions essentially as described before [28]. The medium 
was aseptically degassed with argon during 60 min before inoculation. 
Cultures were kept homogenized by using an agitation speed of 50 rpm. 
Cells were harvested (5750 x g, 7min, 4ºC) in the late-exponential phase 
of growth and suspensions prepared essentially as described elsewhere 
[31]. In brief, cells were washed twice (5750 x g, 5min, 4ºC) with 50 mM 
KPi buffer (pH 6.5) supplemented with 1% (wt/vol) choline and suspended 
in 35 ml of the same buffer with 6% (vol/vol) of deuterium oxide. 
In vivo 13C-NMR experiments were performed online under controlled 
conditions of pH (6.5), temperature (37ºC) and atmosphere (anaerobic 
conditions, argon atmosphere), using the circulating system as described 
by Neves et al. [31]. Substrates specifically labelled with 13C at carbon one 
(20 mM) were added to the cell suspension at time zero and spectra (30 
s) acquired sequentially. For the two pulse substrate experiment, cells of 
D39∆cps actively metabolizing 20 mM of [1-13C]Gal were challenged with 
a 10 mM pulse of [2-13C]Glc. 13C enrichment in different carbons allows 
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traceability of the substrates in deriving intracellular metabolites and end-
products. After substrate depletion and when no changes in the 
resonances due to end-products and intracellular metabolites were 
observed, the NMR experiment was stopped and a total cell extract was 
prepared by passing the cell suspension three times through the French 
press (6.21 MPa); the resulting total extract was incubated 15 min at 80-
90ºC and cooled down on ice. Cell debris and denaturated 
macromolecules were removed by centrifugation (45696 x g, 10 min, 4ºC), 
and the supernatant (herein designated as NMR cell extract) was used for 
metabolite quantification of end-products and minor metabolites that 
remained inside the cells, which was accomplished in fully relaxed 13C-
spectra, at 30ºC. The lactic acid and acetate produced were quantified in 
the NMR cell extract by 1H-NMR on a Bruker AMX300 spectrometer 
(Bruker Biospin GmbH), using formic acid (sodium salt) as an internal 
concentration standard [31].   
Due to fast pulsing conditions during in vivo 13C-spectra acquisition, 
correction factors were determined allowing the conversion of peak 
intensities into concentration of intracellular metabolites. Correction 
factors for resonances due to C1 and C6 of FBP were determined 
(0.73±0.07) to convert peak intensities to concentrations as described by 
Neves et al. [32], but the temperature was kept at 37ºC. Resonances due 
to C1 α-mannose 6-phosphate (α-Man6P) and C1 β-mannose 6-
phosphate (β-Man6P) were determined (0.33 and 0.51, respectively), at 
37ºC. A value of 3 µl (mg protein)-1 of intracellular volume of S. 
pneumoniae was used to determine the intracellular concentrations of 
metabolites [33]. The concentration limit for detection of intracellular 
metabolites under the conditions employed was 3-4 mM. For dry mass 
determination, 1 ml of cell suspension obtained after in vivo 13C NMR 
experiment was filtered through 0.22 µm pore size membranes, dried at 




duplicates for each experiment. The quantitative kinetic data for 
intracellular metabolites were determined as described elsewhere [31]. 
The values presented are averages of at least two independent assays.  
 
Identification of transient resonances 
Transient resonances observed during in vivo NMR experiments were 
assigned by spiking pure compound to NMR extracts obtained from 
actively metabolizing cell suspensions. In brief, during the metabolism of 
the labelled substrate, 1 ml aliquot was withdrawn and perchloric acid (0.6 
M, final concentration) was added. After 20 min stirring on ice the pH was 
set neutral with 2M KOH, and the cell extract was centrifuged (60 min, 
4ºC, 16100 x g). The supernatant was frozen with liquid nitrogen, 
lyophilized and suspended in bi-distilled water.  
 
NMR spectroscopy 
13C spectra were acquired at 125.77 MHz using a quadruple nuclei 
probe head on a Bruker AVANCE II 500 MH spectrometer (Bruker Biospin 
GmbH, Karlsruhe, Germany), as described before [31]. 
Determination of the correction factors was accomplished by 
acquisition of 13C-NMR spectra with a 60º flip angle and a recycle delay 
of 1.5 s, for saturating conditions or 60.5 s (relaxed conditions). For 
assignment of unknown compounds, carbon NMR spectra were recorded 
using a selective de carbon probe head (13C-Dual). 
Carbon chemical shifts are referenced to the resonances of external 
methanol, designated at 49.3 ppm. 
 
Chemicals 
Galactose and mannose were purchased from Sigma-Aldrich. Glucose 
was supplied by Merck and N-acetylglucosamine was purchased from 
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Applichem. [1-13C] labelled compounds (galactose, glucose, mannose 
and N–acetylglucosamine) and [2-13C]glucose, 99% isotopic enrichment, 
were obtained from Cortecnet. DSS and formic acid (sodium salt) were 
purchased from Merck. All other chemicals used were reagent grade. 
 
Results and Discussion 
Carbon and energy metabolism transcriptome of glycan-
derived sugars 
Mucins and other host glycans are composed of a variety of 
monosaccharides. We have previously shown the aptitude of S. 
pneumoniae D39 to use GlcNAc, Gal and Man as sole carbon sources for 
growth (Paixão et al., 2015, Chapter 2). The growth profiles sustained by 
these sugars are markedly different, which indicates differential gene 
expression. Thus, to investigate the effect of the glycan-derived 
monosaccharides on gene expression, a whole-genome transcriptome 
analysis was conducted, in which the transcript levels of cells grown on 
Gal, Man or GlcNAc were compared to those of Glc-grown cells (Tables 
S3.2, S3.3 and S3.4, all provided on the CD). The results are summarized 












Table 3.1. Significantly differentially expressed genes (up- or 
downregulated) in cells of S. pneumoniae D39 grown in CDM 
supplemented with N-acetylglucosamine (GlcNAc), mannose (Man) or 
galactose (Gal) as compared to glucose (Glc), determined by DNA 
microarraysa. 
   Up- or downregulationb 
Locus_tag Gene Product GlcNAc Man Gal 
Sugar-specific catabolismc 
SPD_0071 galM aldose 1-epimerase    0.58 
SPD_1050 lacD tagatose 1,6-diphosphate aldolase    3.00 
SPD_1051 lacC tagatose-6-phosphate kinase    2.87 
SPD_1052 lacB 
galactose-6-phosphate isomerase 
subunit LacB  
  3.05 
SPD_1163  N-acetylneuraminate lyase, putative  1.39 0.75  
SPD_1246 nagB glucosamine-6-phosphate isomerase   0.46  
SPD_1432 galE-1 UDP-glucose 4-epimerase    0.77 
SPD_1488  ROK family protein  1.58 0.83  




  3.11 




  0.47 
SPD_1993 fucU RbsD/FucU transport protein family protein   -0.98  
SPD_1994 fucA L-fuculose phosphate aldolase   -0.82  
SPD_1995 fucK L-fuculose kinase FucK, putative   -1.25  
Glycolysis 
SPD_0445 pgk phosphoglycerate kinase   0.46  
SPD_0526 fba fructose-bisphosphate aldolase   0.45  
SPD_0790 pyk pyruvate kinase   0.57  
SPD_1012 eno enolase   0.61  
SPD_1823 gap glyceraldehyde-3-phosphate dehydrogenase  0.53  
Downstream pyruvate 
SPD_0420 pflB pyruvate formate-lyase   1.25  
SPD_0621 lcto lactate oxidase   0.38  




 1.00  
Sugar-specific transportersc 
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SPD_0088  ABC transporter, permease protein    -0.73 
SPD_0089  ABC transporter, permease protein    -0.80 
SPD_0279 celB 
cellobiose phosphotransferase system IIB 
component  
-2.13 -1.80 -2.41 
SPD_0281 celC 
cellobiose phosphotransferase system IIA 
component  
-2.30 -1.98 -2.29 
SPD_0283 celD 
cellobiose phosphotransferase system IIC 
component  
-1.91 -2.24 -1.61 
SPD_0360 mtlA 
PTS system, mannitol-specific IIBC 
components  
  0.62 
SPD_0502  
PTS system, beta-glucosides-specific IIABC 
components  
-0.65 -0.47 -0.73 
SPD_0559  PTS system IIA component, putative    1.26 
SPD_0560  PTS system, IIB component, putative    1.21 
SPD_0561  PTS system, IIC component, putative    1.55 
SPD_0661 exp5 PTS system, IIABC components  -0.61   
SPD_0773  
PTS system, fructose specific IIABC 
components  




 0.49  
SPD_1040 ptsH phosphocarrier protein HPr   0.56  
SPD_1047 lacE-2 
PTS system, lactose-specific IIBC 
components  
  0.78 
SPD_1057  PTS system, IIB component, putative    1.48 
SPD_1409  sugar ABC transporter, ATP-binding protein   -0.52 
SPD_1493  sugar ABC transporter, permease protein   0.61  
SPD_1494  sugar ABC transporter, permease protein   0.54  
SPD_1495  
sugar ABC transporter, sugar-binding 
protein  
 0.56  
SPD_1496  PTS system, IIBC components   -0.48 -0.72 
SPD_1832  PTS system, IIB component   -0.54  
SPD_1833  PTS system, IIA component   -0.57  
SPD_1959 ulaA ascorbate-specific PTS system enzyme IIC   -0.51 
SPD_1989  PTS system, IID component   -0.63  
SPD_1991  PTS system, IIB component   -0.78  
SPD_1992  PTS system, IIA component   -0.76  
 
a Subtable of Tables S3.2, S3.3 and S3.4, all provided on the CD. 
b Values of ln-ratio. Positive values indicate upregulation and negative values indicate 
downregulation. 
c As reviewed by Paixão et al, 2015 (Chapter 2). 
In bold are depicted the transporters and sugar-specific catabolic genes known or 
putatively involved in the metabolism of GlcNAc, Man or Gal, as reviewed by Paixão et al, 





The number of genes significantly differentially expressed was sugar 
specific. Mannose elicited the largest transcriptional response, with a total 
of 247 genes out of 1738 (about 14.2%) showing altered mRNA levels as 
compared to Glc. In opposition, Gal-grown cells displayed the lowest 
percentage of significantly differentially expressed genes (8.4%) in 
comparison with Glc. A total of 198 genes were significantly differentially 
expressed in cells grown in GlcNAc-containing medium (11.4%). 
Interestingly, only a small percentage (1.8%) of genes significantly 
differentially expressed was common to the three carbon sources (Fig. 
3.2A and Table S3.5).  
 
Figure 3.2. Comparison of the genome-wide transcriptional response to different 
carbohydrate availabilities.  
Venn diagrams of the significantly differentially expressed genes during growth on (A) 
galactose (Gal), mannose (Man) and N-acetylglucosamine (GlcNAc) and (B) adapted to 
grow on galactose, mannose, N-acetylglucosamine or in a mixture thereof (Mix) and 
submitted to a pulse of Glc. Figures were generated using VENNY 
(http://bioinfogp.cnb.csic.es/tools/venny/index.html). 
 
Of these, 12% were upregulated in the presence of the glycan-derived 
sugar, whereas the majority was seemingly activated by Glc. These was 
indeed the case for the SPD_0277-8-9-0-1-2-3 locus comprising the Lac-
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PTS transporter celBCD, a 6-phospho-beta-glucosidase celA, a 
transcriptional regulator and two hypothetical proteins, which was 
downregulated on all conditions tested. Also downregulated was 
SPD_0502, which encodes the IIABC components of a Glc-family PTS 
system (Table S3.5). Thus, expression of two sugar transporters, 
SPD_0502 and CelBCD, supposedly involved in the translocation of beta-
glucosides [18,34,35] is induced by Glc, suggesting a possible role of 
these transporters on Glc internalization. The involvement of transporters 
other than the PTS-Man (ManLMN) on Glc transport has been postulated, 
but not proven to date [18].  
 Among the three sugars, GlcNAc and Man showed the highest 
number of differentially expressed genes in common (46 genes), while 
Gal and GlcNAc had the least number of common differentially expressed 
genes (only 13 genes) (Fig. 3.2A).  In conclusion, growth on Man and 
GlcNAc showed the lowest differentially regulation at the transcriptional 
level, thus the simultaneous utilization of GlcNAc and Man is likely more 
favourable than of one of the previous together with Gal.  
 Overrepresentation of COG categories among the significantly 
differentially expressed genes displayed a sugar dependency (Table S3.6 
on the CD). In Gal-grown cells the COG category of “carbohydrate 
metabolism and transport” (G) was overrepresented (28 genes out of 146, 
fifteen of which were induced) (Tables S3.4 and S3.6, all provided on the 
CD). On GlcNAc, the “amino acid metabolism and transport” (E) and the 
“translation, ribosomal structure and biogenesis” (J) categories showed 
the highest number of genes significantly, differentially expressed (18.7% 
and 14.6%, respectively). While in the E category 8 genes out of 37 were 
induced, only one gene belonging to the J category was upregulated 
(Tables S3.2 and S3.6, all provided on the CD). In Man-grown cells no 
differential COG categories were overrepresented, according to the 




accordance, Man-grown cells displayed the highest percentage (26.3%) 
of genes encoding hypothetical proteins differentially expressed. 
N-acetylglucosamine  
 During exponential growth, 198 transcripts were differentially 
expressed on GlcNAc as compared to Glc (Bayesian p-value < 0.05 / n). 
Of these, only 5.6% belong to the COG category of “carbohydrate 
metabolism and transport” (G). Surprisingly, neither GlcNAc specific 
transporters nor the dedicated catabolic genes (nagA and nagB) were 
altered, except for gene exp5, a putative GlcNAc PTS transporter, which 
is downregulated (Tables 3.1 and S3.2 on the CD). This pattern suggests 
that Exp5 is not involved in the translocation of the amino sugar, but 
further experimental validation is required. In other bacteria, such as 
Streptococcus mutans or the model organisms Bacillus subtilis and 
Escherichia coli, GlcNAc induced the expression of genes encoding the 
specific catabolic pathway [36]. In a previous study, we showed that the 
activity of glucosamine 6-phosphate isomerase (NagB) was 4 times 
higher than that of N-acetylglucosamine 6-phosphate deacetylase (NagA) 
in GlcNAc-grown cells (Paixão et al. 2015, Chapter 2). Re-evaluation of 
the microarray data using a less restrictive criterion (Bayesian p-value < 
0.001) showed that nagB was slightly induced by GlcNAc (1.40 times), but 
the expression of nagA was not altered. In S. mutans, the levels of nagB 
and nagA transcripts also differ (mRNA nagB > nagA) [36], and this profile 
was interpreted as a mechanism to ensure a response to sugar variations 
while keeping the pools of GlcN6P to optimize growth. GlcN6P was 
identified as an allosteric effector that alleviates the repression of nagA 
and nagB mediated by the transcriptional regulator NagR. 
Genes encoding activities in the central carbon pathways, glycolysis 
and fermentation (pyruvate conversion) were not significantly differentially 
expressed (Table 3.1). The expression data are in good agreement with 
our earlier observations showing that fermentation of GlcNAc is 
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essentially homolactic, but fails to explain the lower growth rates on the 
amino sugar (about 1.7 times lower than on Glc) (Paixão et al., 2015, 
Chapter 2). Growth rate is by far a more complex property, which cannot 
be fully explained by differences in the glycolytic flux that might (or not) 
arise from differentially expression of genes. A limiting step, however, can 
be the uptake of GlcNAc as induction of specific transporters was not 
observed.  
Of importance, also induced by GlcNAc is the N-
acetylglucosaminidase encoded by strH. This surface-associated 
exoglycosidase is involved in the breakdown of GlcNAc residues from 
glycans [37,38]. Hence, sensing of free GlcNAc presumably enables S. 
pneumoniae to hydrolyse GlcNAc containing glycans.   
Mannose 
Mannose elicits a global effect and alters considerably the expression 
of genes in glycolysis and pyruvate metabolism, as opposed to GlcNAc 
(and Gal, see below). Of all the transporters previously postulated as 
potentially involved on Man uptake (Paixão et al., 2015, Chapter 2), only 
the putative Man-PTS system SPD_1989-1-2 was differentially expressed 
on Man. The genes were downregulated, suggesting that their product 
might not be involved in Man uptake. Mannose induced a CUT1 ATP-
Binding Cassete (ABC) family transporter (SPD_1493-4-5) and a PTS 
system (SPD_0773) (Tables 3.1 and S3.3 on the CD). The first is present 
in the sialic acid operon and has been related to sialic acid and N-
acetylmannosamine transport [18,39], whereas the second was assigned 
as a fructose transporter [18]. Whether these transporters are involved on 
mannose uptake remains to be investigated. Interestingly, the general 
components of the PTS systems, phosphocarrier protein HPr (ptsH) and 
phosphoenolpyruvate-protein phosphotransferase, Enzyme I (ptsI), were 
induced during growth on Man (Table 3.1), indicating that Man 




mutant of strain D39 showed practically no growth on Man, while 
inactivation of the PTS-Man (manLMN) dramatically reduced the ability of 
strain D39 to grow on mannose (A. M. Cavaleiro, P. Gaspar, T. 
Kloosterman, O. P. Kuipers and A. R. Neves, unpublished data). In strain 
DP1004, a rough derivative of D39,  mutation of ptsI partially reduced the 
growth on Man, but non-PTS systems for Man uptake were not ruled out 
[18].  
The dedicated Man catabolic gene mannose 6-phosphate isomerase 
(manA) was not differentially expressed (even using a less restrictive 
criterion). The absence of significantly differentially expressed sugar-
specific catabolic genes in the presence of Man and GlcNAc might reflect 
the constitutive expression of these genes, as their activities provide 
precursors for biosynthesis. In accordance, we have shown activity of 
ManA and NagA in Glc-grown cells (Paixão et al., 2015, Chapter 2). 
However, we have also reported that in presence of the inducing sugar 
their activities were considerable higher (Paixão et al., 2015, Chapter 2). 
The lack of correlation between the transcript levels and biochemical data 
(enzyme activities) is a recurrent observation in biological systems and 
might reflect other layers of regulation [40]. 
Man induced the expression of glycolytic genes, namely those 
encoding fructose-bisphosphate aldolase (fba), glyceraldehyde-3-
phosphate dehydrogenase (gap), phosphoglycerate kinase (pgk), 
enolase (eno) and pyruvate kinase (pyk) (Table 3.1). We have proposed 
ManA as a metabolic bottleneck in strain D39, since Man-grown cells 
accumulate high amounts of mannose 6-phosphate and expression in 
trans of manA improves the growth on mannose (Paixão et al., 2015, 
Chapter 2). Induction of the glycolytic genes could thereby be a cellular 
response to alleviate the burden associated with the accumulation of the 
phosphorylated intermediate. Indeed, toxicity ascribed to sugar-
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phosphate accumulation has often been associated with defects or arrest 
of growth [41,42]. 
Downstream of the pyruvate node, genes encoding the pyruvate 
formate-lyase (pflB, SPD_0420), the bifunctional acetaldehyde-
CoA/alcohol dehydrogenase (SPD_1834, adh), and lactate oxidase (lcto) 
also showed altered transcription in response to Man (Tables 3.1 and S3.3 
on the CD). pflB was among the most upregulated genes in Man-grown 
cells. The induction of pyruvate formate-lyase and alcohol dehydrogenase 
is in good agreement with the production of formate and ethanol during 
growth on the Man (Paixão et al., 2015, Chapter 2).  
Galactose 
Gal influenced differentially the expression of 146 genes, of which 
44.5% were upregulated. On GlcNAc and Man, the fraction of induced 
genes was 37.4% and 40.9%, respectively, lower values than on Gal. In 
addition, the expression ratios were largest on Gal (Tables S3.2, S3.3 and 
S3.4, all provided on the CD), suggesting that Glc is a stronger repressor 
of Gal metabolism than of Man or GlcNAc.  
Differently from Man and GlcNAc, Gal induced the expression of 
putative transporters and specific Gal catabolic genes (Table 3.1). The 
galactitol-family PTS, SPD_0559-0-1, was induced (3.4- to 4.7-fold) in 
comparison to Glc-grown cells (Tables 3.1 and S3.4 on the CD). 
Previously, we reported high upregulation of this operon in mucin-grown 
cells (Paixão et al., 2015, Chapter 2, Table 3.1). Our  results corroborate  
earlier evidence pinpointing SPD_0559-0-1 as a Gal-transporter [18,43]. 
Additionally, Gal induced the expression of SPD_1057, codifying the EIIB 
subunit of a Gat-PTS, and of SPD_1047 (lacE-2) encoding the lactose-
specific IIBC components of a Lac-family PTS. Upregulation of LacFE was 
also observed for a different isolate of S. pneumoniae D39 on Gal [27]. 
The positive effect suggests an involvement of the systems in the uptake 




transport in  the closely related organisms S. mutans and L. lactis [44,45]. 
Induction of mtlA was observed, but this system is specific for mannitol 
transport, and the increase expression is most likely due to relief of Glc-
mediated catabolite repression [18]. In contrast, the genes SPD_0088-9, 
which encode the permease proteins of a CUT1 ABC transporter 
proposed to take up Gal [18], were downregulated (Tables 3.1 and S3.4 
on the CD). Whether this finding rules out the involvement of the ABC 
transporter in Gal uptake needs experimental confirmation. It should be 
noted however, that the evidence previously presented was relatively 
weak, since inactivation of the transporter resulted only in a mild reduction 
of Gal utilization [18]. A possible explanation is that the inactivation of the 
ABC is masked by the activity of other Gal transporters.  
As expected, Gal induces both the Leloir and tagatose 6-phosphate 
(T6P) pathways (Table 3.1). The Leloir genes galk and galT-2 were 
among the most upregulated genes (Table S3.4 on the CD), while UDP-
glucose 4-epimerase (galE-1) and aldolase 1-epimerase (galM) were 
induced by 2.2- and 1.8-fold, respectively (Table 3.1). The duplicated 
gene galE-2 was downregulated, underpinning the role of galE-1 as the 
functional UDP-glucose 4-epimerase in strain D39. The duplicated gene 
galT-1 was not differentially expressed, strongly pointing to galT-2 as the 
Leloir catabolic gene. Interestingly, we have shown that deletion of galT-
2 resulted in circa 50 times increased expression of galT-1, indicating 
galT-1 as a surrogate of galT-2 (Paixão, et al., 2015, Chapter 2). The T6P 
pathway genes lacB, lacD and lacC, which codify for galactose 6-
phosphate isomerase subunit LacB, tagatose 1,6-diphosphate aldolase 
and tagatose 6-phosphate kinase, respectively, were also highly up-
regulated (Table 3.1). Induction of both pathways in response to Gal is a 
recurrent observation in previous studies from our laboratory (Paixão et 
al., 2015, Chapter 2, [27]).  Curiously, Afzal et al. [46] observed only 
increased expression of the T6P pathway genes in response to Gal in S. 
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pneumoniae D39. The different results in the two studies most likely derive 
from differences in cultivation medium and/or other experimental 
conditions. While we have gathered strong evidence that both pathways 
are functional, determining the relative contribution of each pathway to the 
metabolism of Gal is, however, not trivial and would require estimating the 
flux partitioning between the two routes. 
In addition, Gal induced expression of galR, a transcriptional regulator 
localized upstream of galK-galT-2 and oriented in the opposite direction. 
In other streptococci galR acts as a transcriptional regulator of the Leloir 
pathway (gal operon) [47–49]. In S. mutans, GalR represses the gal 
operon in the absence of Gal, but intracellular Gal acts as an effective 
inducer of the Leloir genes, abolishing the binding of GalR to the 
intergenic region of galR-galK [49]. Contradictory studies were reported 
for the role of galR in S. thermophillus [50,51]. In S. pneumoniae the role 
of galR on Gal metabolism remains to be determined. Gal also induced 
the expression of a lactose phosphotransferase system repressor (lacR2), 
which recently was identified as a transcriptional repressor of the T6P 
pathway in the presence of Glc (and absence of Gal and lactose) [46]. 
The duplicated gene lacR1 (SPD_0771) was downregulated in presence 
of Gal (Table S3.4 on the CD). 
Regarding the fermentative genes, only the phosphotransacetylase 
gene (SPD_0985, pta), involved in the conversion of acetyl-CoA into 
acetyl-phosphate was induced by Gal (Table 3.1). The transcript levels of 
ackA, encoding acetate kinase, were unaltered, in agreement with in silico 
DNA microarray predictions [27]. This behaviour is however surprising, 
considering the remarkable increase (18-fold) in acetate production from 
Gal as compared to Glc (Paixão et al., 2015, Chapter 2). Moreover, genes 
encoding pyruvate formate-lyase (pflB), pyruvate formate-lyase activating 
enzyme (pflA), and the bifunctional acetaldehyde-CoA/alcohol 




was unexpected, since a pronounced shift to mixed acid fermentation 
occurs on Gal (Paixão et al., 2015, Chapter 2, [27]), and induction of the 
mixed-acid pathways by Gal was reported before [27]. Also, Gal 
reportedly enhances the activity of pyruvate formate-lyase in S. mutans 
and L. lactis [52,53]. However, pflB appeared as induced by Gal (ratio 
~1.90) in S. pneumoniae D39 when less restrictive significance criterion 
(p-value < 0.001 as compared to 0.05 / n) was used as in the study by 
Carvalho et al. [27] .  
As for many other studies, we also fail to observe a complete 
correlation between expression profiles and pneumococcal phenotypic 
traits, which ultimately denotes regulation at other cellular layers, such as 
post-transcriptional and/or metabolic levels. Thus, in the next section the 
glycolytic dynamics of S. pneumoniae D39 during catabolism of the 
glycan-derived sugars are investigated.   
 
Glycolytic and end-product profiles on glycan-derived 
monosaccharides    
Catabolism of GlcNAc, Man and Gal was investigated by in vivo 13C-
NMR in non-growing suspensions of cells grown on the specific sugar 
under study. As described, a non-encapsulated derivative of strain D39 
was used, D39∆cps. The kinetics of sugar consumption and end-products 
formation during the catabolism of [1-13C]GlcNAc, Man and Gal are shown 
on Fig. 3.3. Glucose catabolism is shown for comparison on Fig. 3.3D.  
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Figure 3.3. Kinetics of 20 mM [1-13C]-sugar consumption, end-products formation 
and metabolic intermediates derived from the catabolism of different carbon 
sources by non-growing cells of S. pneumoniae D39∆cps.  
(A) N-acetylglucosamine (GlcNAc), (B) mannose (Man), (C) galactose (Gal) and (D) 
glucose (Glc). The metabolism was monitored online by in vivo 13C-NMR. Experiments 
were carried out at 37ºC, under anaerobic conditions and pH control (6.5). Figures are 
from representative experiments from at least 2 replicates. The pyruvate concentration is 
depicted as extracellular concentration. Lines associated to intracellular metabolite time 
courses are simple interpolations. CR, maximal substrate consumption rate; FBP, fructose 
1,6-biphosphate; Man6P, mannose 6-posphate; α-Gal6P, α-galactose 6-phosphate. 
Symbols: ( ), GlcNAc; ( ), Man; ( ), Gal; ( ), Glc; ( ), lactate; ( ) acetate; ( ), 
ethanol; ( ), pyruvate; (  ), FBP; (  ), Man6P; (  ), α-Gal6P. 
 
The metabolism of GlcNAc was essentially homolactic. Lactate 
(33.6±1.1 mM), the main end-product from the fermentation of the amino 
sugar (20 mM), accounted for 84% of the substrate consumed. Acetate 
was also produced (4.0±0.9 mM) as a catabolic product of GlcNAc. 
Pyruvate was detected in vivo, but in quantities that did not allow its 
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0.31±0.03 µmol min-1 mg-1 of protein (Fig. 3.3A), a value higher than on 
Gal or Man, but similar to that on Glc (Fig. 3.3). The fermentation profile 
in non-growing suspensions is homolactic as previously shown for 
growing cells (Paixão et al., 2015, Chapter 2). In fermentative lactic acid 
bacteria, homolactic metabolism has generally been associated with fast 
metabolizable sugars [54]. GlcNAc fermentation in S. pneumoniae seems 
to be no exception, but the molecular mechanisms underlying this 
behaviour have yet to be disclosed (Fig. 3.3).  
The glycolytic intermediate fructose 1,6-biphosphate (FBP), was the 
only intracellular metabolite detected in non-growing cells by in vivo NMR 
(Fig. 3.3A). The FBP pool increased immediately after substrate addition, 
reached the maximal concentration at the onset of GlcNAc exhaustion, 
and subsequently decreased to undetectable levels (Table 3.2, Fig. 3.3A). 
This profile resembles closely the accumulation of FBP during Glc 
metabolism (Fig. 3.3D), suggesting that regulation of glycolysis is similar 
for both sugars. In agreement, no changes in the transcript levels of 
glycolytic and fermentative genes were observed when comparing 
expression on GlcNAc to Glc (Tables 3.1 and S3.2 on the CD). Indeed, it 
is well documented that FBP accumulates to higher amounts during the 
catabolism of fast metabolizable sugars as Glc than less preferred 
carbohydrates. The reasons for the accumulation of this metabolite are 
diverse [31,54–56] and still matter of debate (reviewed in [57]).  
In addition to FBP, the phosphorylated metabolites fructose 6-
phosphate, N-acetylglucosamine 6-phosphate and glucosamine 6-
phosphate were also detected in extracts of cells growing on GlcNAc 
(Paixão et al., 2015, Chapter 2, Table S3.7). While the amount of 
phosphorylated amino sugars was low, fructose 6-phosphate 
accumulated substantially, and thus it is surprising that this metabolite 
was not observed in resting cell suspensions (non-growing). 
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Table 3.2. Maximal concentrations of glycolytic and sugar-specific 
intermediates during the metabolism of N-acetylglucosamine (GlcNAc), 
mannose (Man), galactose (Gal) and glucose (Glc), by non-growing cells 
of S. pneumoniae D39∆Cps, determined by in vivo 13C NMR. 
 
Sugar GlcNAc Man Gal Glca Gal pulse Glc 
FBPmax (mM) 28.6±2.2 11.7±5.1 12.2±6.4 35.0±2.0 
10.1±4.1b/3.8±0.5c
8.0±1.2d 
Man6Pmax (mM) ND 37.1±5.4 ND ND ND 
α-Gal6Pmax (mM) ND ND 36.1±8.1 ND 39.0±0.4/19.1±3.4e 
 
Values determined by 13C-NMR in the NMR cell extracts from the cell suspensions used 
in the in vivo NMR. ND, not detected in vivo or in the NMR cell extract. The values are 
averages of at least two independent experiments.  
a Values reported by (A. M. Cavaleiro, P. Gaspar, T. Kloosterman, O. P. Kuipers and A. 
R. Neves., unpublished data). 
b Maximal FBP accumulation, derived from Gal metabolism. 
c Maximal FBP accumulation, derived from Glc metabolism. 
d Second FBP accumulation, derived from Gal metabolism. 
e Second α-Gal6P accumulation, derived from Gal metabolism. 
FBP, fructose 1,6-biphosphate; Man6P, mannose 6-phosphate; α-Gal6P, α-galactose 6-
phosphate. 
 
Consumption of GlcNAc and Glc was identical in resting cells (Fig. 3.3), 
but Glc supported much faster growth than GlcNAc (Paixão et al., 2015, 
Chapter 2). The poor performance of GlcNAc in supporting growth 
combined with larger accumulation of phosphorylated metabolites in 
growing cells indicate a metabolic bottleneck in anabolic processes, 
whereas catabolic processes are identical for GlcNAc and Glc as 
evidenced from the in vivo 13C-NMR data. In agreement, glycolytic genes 
were not differentially expressed when comparing GlcNAc to Glc (Table 
S3.2 on the CD).  
In Man metabolizing cells, lactate was the major end-product (30.4±6.1 
mM), accounting for 76% of the Man consumed. The acetate produced 
(9.0±3.5 mM) was 4-fold higher than in Glc. Pyruvate was detected in vivo, 




towards mixed acid fermentation is consistent with the profile observed in 
Man-grown cells (Paixão et al., 2015, Chapter 2). The upregulation of 
fermentative genes SPD_1834 (adh) and pflB (Table 3.1) is in accordance 
with this shift. However, a more pronounced shift could be expected, as 
fermentation of non-preferential sugars is generally associated with mixed 
acid profiles [54]. Earlier, we reported Man as a non-preferential sugar for 
growth and that it supported the lowest growth rates (Paixão et al., 2015, 
Chapter 2), and now we show that catabolism of Man (consumption rate 
0.16±0.00 µmol min-1 mg-1 of protein) is 2-times slower than that of Glc. 
What renders Man such a poor substrate is not clear, but the upregulation 
of glycolytic genes during growth on Man can be surmised as cellular 
response to overcome Man-associated metabolic limitations (Tables 3.1 
and S3.3 on the CD). 
The pools of FBP and mannose 6-phosphate (Man6P) accumulated 
during the catabolism of Man (Fig. 3.3B). The Man6P pool increased 
sharply to a steady concentration, which swiftly dropped to concentrations 
below 5 mM at the onset of Man depletion (Table 3.2 and Fig. 3.3B). In 
contrast, FBP became detectable after Man depletion and when the pool 
of Man6P was decreasing (Table 3.2 and Fig. 3.3B). Man6P is also the 
predominant phosphorylated metabolite in Man-grown cells (Table S3.7, 
Paixão et al., 2015, Chapter 2). High concentrations of phosphorylated 
metabolites have often been associated with metabolic toxicity [41,58], 
and accumulation to high-levels of non-glycolytic phosphorylated 
metabolites is a recurrent observation during the metabolism of less 
preferred substrates [59,60]. Thus, it is tempting to suggest that Man6P 
toxicity results in lower glycolytic and growth rates. In line, a strain 
displaying higher Man6P isomerase (ManA) activity grew faster (1.6-fold) 
on Man than strain D39 (Paixão et al. 2015, Chapter 2). In fungi 
(Saccharomyces cerevisiae and Aspergillus fumigatus) deletion of 
phosphomannose isomerase gene led to accumulation of Man6P, which 
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decreased the glycolytic flux [61,62]. In Corynebacterium glutamicum, 
overexpression of manA alleviated the accumulation of Man6P (and F6P) 
and improved Man catabolism [63].  
In this context, induction of glycolytic genes (fba, gap, pgk, eno and 
pyk) as observed in presence of Man (Table 3.1), was most likely to 
alleviate the stress elicited by the accumulation of Man6P, allowing a more 
rapid flow through the central metabolism. On the other hand, we can 
speculate that Man6P might exert repression over Man transporters, thus 
slowing down the uptake of this sugar and subsequent metabolism.  
The profile of Gal consumption was characterized by a plateau 
(concentration approx 20 mM), which preceded efficient conversion of Gal 
to fermentation end-products. This pattern has been described for L. lactis 
when the sugar uptake was exclusively mediated by non-PTS 
transporters, such as Glc catabolism in a PTS-mutant or Gal catabolism 
[44,64]. Transport systems for Gal in S. pneumoniae D39 have not been 
firmly identified, and thus the in vivo NMR data is an additional pointer for 
the involvement of non-PTS systems in Gal uptake. A plateau was also 
observed for Glc, but the length was smaller. Interestingly, GlcNAc and 
Man were used instantly by resting D39 cells, in line with the hypothesis 
that uptake of these sugars is exclusively mediated by PTS transporters 
[18]. The Gal consumption rate was 0.14±0.02 µmol min-1 mg-1 of protein, 
a value similar to the one found on Man, and 2-fold lower than the Glc 
consumption rate (Fig. 3.3C). A similar fold reduction was observed when 
comparing growth rates on Gal and Man with Glc (Paixão et al., 2015, 
Chapter 2), suggesting that for these two sugars catabolism is major in 
the multitude of factors determining growth rates. As in growing cells 
(Paixão et al., 2015, Chapter 2), catabolism of Gal in resting cell 
suspensions showed a pronounced shift to mixed acid fermentation (Fig. 
3.3C), with about 35% of the Gal generating acetate (9.8±0.9 mM), 




mM) was lower than in the other sugars. (Fig. 3.3C) A similar profile was 
observed in L. lactis cells metabolizing Gal [60], but in the pneumococcus 
the deviation towards acetate and ethanol was 4.1- and 1.5-fold higher, 
respectively.  
Yesilkaya et al. [65] attributed the mixed acid profile of Gal-grown cells 
of S. pneumoniae D39 to the activity of pyruvate formate-lyase (PFL) 
(encoded by SPD_0420, pflB) and pyruvate formate-lyase activating 
enzyme (encoded by SPD_1774, pflA). In presence of slow metabolizable 
sugars and anaerobic conditions PFL competes more efficiently with LDH 
for pyruvate. In consequence, one more molecule of ATP is generated 
(via acetate kinase activity), which is certainly an advantage during the 
metabolism of non-preferential sugars (slow metabolizable). The 
metabolic shift to mixed-acid fermentation has been the subject of intense 
research, and the underlying regulatory mechanisms are still under 
debate. Gal-dependent activation of the genes codifying for enzymes 
involved in the mixed-acid branch has been reported [27]. In this study, 
we observed a modest induction of the pflB gene, which is in accordance 
with regulation at the transcriptional level.  
Resting D39 cells accumulated during the metabolism of [1-13C]Gal 
FBP and the specific intermediate of the T6P pathway, α-galactose 6-
phosphate (α-Gal6P) (Fig. 3.3C). A minor resonance due to 3-PGA, was 
observed but reliable quantification was hampered by the strong 
resonance of choline. Also, UDP-Glc was detected in very low 
concentration during Gal catabolism. In contrast to growing cells, 
accumulation of the Leloir intermediates galactose 1-phosphate and 
glucose 1-phosphate was not observed (Table S3.7). It is likely that the 
concentration of these metabolites is below the detection limit of in vivo 
13C-NMR technique. Indeed, the 31P-NMR resonances in spectra of Gal-
grown cell extracts were relatively weak (Paixão et al., 2015, Chapter 2).  
The pool of FBP accumulated once Gal started to decline, but the maximal 
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concentration was relatively low (approximately 12 mM) (Fig. 3.3C). 
Reduced FBP levels might derive from the slow flux through glycolysis, 
and correlate well with the metabolic shift towards mixed-acid 
fermentation. It is well established that FBP is an activator of LDH, 
whereas trioses-phosphate (DHAP and GAP), inhibit PFL [57]. Due to the 
reversibility of the reactions catalysed by FBP aldolase and triose 3-
phosphate isomerase, low trioses-phosphate concentrations are to be 
expected when FBP is low. Thus, the activation of LDH and the inhibition 
of PFL are relieved and a mixed acid profile emerges. As for other 
fermentative organisms, the shift towards mixed acid fermentation is 
multifactorial and involves regulation at the different cellular layers.  
 α-Gal6P was detected after Gal addition, but overlap with the strong 
α-Gal resonance hampered reliable quantification during the first 17 min 
of Gal metabolism. Once the Gal resonances subsided, integration of the 
α-Gal6P resonance was possible: while Gal was abundant, the α-Gal6P 
concentration remained high (above 25 mM), declining rapidly to 
undetectable levels as Gal was nearing depletion (Fig. 3.3C). The high 
accumulation of Gal6P in resting cells, also observed in growing cells 
(Table S3.7, Paixão et al., 2015, Chapter 2), suggests a metabolic 
constraint in Gal processing through the tagatose 6-phosphate pathway. 
In addition, the accumulation of Gal6P is solid evidence for the functionally 
of a PTS system, since to our knowledge this is the only reaction capable 
of generating Gal6P in living cells [44].  
 
Catabolism of Glc in galactose-adapted cells  
Of the three monosaccharides studied, Gal showed the strongest effect 
on glycolytic dynamics and end-products profile (Fig. 3.3C). Thus, we 
asked whether Gal-adapted cells would be able to efficiently catabolise 
the preferred sugar Glc. To test this hypothesis, cells actively metabolizing 




[2-13C]Glc. The kinetics of sugar consumption, end-products and 
metabolic intermediates is depicted in Fig. 3.4, as monitored by in vivo 
13C-NMR.  
 
Figure 3.4. Metabolism of galactose (Gal), challenged with a pulse of glucose (Glc), 
using non-growing cells of S. pneumoniae D39∆cps, monitored by in vivo NMR.  
Kinetics of (A) sugar consumption and end-products formation and (B) pools of 
intracellular metabolites. Cells metabolizing a 20 mM pulse of [1-13C]Gal where challenged 
with a 10 mM pulse of [2-13C]Glc during the maximal consumption rate of Gal. Time course 
kinetics were obtained online by in vivo 13C-NMR. Experiments were carried out at 37ºC, 
under anaerobic conditions and pH control (6.5). Figures are from representative 
experiments of at least 2 replicates. Lines associated with intracellular metabolite time 
courses are simple interpolations. The shaded area represents the time spam for which 
Glc was available, and the arrow the time-point of addition. Symbols: ( ), [1-13C]Gal; (  
), [2-13C]Glc; ( ), total lactate; ( ), acetate (derived from Gal catabolism); ( ), ethanol 
(derived from Gal catabolism); ( ), pyruvate (derived from Gal catabolism); ( ), FBP, 
total fructose 1,6-biphosphate; ( ) α-Gal6P, α-galactose 6-phosphate derived from Gal 
catabolism. 
In this experiment cells were suspended to 24 mg cell dried weight ml-1. As compared to 
the cell suspension in Fig. 3.3C, the biomass is increased by a factor of 1.2, which most 
likely leads to the reduced Gal plateau in the current situation.  
 
The addition of Glc decreased the rate of Gal utilization 3.5-fold in 
comparison with the initial Gal consumption rate (0.14±0.02 µmol min-1 
mg-1 of protein), showing a preference for Glc over Gal. Although Gal 
consumption was hindered by the presence of Glc, S. pneumoniae was 
able to catabolise both substrates simultaneously.  
Glc was readily consumed as soon as it became available, at a 
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Glc as a sole substrate (Fig. 3.3D). This behaviour shows that Gal-
adapted cells are apt to efficiently metabolize Glc. Indeed, no major 
changes in transcription of glycolytic genes or manLMN (PTS-Man) were 
observed on Gal as compared to Glc.  
The rate of lactate production doubled immediately after the pulse of 
Glc, shifting the metabolism to a more homolactic profile (Fig. 3.4A). 
Lactate (43±1.8 mM) accounted for 71% of the total substrate (Glc and 
Gal) consumed, as compared to 60% on Gal alone. This value is in good 
agreement with the estimated (68.2%) from a 2:1 Gal to Glc ratio and the 
60% and 85% sole conversions of Gal and Glc, respectively. Of the total 
lactate, about 37% was labelled on C2, and thereby derived from [2-
13C]Glc. Other products from this substrate were acetate (2.6±0.4 mM) 
and pyruvate (0.8±0.3 mM). The mixed acid products (acetate and 
ethanol) decreased from 33% (Gal alone) to 18% of the total substrate. 
Moreover, pyruvate accumulated to a maximal concentrations 5.5-fold 
higher than those on Gal alone. This behaviour suggests a bottleneck 
downstream of pyruvate. Curiously, the negative effect of Glc on mixed 
acid products was more pronounced on ethanol than acetate.  
Addition of Glc, caused a sudden drop on the pool of α-Gal6P and rise 
of the FBP level, a trend that favours lactate production (Fig. 3.4B). All in 
all, these results show that Glc exerts a negative effect (metabolic 
inhibition) on the mixed acid fermentation profile. 
 
Effect of glucose on the growth of S. pneumoniae  
The significant impact of Glc over Gal catabolism at the metabolic level 
was evident on resting cells of S. pneumoniae. Thus, we deemed 
important to assess the impact Glc during growth of pneumococcus on 
the three glycan-derived monosaccharides. To this end, Glc was added 
to exponential cells growing on Gal, Man, GlcNAc or a mixture thereof 




For all the conditions tested, an increase of growth rate was observed 
upon Glc addition sugar mix (Fig. 3.5 and Table 3.3). This positive effect 
was more pronounced in Gal-adapted cells (Fig. 3.5A and Table 3.3), for 
which the final biomass and the maximal specific growth rates were 
increased by 74% and 172%, respectively. Furthermore, Glc induced 
biphasic growth, with a phase displaying a maximal growth rate of 
0.87±0.07 h-1), followed by slower growth (0.14 ±0.01 h-1). In the sugar 
mix, the final biomass increased by 30%, while the time to reach these 
maximal values was shortened by 43% (Fig. 3.5D). 
Independently of the carbon source in the medium, growing S. 
pneumoniae cells consumed Glc at once after addition (Fig. 3.5). A similar 
behaviour was described for the resting cells (Fig. 3.4). A lag phase, 
typical of the diauxic behaviour associated with adaptation to the 
additional substrate, was not observed for any of the conditions tested. 
The rate of Glc utilization was higher than that of the other sugars, as 
evidenced by the higher quantity of Glc processed over a defined period 
of time. In summary, S. pneumoniae is well equipped to use its preferred 
substrate Glc, regardless of pre-conditioning to other sugars. However, 
utilization of Glc does not exclude co-metabolism of the other sugars. 
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Figure 3.5. Representative growth profiles of S. pneumoniae D39 in presence of 
different carbon sources challenged or unchallenged with a pulse of glucose (Glc) 
and percentage of substrate consumed.  
Growths were conducted in CDM supplemented with: (A) galactose (Gal); (B) N-
aceylglucosamine (GlcNAc); (C) mannose (Man) and (D) a mixture of Gal, Man and 
GlcNAc, challenged or unchallenged with a 10 mM Glc pulse given at mid-exponential 
phase of growth. Cells were grown at 37ºC, under semi-anaerobic conditions, without pH 
control (initial pH 6.5). The black arrow indicates the time of the Glc pulse. The profiles are 
averages of two independent growths (unless stated otherwise) and standard deviation is 
depicted. The percentages of GlcNAc and Man consumed without the Glc challenge 
correspond to only one representative growth. Symbols: (  ), percentage of Glc consumed 
in pulse chase experiments; ( ), percentage of Gal, GlcNAc or Man consumed in 
unchallenged cells; ( ), percentage of Gal, GlcNAc or Man consumed in Glc challenged 




























































































































































Table 3.3. Growth and energetic parameters, carbon and redox balances and substrate consumed, obtained for S. 
pneumoniae D39 grown on CDM in the presence of N-acetylglucosamine (GlcNAc), galactose (Gal), mannose (Man) 
or in a mixture of sugar (GlcNAc, Man and Gal) challenged or not with a 10 mM glucose (Glc) pulse given at mid-
exponential phase of growth.  
 
The controls (unchallenged cells) are displayed as reported (Paixão et al, 2015, Chapter 2). Growth experiments were made at 37ºC without pH 
control (initial pH 6.5). Values represent the average and standard deviation of at least two independent growth experiments and were estimated 
at the time point of growth arrest (maximal biomass). 













[substrate]initial (mM) 12.3±0.6 11.7±0.0 13.4±1.3 12.0±0.0 12.4±0.1 14.1±0.4 6.5±0.3e 6.1±0.8e 
Product yields         
Lactate 1.58±0.04 1.66±0.01 0.04±0.01 1.14±0.07 1.43±0.12 1.42±0.06 1.25±0.02 1.81c 
Formate 0.15±0.07 0.05±0.01 1.47±0.18 0.50±0.01 0.31±0.04 0.15±0.01 0.36±0.06 0.09c 
Acetate 0.06±0.01 ND 0.75±0.13 0.27±0.05 0.20±0.02 0.08±0.00 0.15±0.01 0.03c 
Ethanol 0.03±0.01 0.01±0.01 0.72±0.05 0.24±0.04 0.14±0.04 0.06±0.00 0.18±0.03 0.02c 
µmax (h
-1
)b 0.40±0.04 0.44±0.13 0.32±0.04 0.87±0.07d 0.37±0.06 0.46±0.06 0.54±0.15 0.67±0.19 
OD600max 0.99±0.08 1.35±0.17 1.12±0.26 1.95±0.07 1.03±0.08 1.59±0.07 1.19±0.11 1.55±0.09 
Substrate Consumed (%) 100±0 96±4 84±7 92±1 100±0 100±0 86±2 79c 
Substrate Recovery 84±3 86±0 76±9 83±4 89±3 78±3 79±3 95c 
Redox Balance 83±3 84±1 75±5 82±1 85±3 77±2 81±4 93c 
ATP yield (mol mol-1 substrate) 1.74±0.08 1.67±0.01 2.27±0.31 1.93±0.14 1.98±0.04 1.65±0.06 1.73±0.06 1.89c 
YATP (g biomass mol-1ATP) 16.8±0.9 16.7±0.3 14.9±0.5 18.7±0.5 16.2±0.4 14.6±0.2 16.4±0.4 14.7c 
Ybiomass (g mol-1 substrate) 29.3±2.9 27.9±0.7 34.1±5.8 36.0±1.6 31.9±0.1 24.0±0.6 28.3±1.8 27.7c 
Transcriptional and metabolic responses of S. pneumoniae to sugars 
209 
b Maximal specific growth rate determined in the time range after the Glc pulse. 
c Values of a representative experiment. 
d Maximal specific growth rate. µ2=0.14±0.01 h-1. 
e The value represents the average ± standard deviation of the concentration for all the sugars separately. Individual averages for sugar mixes 
are: Gal, 6.4±0.7 mM; Man, 6.6±0.1 mM and GlcNAc, 6.7±0.2 mM. 
Individual averages for sugar mixes with pulse of Glc are: Gal, 5.7±0.1 mM; Man, 5.9±1.4 mM and GlcNAc, 6.5±0.4 mM. 
ND – Not detected as product of pyruvate metabolism. 
Substrate recovery is the percentage of carbon in metabolized sugar that is recovered in the fermentation products (lactate, ethanol, acetate 
and formate). 














Glucose addition represses mixed acid fermentation profile  
In resting cells actively metabolizing Gal, Glc promoted a more 
homolactic fermentation profile. The effects of Glc addition to the end-
products formed during growth are shown on Table 3.3. Cells 
exponentially growing on Gal, GlcNAc or the sugar mix, when challenged 
with Glc displayed increased lactate yield, which was condition dependent 
(Table 3.3). Curiously, this pattern was not observed for Man-adapted 
cells (Table 3.3). Gal-adapted cells showed the largest change in lactate 
yield, even though no induction of ldh was observed (Table S3.8). 
Furthermore, Glc addition repressed the formation of mixed acid 
fermentation products (acetate, ethanol and formate) to a larger extent 
(except for Gal) than the positive effect on lactate production in all the 
conditions tested (Table 3.3). Generally, Glc repressed the expression of 
genes involved in mixed acid fermentation (SPD_1834, pflB, pta) (Table 
S3.8), and the reduced transcription positively correlates with the reduced 
levels of mixed-acid products (Table 3.3). On Man, however, the addition 
of Glc resulted in elevated levels of pflB, pta and SPD_1834 transcripts, 
but still the mixed acid products were lessened (Tables 3.3 and S3.8). 
These results suggest that under this condition, regulatory mechanisms 
other than transcription are present.  
Based on the results with resting cells we proposed that the partitioning 
between lactate and mixed acid products is largely regulated at the 
metabolic level. Overall, the results with growing cells further strengthen 
this view, without ruling out regulation at the transcriptional level.  
 
Effect of glucose on the expression of genes involved in 
sugar metabolism 
The effect of a Glc challenge to cells growing on the glycan-derived 
sugars was assessed at the transcriptional level (Table S3.8). The 
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number of genes significantly differentially expressed in response to Glc 
was dependent on the sugar (Tables S3.9, S3.10, S3.11 and S3.12, all 
provided on the CD). The largest transcriptional response was observed 
in Man-adapted cells (434 genes out of 1738) and the smallest in cells 
adapted to a sugar mixture (5.5% of the total transcripts) (Fig. 3.2B). In 
Gal-adapted cells, 249 genes were regulated by Glc, whereas in GlcNAc-
adapted cultures 111 genes were differentially expressed after the Glc 
pulse (Fig. 3.2B). The transcriptional response of Gal and Man-adapted 
cells to Glc included altered expression of 157 shared genes, of which 
101 were exclusive of these conditions. Despite the large number of 
common genes in the two conditions, the direction of regulation 
(upregulation vs. downregulation) of these genes was not necessarily the 
same. Indeed, Glc exerted positive (upregulation) and negative 
(downregulation) regulation in all conditions tested. Gal-adapted cells 
showed the highest number of upregulated genes (53% of the total), 
whereas GlcNAc-adapted cells showed the lowest (22.5% of the total) 
(Tables S3.9 and S3.10, all provided on the CD), an indication that Glc is 
a mightier repressor of Gal catabolism than of the catabolism of the other 
sugars. Interestingly, the lesser response in the sugar mix denotes better 
capacity of these cells to cope with a Glc stimulus, which can be perceived 
as improved metabolic fitness.  
The results presented in Fig. 3.2B and Table S3.8 clearly show sugar-
dependent responses to a Glc stimulus. Progression from colonisation to 
invasive disease is presumably associated with a change from an 
environment nearly devoid of Glc (nasopharynx) to niches rich in this 
sugar (blood, inflamed lung). Thus, determination of the transcriptional 
responses to Glc in clinical serotypes of S. pneumoniae should be 
pursued in the future.   
For all the conditions tested, the COG category of “carbohydrate 




CD), with the proportion of genes showing altered expression in response 
to Glc as follows: 32.4%, 28.1%, 16.9% and 12.4% of the total transcripts 
on GlcNAc, sugar mix, Gal and Man, respectively. Also, most of the genes 
belonging to category G were downregulated by Glc, except for Man-
adapted cultures in which a higher number was induced. 
Glucose addition in GlcNAc-adapted cells repressed the expression of 
putative and proven transporters of this amino sugar (Paixão et al., 2015, 
Chapter 2, Table S3.8), among which the PTS-Man SPD_0262-3-4 
(manLMN) was downregulated. This system is most likely the major 
GlcNAc transporter in S. pneumoniae D39 [18]. In addition, is also the 
principal Glc uptake transporter in S. pneumoniae [18]. Downregulation of 
glucose transport proteins in response to Glc is not without precedent, 
and in E. coli is one of the molecular mechanisms in the cellular response 
to prevent phosphosugar stress [66]. 
Genes involved in glycolysis were not differentially expressed upon Glc 
addition. Interestingly, Glc repressed the expression of the dedicated 
GlcNAc-specific catabolic gene nagB, but not nagA in the same 
transcriptional unit. Furthermore, only nagB was found upregulated in 
GlcNAc-growth medium (using a Bayesian p-value < 0.001) as compared 
to Glc. Thus, each gene in the nagAB operon is subjected to specific 
regulation.  
The direction of the regulation elicited by Glc on Man-adapted cells was 
in most opposite to that observed in the other conditions studied (Table 
S3.8). Glc induced the expression of transporters presumably involved in 
Man uptake (Table S3.8), namely the permeases of the CUT1 ABC 
transporter SPD_0088-9, the subunits manLM of PTS-Man and the 
subunits IIABD of the mannose-type PTS encoded by SPD_0293-5-7, as 
well as other sugar transporters (Table S3.8). In addition, Glc induced the 
expression of the glycolytic genes gap and eno (Table S3.8). The 
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expression of the Man-specific catabolic gene, manA, was not affected by 
the Glc stimulus.  
Furthermore, a large set of genes which was found upregulated when 
comparing Man to Glc (eg. glycolytic, fermentative and sugar-specific 
catabolic genes), showed increased fold upregulation in response to the 
Glc stimulus in Man-adapted cells. 
We have shown that Glc hinders the use of Gal (Fig. 3.4) and this 
observation is fully substantiated by the transcriptional response to Glc in 
Gal-adapted cells. In Gal-adapted cells Glc downregulated the transporter 
genes SPD_0559-0-1 and lacEF-2 (Lac-family PTS) (Table S3.8), which 
together with the observed upregulation on Gal as compared to Glc-grown 
cells (Tables 3.1 and S3.8), point towards their involvement on Gal 
uptake. The latter transporter is found in operon-II of the lac gene cluster, 
which comprises also a 6-phospho β-galactosidase, lacG-2 (SPD_1046), 
and the transcriptional activator lacT (SPD_ 1049)  [46]. While lacG-2 was 
not differentially expressed, lacT was downregulated by Glc (Table S3.10 
on the CD), and so was operon-I encoding the T6P pathway (lacABCD). 
Moreover, Glc downregulated the Leloir genes galk and galT-2, as well as 
the transcriptional regulator galR (Table S3.8). Our results provide strong 
evidence supporting the repressing effect of Glc over the catabolism of 
Gal. Previously, Carvalho et al. [27] showed  that while CcpA repressed 
the Leloir genes independently of the carbon source, Gal was an effective 
inducer of this pathway. On the other hand the T6P pathway was weakly 
repressed by CcpA on Glc and activated on Gal. In line, Afzal et al. [46] 
could not observe a regulatory effect of CcpA on the lac gene cluster. 
Instead, LacR was the transcriptional repressor of the lac operon-I (T6P 
pathway) on Glc, but not of operon-II, which was under the control of LacT. 
For the sugar mix, a negative effect over genes encoding sugar 
transporters was observed (Table S3.8). The Gal uptake system 




SPD_0088-9 (involved in Man and Gal uptake) [18] and the IIBC 
components of the PTS system (SPD_1496) putatively involved in 
GlcNAc uptake (Chapter 2) showed altered expression. Furthermore, Glc 
downregulated genes in Gal catabolic pathways (lacAB, galk and galT-2), 
but had no impact on the expression of genes devoted to the catabolism 
of GlcNAc and Man. A clustering analysis revealed that Glc had a 
consistent impact on the N-acetylneuraminic acid processing enzymes: 
N-acetylmannosamine 6-phosphate 2-epimerase (nanE-1) and N-
acetylneuraminate lyase, putative (SPD_1163), which were 
downregulated in all growth conditions except for Man-adapted cells 
(Table S3.13 and Fig. S3.1). Furthermore, Glc affected the expression of 
three sugar transporters: the fructose-PTS (SPD_0773) was upregulated 
in Man and Gal cells, but downregulated in GlcNAc and in the sugar mix, 
and the PTS proteins SPD_1496 (IIBC components) and SPD_0561 (IIC 
component) were upregulated on Man, but downregulated on all the other 
conditions (Table S3.13 and Fig. S3.1). The physiological interpretation of 
these observations requires further experimentation. Also intriguing is the 
opposite direction in regulation observed in the presence of Man as 
compared to the other sugars. While an explanation cannot be put 
forward, one can speculate that the Man signalling cascade is heavily 
intertwined with that of Glc, as both sugars are taken up by the Glc/Man-
PTS, a well-recognized major player in catabolite control in low-GC Gram-
positive bacteria. How the cell discriminates between the two sugars is 
unknown. From our studies it is clear that the cellular responses to Man 
(transcriptional and physiological/metabolic) are large and unique, but the 
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The expression profile of classical virulence factors 
displays a sugar dependency   
It is now well accepted that sugar metabolism and virulence are 
strongly connected, thus contributing in different ways to the pathogenesis 
of the pneumococcus [20,67]. Therefore, we investigated the influence of 
the carbohydrates GlcNAc, Man and Gal on the expression of known 
virulence factors (Tables S3.1 and 3.4). How the ditto virulence factors 
responded to a Glc stimulus during growth on the different sugars or a 
sugar mix was also examined (Table 3.4). 
A clustering analysis identified only two classical virulence genes as 
differentially regulated in the three sugars tested, showing that induction 
of virulence determinants is sugar dependent (Table 3.4 and Fig. S3.2). 
The immunoglobulin A1 protease precursor (SPD_1018, iga) [68] was 
upregulated in Gal- and Man-containing medium and downregulated in 
presence of GlcNAc, whereas the serine protease (SPD_2068) [69] gene 
was upregulated in all growth conditions. Interestingly, Man also induced 
the expression of DNA-binding response regulator ciaR, which was shown 
to regulate the serine protease. Mutants in both genes show reduced 
virulence, but in the ∆ciaR is most likely due to downregulation of the 
serine protease [70]. The effect of Glc on the expression of virulence 
genes was also sugar dependent (Table 3.4). A clustering analysis 
showed that a single virulence gene was regulated by Glc in all the 
conditions studied (Table S3.13 and Fig. S3.1). This gene, SPD_0373, 
which is found in an operon associated to virulence in bacteraemia and 
pneumonia [71] was downregulated by Glc, except for Man-adapted cells. 
Galactose influenced the expression of the largest pool of virulence 
genes (8.2% of the significantly differential expressed genes), of which 
5.5% were upregulated in this sugar (Table 3.4). Of note, the classical 
virulence factor β-galactosidase (bgaA) was highly induced (Table 3.4). 




pathogen interactions [72,73]. Moreover, the catabolic genes lacD and 
galK were upregulated. We have shown that lacD and galK mutants are 
impaired in their ability to colonise the nasopharynx and display 
attenuated virulence in a respiratory infection murine model, after 
intranasal challenge (Paixão et al., 2015, Chapter 2). Our earlier 
assumption that Gal metabolism is linked to virulence (Paixão et al., 2015, 
Chapter 2) is further strengthened by the transcriptome data. Interestingly, 
the expression of bgaA, lacD and galK was downregulated in Gal-adapted 
cells by Glc (Table 3.4). Other virulence factor genes also negatively 
regulated by Glc in Gal-adapted cells were tpx (thiol peroxidase), and iga 
(immunoglobulin A1 protease precursor). Glc induced the expression of 
the choline binding protein (pcpA), a protein involved in the adherence to 
nasopharyngeal and lung epithelial cells [74], and virulence determinant 
in mouse models of pneumonia and sepsis [75,76].  
In GlcNAc-grown cells there was upregulation of strH, encoding the N-
acetylglucosaminidase (Table 3.4). The removal of terminal GlcNAc by 
StrH from human N-glycans has been implicated in pneumococcal 
colonisation and pathogenesis, since it can facilitate sugars (GlcNAc) for 
growth, but it might also promote resistance to opsonophagocytic killing 
by avoiding complement deposition [37,38,77]. Interestingly, the gene 
was not downregulated in Glc challenged GlcNAc-adapted cells. In this 
sugar, all virulence genes responding to the Glc stimulus were 
downregulated (Table 3.4). Curiously, Glc stimulus repressed genes 
common to two sugar-adapted conditions (bgaC, bgaA, pflB, pflA, galK) 
(Table 3.4). This observation could indicate that while expressed in 
colonisation states (glycans as carbon sources), these genes are 
negatively regulated in conditions where Glc is the predominant sugar, 
like the blood or inflamed lungs. Thus it is tempting to suggest that while 
important for colonisation, those functions are not required in invasive 
disease.  
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Table 3.4. Significantly differentially expressed virulence factors (up- or downregulated) of cells of S. pneumoniae D39 
grown in CDM supplemented with N-acetylglucosamine (GlcNAc), mannose (Man) or galactose (Gal) as compared to 
glucose (Glc) grown cells, or adapted to these single sugars or to a mixture thereof challenged with a Glc pulse and 
compared to unchallenged cells, determined by DNA microarrays.a,b 
   Up- or downregulationc 
Locus_tag Gene Product GlcNAc Man Gal    Mix
 d 
   without Glc with Glc without Glc with Glc without Glc with Glc with Glc 
SPD_0063 strH beta-N-acetylhexosaminidase  0.43  0.90 1.11   -0.48 
SPD_0065 bgaC Beta-galactosidase 3   -0.81  0.64   -1.38 
SPD_0126 pspA pneumococcal surface protein A   0.68  0.76 -0.79 -0.50 
SPD_0250  pullulanase, extracellular    0.47 1.00 -0.70   
SPD_0373  hypothetical protein SPD_0373   -1.10  0.76 1.43 -1.50 -1.30 
SPD_0420 pflB pyruvate formate-lyase   -0.53 1.25 0.70   -0.99 
SPD_0558 prtA 
cell wall-associated serine 
protease PrtA  




 -0.33  0.71 1.61 -0.82  
SPD_0634  hypothetical protein SPD_0634  -0.89  -1.24     
SPD_0635  
cation-transporting ATPase, E1-
E2 family protein  




     -0.47  
SPD_0701 ciaR 
DNA-binding response regulator 
CiaR  
0.82  0.57 -0.53    





0.82       
SPD_0889 phtD 
pneumococcal histidine triad 
protein D precursor  




SPD_1012 eno enolase    0.61 0.33    
SPD_1018 iga 
immunoglobulin A1 protease 
precursor  




    3.00 -2.02  
SPD_1384  cation efflux family protein     -0.58  0.44  
SPD_1409  
sugar ABC transporter, ATP-
binding protein  
 -0.81  0.86 -0.52  -0.68 
SPD_1464 tpx thiol peroxidase      0.80 -0.64 -0.47 




  -0.62    0.69 
SPD_1652  
iron-compound ABC transporter, 
iron-compound-binding protein  
-0.47   -0.58 -1.16 0.97  
SPD_1726 ply pneumolysin  -0.36  -0.56     
SPD_1774 pflA 
pyruvate formate-lyase activating 
enzyme  
 -0.67  0.73   -0.48 




  0.53 0.39    
SPD_1965 pcpA choline binding protein PcpA     0.28  0.50  
SPD_2068  serine protease  1.06  0.73 -0.92 0.68   
 
a Subset table of Tables S3.2, S3.3, S3.4, S3.9, S3.10, S3.11 and S3.12, all provided on the CD. 
b As reviewed in Table S3.1. 
c Values of ln-ratio. Positive values indicate upregulation and negative values indicate downregulation. 
d Mixture of Gal, Man and GlcNAc. 
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Induction of pflB and the glycolytic genes eno and gap during growth 
on Man (Table 3.4) is consistent with their roles in early phases of 
infection, since Man exists in gycoconjugates. pflB, was recently found to 
contribute to attenuated colonisation of the nasopharynx and lungs and 
delayed bacteraemia in mice infected intranasally [65], whereas eno and 
gap were shown to bind to plasminogen and plasmin, and hence can be 
of importance for the dissemination of the pathogen through host tissues 
[78,79]. These genes were still upregulated when Man-adapted cells were 
spiked with Glc, but the fold-expression values were smaller. 
Furthermore, expression of the choline binding protein (pcpA), of the cell 
wall-associated serine protease (prtA) of several glycosidase genes (strH, 
bgaC, bgaA) as well as pflA and pflB were induced by Glc in Man-adapted 
cells.  
In S. pneumoniae cells growing on a sugar mix, Glc exerted mainly 
negative regulation. In addition to the genes mentioned above, the thiol 
peroxidase (tpx) and the pneumococcal surface protein A (pspA) were 
also downregulated. The gene encoding the zinc-containing alcohol 
dehydrogenase (SPD_1636) was, however, upregulated (Table 3.4). 
Virulence studies revealed that this gene is implied in survival in the 
bloodstream [80].  
Of all the conditions tested, the smallest transcriptional response 
elicited by Glc was for cells adapted to the sugar mix (Tables S3.9, S3.10, 
S3.11 and S3.12, all provided on the CD). Curiously, it was in this 
condition that the highest fraction of virulence genes influenced by Glc 
was found (10.4% of the significantly differentially expressed genes) in 
comparison to 6.3%, 4.8% and 4.4% in GlcNAc-, Man- and Gal-adapted 
cells, respectively. This result strengthens our hypothesis that cells 
growing on the sugar mix are better equipped to cope with ever-changing 
environments. In these cells, a major adaptation is apparently the 




note, most of the virulence genes were negatively regulated by a Glc 
stimulus except in Man-adapted cells for which a significant number of 
virulence genes were upregulated. The S. pneumoniae physiological 
responses to Man are far from being understood and should be the focus 
of future research. In light of the transcriptional response to a Glc stimulus 
during growth on Gal, GlcNAc and the sugar mix, we can speculate that 
the development of pneumococcal virulence traits occurs in the ecological 
niche (nasopharynx), during colonisation, where Gal, Man and GlcNAc 
are prevalent in comparison to free Glc. Disease, on the other hand is 
accidental, as it culminates in a dead-end for the colonising 
microorganism, and likely occurs from an imbalance between the host and 
the microbe. In the disease state, the bacterium represses functions 
essential for colonisation, but no longer needed when Glc is the 
predominant substrate for growth. In accordance with this hypothesis, we 
have shown that pneumococcal mutants in the Gal catabolic genes 
administrated intravenously were not attenuated in murine models of 
disease (Paixão et al., 2015, Chapter 2).  
Overall, our results show that sugars influence the virulence potential 
of S. pneumoniae D39 both by modulating the expression of specific 
catabolic pathways (in vivo fitness) as well as the expression of classical 
virulence factors (Table 3.4). Similar findings have been reported for other 
Streptococcaceae, such as S. mutans and S. suis [81,82]. Indeed, 
successful infections rely on colonisation, multiplication and transmission 
to a new host, and therefore the line between factors required for growth 
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Conclusions 
In this work we have conducted a systems approach to evaluate the S. 
pneumoniae response to sugar availability. The combined transcriptional, 
physiological and metabolic data collected revealed a strong 
carbohydrate-dependency on the phenotypic traits of S. pneumoniae. 
Despite the relatively simple metabolism of S. pneumoniae, which 
processes sugars through the Embden-Meyerhof-Parnas pathway to 
pyruvate, the transcriptional and metabolic responses elicited by each 
monosaccharide are remarkable and specific. This is especially relevant 
considering that generally this bacterium resides in the human 
nasopharynx, an environment poor in Glc, but rich in glycans. But during 
progression to disease and in disease states S. pneumoniae is subjected 
to changing environments that presumably are enriched in Glc. Our 
results firmly show that Glc is a preferential substrate for growth of S. 
pneumoniae and while growing on other sugars the bacterium avidly uses 
Glc when available. The specific response to the Glc stimulus results in 
changes both at the metabolic level (Figs. 3.4 and 3.5) and in gene 
regulation (Table S3.8), which allow for short and long term adaptation. 
Interestingly, cells adapted for growth on a sugar mixture displayed the 
smallest transcriptional response to Glc, suggesting improved metabolic 
resilience of S. pneumoniae when exposed to a multitude of sugars. In the 
human nasopharynx, S. pneumoniae is exposed to a fluctuating nutritional 
milieu that results from a fragile balance between varied factors (host, 
microbiota, environmental stimulus). In addition, deglycosylation of 
human glycans by bacterial glycosidases generates a varied sugar 
mixture. In the context of our observations, exposure to such a diverse 
environment improves the fitness of S. pneumoniae.  
Carbohydrates specifically modulate the expression of virulence 




suggest that the nasopharynx is the reservoir for the development of 
niche-specific virulence traits, essential for successful colonisation of the 
niche. Most of these virulence factors are downregulated by a Glc 
stimulus, and are therefore not required in disease. Collectively, our data 
strengthens the link between sugar metabolism and virulence. Indeed, 
effective infections rely on colonisation, multiplication and transmission to 
a new host, and therefore factors required for growth are also virulence 
determinants. 
The “omic” data collected at different regulatory layers can in the future 
be used to fuel multi-scale mathematical models. Such mathematical 
representation of metabolism hopefully will contribute to deepen our 
understanding of how a functional state arises from the components, and 
ultimately will facilitate the identification of novel targets for alternative 
therapeutic and preventive drugs. 
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Gene annotation_D39 (as described in 
NCBI) References 
SP2190 SPD_2017 cbpA choline binding protein A [1–3] 
SP1693 SPD_1504 nanA sialidase A [1–4] 
SP0648 SPD_0562 bgaA beta-galactosidase [1] 
SP0057 SPD_0063 strH beta-N-acetylhexosaminidase [1] 
SP0314 SPD_0287  hyaluronate lyase [1–3] 
SP0966 SPD_0854 pavA adherence and virulence protein A [1–3,5] 
SP1128 SPD_1012 eno phosphopyruvate hydratase (enolase) [1,6] 
SP1923 SPD_1726 ply pneumolysin [1–3,7] 
SP0117 SPD_0126 pspA surface protein A [1–3,8] 
SP1937 SPD_1737 lytA autolysin/N-acetylmuramoyl-L-alanine 
amidase 
[1–3,8,9] 
SP1650 SPD_1463  ABC transporter substrate-binding protein [1,3,10–12] 
SP1032 SPD_0915  iron-compound ABC transporter iron 
compound-binding protein 
[1,10,13,14] 




SP1687 SPD_1499 nanB neuraminidase B [1,4] 
SP1154 SPD_1018 iga immunoglobulin A1 protease precursor [1,15] 
SP0641 SPD_0558 prtA cell wall-associated serine protease PrtA [2,3,16] 
SP1638 SPD_1450  iron-dependent transcriptional regulator [10,17] 




SP1552 SPD_1384  cation efflux family protein [10,19] 
SP0240 SPD_0222  phosphoglycerate mutase family protein [10,13] 
SP0376 SPD_0344  DNA-binding response regulator [10,20,21] 
SP0728 SPD_0634  conserved hypothetical protein [10,22] 
SP0729 SPD_0635  
cation-transporting ATPase, E1-E2 family 
protein 
[10,22] 
SP2170 SPD_1998 adcB zinc ABC transporter, permease  [10,23] 
SP1853 SPD_1634 galk galactokinase 
Chapter 2, 
Paixão et al., 
2015 
SP1190 SPD_1050 lacD tagatose 1,6-diphosphate aldolase 
Chapter 2, 
Paixão et al., 
2015 
SP1651 SPD_1464 tpx thiol peroxidase [24] 
SP0746 
SPD_0650 clpP 
ATP-dependent Clp protease, proteolytic 











Gene annotation_D39 (as described in 
NCBI) References 
SP0060 SPD_0065 bgaC Beta-galactosidase 3 [28] 
SP0082 SPD_0080  cell wall surface anchor family protein [29] 
SP0340 SPD_0309 luxS S-ribosylhomocysteinase [30] 
SP0409 SPD_0373  hypothetical protein [31] 
SP0459 SPD_0420 pflB formate acetyltransferase [32] 
SP0834 SPD_0729  hemolysin-related protein [33] 
SP0908 
SPD_0802  
S1 RNA-binding domain-containing 
protein 
[34] 
SP1161 SPD_1025 lpdA dihydrolipoamide dehydrogenase [35] 
SP1241 
SPD_1098  
amino acid ABC transporter amino acid-
binding  protein/permease  
[36,37] 
SP1795 SPD_1582  sucrose-6-phosphate hydrolase [38] 
SP1999 SPD_1797 ccpA catabolite control protein A [38,39] 
SP2136 SPD_1965 pcpA choline binding protein PcpA [17,40,41] 
SP0268 SPD_0250  pullulanase, extracellular [42,43] 
SP0927 SPD_0818  
transcriptional regulator, LysR family 
protein 
[25,44] 
SP0390 SPD_0356 cbpG pseudo [45] 
SP0730 SPD_0636 spxB pyruvate oxidase [46,47] 
SP0965 SPD_0853 lytB endo-beta-N-acetylglucosaminidase [2,45] 
SP1573 SPD_1403 lytC 1,4-beta-N-acetylmuramidase [2,45] 
SP0930 SPD_0821 cbpE choline binding protein E [2,45] 
SP2201 SPD_2028 cbpD choline binding protein D [2,45] 
Sp1175 SPD_1038 phpA histidine triad protein A [40,48,49] 
Sp1174 SPD_1037  histidine triad protein [40,48,49] 
sp1003 SPD_0889 phtD histidine triad protein D [40,48,49] 
SP0664 SPD_0577 zmpB zinc metalloprotease Zmp [50] 
SP0330 SPD_0301 regR 
sugar binding transcriptional regulator 
RegR 
[51] 
SP2236 SPD_2064 comD sensor histidine kinase ComD [44,52] 
SP0798 SPD_0701 ciaR DNA-binding response regulator CiaR [53,54] 
SP1855 SPD_1636  zinc-containing alcohol dehydrogenase [55] 
SP1976 SPD_1774 pflA pyruvate formate-lyase activating enzyme [32] 
sp2239 SPD_2068  serine protease [40,56] 
SP1580 SPD_1409  
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Table S3.5. Clustering of genes significantly, differentially expressed in 
the microarrays analysis of S. pneumoniae D39 grown in galactose, 






Gal vs Glc 
GlcNAc vs 
Glc 
SPD_0249 hypothetical protein SPD_0249  DOWN DOWN UP 
SPD_0277 6-phospho-beta-glucosidase  DOWN DOWN DOWN 
SPD_0278 hypothetical protein SPD_0278  DOWN DOWN DOWN 
SPD_0279 
cellobiose phosphotransferase system 
IIB component  
DOWN DOWN DOWN 
SPD_0280 transcriptional regulator, putative  DOWN DOWN DOWN 
SPD_0281 
cellobiose phosphotransferase system 
IIA component  
DOWN DOWN DOWN 
SPD_0282 hypothetical protein SPD_0282  DOWN DOWN DOWN 
SPD_0283 
cellobiose phosphotransferase system 
IIC component  
DOWN DOWN DOWN 
SPD_0334 
oligopeptide ABC transporter, 
oligopeptide-binding protein AliA  
DOWN DOWN DOWN 
SPD_0404 acetolactate synthase catalytic subunit  DOWN DOWN DOWN 
SPD_0405 
acetolactate synthase 3 regulatory 
subunit  
DOWN DOWN DOWN 
SPD_0407 hypothetical protein SPD_0407  DOWN DOWN DOWN 
SPD_0409 threonine dehydratase  DOWN DOWN DOWN 
SPD_0473 immunity protein BlpY  UP UP UP 
SPD_0502 
PTS system, beta-glucosides-specific 
IIABC components  
DOWN DOWN DOWN 
SPD_0954 hypothetical protein SPD_0954  DOWN DOWN DOWN 
SPD_0955 
amino acid or sugar ABC transport 
systems, permease protein  
DOWN DOWN DOWN 
SPD_1004 
glyceraldehyde-3-phosphate 
dehydrogenase, NADP-dependent  
DOWN DOWN DOWN 
SPD_1018 immunoglobulin A1 protease precursor  UP UP DOWN 
SPD_1176 ABC transporter, ATP-binding protein  UP UP UP 
SPD_1179 hypothetical protein SPD_1179  UP UP UP 
SPD_1569 aquaporin  DOWN DOWN DOWN 




DOWN DOWN DOWN 
SPD_1600 anthranilate phosphoribosyltransferase  DOWN DOWN DOWN 
SPD_1601 anthranilate synthase component II  DOWN DOWN DOWN 
SPD_1602 anthranilate synthase component I  DOWN DOWN DOWN 
SPD_1606 MgtC/SapB family protein  DOWN DOWN DOWN 
SPD_1607 ABC transporter, permease protein  DOWN DOWN DOWN 
SPD_1608 ABC transporter ATP-binding protein  DOWN DOWN DOWN 
SPD_2052 hypothetical protein SPD_2052  DOWN DOWN DOWN 
SPD_2068 serine protease  UP UP UP 
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Table S3.7. Intracellular intermediates of sugar-specific catabolic patways 
of S. pneumoniae determined in resting cells (by in vivo NMR) or in 
growing cells (ethanol extracts), metabolizing N-acetylglucosamine 
(GlcNAc), mannose (Man) or galactose (Gal). 
Sugar Intermediates Resting cells Growing cellsa 
GlcNAc       
 GlcNAc6P - + 
 GlcN6P - + 
 F6P - + 
 FBP + + 
 G6P - + 
  3-PGA - + 
Man    
 Man6P + + 
 FBP + + 
 3-PGA - + 
  G6P - + 
Gal    
 Gal6P + + 
 TPB - + 
 FBP + + 
 α-Gal1P - + 
 α-G1P - + 
 G6P - + 
  3-PGA - + 
 
a as determined by Paixão et al., 2015 (Chapter 2). 
 
Abbreviations:  
+, presence; -, absence; GlcNAc6P, N-acetylglucosamine 6-phosphate; GlcN6P, 
glucosamine 6-phosphate; F6P, fructose 6-phosphate; FBP, fructose 1,6-biphosphate; 
G6P, glucose 6-phosphate; 3-PGA, 3-phosphoglycerato; Man6P, mannose 6-phosphate; 
Gal6P, galactose 6-phosphate; TPB, tagatose 1,6-biphosphate; α-Gal1P, α-galactose 1-
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Table S3.8. Summary of the significantly differentially expressed genes 
(up- or downregulated) of cells of S. pneumoniae D39 grown in CDM 
supplemented with N-acetylglucosamine (GlcNAc), mannose (Man), 
galactose (Gal) or in a mixture thereof challenged with a glucose (Glc) 
pulse and compared to unchallenged cells, determined by DNA 
microarrays. 
Locus_tag Gene Product GlcNAc Man Gal Mix c 
Sugar-specific catabolismd 
SPD_1050 lacD tagatose 1,6-diphosphate aldolase   -2.02  
SPD_1051 lacC tagatose-6-phosphate kinase    -1.76  
SPD_1052 lacB 
galactose-6-phosphate isomerase 
subunit LacB  
 0.32 -2.10 -1.05 
SPD_1053 lacA 
galactose-6-phosphate isomerase 
subunit LacA  
  -1.95 -1.41 




-0.53 0.66   








 0.45 -1.78 -0.50 
SPD_1634 galK galactokinase   0.77 -1.69 -0.89 
SPD_1993 fucU 
RbsD/FucU transport protein family 
protein  
-0.70  -0.65  
SPD_1994 fucA L-fuculose phosphate aldolase  -0.80  -0.90 -0.40 
SPD_1995 fucK L-fuculose kinase FucK, putative  -1.38   -0.71 
Glycolysis 




 0.39   
Pyruvate metabolism 
SPD_0420 pflB pyruvate formate-lyase -0.53 0.70  -0.99 
SPD_0621 lctO lactate oxidase  -0.93 0.98  -0.63 
SPD_0985 pta phosphotransacetylase  -0.34 0.56 -0.80  
SPD_1834 adh 
bifunctional acetaldehyde-
CoA/alcohol dehydrogenase  
-0.95 0.53  -1.63 
Sugar-specific transportersd 
SPD_0066  PTS system, IIB component     -0.54 
SPD_0088  
ABC transporter, permease 
protein  
-1.49 1.83  -1.66 
SPD_0089  
ABC transporter, permease 
protein  
-1.32 1.60  -0.85 
SPD_0090  
ABC transporter, substrate-binding 
protein  








protein, IID component  
-0.50  -0.51  
SPD_0263 manM 
PTS system, mannose-specific IIC 
component  
-0.53 0.41   
SPD_0264 manL 
PTS system, mannose-specific 
IIAB components  
-0.61 0.55   
SPD_0279 celB 
cellobiose phosphotransferase 
system IIB component  
-0.91  1.20 -1.06 
SPD_0281 celC 
cellobiose phosphotransferase 












SPD_0293  PTS system, IIA component   0.48   
SPD_0295  PTS system, IIB component   0.44   
SPD_0297  PTS system, IID component   0.58   
SPD_0559  
PTS system IIA component, 
putative  
 1.11 -0.67 -1.69 
SPD_0560  
PTS system, IIB component, 
putative  
 1.31 -0.89 -1.70 
SPD_0561  
PTS system, IIC component, 
putative  
-0.67 1.10 -0.82 -1.15 
SPD_0661 exp5 PTS system, IIABC components    0.54  
SPD_0739  
membrane lipoprotein TmpC 
precursor  
   -0.39 
SPD_0773  
PTS system, fructose specific IIABC 
components  
-0.52 0.60 0.45 -0.51 
SPD_1040 ptsH phosphocarrier protein HPr    -0.43  
SPD_1047 lacE-2 
PTS system, lactose-specific IIBC 
components  
  -0.79  
SPD_1048 lacF-2 
PTS system, lactose-specific IIA 
component  
  -0.64  
SPD_1057  
PTS system, IIB component, 
putative  
-0.70 1.14  -1.79 
SPD_1409  
sugar ABC transporter, ATP-binding 
protein  
-0.81 0.86  -0.68 
SPD_1493  
sugar ABC transporter, permease 
protein  
 1.09 -0.76  
SPD_1494  
sugar ABC transporter, permease 
protein  
 1.04 -0.58  
SPD_1495  
sugar ABC transporter, sugar-
binding protein  
-0.72 1.62 -0.55  
SPD_1496  PTS system, IIBC components  -0.96 1.36 -0.72 -0.91 
SPD_1664  
PTS system, trehalose-specific 
IIABC components  




binding protein  
-0.83 0.94  -0.64 
SPD_1935 malC 
maltodextrin ABC transporter, 
permease protein  
 0.48   
SPD_1991  PTS system, IIB component    -0.78  
SPD_1992  PTS system, IIA component    -0.71  
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a Subtable of Tables S3.9, S3.10, S3.11 and S3.12 provided on the CD. 
b Values of ln-ratio. Positive values indicate upregulation and negative values indicate 
downregulation.  
c Mixture of Gal, Man and GlcNAc. 
d As reviewed by Paixão et al. 2015 (Chapter 2). 
In bold are depicted the transporters and sugar-specific catabolic genes known or 
putatively involved in the metabolism of GlcNAc, Man or Gal, as reviewed by Paixão et al. 





Table S3.13. Clustering of genes significantly, differentially expressed in 
the microarrays analysis of S. pneumoniae D39 grown in galactose, 
mannose, N-acetylglucosamine or in a mixture thereof challenged with 












SPD_0277 DOWN DOWN DOWN UP 
6-phospho-beta-
glucosidase  
SPD_0373 DOWN DOWN UP DOWN 
hypothetical protein 
SPD_0373  
SPD_0476 UP UP DOWN UP 
hypothetical protein 
SPD_0476  
SPD_0561 DOWN DOWN UP DOWN 
PTS system, IIC 
component, putative 
SPD_0724 DOWN DOWN UP DOWN 
phosphopentomuta
se  
SPD_0725 DOWN DOWN UP DOWN pseudo 
SPD_0771 DOWN DOWN UP UP 
lactose 
phosphotransferase 
system repressor  
SPD_0772 DOWN DOWN UP UP 
1-
phosphofructokinas
e, putative  
SPD_0773 DOWN DOWN UP UP 
PTS system, 
fructose specific 
IIABC components  
SPD_1163 DOWN DOWN UP DOWN 
N-
acetylneuraminate 
lyase, putative  
SPD_1215 UP UP DOWN UP 
cytoplasmic alpha-
amylase  
SPD_1299 DOWN DOWN UP DOWN 
hypothetical protein 
SPD_1299  
SPD_1300 DOWN DOWN UP DOWN 
thiamine 
biosynthesis protein 















SPD_1301 DOWN DOWN UP DOWN 
NADPH-dependent 
FMN reductase  
SPD_1496 DOWN DOWN UP DOWN 
PTS system, IIBC 
components  





SPD_2009 DOWN DOWN UP DOWN 
hypothetical protein 
SPD_2009  




SPD_2013 DOWN DOWN DOWN DOWN glycerol kinase  










Figure S3.1. Visual representation of the clustering analysis performed for 
monosaccharides challenged with a pulse of glucose versus unchallenged cells, 
targeting the selected categories of genes. 
Colour scale: ln-ratio of expression. Red, upregulated gene in the microarrays; green, 
downregulated gene in the microarrays. The figure was generated targeting the gene 
categories of interest (glycolysis, pyruvate metabolism, sugar dedicated transporters and 
catabolic genes as reviewed by Paixão et al., 2015, (Chapter 2), classical virulence 
factors). According to NCBI annotation: SPD_0373, hypothetical protein; SPD_0561, PTS 
system transporter subunit IIC; SPD_1163, N-acetylneuraminate lyase; SPD_1496, PTS 
system transporter subunit IIBC; SPD_1497, N-acetylmannosamine-6-phosphate 2-
epimerase (nanE-1). Glc, glucose; Man, mannose; Gal, galactose; GlcNAc, N-





Figure S3.2. Visual representation of the clustering analysis performed for Gal, Man 
or GlcNAc versus Glc, targeting the selected categories of genes. 
Colour scale: ln-ratio of expression. Red, upregulated gene in the microarrays; green, 
downregulated gene in the microarrays. The figure was generated targeting the gene 
categories of interest (glycolysis, pyruvate metabolism, sugar dedicated transporters and 
catabolic genes as reviewed by Paixão et al., 2015, (Chapter 2), classical virulence 
factors). According to NCBI annotation: SPD_1018, immunoglobulin A1 protease (iga); 
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Streptococcus pneumoniae is a common asymptomatic commensal of 
the nasopharynx. However, this bacterium is better known as a leading 
cause of bacterial meningitis, pneumonia, septicaemia and otitis media. 
The ever-increasing antibiotic resistance issues and the re-emergence of 
non-type vaccine strains call for the identification of new targets for the 
development of novel therapeutic and preventive drugs. Accumulating 
evidence strengthens the view that pathogenesis and central metabolism 
are profoundly interconnected, and thus the barrier between basic 
pneumococcal physiology and virulence is now more diffuse. The focus 
of this thesis was to deepen our understanding of carbon metabolism and 
its regulation in S. pneumoniae. Carbon metabolism is central to the 
physiology of this heterotroph bacterium, which relies on the efficient 
acquisition of sugars for energy generation and production of catabolic 
intermediates needed for biosynthesis. This work further contributed to 
disclose interdependencies between carbohydrate metabolism and 
S. pneumoniae virulence. 
 
Living on mucins and the particular case of the 
mucin-degrading S. pneumoniae 
The highly hydrated mucus gel overlaying the epithelial surfaces of the 
human body (e.g. respiratory, oral, gastrointestinal tracts) is a first line of 
defence against invading microorganisms, impurities, chemical (toxins), 
enzymatic and mechanical disruptions. Besides being a physical barrier it 
is also a matrix rich in host antimicrobial molecules (e.g. lysozyme, IgA, 
lactoferrin) [1]. The mucus major components are the high molecular 
weight glycoprotein mucins, which are constituted by a protein core 
heavily decorated with carbohydrate polymers of varied nature and size. 
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The carbohydrates present in mucins  provide alternative binding sites to 
bacterial adhesins and, hence enable bacteria to thrive evading 
interactions with the underlying epithelium [2]. For example, the ability of 
the probiotic bacterium Lactobacillus rhamnosus GG to persist in the 
human gut as recently been associated with the ability of a protein in the 
pilli to bind host mucins [3]. Remarkably, mucins are also a valuable 
nutritional reservoir of carbon and energy sources particularly important 
in niches where free carbohydrates are limited, such as the nasopharynx 
or micro niches in the gastrointestinal tract, enabling bacterial survival and 
colonisation on these surfaces [2,4,5]. Mucins are heavily O-glycosylated 
glycoproteins, generally composed of the monosaccharides N-
acetylgalactosamine (GalNAc), galactose (Gal), N-acetylneuraminic acid 
(NeuNAc), N-acetylglucosamine (GlcNAc) and fucose (Fuc) [6,7], which 
carbohydrate content can reach up to 80% of the mucin molecular mass 
[2]. Bacteria have evolved strategies to circumvent the mucin barrier and 
take advantage of this structure. Among others, those mechanisms 
encompass production of mucin-degrading enzymes that release 
carbohydrates from O- or N-linked oligosaccharide side chains 
(glycosidases) and proteins (proteases) that destabilize the mucus gel 
properties [1]. Thus, the ability to utilise mucin depends, to great extent, 
on these activities. 
The ability to degrade mucin is present in a number of members of the 
human microbiota, and in particular of inhabitants of the nasal and oral 
cavity, and the gastrointestinal tract. Interestingly, it was estimated that 
only approximately 1% of the total human fecal microbiota was able to use 
mucin [8]. Among these are organisms belonging to the genera 
Bifidobacterium, Ruminococcus, Clostridium and Bacteroides [9,10] (for a 
detailed overview see [2]). Recently, a new species isolated from the gut, 
Akkermansia muciniphila, was shown to use mucin as sole carbon and 
energy source [4]. Despite possessing a number of glycosidases [2], A. 
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muciniphila only grows on a few monosaccharides (GalNAc, GlcNAc and 
Glc) and it strictly requires a protein source; in such semi-defined 
conditions the growth parameters are poorer than on mucin [4]. 
Accumulating evidence indicates that microbiota in general, such as the 
non-mucin degrading intestinal bacteria E. coli, can benefit from sugars 
derived from mucin-degrading organisms [9,11]. Furthermore, it has been 
shown that the joint action of mucin-degrading organism increases mucin 
degradation [12], which is likely to benefit all ecological partners. 
Oral Streptococcus species are also able to use mucin (e.g. S. mitis, 
S. sanguis, and S. milleri) [13]. In Streptococcus intermedius UNS35, 
growth on mucin significantly increase the levels of several glycosidases 
and induced the activity of Man and GlcNAc PTSs. The authors suggested 
that these mechanisms may facilitate the persistence and growth of S. 
intermedius in vivo [14]. In contrast, its ecological cohabitant 
Streptococcus mutans is unable to use mucin as sole carbon and energy 
source [13]. However, enhanced survival was observed upon addition of 
mucin to sucrose-starved biofilms [15] or to a medium rich in  amino acids 
[16]. In the latter, an intact tagatose 6-phosphate (T6P) pathway was also 
required for growth, suggesting that the mucin somehow provides a 
source of Gal. Thus, one can speculate that S. mutans may benefit from 
mucins once free carbohydrates become limited in the oral cavity. Of the 
mucin sugar constituents, S. mutans is able to use Man, GlcNAc and Gal 
as sole carbon sources [17–20]. 
The nasal cavity inhabitant S. pneumoniae possesses an incredible 
array of extracellular glycosidases with different substrate specificities 
(reviewed in [21]), which permits its growth on different glycoconjugates 
such as N-linked glycans and glycosaminoglycans (hyaluronic acid) 
[22,23]. Furthermore, S. pneumoniae is able to grow on mucin (O-linked 
glycan) as sole carbon source [24]. This ability is strictly associated with 
the expression of a number of glycosidases (Chapter 2), which act on the 
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mucin releasing neuraminic acids (NeuNAc and N-glycolylneuraminic 
acid), Gal and GalNAc, and to a less extent GlcNAc and Fuc [7]. Yesilkaya 
and co-authors showed that growth on mucin is heavily dependent on 
neuraminidase A (NanA) activity which releases the terminal N-
acetylneuraminic acid of the oligosaccharide side chains [24], as this 
feature is seemingly essential for further breakdown of the carbohydrate 
polymers by other glycosidases [7,25,26]. Curiously, nanA was not among 
the differentially expressed genes on mucin as compared to Glc (Chapter 
2). This finding leads us to propose that constitutive expression of nanA 
is sufficient to ensure the release of NeuNAc terminal moieties. 
Constitutive expression of glycosidase genes has been reported for 
enteric bacteria [9]. This mechanism was hypothesized to confer a 
selective advantage over organisms that do not express the glycosidases 
constitutively in conditions where the substrates are limiting for growth. 
We can speculate that the same holds true for S. pneumoniae, since it 
exclusively relies on carbohydrates to grow, particularly hexoses that are 
scarce in the airways.  
In Chapter 2 of this thesis we identified Gal, Man and GlcNAc as the 
monosaccharide constituents of porcine gastric mucin (model 
glycoprotein) that can potentially sustain growth of S. pneumoniae strain 
D39 in the host. Based on a transcriptome analysis comparing mucin vs. 
Glc we singled out upregulated genes involved in the catabolism of 
sugars, and combined this information with the growth-sustaining 
monosaccharides identified in sugar phenotype assays containing 
representative mucin carbohydrate moieties. Interestingly, Gal processing 
genes represent the largest fraction of genes induced by mucin (Chapter 
2), which emphasizes a cellular demand for Gal pathway functionality 
during growth on mucin. This finding is in line with an earlier study showing 
that upon pneumococcal growth the Gal content in porcine gastric mucin 
was reduced by 30%. Of the sugars capable of supporting growth of strain 
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D39, Gal suffered the largest decrease [7]. Thus, we propose that Gal is 
the main mucin moiety used for growth of the bacterium in the 
nasopharynx. Furthermore, Gal is a widespread sugar in glycoproteins.  
We also observed induction of transporters specific for substrates in 
which the bacterium is unable to grow (e.g. NeuNAc) (Chapter 2). Similar 
observations have been reported for other organisms and S. pneumoniae 
and are associated with non-metabolic roles for the incoming substrate 
[11,27–29]. D39 has a frame shift mutation in the N-acetylneuraminate 
lyase gene of nanAB operon [30,31], and we (and others) have related 
this genotypic trait to its inability to grow on sialic acid. Recently, NeuNAc 
was found to act as a signalling molecule in the pneumococcus, including 
strain D39, that promotes increased colonisation, invasion of the host’s 
lower respiratory tract and biofilm formation in vitro [32–34]. According to 
Gualdi et al. [31], the D39’s inability to catabolise NeuNAc is not hindering  
the regulation of the nanAB locus or the strain’s virulence. On the other 
hand, upregulation of NeuNAc transporters on mucin suggests that the 
amino sugar is still transported to exert exclusively regulatory functions or 
that the transporters display specificity for other sugars as well. A detailed 
biochemical characterization of each transporter to elucidate sugar 
specificity should be carried out in the future. Previously, Bidossi et al., 
[30] demonstrated that the ABC transporters encoded in sialic acid operon 
were also implicated in the uptake of ManNAc. This metabolite is the first 
intermediate in the sialic acid pathway (Chapter 2, Fig. 2.1).  
We and others have shown that S. pneumoniae has the genetic 
potential, including glycosidases, transporters and catabolic pathways, for 
the use of the glycan-constituent sugars Gal, Man, GlcNAc as sole carbon 
sources (Chapter 2, [7,30,35,36]). However, experimental validation of the 
catabolic pathways was missing. In this study, we ascertained at the 
biochemical and genetic levels the in silico predictions (Fig. 4.1) for the 
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Gal, Man and GlcNAc catabolic pathways in S. pneumoniae strain D39 
(Chapter 2).  
The phosphorylated intermediates mannose 6-phosphate (Man6P) 
(Man pathway), N-acetylglucosamine 6-phosphate (GlcNAc6P) and 
glucosamine 6-phosphate (GlcN6P) (GlcNAc pathway), and tagatose 1,6-
bisphosphate (TBP), galactose 6-phosphate (Gal6P) (T6P pathway for 
Gal) and α-galactose 1-phosphate (α-Gal1P) and α-glucose 1-phosphate 
(α-G1P) (Leloir pathway for Gal) were detected in ethanol extracts of 
exponentially growing cells. Moreover, induction of the dedicated 
enzymes of each pathway (ManA, NagA and NagB, GalK and LacD) was 
observed in sugar-grown cells (Chapter 2). Interestingly, ManA and NagB 
activities were also detected in Glc-grown cells, while the activities of GalK 
and LacD were only measured in Gal-grown cells. Constitutive expression 
of manA and nagA probably reflects the involvement of their functions in 
processes of cellular biosynthesis (Fig. 4.1).   
The combined biochemical data (phosphorylated intermediates and 
enzyme activities) (Chapter 2) and the increased transcript levels of Leloir 
and T6P pathway specific genes (galK, galT-2, galE-1, galM and lacBCD 
on Gal-grown cells (Chapter 3); lacABD and galM on mucin (Chapter 2)) 
prove without doubt the simultaneous activity of both Gal pathways in S. 
pneumoniae (Fig. 4.1)  [35]. Even though this behaviour is seemingly 
energetically costly, it is not a unique feature of the pneumococcus. S. 
mutans, Streptococcus oligofermentans, Streptococcus gordonii and 
Lactococcus lactis also possess both pathways and simultaneous activity 
has been demonstrated [18,37–39]. While in the oral Streptococcus the 
T6P pathways is apparently the preponderant route for Gal catabolism 
[18,37,38], in the dairy bacterium L. lactis this feature is strain dependent 
[39]. The assessment of the relative contribution of each pathway is not 
trivial and requires flux partitioning determination, using advanced 
labelling techniques coupled to mass spectrometry and/or nuclear 
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magnetic resonance detection. In S. pneumoniae this deserves further 
investigation, but our genetic data revealed that Gal catabolism requires 
at least an active galactokinase, as mutants in galK were unable to grow 
on Gal despite the presence of an intact T6P pathway (Chapter 2). 
Mutations in manA and nagA rendered strains unable to grow on Man 
and GlcNAc, respectively, and a double knockout mutant D39∆lacDgalK 
failed to grow on Gal. As a conclusion, mutant analysis demonstrated that 
S. pneumoniae D39 possesses no additional pathways for the catabolism 
of Man, GlcNAc and Gal. 
 
Figure 4.1. Schematic representation of the pathways for the dissimilation of 
galactose (Gal), mannose (Man) and N-acetylglucosamine (GlcNAc) in S. 
pneumoniae D39.  
Reactions are catalysed by the following protein encoding genes: galM, aldolase 1-
epimerase (mutarotase); galK, galactokinase; galT-1, galT-2, galactose 1-phosphate 
uridylyltransferase; galE-1, galE-2, UDP-glucose 4-epimerase; pgm, 
phosphoglucomutase/phosphomannomutase family protein; lacA, galactose 6-phosphate 
isomerase subunit LacA; lacB, galactose 6-phosphate isomerase subunit LacB; lacC, 
tagatose 6-phosphate kinase; lacD, tagatose 1,6-diphosphate aldolase; pgi, glucose 6-
phosphate isomerase; manA, mannose 6-phosphate isomerase; nagA, N-
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acetylglucosamine 6-phosphate deacetylase; nagB, glucosamine 6-phosphate isomerase; 
gki, glucokinase; pgi, glucose 6-phosphate isomerase; pfkA, 6-phosphofructokinase; fba, 
fructose-biphosphate aldolase; tpiA, triosephosphate isomerase. The lower glycolytic 
pathway is represented by a dashed arrow. 
Intermediates: Gal, galactose; α-Gal, α-galactose; α-Gal1P, α-galactose 1-phosphate; α-
G1P, α-glucose 1-phosphate; UDP-Glc, UDP-glucose; UDP-Gal, UDP-galactose; Gal6P, 
galactose 6-phosphate; T6P, tagatose 6-phosphate; TBP, tagatose 1,6-diphosphate; 
Man6P, mannose 6-phosphate; GlcNAc6P, N-acetylglucosamine 6-phosphate; GlcN6P, 
glucosamine 6-phosphate; Glc, glucose; G6P, glucose 6-phosphate; F6P, fructose 6-
phosphate; FBP, fructose 1,6-biphosphate; GAP, glyceraldehyde 3-phosphate;  DHAP, 
dihydroxyacetone phosphate. 
Underlined intermediates represent the sugar-specific pathway intermediates determined 
in ethanol extracts of cells grown in the glycan-derived sugar. 
Values are the specific activities (U mgprotein-1) measured in glycan-derived sugar or in 
Glc-grown cells (black).  
Black arrows indicate differential expression in mucin-grown cells as compared to Glc-
grown cells. Coloured arrows indicate differential expression in the glycan-derived sugar 
as compared to Glc. The direction of the arrow indicates upregulation (up) or 
downregulation (down). 
*Using a less restrictive criterion for microarrays analysis. 
For the sake of simplicity the identity of putative transporters is not depicted in the figure. 
 
Man, Gal and GlcNAc catabolic pathways are present and conserved 
among pneumococcal genomes (Tables S2.8 and S4.1), however events 
like single nucleotide polymorphisms that result in loss of activity cannot 
be excluded. A good example is provided by the inability of strain D39 to 
catabolise NeuNAc. Thus, while the high conservation of the pathways 
provides a measure of their physiological relevance, pathway activity 
needs to be confirmed in different pneumococcal serotypes.  
The first step in sugar catabolism is transport across the cell envelope. 
The focus of this work was the intracellular metabolism, but our data, and 
in particular the expression data (Chapter 2 and 3) provide important 
information for the identification of sugar transporters. However, in most 
cases biochemical characterization is recommended to firmly ascertain 
substrate specificity. 
Metabolism through the Leloir is usually associated with the entry of 
Gal via non-PTSs (secondary carriers or ABC). Indeed, Bidossi et al. [30] 
designated Gal uptake to a CUT1 family ABC transporter but  further 
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experimentation is needed since a loss of function mutant displayed only 
mild reduction of the Gal phenotype [30] and our expression data revealed 
downregulation of the encoding genes on Gal (Chapter 3). Nevertheless, 
the ability of ptsI mutants to grow on Gal ([30], and our own unpublished 
data) further corroborates that S. pneumoniae internalizes Gal through 
still unknown non-PTSs permeases.  
On the other hand, accumulation of Gal6P in growing (Chapter 2) and 
resting cells (Chapter 3) substantiates the entry of Gal through a PTS 
system, which is a requisite for T6P pathway activity. The increased 
expression levels of the galactitol-family PTS SPD_0559-0-1 on mucin 
(Chapter 2) and on Gal-adapted cells (Chapter 3) further supports the 
involvement of this system in Gal translocation [30,40]. This Gat-PTS has 
homology to the high affinity galactose-specific PTS present in S. 
gordonii, S. oligofermentans and S. mutans [37,38,41]. Regardless of the 
transporter identity in S. pneumoniae, the affinity of this uptake system(s) 
for Gal is low (Chapter 2).  
S. mutans strain UA159 also lacks the high-affinity galactose-PTS, 
which correlates with inefficient dissimilation of Gal via the T6P pathway. 
Translocation of Gal in this strain occurs via the glucose–PTS permease 
EIIMan (ManLMN) and the lactose-PTS permease EIILac (LacFE), but the 
Gal-PTS activity is low [18]. In S. pneumoniae, Gal induced the expression 
of other PTSs genes including lacE-2, a lactose-PTS known to internalize 
Gal [35], and SPD_1057, a Gat-PTS also induced on mucin Chapter 2, 
hence their contribution for Gal translocation cannot be ruled out.   
Man and GlcNAc transporters were not found differentially positively 
regulated in Man- and GlcNAc-grown cells, respectively (Chapter 3). 
Whether this behaviour is due to wrong assignment of the protein 
functions or that the genes encoding the uptake systems are constitutively 
expressed remains to be elucidated. As a concluding note, the importance 
of carbohydrates for the pneumococcal lifestyle is apparent form its 
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genomic potential: S. pneumoniae  possesses the highest number of 
carbohydrate transporters, relative to its genome size, as compared to 
other sequenced prokaryote genomes [42]. Induction of transporters, 
other than the expected, reiterates the need for an in depth biochemical 
characterization of sugar uptake systems in S. pneumoniae. 
The ability of S. pneumoniae to use mucin as sole carbon source and 
take advantage of mucin-constituent sugars reveals an evolutionary 
adaptation of S. pneumoniae to life in the nasopharynx.  
 
Monosaccharide nutrition in the pneumococcus 
S. pneumoniae is a strictly fermentative bacterium and therefore relies 
exclusively on carbohydrates to grow. In its natural habitat, the 
nasopharynx, free sugars are in general scarce. This is particularly true 
for the usually preferred carbohydrate of Gram-positive bacteria  Glc, 
which content is below 1 mM [43–45]. However, we have experimentally 
proved that the pneumococcus has the catabolic pathways for the 
molecular breakdown of the monosaccharides Gal, Man and GlcNAc 
present in host glycoproteins, such as mucins (Chapter 2). Besides those 
three sugars we have shown that S. pneumoniae D39 has the ability to 
grow on GlcN as sole carbon source, but not on NeuNAc, GalNAc and 
GalN (Chapter 2). The lack of growth on NeuNAc has been discussed 
above, but the inability to use GalNAc and GalN was not investigated in 
detail. GalNAc accounts for up to 15% of the molecular mass of porcine 
gastric mucin, but is reduced by 35% in the mucin upon pneumococcal 
growth [7]. Catabolism of GalNAc in bacteria comprises transport by a 
PTS yielding N-acetylgalactosamine 6-phosphate (GalNAc6P), 
conversion to galactosamine 6-phosphate (GalN6P) by GalNAc6P 
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deacetylase, and finally isomerisation/deamination to T6P via GalN6P 
isomerase (coded by agaS) [46,47]. Genes encoding homologues of the 
GalNAc-PTS and agaS were in the genome sequence of D39, 
respectively SPD_0293-5-6-7 and SPD_0070. However, the only gene 
encoding an amino sugar deacetylase in D39 is nagA (GlcNAc 
catabolism) and a peptidoglycan GlcNAc deacetylase. In E. coli and 
Lactobacillus casei NagA can also catalyse the conversion of GalNAc6P 
to GalN6P [46–48]. Whether the specificity range is different (narrower) in 
S. pneumoniae or the inability to grow in GalNAc arises from a different 
mechanism remains to be investigated. More interestingly is the lack of 
growth on Fuc, despite the presence of a complete Fuc catabolic pathway 
[28]. However, S. pneumoniae  apparently lacks the enzymes required for 
processing the terminal product of Fuc catabolism, L-lactaldehyde 
(Chapter 2, [30]). The transporter in the Fuc operon, SPD_1989-0-1-2, is 
selective for fucosylated-oligosaccharides which are then processed by 
intracellular glycosidases releasing Fuc [28,49], but specific import of the 
monosaccharide by other transporters cannot be excluded. The peculiar 
inability to use Fuc despite the genomic capacity suggests a role of Fuc 
on non-metabolic functions, such as virulence [50,51] or participation in a 
sensing mechanism for fucosylated-compounds [28] (vide introduction for 
a detailed description). Transport and intracellular hydrolysis of these 
oligosaccharides can provide a nutritional competitive advantage in a 
relatively monosaccharide poor environment, as the free sugars are 
released in the bacterium cytoplasm.  
In the general survey conducted by Bidossi et al. [30], 32 different 
substrates, of which 8 were monosaccharides, were able to support 
pneumococcal growth, but strain variance was also reported. In our study 
a detailed characterization of growth on Gal, Man, GlcNAc and Glc is 
provided (Chapter 2). In both studies Glc supported the fastest growth, 
but differences on growth rates were observed for the other sugars 
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(Chapter 2 vs. [30]) which might stem from the use of rather dissimilar 
growth conditions or strain DP1004, a rough derivative of D39. Indeed, 
previous work in our lab established difference in growth rate between 
D39 and its rough derivative R6 growing in identical environmental 
conditions [52]. We found the specific growth rate to be independent of 
the initial substrate concentration for GlcNAc, Man and Glc. For Gal, 
however, the growth rate was considerably reduced (1.5-fold) in the lower 
sugar concentration and, in a sugar mixture, Gal was partially consumed 
and only after depletion of GlcNAc and Man (Chapters 2 and 3). The 
absence of a high affinity Gal transporter was evoked to explain these 
observations.  
The presence of the high affinity Gal transporter in some strains of the 
cariogenic dental pathogen S. mutans and in the oral commensal S. 
gordonii has been proposed to give a competitive advantage for efficient 
use of Gal in ecological settings particularly in fasting periods [38,41]. In 
S. mutans efficient Gal uptake permits the creation of an acid environment 
detrimental for S. gordonii survival, whereas in S. gordonii efficient Gal 
metabolism permits a more effective antagonism likely through H2O2 
production which inhibits S. mutans growth [38,41]. In the latter case Gal 
seems to promote a less cariogenic oral flora [38]. The absence of such 
a transporter in S. pneumoniae can be a drawback for efficient Gal 
metabolism in the host. Thus, it is tempting to speculate that in the 
nasopharynx Gal concentration is a not a limiting factor, most likely due  
to the activity of at least two pneumococcal galactosidases [7] or the 
galactosidase activity of other bacteria in the same niche, combined with 
Gal abundance in host glycoproteins. In support, Gal is one of the 
carbohydrates profusely released from the mucins upon the action of S. 
pneumoniae [7]. Moreover, despite being a less preferred sugar, the 
ATPyield is higher in Gal-grown cells than in other carbohydrates, in line 
with higher amounts of acetate produced (Chapter 2). Indeed, growth in 
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non-preferential sugars (slow metabolizable carbon sources) is usually 
associated with mixed acid fermentation profiles in several 
Streptococcaceae [53,54]. In agreement, cells of S. pneumoniae D39 
grown in Gal-containing medium, retrieved a pronounced shift towards a 
mixed acid fermentation products (Chapter 2, [35]), which was attributed 
to the activity of pyruvate formate lyase (PFL) and pyruvate formate-lyase 
activating enzyme (PFL-AE) [36]. The metabolic enzyme PFL competes 
with lactate dehydrogenase (LDH) for pyruvate. The concomitant 
generation of one more molecule of ATP (via acetate kinase) is certainly 
an advantage during the metabolism of slow metabolizable sugars. 
Overall, our results support the general idea that in laboratorial conditions 
Gal is a non-preferred substrate for bacterial proliferation [55], however in 
complex and ever-changing natural habitats a multitude of factors can 
skew the sugar preference palette to a primary use of Gal. Indeed, 
attenuation in animal models of disease of S. pneumoniae mutants on the 
galactose pathways provides strong evidence for the key role of Gal 
catabolism by S. pneumoniae in its natural habitat (Chapter 2). 
In this study, Glc is proven the preferred sugar of the pneumococcus, 
as previously suggested by us and others [30,35]: i) glucose supports the 
fastest growth rates of all monosaccharides tested (Chapter 2); ii) in sugar 
mixtures, Glc is the first to be consumed (Chapter 3); iii) in pulse 
experiments, Glc utilization starts immediately after the stimulus, 
independently of the carbon source used for growth (Chapter 3). Since 
Glc is an abundant substrate in the bloodstream and infection sites 
[44,45], we hypothesize that the sugar is relevant in the development of 
disease as it favours fast growth. In contrast, we can speculate that growth 
on the non-preferential sugar Gal, abundant in the airway mucins, allows 
the pneumococcus to thrive in the host as a commensal coloniser. In this 
milieu poor in nutrients that can support fast growth, fast metabolic activity 
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is likely deterred by other niche adaptation features required for 
persistence. 
The ability to co-metabolize sugars (e.g. Man and GlcNAc) (Chapter 
2), the readiness to use Glc, and the smaller transcriptional response to 
Glc in cells adapted to grow on a sugar mixture (Chapter 3) indicate a 
relatively high metabolic flexibility of S. pneumoniae. Furthermore, the 
diversity of transporters and the broad range of catabolic substrates, the 
redundancy of the transport systems and of some catabolic pathways 
encoded in pneumococcal genomes empower the microbe to survive in 
varied conditions. This potential can present a fitness advantage in the 
pneumococcal ecological niche (nasopharynx) as well as when it has to 
cope with dramatic nutritional changes in the passage to invasive states. 
Tuning of the catabolic capabilities to sugar availability is a dynamic 
adaptive strategy that enables the pneumococcus to benefit from the 
carbon sources available and compete with the colonisers in the host. 
Indeed, efficient uptake and metabolism of sugars impacts the growth and 
the relative proportions of the colonising species [19,38,41].  
Interestingly, as compared to the other nasopharyngeal colonisers 
Haemophilus influenzae and Neisseria meningitides, S. pneumoniae is 
able to use a larger diversity of substrates, a feature likely endowing the 
pneumococcus a competitive advantage. In this respect, S. pneumoniae 
is more similar to oral and intestinal microbiota [56]. Accumulating 
evidence sustains that the range of nutritional diversity is driven by niche 
specific adaptations [56–58]. For example, S. thermophilus adapted for 
growth in milk has a narrow substrate utilization capacity using lactose 
and saccharose preferentially, whereas Glc and fructose support poorer 
growth [59]. In contrast, the cariogenic microorganism S. mutans can 
metabolize a vast array of carbohydrates most of them common dietary 
sugars (e.g. glucose, fructose, maltose and sucrose) reflecting the nature 
of its habitat [20,60]. Apparently S. pneumoniae seems more adapted to 
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the nutritional environment in the nasopharynx than its counterparts H. 
influenzae and N. meningitidis. A full explanation for this observation 
cannot be put forward, but it is possible that S. pneumoniae may have 
inhabited other richer niches, like the oral cavity, where free sugars from 
host diet are available and thus acquired wide metabolic capabilities, 
which were not lost through genome reduction events in S. pneumoniae. 
Thus, the pneumococcal metabolic flexibility and redundancy in sugar 
transporters and pathways might represent a strategy to survive in 
environments with ever changing sugar availabilities. 
 
Carbohydrate regulation in S. pneumoniae 
Adaptation to changing host environments involves specific responses 
to varied cues that result in changes in gene regulation and metabolism. 
The pneumococcal response to carbohydrates was evaluated in this 
study. 
Gal gene clusters are differently organized among LAB and regulatory 
mechanisms are variable and species-specific [61]. In S. pneumoniae, the 
Leloir genes are widespread in the chromosome whereas the T6P 
pathway genes are organized in two operons (Chapter 2, [62]). In our 
work, analysis of mutants in Gal catabolic pathways unravelled a subtle 
“regulatory” link between the Leloir and the tagatose 6-phosphate 
pathways (Chapter 2). We unexpectedly found that a galK pneumococcal 
mutant was unable to grow on Gal, despite possessing a complete T6P 
pathway. On the other hand, lacD deficient strain was able to grow on Gal 
after a prolonged lag phase (Chapter 2). The latter phenotype could be 
explained by alleviation of the repression mediated by the transcriptional 
regulator carbon catabolite protein A (CcpA) over the Leloir genes prior to 
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the functional expression of the pathway [35], and/or induction of a non-
PTS system for Gal uptake. This hypothesis is substantiated by our own 
data showing nil GalK (and LacD) activity during growth on Glc (Chapter 
2). Gal-mediated induction of Gal permeases has been reported for L. 
lactis [39]. 
The peculiar phenotype of the galK mutant is not easily explainable. A 
polar effect on the galT-2 gene downstream of galK, resulting in the 
unintentional elimination of Gal1P uridylyltransferase activity, could lead 
to severe growth defects. However, growth on Glc was not affected by the 
galK mutation and complementation in trans with galT-2 did not restore 
growth on Gal. A galK mutant of S. mutans strain UA159 displayed a 
similar phenotype [63]. In common, S. pneumoniae and S. mutans strain 
UA159 lack a high-affinity PTS for Gal. Even though the absence of a 
high-affinity PTS is expected to limit the pathway capacity, a complete 
blockage is unlikely. Furthermore, PTS-mediated transport of Gal occurs 
in S. pneumoniae D39, since Gal6P has been detected in extracts of cells 
metabolizing Gal as well as in resting cells by in vivo 13C-NMR (Chapter 
2, Chapter 3, [35]). In summary, in S. pneumoniae Gal catabolism requires 
a functional galactokinase and we suggest that Gal1P acts as an inducer 
of the expression of Gal catabolic genes (Chapter 2). 
GalR has been reported as a transcriptional regulator of the Leloir 
pathway in other streptococci [64–66]. In S. pneumoniae it is responsive 
to carbohydrates (induced in Gal and repressed upon the Glc pulse) but 
its involvement in Gal regulation still needs to be addressed (Chapter 3). 
Recently, LacR was shown to be a repressor of the T6P pathway in Glc 
[62]. Firm identification of the molecular mechanisms underlying the 
coordination of Leloir and T6P pathways in the pneumococcus certainly 
deserves further investigation.  
This work provides, for the first time, an integrated approach of the 
pneumococcal response to carbohydrate availability at different regulatory 
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layers, retrieving clues of possible metabolic constraints and hints on 
regulatory layers. Our results demonstrate that the transcriptional, 
metabolic and physiological responses to Gal, Man and GlcNAc are 
sugar-dependent (Chapters 2 and 3). 
In GlcNAc no significant differences were observed at the 
transcriptional (glycolytic, fermentative and sugar-specific catabolic 
genes) and metabolic levels in comparison to Glc-grown cells. The end-
products profile (lactate as main product) is in agreement with the 
generalized view that the fermentation of fast metabolizable sugars is 
homolactic. The underlying mechanism encompasses the accumulation 
of high amounts of FBP, a known LDH activator (Chapter 3). The rate of 
GlcNAc and Glc utilization in resting cells (anabolism uncoupled) was also 
similar. In light of these results it surprising that the growth rates on 
GlcNAc and Glc-grown are not identical, with Glc sustaining much faster 
growth (Chapter 2). A clue to this phenotype is provided by the 
accumulation of other phosphorylated metabolites in growing cells: 
fructose 6-phosphate, N-acetylglucosamine 6-phosphate and 
glucosamine 6-phosphate (Chapter 2). In particular, fructose 6-phosphate 
accumulated substantially. The large accumulation of phosphorylated 
metabolites in growing cells combined with the poorer performance of 
GlcNAc in supporting growth, indicate a metabolic bottleneck in anabolic 
processes.   
In S. pneumoniae, likewise in S. mutans, differential regulation of nagB 





Figure 4.2. Model for transcriptional and metabolic regulation of central metabolic 
pathways in S. pneumoniae D39 during growth on GlcNAc.   
Reactions are catalysed by the following protein encoding genes: nagA, N-
acetylglucosamine 6-phosphate deacetylase; nagB, glucosamine 6-phosphate isomerase; 
gki, glucokinase; pgi, glucose 6-phosphate isomerase; pfkA, 6-phosphofructokinase; fba, 
fructose-biphosphate aldolase; tpiA, triosephosphate isomerase; gap, glyceraldehyde 3-
phosphate dehydrogenase; pgk, phosphoglycerate kinase; gpmA, 
phosphoglyceromutase; eno, enolase; pyk, pyruvate kinase; ldh, L-lactate 
dehydrogenase; spxB, pyruvate oxidase; lcto, lactate oxidase; pflB, pyruvate formate-
lyase; pta, phosphotransacetylase; ackA, acetate kinase; adh, bifunctional acetaldehyde-
coA/alcohol dehydrogenase. 
Intermediates: GlcNAc6P, N-acetylglucosamine 6-phosphate; GlcN6P, glucosamine 6-
phosphate; G6P, glucose 6-phosphate; F6P, fructose 6-phosphate; FBP, fructose 1,6-
biphosphate; GAP, glyceraldehyde 3-phosphate;  DHAP, dihydroxyacetone phosphate; 
BPG, 1,3-biphosphoglycerate; 3-PGA, 3-phosphoglycerate; 2-PGA, 2-phosphoglycerate; 
PEP, phosphoenolpyruvate. 
Green boxes indicate upregulation in GlcNAc-grown cells as compared to Glc. nagB is 
upregulated using a less restrictive criterion for microarrays analysis. Red dashed lines 
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represent transcriptional repression in presence of Glc. Purple dashed arrow represent 
metabolic regulation of enzymes. Highlighted in big bold purple font is the glycolytic 
intermediate accumulated in resting cells as determined by in vivo 13C-NMR.   
 
It is well described that metabolism through non-preferential sugars 
generates mixed-acid fermentation profiles. Gal catabolism in S. 
pneumoniae was not the exception (Chapters 2 and 3, [35,36]). Results 
from our laboratory showed that in S. pneumoniae, the fermentative 
pathways are under the control of  the transcriptional regulator CcpA [35]. 
CcpA activates ldh and represses pta, ackA, adh and pflB, hence 
favouring homolactic fermentation, i.e., fast growth by ensuring the 
efficient regeneration of reducing equivalents for glycolysis. However, 
repression of mixed acid genes is counterbalanced by Gal activation [35], 
suggesting other mechanisms in effect. In Chapter 3 we provide more 
evidence for the transcriptional regulation of Gal catabolism, however this 
type of regulation does not suffice to fully explain the observed 
phenotypes. Indeed, the gene expression pattern (only pta is upregulated 
in this study) does not fully correlate with the metabolic shift, which can 
only be explained through metabolic modulation of enzyme activities 
(Chapter 3).  
The differences in gene expression profiles between this study and that 
of Carvalho et al. [35] can derive from the dissimilar analysis of the 
microarray data (criteria for significance and/or in silico comparative 
transcriptome) or the use of a different D39 isolate. Indeed, phenotypic 
differences between the two isolates are evident when comparing the 
work in this thesis with previous data [35], of which  different growth rates 
and end-product profiles on Glc and Gal are obvious. This is not 
surprising, as the sequences of two isolates of S. pneumoniae D39 
showed a number of mutations, which could be correlated with phenotypic 
traits of the isolates. For example, a mutation in the spxB in one of the 
Chapter 4 
270 
isolates correlated with lower H2O2 production and larger and less 
transparent colonies [68].  
At metabolic level, the low FBP accumulation likely results in low levels 
of the known PFL inhibitors, DHAP and GAP, thus resulting in the 
alleviation of PFL activity and a consequent shift towards mixed acid (Fig. 
4.3). 
 
Figure 4.3. Model for transcriptional and metabolic regulation of central metabolic 
pathways in S. pneumoniae D39 during growth on Gal. 
Reactions are catalysed by the following protein encoding genes: galM, aldolase 1-
epimerase (mutarotase); galK, galactokinase; galT-1, galT-2, galactose 1-phosphate 
uridylyltransferase; galE-1, galE-2, UDP-glucose 4-epimerase; pgm, 
phosphoglucomutase/phosphomannomutase family protein; lacA, galactose 6-phosphate 
isomerase subunit LacA; lacB, galactose 6-phosphate isomerase subunit LacB; lacC, 
tagatose 6-phosphate kinase; lacD, tagatose 1,6-diphosphate aldolase; gki, glucokinase; 
pgi, glucose 6-phosphate isomerase; pfkA, 6-phosphofructokinase; fba, fructose-
biphosphate aldolase; tpiA, triosephosphate isomerase; gap, glyceraldehyde 3-phosphate 
dehydrogenase; pgk, phosphoglycerate kinase; gpmA, phosphoglyceromutase; eno, 
enolase; pyk, pyruvate kinase; ldh, L-lactate dehydrogenase; spxB, pyruvate oxidase; lcto, 
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lactate oxidase; pflB, pyruvate formate-lyase; pta, phosphotransacetylase; ackA, acetate 
kinase; adh, bifunctional acetaldehyde-coA/alcohol dehydrogenase. 
Intermediates: Gal, galactose; α-Gal, α-galactose; α-Gal1P, α-galactose 1-phosphate; α-
G1P, α-glucose 1-phosphate; UDP-Glc, UDP-glucose; UDP-Gal, UDP-galactose; Gal6P, 
galactose 6-phosphate; T6P, tagatose 6-phosphate; TBP, tagatose 1,6-diphosphate; G6P, 
glucose 6-phosphate; F6P, fructose 6-phosphate; FBP, fructose 1,6-biphosphate; GAP, 
glyceraldehyde 3-phosphate;  DHAP, dihydroxyacetone phosphate; BPG, 1,3-
biphosphoglycerate; 3-PGA, 3-phosphoglycerate; 2-PGA, 2-phosphoglycerate; PEP, 
phosphoenolpyruvate. 
Green boxes indicate upregulation in Gal-grown cells as compared to Glc. Red box 
indicate downregulation in Gal-grown cells as compared to Glc. Red dashed lines 
represent transcriptional repression in presence of Glc. Pink transporter highlight a 
metabolic bottleneck in Gal catabolism. Highlighted in pink are the glycolytic and Gal-
specific catabolic intermediates detected in resting cells by in vivo 13C-NMR. The size of 
the font is indicative of the pool size. Accumulation of DHAP and GAP are not detected in 
vivo but low accumulation as compared to Glc-grown cells is inferred due to the 
reversibility of the reactions catalysed by FBP aldolase and triose 3-phosphate isomerase. 
Pink dashed lines represent relief of LDH activation. Green dashed lines represent relief 
of PFL inhibition. 
 
In S. pneumoniae, the two pathways for Gal catabolism are 
transcriptionally regulated, with Gal acting as inducer and Glc inhibitor 
(Chapter 3). Previously, the Leloir pathway was found to be regulated in 
a CcpA-independent manner [35]. In the same study, the T6P pathway 
was induced by CcpA, but CcpA-independent regulation of the pathway 
has also been described [35,62]. The contribution of specific Gal 
transcriptional regulators should be experimentally addressed to 
understand these regulatory mechanisms. We show that expression of 
transcriptional regulator galR was modulated by Gal and Glc, while LacR 
was induced on Gal (Chapter 3). This regulator has been found to repress 
the T6P pathway in the absence of Gal and lactose and presence of Glc 
[62].  
The inefficient Gal catabolism can be partially explained by the lack of 
a high affinity Gal transporter, but the intense accumulation of Gal6P in 
resting cells (as well as growing cells, only qualitative) suggests a 
metabolic bottleneck during the Gal molecular breakdown (Chapters 2 
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and 3). Which step(s) is inhibited remains to be elucidated. The inhibitory 
effect of Gal6P on growth of S. mutans is documented [18].  
Interestingly, the slow metabolizable sugar Man only presented a 
modest shift to mixed acid fermentation, largely maintaining a homolactic 
fermentation, suggesting alternative mechanisms for regulation of the 
metabolic shift (Chapters 2 and 3). Man elicited a global effect on 
glycolytic (fba, gap, pgk, eno and pyk) and fermentative genes (induction 
of adh, pflB and lctO). The induction of glycolytic genes might be a way to 
alleviate the stress promoted by the high accumulation of Man6P. The 
deleterious effects of phosphorylated compounds in growth and 
metabolism are well-documented [69,70]. Our results strongly indicate a 
metabolic bottleneck likely at level of mannose 6-phosphate isomerase 
(Fig. 4.4) (Chapters 2 and 3). 
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Figure 4.4. Model for transcriptional and metabolic regulation of central metabolic 
pathways in S. pneumoniae D39 during growth on Man. 
Reactions are catalysed by the following protein encoding genes: manA, mannose 6-
phosphate isomerase; gki, glucokinase; pgi, glucose 6-phosphate isomerase; pfkA, 6-
phosphofructokinase; fba, fructose-biphosphate aldolase; tpiA, triosephosphate 
isomerase; gap, glyceraldehyde 3-phosphate dehydrogenase; pgk, phosphoglycerate 
kinase; gpmA, phosphoglyceromutase; eno, enolase; pyk, pyruvate kinase; ldh, L-lactate 
dehydrogenase; spxB, pyruvate oxidase; lcto, lactate oxidase; pflB, pyruvate formate-
lyase; pta, phosphotransacetylase; ackA, acetate kinase; adh, bifunctional acetaldehyde-
coA/alcohol dehydrogenase. 
Intermediates: Man6P, mannose 6-phosphate; G6P, glucose 6-phosphate; F6P, fructose 
6-phosphate; FBP, fructose 1,6-biphosphate; GAP, glyceraldehyde 3-phosphate;  DHAP, 
dihydroxyacetone phosphate; BPG, 1,3-biphosphoglycerate; 3-PGA, 3-phosphoglycerate; 
2-PGA, 2-phosphoglycerate; PEP, phosphoenolpyruvate. 
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Green boxes indicate upregulation in Man as compared to Glc. Green dashed lines 
represent transcriptional repression in presence of Glc. Blue shadow highlight a metabolic 
bottleneck in Man catabolism.  
Highlighted in blue are the glycolytic and Man-specific catabolic intermediates detected in 
vivo by 13C-NMR. The size of the font is indicative of the size of the pool. Accumulation of 
DHAP and GAP is not detected in vivo, but a lower accumulation as compared to Glc-
grown cells is inferred due to the reversibility of the reactions catalysed by FBP aldolase 
and triose 3-phosphate isomerase. 
Blue dashed lines represent relief of LDH activation. Orange dashed lines represent relief 
of PFL inhibition. 
 
The addition of Glc to cells adapted for growth on the glycan-
constituent sugars generally repressed mixed acid fermentation, except 
for Man (Figs. 4.2, 4.3, 4.4). Interestingly transcript levels of ldh were not 
increased in any of the conditions examined. The transcriptional response 
to Glc was sugar-dependent. Clearly downregulation of Gal catabolism 
supports the hypothesis that Glc displays a repressing effect over Gal 
catabolism. In opposition Gal, Man and GlcNAc do not repress Glc 
metabolism, as denoted by the instantaneous utilization of the sugar upon 
the Glc challenge (Chapter 3).  
Overall, our data shows that exposure to different carbohydrates and 
the underlying adaptation involves specific mechanisms comprising both 
genetic and metabolic regulation. The acquisition and catabolism of 
nutrients is a hierarchical and orchestrated process tuned to allow the 
bacterium to persist and in opportune conditions cause disease. The work 
in this thesis contributes to expand our still limited understanding of this 
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Sugar metabolism and virulence 
Growing evidence from studies on human bacterial pathogens   
indicate that central carbon metabolism can dramatically impact the 
pathogenic potential and emphasize the role of sugar acquisition and 
catabolism on the in vivo fitness of the bacterium. Indeed, the expression 
of sugar specific metabolic pathways is required for survival in different 
niches by allowing the pneumococcus to exploit the available 
carbohydrates, but a sugar stimulus also influences in a specific fashion 
the virulence potential of the bacterium by modulating the expression of 
genes encoding virulence factors. 
In this work we found that Gal catabolism is of key importance for 
pneumococcal growth in the nasopharynx and subsequent invasive 
states. This conclusion stems out from our observations that mutants in 
Gal catabolic genes, particularly D39∆lacD∆galK, showed attenuated 
ability to colonise and reduced virulence following intranasal infection in 
mouse models of colonisation and disease (bronchopneumonia with 
bacteraemia) (Chapter 2). In contrast, mutans in Man (D39∆manA) or 
GlcNAc (D39∆nagA) pathways, performed essentially as the wild-type 
strain D39. The lack of any effect upon direct administration of mutant 
strains in blood, indicates that Gal catabolism is key in the nasopharynx 
but not in the blood. Gal catabolic genes represent the highest fraction of 
genes induced by mucin (Chapter 2), an observation that is in agreement 
with the hypothesis that Gal is the primary carbon source for S. 
pneumoniae D39 in the nasal cavity. We suggested that deficient Gal 
catabolism could impact the expression of virulence traits, such as 
capsule. In an earlier study, Gal-grown cells were show to produce the 
double amount of capsule as compared to Glc-grown, but whether it is the 
capsule or other factor remains to be elucidated. Indeed, Gal induced well-
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established virulence genes (e.g. bgaA) as well as the new herein 
proposed (lacD, galK) (Chapter 3). 
Surprisingly, during this work we found that S. pneumoniae cultures 
growing on Gal formed visible aggregates, which led us to inspect the 
cells under the microscope. Unexpectedly, Gal-grown cells displayed a 
different morphology as compared to Glc-grown cells. We went further 
and used different molecular dyes to assess cell morphology under 
fluorescence microscopy. Cells were grown in CDM supplemented with 
Gal or Glc and samples were taken at mid-exponential and early 
stationary phases of growth (Fig. 4.5). Interestingly, we observed that Gal-
grown cells have an elongated shape with sharp poles, and that this 
phenotype becomes more pronounced at later stages of growth or under 
lower Gal concentrations. Concomitantly, formation of chains is observed 
(Fig. 4.5). We hypothesised that this morphological adaptation might 
confer a strategic advantage for the pneumococcus to survive in the 
nasopharynx, while benefiting from Gal residues of mucins. It was shown 
that long pneumococcal chains are selected for stable colonisation by 
enhancing adherence to epithelial cells. In opposition, short chains are 
more likely to evade complement deposition (less complement activation) 
and subsequent phagocytosis, and therefore may be selected to invade 
the host, accounting for the diplococcal morphology in clinical samples 
[71,72]. Rodriguez et al., [71] hypothesised that the environmental niche 
provide a signal for long chain formation, thus enhancing adherence of 
the pneumococcus. Here we propose that Gal, might be that signal.    




Figure 4.5. Cell morphology of S. pneumoniae grown in Gal in comparison to Glc. 
Cells were grown in CDM with 30 and 10 mM of Gal or Glc. Samples were collected at 
mid-exponential and early stationary phases of growth. For direct comparison optical 
density at 600 nm was adjusted to 0.5 with fresh medium. For membrane labelling Nile 
Red was used (A). To assess side wall elongation VanFL was used (probe for 
peptidoglycan synthesis) (B). Visualization was carried out on a Zeiss Axiovert 
microscope. Exposure times were: phase contrast 100 msec; Texas Red and GFP 1000 





We also observed that unlike Glc-grown cells, on Gal-grown cells the 
nascent peptidoglycan was not only positioned at the division site in the 
midcell (division septum) or at the constriction site between sister cells, 
which will form the new cell poles once division is complete. In Gal 
cultivations, several septa were observed and this effect was more 
pronounced at the stationary phase of growth in cultures with lower Gal 
concentration. These results suggest that peptidoglycan synthesis takes 
place at multiple division sites along the elongated cell. A model for 
sidewall elongation in which peptidoglycan insertion occurs 
simultaneously at multiple Z-ring-associated sites was proposed for the 
ovococci L. lactis. Moreover, filamentation resulted from septation 
inhibition and the contribution of penicillin binding proteins PBP2x (septal 
growth) and PBP2b (peripheral growth (elongation)) was described [73]. 
The biological role of filamentation in bacteria is wide (reviewed in [73]). 
In particular, filamentation increases the total bacterial surface, and this 
can be rationalized as a response to maximize nutritional uptake [74]. In 
S. pneumoniae the elongated filamentous phenotype can be perceived as 
a physiological advantage in the the nasopharynx milieu, where free 
sugars are scarce. The altered shape of the pneumococcus in response 
to carbohydrates is novel and certainly deserves future characterization. 
A Glc stimulus during exponential growth of S. pneumoniae produced 
sugar specific responses on expression of virulence genes. However, Glc 
exerted mostly negative regulation over the known virulence genes (bgaA, 
pflA, pflB, galK), suggesting that these factors are required for 
colonisation, but not in disease states.  
 The profile and dynamics of gene expression presented in Chapter 3 
highlight that the virulence potential of the pneumococcus is clearly 
influenced by the carbon source either by modulation of catabolic 
pathways and/or classical virulence factors.  
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Concluding note 
This work provides a valuable contribution to the comprehension of 
carbohydrate metabolism in S. pneumoniae and its influence in 
pneumococcal colonisation and disease. The challenging goals set out in 
the beginning of this endeavour were at most achieved by a combined 
approach comprising a detailed physiological characterization, metabolic 
profiling, transcriptional profiling, mutant characterization, and virulence 
studies in animal models of disease. The data generated at the different 
“omic” layers has just begun to be analysed in the framework 
mathematical representations. The multi-level data herein generated can 
be used to fuel mathematical models of metabolism and regulation [75], 
which are expected to predict factors essential during colonisation and 
invasive states. The application of genome scale model to predict novel 
drug targets for cancer therapies has been reported [76]. Thus, new 
strategies could be followed aimed at developing therapeutics targeting 
sugar catabolic pathways to fight pneumococcal disease. Collectively, our 
data powerfully strengthens the link between physiology and 
pathogenesis. Furthermore, our research paves the way for new lines of 
investigation. Certainly the unexpected changes in S. pneumoniae cell 
shape in response to Gal deserve future scrutiny. Questions such as “is 
this response specific to Gal?”, “does the altered morphology impact the 
ability to colonise and cause disease?, “what is the molecular 
mechanism?” and “what is the physiological relevance?” should be 
addressed in the future. We speculate that a meticulous and targeted 
analysis of the transcriptome data will unveil some clues to initiate such 
studies.  
Also intriguing was the inability of a galK mutant to grow on Gal. 
Considering the role of Gal catabolism in the ability to colonise and cause 
disease we imagine that unravelling the molecular mechanism is of 
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importance to further our understanding of carbon metabolism in the host. 
Furthermore, the production of virulence factors, including capsule, 
should be assessed in Gal-catabolic mutants. How the catabolic mutants 
perform in mucin containing medium should also be examined and the 
derived knowledge is expected to corroborate our findings in the animal 
models.  
 Inspiration for future research in the field of pneumococcal physiology 
and metabolism is provided by the many pointers deriving from our 
transcriptome studies. For example, the genes SPD_0502 and celBCD 
were induced by Glc in all the conditions tested, and hence a role on Glc 
transport can be surmised. Experimental validation can be accomplished 
by mutating these genes in a S. pneumoniae Glc/Man-PTS mutant. In fact, 
the hypothesis that SPD_0502 and celBCD are involved in Glc uptake has 
been tested in our laboratory, in a larger effort to unravel the complement 
of Glc transporters in S. pneumoniae.  
In conclusion, the data presented in this thesis extends considerably 
our knowledge on S. pneumoniae basic physiology and on how 
carbohydrate acquisition and metabolism influences the pathogenic 
potential of the bacterium. Growing evidence supports a strong 
intertwinement between central metabolism and virulence. Additionally, 
this thesis raises new research questions that can advance our 
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Table S4.1. Conservation of Man and GlcNAc metabolic genes in different 

































































































































































































































































The table was obtained by a unidirectional Blast search, where the genes of S. 
pneumoniae D39 was used a query to find homologs in the 25 other genomes. Only the 
best hit in each genome is shown. Each cell contains the locus tag, e-value and the number 
of blast hits. The e-value is reflected in the blue colour code. The darker the blue colour, 
the lower the e-value (and more significant hit). 
This table is also available on the CD. 
 
 
 

